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SUMMARY
S u m m a r y
This thesis mainly deals with steroid-growth factor 
interaction in the regulation of growth and steroid metabolism of 
LNCaP, DU145 and PC3 human prostate cancer cell lines. Growth 
response to both androgens and oestrogens and to TGFa and 
T G F p i were investigated; in addition, content and status of 
steroid (AR and ER) and growth factor (EGFR and T G F p R ) 
receptors were assessed using multiple approaches, including 
ligand binding assay, immunocytochemistry and reverse 
transcriptase-PCR (RT-PCR). Furthermore, immunofluorescent 
staining was used to evaluate expression of EGF, TGFa and TGFBi 
and of the 27 kDa heat shock protein (hsp27) as a marker of 
oestrogen sensitivity. On the other hand, patterns of both 
testosterone (T) and oestradiol (E2 ) metabolism were studied 
using incubation of cultured cells with labelled steroid precursor 
and reverse phase-HPLC (RP-HPLC) analysis of precursor 
degradation and formation of metabolic products. Possible 
influence of both TGFa and TGFBi on rates and direction of 
metabolism of both steroids was also determined.
Growth of LNCaP cells was significantly stimulated by 
physiological concentrations of the two major androgens (T and 
dihydrotestosterone: 30.2% and 33.8% respectively, P<0.03) and 
of E2 (65.8% , P=0.009), using stringent culture conditions.
Interestingly, increasing concentrations of E 2 (0 .01-100 nM ) 
induced a significant inhibition of the proliferative activity of PC3 
cells (55.2% at 100 nM E2 , P<10-6), while neither androgen
xxv
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significantly affected growth of this cell line. In contrast, DU 145 
cells proved insensitive to the addition of either androgens or 
oestrogens.
Presence of androgen binding sites in prostate tumour cell 
lines was ascertained using radioligand binding assay and RT-PCR 
approaches. High affinity AR were detected in both soluble and 
pellet fractions of LNCaP and DU145 cells, whilst PC3 cells 
showed only nuclear AR. These results were also supported by 
PCR system, where ampifiable AR mRNA was found in all three 
cell lines.
Multiple evidence for high affinity sites of oestrogen 
binding in LNCaP cells was obtained: i) biochemical assay allowed 
the detection of high affinity, low capacity binding sites in both 
soluble and nuclear cell fractions; ii) immunocytochemical and 
immunofluorescent assays showed a consistently intensive 
staining for both ER and PgR, as well as hsp27; iii) the RT-PCR 
system documented the presence of normal or a variant ER 
mRNA in PC3 cells; the latter, which lacks the entire exon 4, has 
been recently characterised in our laboratories in human 
mammary carcinoma cells. Presence of ER in PC3 cells was also 
documented by biochemical and cytochemical assays as well as, 
indirectly, by hsp27 staining. However, the relative estimate of 
ER expression displayed levels significantly and consistently 
lower than those found in LNCaP cells. This finding was 
confirmed using the RT-PCR approach, where transcript levels for 
both normal and variant ER mRNA were proportionally lower 
than in LNCaP cells. Conversely, DU145 cells were found to be
xxvi
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consistently ER-negative using biochemical and cytochemical 
assays, hsp27 staining and RT-PCR system.
The evidence that the E2 -induced growth was completely 
reversed in LNCaP cells by the addition of the pure antioestrogen 
IC I-182,780, clearly suggests that E2 acts via its own receptor. 
The possibility that the inhibitory effect exerted by E2 on growth 
of PC3 cells could be mediated via an increase of TGF6 production 
was also supported by the fact that use of a neutralising antibody 
raised against TGFBi produced a three-fold increase of cell 
growth; this effect was almost completely abolished after
A
addition of 100 nM E2 . However, Northern blot analysis did not 
reveal any increase of TGFBi mRNA following E2 administration in 
this cell line.
Growth of PC3 cells was significantly stimulated by TGFa  
(36% at 50 ng/ml, P<0.003) and inhibited by TGFBi (55% at 5 
ng/ml, P<10-6) after 48 hours exposure in routine medium. 
Proliferative activity of DU 145 cells was minimally affected by 
T G F a , but significantly inhibited by TGFpi (28% at 5 ng/ml, 
P<0.009). In contrast, LNCaP cells proved to be poorly sensitive, 
at least in the short-term, to either growth factor.
Radioreceptor assay showed presence of high affinity  
binding sites for EGF in all three cell lines and for TGFp in DU 145 
and PC3 cells, whilst no detectable site of TGFp binding was found 
in LNCaP cells. DU145 cells displayed the highest EGFR content, 
LNCaP the lowest; TGFpR were expressed in greater amounts in 
PC3 than in DU145 cells. EGFR binding data were also confirmed 
using Western blot analysis, the DU145 cells having EGFR
xxvii
SUMMARY
expression levels higher than PC3 and LNCaP cells. In addition, 
immunofluorescent staining revealed high amounts of both EGFR 
and TGFa, and fairly high EGF in DU 145 and, to a lesser extent, in 
LNCaP cells; by contrast, PC3 cells exhibited low levels of both 
receptor (EGFR) and ligands (EGF, TGFa), but appreciable levels of 
endogenous TGFBi. Overall, these results suggest a differential 
sensitivity to TGFa and TGFBi by prostate cancer cells; TGFa  
response seems to be not proportional to the EGF-R content of 
individual cell lines, while TGFPi response appears to be 
inversely related to the androgen-sensitivity of cells.
The ability of human prostate cancer cells to metabolise 
steroids was assessed using an approach which allows the 
evaluation of conversion metabolic rates after administration of 
labelled steroid precursor (T or E2 ) at physiological concentration 
(0.5-10 nM) for various exposure times. Analysis of both 
precursor degradation and formation of metabolic products was 
carried out using reverse phase-HPLC (RP-HPLC) and "on line" 
radioactive detection after either 24 or 72 h incubation. Overall, 
different prostate cancer cells degraded T and E 2 q u ite  
differently, alternatively favouring reductive or oxidative 
metabolic pathways. In particular, both LNCaP and DU145 cells 
retained high levels of unconverted T, with a limited production 
of A4-Ad and its 17-keto derivatives ( if  any) and relatively high 
amounts of DHT and 3a-diol; similarly, these cell lines maintained 
the most part of E2 undegraded, with a limited E i formation. In 
contrast, PC3 cells quickly degraded T and exhibited high 
formation rates of A4Ad and 17keto metabolites, whilst neither
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DHT nor 3a-diol were detected after either short or longer 
incubation times; equally, E2 was rapidly oxidised to E i, with an 
appreciable production of 16aO H E i. No detectable formation of 
steroid conjugates was noted in either PC3 or DU 145 cells, whilst 
a remarkable production of T conjugates (43 to 57%) was 
observed in LNCaP cells at 24 h and, to a far lesser extent (<10%), 
at 72 h.
The effects of both TGFa and TGFBi on rates and direction of 
T and E2 metabolism were explored. They varied markedly 
depending on the cell line studied. Either growth factor enhanced 
reductive pathways of both T and E2 metabolism in LNCaP cells, 
while oxidative pathways were respectively increased and 
reduced by TGFa and only moderately affected by TG FPi. In 
DU 145 cells, TGFa caused a rise in the extent of both T  and E2 
oxidative reactions, with a corresponding decrease of the 
reductive pathway; TGFpi paralleled the effects of TGFa on T  
metabolic pathways, but had an opposite, minor influence on E2 
metabolism in this cell line. Finally, T metabolic pathways were 
minimally affected by either growth factor in PC3 cells. Both 
T G F a  and TGFBi, reduced the conversion of E2 to Ei in PC3 cells 
and decreased 16aO H Ei formation, with an additional increase of 
the oxidative way. The influence exerted by TGFs on the overall 
direction of steroid metabolism in prostate tumour cells, although 
apparently moderate, could be important in determining the 
actual concentration of biologically active metabolites of steroids 
and, therefore, may be relevant also to their growth regulation.
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SUMMARY
These results are used as the basis for a model of prostate cancer 
progression, whether hormone-sensitive or insensitive.
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INTRODUCTION
1. Steroids and Cancer
1.1. Historical  Overview
In the last 50 years the relationship between hormones 
and cancer has been extensively investigated, but only poorly 
elucidated. In particular, the potential involvement of steroids 
in the phenomena of tumour initiation, promotion and 
progression remains today a dilemma. Notwithstanding, the bond 
existing between steroid hormones and some human neoplasias 
was already grasped since the eighteenth century, long time 
before the discovery of specific receptor proteins as essential 
intermediaries of steroid action at target tissue level.
After the early observations by Hunter [Hunter, 1786] on 
the dependence of prostatic function and development on 
gonadal androgens, much work accumulated on the use of 
hormonal manipulation as a tentative intervention therapy in 
patients having prostate cancer [White, 1895; Cabot, 1896]. 
Subsequent pioneering studies (reviewed by [Sharifi &  Kiefer, 
1987]) eventually led Charles Huggins and colleagues [Huggins &  
Hodges, 1941; Huggins et a l ., 1941] to conclude that androgen 
withdrawal is an effective approach in the management of 
prostate cancer. On the other hand, in a well-known work, 
Beatson [Beatson, 1896] reported that some premenopausal 
patients with advanced breast cancer experience both subjective 
and objective responses following the ablation of ovaries. A link,
3
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although indirect, between gonadal function and tumour growth 
was therefore established.
Since then, an enormous amount of experimental work has 
been accruing, but so far clinicians are still at a loss in the 
management of most human endocrine-related cancers. The 
reason for this failure is not unique and mainly lies in the 
restricted knowledge of several key phenomena, including 
malignant transformation, control of tumour cell growth, 
mechanisms of neoplastic progression.
Concerning steroids, the situation is confused by the 
complexity inherent in the nature of these hormones. Firstly, 
although steroids are normally categorised in several classes, 
their activity is rather expressed by a continuous spectrum of 
biological effects, a significant extent of overlapping being 
generally encountered. In the second place, different steroid 
classes may give rise to either synergistic or antagonistic actions 
in target tissues; examples in point are given by the well-known 
antagonism between oestrogens and androgens in both human 
breast and prostate [Huggins & Clark, 1940], and between 
oestradiol and progesterone in uterine tissues [Courrier, 1950]. 
Finally, steroid action appears to be multifaceted by the presence 
of numerous biologically active metabolites, particularly  
oestrogens, having a wide range of specific, even opposite, 
effects [Dao, 1979]. Formation of these metabolic products may 
easily occur in target tissues, wherein the expression of several 
steroid enzyme activities has been recently documented; it is 
enough to consider the relevance currently stressed on
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catecholoestrogens (CCE) in human breast tissues or the 
paramount importance of dihydrotestosterone (D H T) in prostate 
development and function, in humans.
Additionally, it is now well established that tissue response 
to steroids varies considerably among tissues, in both qualitative 
and quantitative terms. At the beginning of fifties, Dorfman 
[Dorfman, 1948] indicated that different breeds of chicks exhibit 
a substantially divergent comb-growth response to testosterone. 
Later, Bardin and colleagues [Bardin et a l ., 1970] revealed that 
the lack of androgen response in normally androgen-sensitive 
tissues of mice or rats having the testicular feminization 
syndrome is due to the absence of specific binding sites required 
to elicit androgen action. This stimulating area has been pursued 
extensively, yielding a large body of evidence relevant to the 
understanding of the molecular biology of steroid action in 
regulation of both normal and malignant cell growth.
1.2. Oestrogens and Breast Cancer
For more than half a century, oestrogens have been 
implicated as causative agents in tumour development. This 
assumption has been corroborated by the evidence that chronic 
exposure to sex steroids may produce either benign or malignant 
growth at different organ sites in mammals, including primates 
and man [Li &  Nandi, 1990]. However, data suggesting that 
physiological levels of steroids are carcinogenic in humans are
5
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considerably sparse. This is not surprising in view of the 
"multihit" nature of breast cancer development: several years 
before clinical evidence, breast tumours originate from an initial 
transformation induced by carcinogen(s) and a subsequent lag 
period, of extremely variable length, where different promoters, 
either systemic or local, may act in concerted pathways whose 
net effect finally leads the committed cells to grow.
1.2.1. Oestrogens and carcinogenesis in animal models
Data concerning oestrogen-induced tumours in 
experimental animals appear of relevance, not only in theoretical 
but also in practical terms.
A wide range of neoplastic forms has been produced in 
different animal species (including mouse, hamster, rat, rabbit 
and dog) following oestrogen administration; however, the 
pharmacological doses used, as well as the duration of exposure, 
often extended to a significant portion of the life span of the 
species involved, would suggest that these data be taken with 
some caution.
Probably, the oestrogen-induced tumours in hamster 
kidney and liver represent the experimental models most 
extensively investigated in hormonal carcinogenesis [Li &  Li, 
1984]. In particular, the Syrian hamster kidney seems to be an 
ideal system, since it behaves as an oestrogen-responsive tissue 
[Li &  Li, 1978; Li &  Li, 1981] and since spontaneous renal 
tumours are virtually non-existent in hamster [Pour et a l.y 1979]. 
In this model, oestrogens induce multiple bilateral renal tumours
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in either intact or castrated male Syrian hamsters, at an 
incidence that approximates 100% [Li & Li, 1987]; on the other 
hand, renal tumorigenesis can be completely prevented through 
the concomitant administration of antioestrogens, progesterone 
or androgens [Antonio et al., 1974]. It has been suggested that 
oestrogens can affect neoplastic transformation through both 
hormonal and metabolic activity, the former being defined as 
receptor-mediated effects on growth or synthesis of induced 
proteins, the latter as the generation of biologically active 
metabolites and their subsequent interaction with cellular 
macromolecules [Li & Li, 1990].
Studies on breast cancer oncogenesis in rodents have been 
based on mammary carcinoma experimentally induced by 
chemicals and viruses [Moore et a l ., 1979; Nicholson et a l ., 1988]. 
In particular, 7,12-dimethylbenz(a)anthracene (D M B A ) and
mouse mammary tumour virus (M M T V ) model systems have 
been used. In either model, rates of tumour development and
growth appear to be under hormonal control. Studies on the 
DMBA-induced tumours, pioneered by Charles Huggins [Huggins 
et a l .y 1961], have shown that the highest proportion of
developing tumours occurs when the carcinogen is administered 
to virgin rats soon after the beginning of oestrus, namely
between 40 and 46 days of age; malignant transformation 
appears to affect mainly the terminal end buds (TEB) of the 
glandular tree, whilst the more differentiated alveolar buds (AB) 
are seemingly insensitive to DMBA [Russo & Russo, 1987]. On the 
other hand, there is evidence that formation of DMBA-induced
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mammary cancer in rats is inhibited by castration of animals 
prior to DMBA administration; in addition, most tumours (>85%) 
produced in intact animals are hormone-dependent and regress 
after oophorectomy [Nicholson et al., 1988]. The process of M M TV  
induction of breast tumours in rodents has been extensively 
investigated. The retrovirus is transmitted to neonatal mice 
through breast milk, commonly leading to development of 
mammary cancer when animals are 6 to 9 months old. It is of 
interest to note that reverse transcribed DNA of M M T V  contains 
a peculiar regulatory sequence known as long terminal repeat 
(LTR) which, when integrated, may interact with adjacent genes 
by subverting their normal regulatory processes [Dickson et al., 
1984; van de Vijver & Nusse, 1991]; these genes includes 
sequences, known as hormone-responsive elements (HREs), 
which determine the cell responsiveness to hormones and are 
specifically recognised by hormone receptors [Ponta et al., 1985]. 
Thus, insertion of M M TV at different integration sites may well 
alter the function of those genes which are believed to primarily 
mediate hormone action.
Mammary tumours can also be produced in rats exposed to 
N-nitrosomethylurea (N M U ) [Gullino et al., 1975]. NMU-induced 
tumours have been reported to be hormone-dependent and 
endowed with receptors specific to oestrogens, progesterone, 
androgens and prolactin [Arafah et al., 1980]. In this system, 
tumour regression can be observed after ovariectomy or 
following treatment with either antioestrogens or luteinizing 
hormone-releasing hormone analogues [Rose et al., 1980].
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Interestingly, tumour growth can be reactivated with oestradiol 
administration [Pruitt et a l ., 1979], indicating that this tumour 
model is oestradiol-dependent. In addition, the finding that both 
oestrogen and progesterone receptors are significantly reduced 
after ovariectomy, whilst prolactin receptor levels are almost 
unaffected [Arafah et a l ., 1980] reinforces the oestrogen-
dependence of NMU-induced mammary carcinoma while it partly 
abridges the potential role of prolactin, at least in this 
experimental model.
1.2.2. Risk factors for breast cancer
A constellation of factors influences the risk for breast 
cancer [Bland, 1987]. They include reproductive experience, 
ovarian activity, dietary habit and specific endocrine 
components.
Variables related to reproductive life  have been 
consistently associated with risk for female breast cancer. Most 
of them involve an either absolute or relative hyperoestrogenism 
as the critical element (for a review see [Zumoff et a l.y 1975]). 
Over the last thirty years, breast cancer risk has been in turn 
ascribed to an excess of total oestrogens, to an excess of 
oestrogens not counteracted by progesterone or to an unbalance 
among several oestrogen fractions. A ll these hypotheses 
originated from both epidemiological and clinical observations on 
the relationship between reproductive factors and the incidence 
of breast cancer.
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Overall, epidemiological data suggest that the younger the 
age at first birth, the greater the protection from breast cancer 
acquired. It has been previously reported that nulliparity only 
slightly raises the risk of developing breast cancer [MacMahon et 
a l ., 1970], whilst the birth of the first child after the age of 30 
produces a relative risk of 2.2 to 2.7 [Brinton et a l ., 1983].
Apparently, the age of 35 may represent a crucial point; in fact, 
any full-term pregnancy before this age confers some degree of 
protection [Trichopoulos et a l ., 1983]. Women over the age of 30 
at the time of their first birth have a risk greater than women 
who never become pregnant. However, increasing parity seems 
to have a significant protective effect, which is maintained even 
when adjusted for age at first birth and other risk factors [Pathak 
et al., 1986]. The evidence that early pregnancy is associated 
with a reduced breast cancer could imply that it either modifies 
some etiological factors responsible for breast cancer or changes 
breast tissue itself by making it less susceptible to malignant 
transformation. It has been documented that a first pregnancy 
has a lasting impact on the hormonal milieu of individual female; 
for instance, a rise of circulating oestriol and decreases in 
dehydroepiandrosterone (DHA), its sulphate (DHAS) and prolactin 
levels can all persist many years after delivery [Musey et al., 
1987]. Firstly, Huggins and Jensen [Huggins &  Jensen, 1955] and 
later Lemon [Lemon et al., 1966] designed the hypothesis of the 
"impeded oestrogens" to explain the protective role exerted by 
pregnancy on breast cancer development. Since oestriol (E3) was 
thought to oppose the action of oestradiol (E2 ) and oestrone (E i) ,
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the authors postulated that the higher E3 excretion levels found 
in pregnant women may counterbalance the carcinogenic 
potential of both E2 and E i. Lemon therefore introduced the "E3 
quotient", namely the ratio of urinary E2 plus E j to E3 , to 
discriminate high and low risk subjects in Asian and North 
American women having a substantially different incidence of 
breast cancer. However, this hypothesis has been subsequently 
contradicted by a number of experimental data. In first place, 
Clark and associates [Clark et al., 1977] indicated that E3 exhibits 
the same oestrogenic potency as E2 and Ei when used for longer 
exposure intervals. Secondly, the higher E3 quotient found in 
women, like Japanese, at low risk of breast cancer should be 
regarded as a consequence of reduced levels of E2 and E i rather 
than the effect of an E3 excess [Zumoff, 1981]. Nevertheless, 
Lemon's observations are praiseworthy since they have drawn 
our attention to steroid excretion patterns as a possible reflection 
of the endocrine status of both normal and diseased breast 
tissues. Data coming from our laboratory have, for instance, 
revealed a bimodal expression of steroid excretion profiles in 
breast cancer patients, which is significantly related to both 
steroid receptor content of primary tumours and overall 
prognosis of patients [Castagnetta et a l ., 1981; Castagnetta et al., 
1985; Castagnetta et al., 1986a].
The possibility that an imbalance between oestrogens and 
progesterone is in some way related to breast cancer 
development has been previously introduced by Sommers 
[Sommers, 1955]. The author observed a noticeable incidence of
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hyperplastic lesions in endometria obtained at autopsy from 
women who died of breast cancer, suggesting that this could be 
due to the action of unopposed oestrogens. This evidence was 
further refined by Grattarola [Grattarola, 1964] who documented 
that breast cancer patients denote endometrial patterns 
significantly different from those found in healthy controls. In 
particular, almost 80% of breast cancer patients exhibited some 
endom etrial abnormalities (p ro life ra tive  endom etrium , 
adenomatous or atypical hyperplasia) which are suggestive of 
anovulatory cycles; by contrast, more than 70% of normal 
controls displayed a progestative endometrium. This evidence 
was initially attributed to an oestrogen excess not compensated 
by progesterone, which would give rise to anovulatory cycles. On 
this basis, subsequent work by Sherman and Korenmann 
[Sherman & Korenman, 1974] connected several risk factors for 
breast cancer (nulliparity, obesity, early menarche and late 
menopause) to the presence a luteal insufficiency, i.e. lack of a 
full progesterone phase or an oestrogen "window" (see below). 
However, data coming from clinical research have not always 
confirmed this conjecture. On one hand, studies on either 
infertile women with a history of progesterone deficiency or 
anovulatory women indicated respectively a 5.4 and a 3-4 fold 
increase of breast cancer risk [Cowan et a l.y 1981; Coulam &  
Annegars, 1983]. On the other hand, normal luteal phases were 
found in both women at high genetic risk of breast cancer and a 
group of premenopausal breast cancer patients [McFayden et a l ., 
1976].
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Many epidemiological investigations have indicated that 
bilateral ovariectomy before the age of 40 significantly reduces 
the risk of developing breast cancer [Trichopoulos et a l ., 1972; 
Helmrich et a l ., 1983; Irwin et a l., 1988]. On the other hand, early 
menarche and late menopause produce a small increase (from 1.4 
to 3.3 times) of risk [Roush et a l., 1987]. This evidence indicates 
that ovarian function plays a continuing role throughout a 
woman's reproductive life; in particular, number of physiological 
ovarian cycles before first pregnancy may provide a clue to 
unravel the intimate relationship existing between age at 
menarche, age at first pregnancy and breast cancer. 
Korenmann’s "oestrogen window" hypothesis is mainly based on 
the view that unopposed oestrogen stimulus is the most 
favourable state for breast tumour induction (the "open" 
window) and that the extent of risk depends upon the length of 
oestrogen exposure (how long the window is "open") [Korenman, 
1980]. Following this hypothesis, breast susceptibility to 
carcinogen action declines as soon as a normal luteal secretion of 
progesterone occurs, becoming minimal during pregnancy. The 
pubertal years prior to the establishment of regular ovulatory 
menstrual cycles and the perimenopausal interval of waning 
follicle maturation and ovulation represent the two main "open 
window" periods. Several factors, like obesity, late pregnancy, 
earlier menarche and delayed menopause may prolong these 
periods and therefore be associated with an increased 
susceptibility of breast tissues to environmental carcinogens. To 
corroborate this hypothesis, Korenmann considered evidence
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coming from separate studies on atomic bomb survivors of 
Hiroshima and Nagasaki, and on tubercolotic women receiving 
repeated chest fluoroscopies. In the A-bomb survivors, no 
increase of breast cancer incidence was seen in children who 
were exposed to irradiation before the age of 1 0 , whilst a 
conspicuous risk exposure was observed between 10 and 14 
years, namely just before menarche, suggesting that cells are 
being transformed at a time of non-opposed oestrogen stimulus. 
Over that age, irradiation-induced risk decreased rapidly, but it 
seemed to reappear after the age 50, i.e. around menopause 
[Tokunaga et a l , 1979]. In the repeatedly fluoroscoped women 
having tubercolosis, the highest risk increment over un-x-rayed 
controls was found in the 15-20 years age group, while no 
increase was observed after the age of 30 [Hrubec et a l ., 1989]. 
However, other reports evidently conflict this theory. In 
particular, Anderson et a l  [Anderson et a l ,  1982] observed that 
the peak of proliferative activity of breast cells occurs in the 
luteal phase of the menstrual cycle, under the influence of both 
oestrogen and progesterone. Although the oestrogen window 
hypothesis has been partly contradicted by other clinical and 
epidemiological evidence, it appears meaningful mainly because 
has stressed the key role of endocrine environment in breast 
cancer development.
Despite the ever-growing literature on the relationship 
between diet and cancer, data are often contradictory and 
difficult to decipher. Different case-control studies have reported 
a significant association between obesity and increased breast
14
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cancer risk in post-menopausal years [Byers & Graham, 1984], 
Initially, Siiteri and colleagues [Siiteri et a l ., 1974] suggested that 
this increase could be ascribed to E i. This assumption was mainly 
based on the evidence that Ei is the main circulating oestrogen in 
post-menopausal women and that the aromatisation of 
androstenedione to Ei preferentially takes place in the adipose 
tissue which could therefore represent a significant source of 
oestrogens in the obese post-menopausal female. It is unclear 
whether or not obesity and fat intake are independently 
associated with breast cancer risk, but it seems likely that an 
excess of caloric intake may be important in post-menopausal 
breast cancer because it affects body fat levels [Byers &  Graham,
1984]. However, the potential role of Ei in human breast cancer 
development remains to be established.
Several epidemiological studies have suggested that a diet 
rich in fiber and complex carbohydrates is associated with a 
decreased risk of breast cancer [Kolonel et a l., 1981; Brisson et a l ., 
1989; van't Veer et a l ., 1990]; in particular, women consuming 
grain fiber during their teens have a reduced risk in both young 
and old age [Pryor et a l ., 1989]. It is well recognised that either 
incidence or mortality rates of hormone-related cancers, 
including breast, are considerably higher in the western world 
compared to Asian and some east European countries, where 
vegetarian or semi vegetarian diet is prevailing [Rose et a l ., 1986]. 
Although it has been earlier ascertained that dietary fiber 
reduces the enterohepatic circulation of oestrogens [Adlercreutz 
et a l .y 1986], the overall mechanism by which diet may affect
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breast cancer development remains largely unknown. Recently, 
the discovery of phytoestrogens and other oestrogenically active 
compounds in human urine [Adlercreutz et a l ., 1987] has 
disclosed a new scenery for investigating this potentially 
important issue. Phytoestrogens, such as lignans and isoflavones, 
are diphenolic plant constituents which are excreted in large 
amounts by subjects consuming vegetables, soybeans and whole- 
grain products. The finding that urinary levels of these 
compounds are significantly lower in breast cancer patients with 
respect to omnivorous and vegetarian controls [Adlercreutz et a l ., 
1982] has encouraged researchers to explore the likelihood that 
dietary weak oestrogens exert a protective role for breast cancer. 
For instance, it has been recently suggested [Adlercreutz, 1990] 
that both lignans and isoflavones stimulate synthesis of sex 
hormone binding globulin (SHBG) in human liver; the SHBG
increase would in turn produce a reduction of either the
albumin-bound or the free fraction of sex hormones (oestradiol,
testosterone), rescuing breast tissues from an exceeding stimulus 
of biologically available steroids. Many questions about the
relationship between dietary oestrogens, their biological effects 
and sex steroid metabolism and function in man remain open; 
however, data accumulated thus far seem to reinforce the 
epidemiological view that western diet is one of the main factors 
responsible for the higher incidence of breast and other 
hormone-related cancers in western countries.
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1.2.3. Plasma and tissue oestrogens
Bioavailable oestrogens in blood
Since methods for measuring blood oestrogens became available, 
much attention has been devoted to investigate their plasma 
levels in relation to breast cancer. In man, the most part 
(between 40 and 50%) of circulating E2 is bound to SHBG with 
high affinity; the majority of the remainder is loosely and non- 
specifically bound to serum albumin, leaving a very small 
fraction (less than 2%) totally free of protein binding. From early 
studies, evaluating plasma levels of total oestrogens in breast 
cancer patients and healthy controls in both pre- and 
postmenopausal women, no clear picture emerged. In a 
comprehensive study, England and colleagues [England et a l ., 
1974], taking into account the ovulatory status of subjects, found 
only a marginally significant increase of blood E 2 in 
premenopausal breast cancer patients with respect to both 
normal women and women with benign breast disease; a large 
scattering of values was also encountered in cancer cases. On the 
other hand, Sherman et al. [Sherman et a l ., 1979] failed to show 
any significant difference in the mean E2 levels between controls 
and disease-free breast cancer patients in premenopause. Even 
more conflicting results have been obtained in postmenopausal 
women concerning blood concentrations of E2 , E i and Ei sulphate 
(EiS).
The development of suitable methods to isolate and 
estimate the different fractions of circulating oestrogens has
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enabled researchers to attempt to assess the E2 fraction which 
can cross plasma membranes and be available to a tissue, i.e. the 
"biologically active" fraction. It has been generally assumed that 
not only free E2 , but also some protein-bound E2 may be 
accessible for tissue uptake, provided that dissociation from 
binding protein occurs rapidly (within seconds) in relation to the 
transit time of a capillary bed. However, Pardridge and 
colleagues [Pardridge & Landow, 1984] pointed out that 
dissociation constant of steroid binding to albumin measured in  
vitro  is much lower than that calculated in vivo, i.e. steroids seem 
to be more loosely bound than expected from in vitro studies; the 
higher dissociation rate found in vivo could imply a 
conformational change of binding protein which facilitates the 
release of the ligand. Following data obtained on rat liver and 
brain (reviewed by [Pardridge, 1981]), it has been suggested 
that, as far as glandular breast tissue is concerned, also the 
albumin-bound E2 fraction may well be available [Siiteri et a l ., 
1982].
Vihko and Apter [Vihko & Apter, 1986] reported that girls 
having early menarche show a greater increase of serum E2 and 
significantly lower concentrations of SHBG with respect to other 
girls; this was apparent since the age of 10 and persisted up to 
five years after menarche. It may be that the resulting higher E2 
to SHBG ratio may account for the early appearance of menarche. 
However, it may also be relevant to an increased breast cancer 
risk in these girls.
18
INTRODUCTION
Siiteri and associates [Siiteri et a l ., 1981] showed that
breast cancer patients have an overall increase of bioavailable E2 
in their blood, suggesting that this condition may favour breast 
cancer genesis. This evidence was subsequently confirmed by 
several case-control studies [Moore et al., 1982; Reed et al., 1983; 
Langley et al., 1985; Siiteri et al., 1986; Takatani et al., 1987] 
which documented higher concentration of non-protein-bound E2 
in breast cancer with respect to normal women; however, the 
differences between the two groups were always very small, the 
case to control ratio of free E2 ranging from 1.11 to 1.41. A 
comparison of British women (representing a high-risk 
population) with Japanese women (representing a low-risk 
population) revealed that the latter had higher levels of SHBG- 
bound E2 (supposed to be not biologically available) than did the 
British counterparts [Moore et al., 1983]. However, the same 
authors were unable to confirm this trend in five different racial 
groups living in Hawaii, in spite of a five-fold range of incidence 
rates of breast cancer [Goodman et al., 1988].
In a prospective study on the Guernsey Island population, 
Bulbrook et al. collected blood samples from 5000 ostensibly 
healthy women over the age of 35; volunteers were therefore 
screened for breast cancer by palpation and mammography. 
Preliminary results indicated that plasma levels of both free and 
albumin-bound E 2 were significantly higher in subjects who 
subsequently developed breast cancer (named precancer cases) 
with respect to age-matched controls [Moore et al., 1986]; in 
addition, SHBG amounts in precancer cases were at the lower
19
INTRODUCTION
ends of control ranges. Unfortunately, as the study progressed, 
the differences between cases and controls became statistically 
not significant, the SHBG levels being found within the normal 
range. Bulbrook et al. [Bulbrook et a l ., 1988] proposed that this 
could be a reflection of tumour growth rates, in that rapidly 
growing tumours, which would originate in women having lower 
SHBG and higher free E2 levels, would have an earlier clinical 
appearance than tumours growing more slowly, which conversely 
associate with SHBG levels at the upper end of the normal range. 
Thus, the overall incidence of breast cancer is not reflected by 
different plasma SHBG levels, simply the age of clinical detection 
being younger in patients who have lower SHBG plasma levels.
Although methods to estimate SHBG are uncomplicated and 
reliable, many case-control studies comparing breast cancer 
patients and matched controls have yielded results largely at 
variance [Meyer et a l ., 1986; Ota et al., 1986; Takatani et a l ., 
1987]. This has been ascribed to the fact that these studies 
disregard tumour growth rates [Bulbrook et al., 1989]. This 
rather simplistic interpretation neglects other potentially  
effective elements. In first place, it has been shown that SHBG is 
relatively unstable in frozen plasma samples in long-term  
storage conditions; this may produce a significant increment of 
the free E2 fraction [Siiteri et a l ., 1986] and may account for the 
extremely conflicting reports in the existing literature. Secondly, 
there is increasing evidence that SHBG-bound E2 can also enter 
cells. Immunocytochemical studies have revealed presence of 
SHBG within various steroid target tissues, including prostate
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[Bordin & Petra, 1980] and human breast cancer [Tardivel- 
Lacom be et al., 1984]. Experimental observations on human 
prostate and decidual endometrium, using 1 2 5 Io d in e -la b e lle d  
SHBG, are suggestive for SHBG binding sites on the membrane of 
oestrogen target cells [Strel'chyonok et al., 1984; Hryb et al.,
1985]. In particular, SHBG seems to bind decidua membranes 
only when complexed to oestradiol, but not when it is devoid of 
steroid or carrying testosterone [Hryb et al., 1990]; this evidence 
has been recently confirmed in premenopausal human 
endometrium, where SBHG affinity for its receptor increases in 
presence of oestradiol and is reduced by androgens [Fortunati et 
al., 1991]. These findings would imply that, if also SHGB-bound E2 
may be accessible to a tissue, then a decrease of SHBG levels in 
cancer patients will not necessarily turn in a greater biovailable 
E2 fraction.
Bulbrook et al. [Bulbrook et al., 1988], showed that levels of 
circulating androgens appear to be correlated to the age of breast 
cancer appearance. The authors postulated that androgens act as 
growth inhibitors; since the normal range for plasma steroids is 
five-fold, balance between growth inhibiting androgens and 
growth promoting oestrogens may comprise a ten-fold range, 
wherein physiological levels of each steroid may yet be 
important to clinical manifestations of breast cancer. However, 
simple measurement of plasma concentrations of steroids may be 
in any event misleading unless we precisely define levels of 
biologically available hormone; mechanisms controlling the 
release of both albumin- and SHBG-bound E2 to plasma
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membranes are only poorly understood and there is obvious 
hazard in extrapolating data coming from animal model systems 
to human breast. Anyway, a central question which remains to 
be established is to what extent hormone plasma levels reflect 
concentration and endocrine environment of tissues. As discussed 
in the successive sections, either normal or cancer target tissues 
appear endowed with key enzyme activities of steroid 
metabolism and exhibit levels of endogenous steroids which are 
about ten up to one hundred (or more) times higher than the 
respective plasma values. Therefore, increases of 0.25 to 0.65% 
in plasma free E2 are highly unlikely to represent a critical factor 
in determining the level of bioavailable oestrogen to the tumour 
cells.
Oestrogens in breast tissues
A variety of steroids and their derivatives have been analytically 
identified and measured in both normal and cancerous human 
breast [Bonney et a l ., 1983a; Vermeulen et a l ., 1986]; they
include E 2 , E i, E iS , testosterone (T ), D H A  and DHAS, 
androstenedione (A 4 Ad), androstenediol (A 5 A d io l) and 
progesterone (Pg). Numerous investigations have shown that 
either concentration or profile of oestrogens in blood and breast 
tissues are substantially divergent in humans [van Landeghem et 
a l ., 1985a; Vermeulen et a l ., 1986]. In particular, similar
concentrations of breast tissue E2 are present in pre- and 
postmenopausal women, in spite of the conspicuous fall of the 
respective plasma levels after menopause [Thijssen et a l.y 1986];
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in addition, either pre- or postmenopausal breast tissues display
i
E 2 concentration significantly higher than that found in plasma 
[van Landeghem et a l ., 1985a]. Therefore, the lack of correlation 
between E2 levels in tissue and circulation suggests that local 
factors are principally responsible for the oestrogen content and 
pattern within the breast. Selective, against-gradient uptake 
from blood, local biosynthesis and metabolism, or binding to low 
affinity-high capacity binding sites have been in turn implied.
There is evidence that a positive arteriovenous gradient 
across mammary cancer tissues exists for A4Ad, DHA, T and Pg, 
whilst it is not significant for both E2 and Ei [Vermeulen &  
Deslypere, 1989]. Previous studies, however, indicated that 
breast tumours exert an active uptake of oestrogens from the 
bloodstream [Deshpande et a l.y 1976]. James and colleagues 
[James et a l.y 1987], using an elegant experimental model, 
demonstrated that E i accumulates in breast cancer tissues 
following simultaneous infusion of 14C - E i  and 3H - A 4A d 
immediately prior to surgery. Nevertheless, the proportion of 
labelled E i in cancer tissue which derived from A4Ad (i.e. 
produced by the aromatase enzyme system) was extremely 
variable, ranging from 0% up to 89%; this would suggest that local 
factors may differently regulate endogenous production of 
oestrogens in individual tumours. Recently, Blankenstein et al. 
[Blankenstein et al., 1992] have shown that the maintenance of 
intratumoural E 2 levels cannot be accounted for solely by a 
tumour-directed gradient of aromatase substrates and their 
precursors in fatty tissue surrounding tumour mass; the authors
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concluded that mechanisms which sustain E2 concentration in 
breast cancer tissues are not substrate-driven, the A 4A d 
concentration being found much lower than the reported Km for 
the respective aromatase activity (A4Ad —  > E i ) .  As far as 
intratissue E i levels are concerned, it has been suggested that 
circulating EiS may provide a major source for Ei accumulation in 
human breast. Infusion studies, using either 3H - E i S  or E i - 35S,  
have demonstrated that EiS, as such, does not contribute to the 
E i content of breast tumours in postmenopausal women, unless it 
is earlier hydrolysed to Ei by sulphatase enzyme [Purhoit et al., 
1992]. This supports the view that breast sulphatase levels may 
be important in determining the actual E i intratum our 
concentration.
Previous reports on populations at high incidence of breast 
cancer have indicated that the E2 content of tumour tissues is 
higher than that found in normal breast, while this difference is 
less pronounced concerning Ei [van Landeghem et al., 1985a; 
Thijssen et al., 1987]. Comparison of E2 and Ei concentrations in 
normal and malignant human breast tissues from either pre- or 
postmenopausal women has revealed that a significantly greater 
amount of E2 is present in cancerous specimens with respect to 
non-malignant samples, irrespective of age and plasma levels 
[van Landeghem et al., 1985a; Thijssen et al., 1986]. In addition, a 
statistically significant accumulation of E2 in oestrogen receptor 
(ER) positive tumours with respect to ER negative ones was 
observed; however, no significant correlation was found between 
E 2 concentration and ER levels. Therefore, it seems highly
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unlikely that elevated tumour E2 may be dependent on selective 
uptake from blood or binding to specific receptor sites.
More recently, Thijssen and colleagues [Thijssen et a l ., 
1990] compared E2 and Ei concentrations in normal and 
malignant breast tissues obtained from Dutch and Polish women, 
the latter representing a population at a relatively low incidence 
of breast cancer; interestingly, while E2 levels displayed the same 
pattern in the two groups (significantly higher amount in tumour 
tissues from either pre- or postmenopausal patients than in 
controls), the Ei concentration was approximately 50% lower in 
malignant breast tissues from Polish women with respect to 
Dutch women of the corresponding menopausal status. This 
suggests that endogenous E i levels may be related to breast 
cancer incidence, but further investigations are needed to 
confirm whether or not E i is involved in determining the 
different incidence of breast cancer seen in distinct geographical 
areas.
Overall, the experimental and clinical evidence discussed so 
far speaks for the apparent autonomy of human breast cancer 
tissues in maintaining elevated endogenous E2 irrespective of 
available oestrogen in blood. On a biochemical point of view, 
balance between biosynthetic and catabolic processes could 
eventually regulate the intratumoural E2 levels. However, this is 
not the whole story. Recently, Adams et al. [Adams et al., 1988a] 
suggested that human breast stromal fibroblasts secrete a 
polypeptide which increases the conversion of E i into E2 
(reductive pathway) in breast epithelial cells; in addition, insulin-
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like growth factors I & II  (IG F-I & II)  have been shown to
enhance this pathway, while they do not affect the opposite 
direction (E2 - - - >E i ,  oxidative pathway) in MCF7 human breast 
cancer cells [Singh & Reed, 1991]. These observations emphasise 
that local factors may modulate, in a paracrine fashion, key 
enzymes of steroid metabolism and therefore determine the 
actual amount of E2 to which breast epithelial cells are exposed.
1.2.4. Hydroxylated oestrogens
In humans, the metabolism of E2 is mostly oxidative,
consisting of an initial conversion to E i through the generation of
a keto function on the 17p-hydroxy group. The subsequent 
metabolic fate of E2 is essentially determined by the activity of 
two cytochrome P450-dependent enzymes, which hydroxylate 
the parent oestrogen at either the C-16a or the C-2 position. 
Hydroxylation at the C-2 or the C-4 position leads to production 
of the so-called catecholoestrogens (CCE, namely 2- and 4- 
hydroxy-Ei  and E2 ), while the C-16a reaction yields in sequence 
1 6 a - h y d r o x y - E 1 ( 1 6 a O  H E  1 ) and E 3 . The C-2 and C-16a  
hydroxylations represent mutually exclusive pathways of E2 
metabolism, since it is highly unlikely that both reactions occur 
on the same molecule. These cytochrome P450 enzyme activities 
are generally unsaturated, thus any increase in one pathway will 
actually withdraw substrate from the other, resulting in a 
reduced product formation by the competed pathway.
Although CCE formation is commonly believed to be a 
terminal metabolic step, yielding bio logically  inactive
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metabolites, several pieces of evidence suggests that this is not 
so. In first place, early studies suggested that 2-hydroxylated 
oestrogens may be potentially important for catecholaminergic 
function in the brain [Fishman & Norton, 1975]; secondly, there is 
convincing evidence that 4-hydroxylated metabolites may 
behave as long-acting oestrogens [Weisz, 1991]. The assumption 
that 2 -hydroxylation produces peripherally inactive, or mildly 
anti-oestrogenic derivatives, is based mainly on studies where 
cultured cells are exposed to high concentrations of CCE under 
conditions which favour their oxidative degradation and induce 
cell damage [Schneider et a l ., 1984]. However, recent in vivo 
studies have supported the anti-oestrogenic effect of 2 O HE2 
[M ichnovicz et al., 1986; Galbraith & Michnovicz, 1989]. On the 
other hand, 1 6 a O H E i has been shown to be an exceptionally 
potent uterotrophic agent with respect to the same E2 [Martucci 
& Fishman, 1979]. This ketol has an extremely low affinity for 
SHBG; thus, although circulating levels of 1 6 aO H E i in man are 
low, its biological impact may be exaggerated by a larger 
availability to target tissues. A unique property of 16aO H E i is the 
ability of covalently binding to primary aminogroups of proteins 
[Yu & Fishman, 1985]; unlike all 17-keto oestrogens, which form 
only transient Schiff bases with aminogroups of various proteins, 
1 6 a O H E i spontaneously undergoes a subsequent non-enzymatic 
Heyns rearrangement, yielding a 16-keto-17-amino derivative 
which covalently binds proteins. The driving force of this 
rearrangement lies in the generation of a 16-keto function 
instead of the one 17-keto, indicating that 16aO H E i and its more
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labile epimer I 6 P O H E 1 are the sole natural oestrogens with the 
potential of forming covalent bonds; I 6 PO H E 1, however, is rapidly 
transformed in 17-ketoE2 which is unlikely to survive intact the 
Schiff base formation, thus leaving 1 6 a O H E i as the only 
oestrogen metabolite capable of covalently binding proteins by 
this route. Ultimately, since 2- and 16a-hydroxylation represent 
two opposing, mutually exclusive pathways, a relative change in 
one with respect to the other would shift the oestrogen balance 
within a given target tissue toward either a proestrogenic or an 
antioestrogenic state.
Several investigations have indicated that 2-hydroxylase 
activity can easily be modified by a variety of stimuli, in humans; 
by contrast, 16a-hydroxylation appears to be refractory to most 
influencing factors in many experimental conditions. In an 
elegant model, using E2 specifically labelled at the C-2, C-16a, or 
C -17a  position, Schneider et al. [Schneider et a l ., 1982] assessed 
the extent of both reactions in breast cancer patients and 
matched controls by measuring the release of 3H into the body 
water pool. Interestingly, 1 6 a -h y d ro x y la tio n  exh ib ited  
significantly higher (50%) values in patients with respect to 
controls; this evidence could not be biased by menopausal status 
of subjects since the overall metabolic pattern was previously 
found to be time invariant [Fishman et a l ., 1980]. However, in 
order to exclude the possibility that this difference could be a 
consequence of tumour formation, the authors extended these 
studies to women at high familial risk of breast cancer. Women at 
high breast cancer risk displayed a significant increase in the
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extent of 16a-hydroxylation with respect to matched subject at 
normal risk [Osborne et a l ., 1988]. In support to this observation, 
studies using mice of different strains, all aged 6 -1 0  weeks (long 
before the spontaneous appearance of tumours), showed that the 
percent of 16a-hydroxylation was closely related to the incidence 
of subsequent mammary tumours. In particular, strains such as 
the C3H/OuJ and the R III, having a cancer incidence which 
approximates 1 00%, displayed 2 0 % extent of 16a-hydroxylation, 
while in strains like the C57Br/Cd7, at zero incidence of 
mammary tumours, the percent of the reaction was much lower 
(below 4%). In this respect, suitable cross-nurturing studies have 
explored the relationship existing between the M M TV  and 16a- 
hydroxylation in the aforementioned mice strains. These studies 
showed that the extent of the reaction dropped by half in strains 
whose M M TV-positive status was reversed to negative by 
appropriate foster nurturing from birth; on the contrary, 
normally M MTV-negative C57Br/Cd7 strain, made M M T V -  
positive by nurturing on C3H/OuJ mothers, exhibited a 
significantly increased 16a-hydroxylation [Bradlow et a l ., 1985].
Complements to this literature come from tissue culture 
studies on the terminal duct lobular units (TD LU ) [Telang et a l ., 
1989]; the latter have been reported to be the morpho-functional 
site where mammary tumours originate. In these studies TDLU  
were isolated from areas adjacent to breast tumours (TD LU -H ) 
and from tissues of reductive mammoplasty (T D L U -L ); in 
addition, organ cultures of terminal end buds (TEB) from mice 
strains at different incidence of breast cancer were also
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investigated. Measurement of either 2- and 16a-hydroxylation  
or ras oncogene p21 expression revealed higher levels of both 
16a-hydroxylation and ras oncogene in TDLU-H and in TEB from 
mice strains at high breast cancer risk with respect to TD LU -L  
and TEB from strains at low incidence of mammary tumours.
A ll this body of evidence provided a stimulating 
background for development of preventive strategies based on 
dietary or pharmacological reduction of breast cancer risk. 
Although 16a-hydroxylation behaves in a constitutive fashion, 
being commonly refractory to alteration, it seems reasonable that 
a significant enhancement of 2 -hydroxylation, shunting the 
shared substrate (E i) away from the production of both 16aO H E] 
and E3 , would be biologically equivalent to a decrease of 
16a-hydroxylation. Numerous factors have been shown to 
markedly increase 2 -hydroxylation in man; they include 
cigarette smoking, exercise, drugs like cimetidine, different 
dietary habits (high protein and low fat diets, fish oil diet). 
Unfortunately, none of them suits their clinical use as preventive 
agents against breast cancer. Recently, however, Bradlow et al. 
[Bradlow  et a l ., 1991] have suggested that the indole-3-carbinol 
(I3C), which is present in cabbages and in other vegetables of the 
cruciferous family, could represent an appropriate candidate for 
this kind of intervention manoeuvre. Preliminary results 
obtained either in vitro, on MCF7 human breast cancer cells, or in 
vivo, on both mice and human volunteers, indicated that I3C  
induces a two to four-fold increase of 2 -hydroxylation which is
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sufficient to decrease formation of 16a - h y d r o x y 1 a t e d
!
metabolites.
Overall, this CCE hypothesis has not yet encountered 
general consensus, nor has it been fully defined. However, it 
draws attention to the importance of tissue specific processing of 
oestrogens for local potentiation and diversification of their 
function and yields a possible new approach to prevention of 
breast cancer.
1 .2 .5 . E xogenous oestrogens
O ra l contraception
Combined estro-progestogen oral contraceptives (OC) were first 
marketed in Britain in 1960, consisting of early preparations at 
relatively high hormone dosage; over the subsequent decades, 
noticeable changes in the OC formulation have occurred, reducing 
the steroid dose to as little as 20 pg oestrogen or as little as 50 pg 
of a new generation of progestagens having higher bio-potency 
and reduced affinity for androgen receptors (A R ). The 
increasingly large number of women assuming OC steroids, 
combined with the conviction that steroids provoke or promote 
abnormal breast growth, has provided for years a source of 
major concern to such a point that this has become one of the 
most investigated areas of epidemiology. Since the early eighties, 
results of several case-control and cohort studies have been 
reported (for a review see [Vessey, 1988]). Firstly, the Royal 
College of General Practitioners (RCGP) and the Oxford Family 
Planning Association (OFPA) cohort studies, respectively
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involving the follow-up of 23,000 and 9,653 women using OC, 
have indicated no significant differences in breast cancer 
incidence between users and non-users [Royal College of General 
Practitioners, 1974; Vessey et a l ,  1977]; the same evidence came 
from the Walnut Creek and the US Nurses Health studies 
[Ram charan et a l ., 1980]. However, these early investigations 
primarily included married women who used OC mainly to space 
out their children; this could overlook any excess risk of breast 
cancer linked to prolonged use of OC in younger women delaying 
their first pregnancy. Since 1979, when this possibility was 
initially suggested, 12 case-control studies on the use of OC in 
young women have been published; most of them concentrated 
on OC use before the first term birth (BFTB) or before age 25 
years. Some studies [Pike et a l ., 1983; M eirik et a l ., 1986; 
M cP herson et al., 1987] reported an increased risk of breast 
cancer in early OC users, while other studies [Stadel et al., 1985; 
Paul et a l ,  1986] did not. Reasons for these conflicting findings 
may be many-sided. In first place, two major sources of bias 
(reviewed by [Skegg, 1988]) should be mentioned: 1) women 
having breast cancer may recollect their OC use better than 
controls; 2 ) women taking the pill would experience a more 
careful breast surveillance than non-users, leading to an earlier 
tumour detection or even to discovery of cancers that would 
otherwise have remained hidden. Additionally, the wide range of 
pilss taken, in terms of both ratio and overall dose of oestrogens 
and progestins, provide confounding elements. Subsequent large 
studies, however, have all contradicted that OC may increase
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breast cancer risk, even in long-term users. In particular, the 
Cancer and Steroid Hormone study , from the Centers for Disease 
Control (CDC) in Atlanta, has emphasised that there was no 
increased risk in women before the age of 20 or 25; this was true 
even in those using OC for more than 15 years, irrespective of the 
hormone dose or type of preparation [The Cancer and Steroid 
Hormone Study, 19861. Further, more recent results from the 
W HO [WHO Collaborative Study of Neoplasia and Steroid 
Contraceptives, 1990] and the UK national case-control [UK  
National Case-Control Study Group, 1989] studies, and the review 
and meta-analysis of the existing data [Romieu et a l ., 1990], 
continue to be inconsistent. Although this evidence is very 
reassuring, there still is the possibility that a potential risk of 
breast cancer in young OC users may persist into older age, when 
the disease becomes more prevalent; more, a long, as yet 
unobserved, latent effect may well be involved, bearing in mind 
the long dormant phase of human breast cancer. Therefore, data 
in the next two decades are awaited with interest to ascertain 
whether or not OC use may have a lasting adverse influence on 
breast cancer risk, especially in women aged over 45 years.
Hormone replacement therapy
Hormone replacement therapy (HRT) is commonly used to relieve 
the symptoms of the menopause and, given for much longer 
periods, to offer a clinically useful degree of cardiovascular 
protection and to prevent or limit bone loss. In the United States, 
HRT has become very popular since 1960s; suffice it to say that
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in 1974 the widely used Prem arin®, a conjugated equine 
oestrogen preparation, was the fourth most frequently  
prescribed drug in the country [Kennedy et a l ., 1985].
Considering that the number of postmenopausal women in our 
society is vast and that a considerable proportion of these women 
will seek the benefits of the oestrogen replacement therapy, it is 
an obvious, basic concern to determine the potential risk of 
breast cancer in these subjects; however, due to the magnitude of 
the problem, even a small increase in risk will actually produce 
several thousands of women dying of breast cancer. Therefore, it 
seems essential to provide a highly accurate measure of breast 
cancer risk in women receiving HRT. Unfortunately, this can only 
assessed through observational studies, but the fact that the risk 
extent (if any) is highly likely to be small makes this task very 
difficult to achieve.
Over the past fifteen years, 21 case-control studies and 10 
cohort studies have tried to weigh breast cancer risk in relation 
to HRT (for a review see [Mann, 1992]). Overall, no sign of a 
dramatic increase of risk attributable to HRT use has been 
reported; none the less, variation in the relative risks observed is 
markedly large, much greater than the expected divergence 
among different studies. This could be the outcome of several 
bias factors, including preceding differences in breast cancer risk 
or diverse therapeutic regimens used in these studies. It is worth 
mentioning that only a small proportion of women were followed 
for more than 10 years and that differences in duration of 
therapy, dosage and type of preparation used may account at
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least for some of the conflicting results obtained thus far. Some 
reports have shown a consistent and significant trend of parallel 
increase in relative breast cancer risk (up to 2.32) and duration 
of treatment (up to 20 years or more) [Brinton et a l ., 1986;
Ewertz, 1988; Bergkvist et a l ,  1989a]; other case-control studies, 
however, have failed to find such an association [La Vecchia et 
a l ,  1986; Nomura et a l ,  1986; Colditz et a l ,  1990]. The reason for 
this distinction is mostly unknown, but a likely explanation 
resides in the criteria used for selecting appropriate control 
groups; the latter, in fact, essentially fall in two general 
categories: hospitalised patients and healthy population controls. 
The finding that hospital-based studies could not find any risk 
increase, while the studies using healthy controls did find, would 
suggest that using hospitalised subjects, which are more likely to 
be prescribed elective drugs for lengthy periods, may cause an 
underestimate of the true relative risk. Concerning dose of HRT  
regimens, women receiving less than 0.625 mg/day of conjugated 
oestrogens did not show any appreciable increase of breast 
cancer risk; use of higher doses (>1.25 mg/day), however, was 
found to associate to a rise, although small (<2 .0 ), of the relative 
risk [Dupont & Page, 1991a]. Interestingly, two out of the three 
studies which found a significantly increased risk in long-term 
HRT users were European; this appears of importance in view of 
the fact that oestradiol compounds are far more commonly used 
in Europe than in North America, where conjugated oestrogens 
are widespread.
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In the attempt to better explore the likelihood that HRT use 
adversely affects breast cancer risk, a limited number of meta­
analyses have also been reported. This approach, which combines 
risk estimates from different studies into a single one, has 
however the inconvenience of being unable to deem properly the 
methodological strengths and shortcomings of individual studies. 
The meta-analysis carried out by the CDC in Atlanta concluded 
that, across all studies involved, there is evidence of a duration- 
related increase of breast cancer risk in women who used HRT, 
but that this increase is limited (10% for each 5 years treatment) 
[Steinberg et al., 1991]; Dupont and Page [Dupont & Page, 1991b], 
in another meta-analysis, found an even smaller risk increase.
Recently, attention has been drawn also on the effects of 
HRT on breast cancer mortality, rather than on incidence. Based 
on the Swedish cohort study of Bergkvist and coworkers 
[Bergkvist et al., 1989a; Bergkvist et al., 1989b], Ross and 
Bernstein [Ross &  Bernstein, 1991] have estimated that, up to 6 
years of treatment, mortality rates of breast cancer in HRT users 
and non-users are comparable, but thereafter ( 8 -1 0  years use) 
the mortality gradually increases in users, attaining an overall 
excess of 40%. This evidence may seriously alarm women against 
HRT use, but it should be kept in a more appropriate context. 
Ross and associates [Ross et a l , 1989], using a simple risk-benefit 
mortality model for HRT, indicated that over 100,000 women 
using conjugated equine oestrogens for more than 10 years, the 
net expected effect is to have 300 fewer deaths; this represents 
an approximately 17% reduction in the annual mortality from all
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causes. The authors concluded that, in terms of mortality rates, 
the overall risk-benefit equation balances strongly in favour of 
benefit.
Although the balance of the evidence, coming from the 
plethora of reports, is rather reassuring, there is a need for 
definitive studies to precisely measure the risks of contemporary 
HRT preparations, instead of chaotic data collection which merely 
serve to leave us puzzled!
1.3. Androgens and Prostate Cancer
Over the last 50 years the endocrinology of the human 
prostate has been dominated by the belief that development, 
growth and maintenance of morphology and functional activity of 
the normal adult gland are largely dependent upon testicular 
secretion of testosterone, the main circulating androgen in man. 
This concept essentially matured from the original observation 
on androgen-dependence of human prostate cancer, that is to say 
that, as often happens in science, knowledge of physiological 
processes may well be refined by learning more on pathological 
condition.
Although the use of orchidectomy as palliative measure 
against severe cases of enlarged prostates was first suggested in 
the last decade of the nineteenth century [White, 1895; Cabot, 
1896], the cornerstone of our understanding of prostatic cancer is 
represented by the work of Dr. Charles Huggins and his 
colleagues [Huggins & Hodges, 1941; Huggins et a l ., 1941]; these
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surgeons in itia lly  established the benefits of androgen 
withdrawal in patients having advanced prostatic carcinoma. 
Since then, several other endocrine manoeuvres, including 
treatment with oestrogens, progestins, antiandrogens or 
luteinizing hormone releasing hormone (LH R H ) superagonists, 
have been in turn proposed to achieve a decline of androgenic 
stimuli. Notwithstanding, after an initial objective response rate 
of 80-90%, patients experiencing these hormonal manipulations 
fail to respond any further and relapse within one or two year, 
with a median survival of six months after first recurrence 
[Whitmore, 1973; Lepor et al., 1982]. It is therefore frustrating 
to notice that prognosis for prostate cancer patients is not 
fundam entally changed from when M axim ilian  Bruch 
commented, one and half a century ago, that the disease was 
’’serious, of bad prognosis, commonly lethal and rarely cured, 
even with excision" and also observed that "the cure employed is 
palliative" [Manci & Gardner, 1986]. It is now clear that factors 
other than androgens are likely to be involved in the regulation 
of abnormal prostatic growth and that the "micromilieu" which 
hosts both epithelial and stromal prostate cells could represent a 
crucial site where steroid hormones and peptide growth factors 
may directly and reciprocally influence tumour development and 
growth.
1.3.1. C arcinogenic role of androgens
The potential role of androgens in carcinogenesis of the 
human prostate has been extensively investigated. Although
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development of prostatic cancer has been classically viewed as a 
multi-step process, involving progression from low histologic 
grade, small, latent carcinoma towards large, higher grade, 
metastasising carcinoma, recent experimental evidence suggests 
that a variety of pathogenetic pathways may exist [Bosland, 
1992].
Different rat strains have been used as fruitful model 
systems to explore the possible contribution of steroid hormones 
(especially androgens and oestrogens) to development of prostate 
tumours. A significant association between androgen 
administration and tumour formation has been revealed in Noble 
(NBL) rats [Noble, 1977], in AXC [Shain et a l , 1975], Wistar (W ) 
[Bosland et a l ., 1983] and Lobund-Wistar (L-W ) [Pollard et a l ., 
1982] rats. In the latter, for instance, incidence of spontaneous 
prostate cancer has been reported to be partly enhanced by 
testosterone (T), but highly significantly increased when rats 
were treated with T following a single-dose injection of N- 
nitrosomethylurea (N M N U ) [Pollard & Luckert, 1986]. This 
finding has been confirmed in W rats, where a single injection of 
a prostatic carcinogen, such as 3,2'-dimethyl-4-aminobiphenyl 
(DM AB), DMBA or NMNU, given after sequential treatment with 
cyproterone acetate and testosterone propionate, produced 
adenocarcinomas of the dorsolateral region (DLP) of the prostate 
gland [Bosland et a l ., 1990]. Previous reports [Pour &  Stepan, 
1987] indicated that continuous administration of testosterone to 
W-derived MRC rats, following treatment with the carcinogen 
N-nitrosobis(2-oxopropyl)amine (BOP), induced a high proportion
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of prostatic carcinoma (over 60%) in the DLP, regardless of 
whether the rats were orchiectomized or not; by contrast, using 
short-term administration of testosterone, a significantly lower 
incidence of tumours was observed. On this basis, the authors 
concluded that testosterone may play a role in the initiation of 
prostatic carcinogenesis, whereas the promotional phase is likely 
to be governed by interaction of androgen with other factors; this 
conjecture, however, appears to be rather speculative in the view 
that many variables (strain of rats, length and type of exposure 
to both carcinogen(s) and hormone, dosage and route of 
administration, etc) may critically affect the end result in these 
experimental models. In this respect, trenbolone (a synthetic 
androgen) and testosterone have been found to have only a weak 
promoting potential on Syrian hamster embryo cells or even an 
anti-transforming effect when associated with DM BA [Lasne et 
a l . ,  1990]. Furthermore, other studies have failed to see any 
prostatic carcinoma in castrated F344 rats after administration of 
DM AB during peak cell proliferation induced by dietary 
methyltestosterone [Shirai et al., 1987]. The same authors 
observed that when intact F344 rats were treated with DMAB  
and ethinyl oestradiol instead of methyltestosterone, a large 
proportion (85.7%) of animals displayed prostatic tumours, while 
this occurred in only 5.2% of rats receiving DMAB alone [Shirai et 
al.,  1988]. This evidence is also supported by the observation of 
el Abed and colleagues [el Abed et al., 1987] on Sprague-Dawley 
rat strain sensitive to DMBA treatment; the authors, measuring 
serum levels of testosterone, androstenedione, progesterone and
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its 17-hydroxy derivative, E2 and E i after D M B A  treatment, 
found that the preovulatory surge of both oestrogens on 
proestrus days was significantly increased, while no such 
stimulation was seen for any other steroid at any time of the 
oestrus cycle. Another confirmation comes from Bosland 
[Bosland, 1992] who found that chronic administration of E2 to 
rats in combination with low-dose testosterone results in 
development of low-grade prostate carcinomas which* exclusively 
originate from the dorsolateral and the anterior prostate. This 
evidence has also been strengthened by the previous finding that 
high incidence rates of prostate adenocarcinoma can be obtained 
in NBL rats treated for 18 months or longer with silastic implants 
of testosterone and oestrogens [Drago, 1984]. Most interestingly, 
Pollard and colleagues [Pollard et a l.y 1987] investigated the 
individual role of testosterone and DH T as tumour promoting 
agents in prostate cancer-susceptible L-W  rats. The authors 
found that 3 month old rats, treated for 14 months with 
subcutaneous depots of testosterone or DHT, only testosterone 
administration produced a 24% incidence of cancer, while no 
tumour formation was observed in DHT-treated rats; in the latter 
the significant reduction in weight of testes, the dramatic fall of 
plasmatic testosterone and the absence of spermatogenesis, all 
suggested an antiandrogenic effect of DHT. More recently, Leav 
et a l  [Leav et a l , 1989] compared cell proliferation and histology 
of both ventral (VP) and DLP prostate lobes in intact NBL rats 
after testosterone or DHT were administered separately or in 
combination with various oestrogens for 16 weeks. Using a
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stathmokinetic in vivo metaphase-arrest technique, the authors 
showed that combined treatment of rats with testosterone and E2 
produced florid dysplasia and markedly increased the mitotic 
index of the DLP region; by contrast, either joint administration 
of D H T and oestrogens or treatment with T or D H T alone 
respectively provoked only mild proliferative lesions in DLP or 
simply maintained the morphological integrity of both VP and 
DLP regions. It was concluded that protracted androgen- 
supported oestrogen stimulation of DLP appears to be essential to 
achieve an important increment of the overall proliferative 
activity in this prostate area.
Although the prostate gland is commonly considered as the 
prototypic androgen-dependent tissue, there is convincing 
evidence that oestrogens per se may induce division and 
differentiation of prostatic epithelial cells in many species [Leav 
et a l ., 1978; Schulze & Barrack, 1987]. In addition, presence of 
oestradiol binding sites has been detected in both rat [Swaneck et 
a L ,  1982; Mobbs & Johnson, 1986] and human [Donnelly et a l ., 
1983; Ekman et a l ., 1983] prostate. Keeping with the above 
indications, it would seem reasonable, as the present thesis will 
also suggest, to reconsider a major role for oestrogens in both 
normal and malignant prostate growth.
1 .3 .2 . A n a ly tica l ep idem iology
While several risk factors for breast cancer have been 
clearly identified and, at least partly, weighed, the same does not 
apply to cancer of the human prostate; results from either case-
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control or cohort studies are often confusing and contradictory. 
Some factors, such as urbanisation, family history and marital 
status show only a weak relationship with risk of prostate cancer, 
while several others, including socioeconomic status, sexual and 
social habits, religion, are inconsistent in this respect (for a 
review see [Boyle & Zaridze, 1993]). However, some 
epidemiological information appears to be well established.
In the first place, prostate cancer is a disease of the older 
age; its incidence significantly increases with age in a virtually 
logarithmic fashion. This is consistently true, regardless of race or 
geographical area. The finding that both prostatic carcinoma and 
benign prostatic hyperplasia (BPH) are conditions rarely present 
in men under the age of 50, has stimulated researchers to 
investigate the possible etiological relationship between the two 
diseases. In particular, the fact that nodular hyperplasia was 
frequently associated with foci of prostate cancer in autoptic 
material, eventually led Armenian and his colleagues [Armenian 
et a l ., 1974] to consider the likelihood that BPH may be a risk 
factor for the subsequent development of malignancy. However, 
there is an overall consensus that BPH does not represent a 
premalignant condition and that prostatic cancer and BPH do not 
have a common aetiology [Greenwald et a l ., 1974], being derived 
from separate regions of the prostate gland which are thought to 
be governed by a totally different hormonal milieu. BPH in fact 
develops from the periurethral glands pertaining to the upper 
segment of the urethra above the verumontanum [McNeal, 1972;
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Blacklock & Bouskill, 1977], whereas prostatic carcinoma arises in 
the peripheral zone of the "true" prostate [McNeal, 1975].
Secondly, there is a one hundred-fold variation in incidence 
of prostatic cancer throughout the world, the highest incidence
occurring in Scandinavia and North America, the lowest in Asian
countries; the age-adjusted rate in various parts of the United
States is 10 to 30 times higher than in Japan and up to 125 times
that in China [Skeet, 1976; Miller, 1988]. Additionally, a striking 
difference in both incidence and mortality rates of prostate 
cancer exists between the black and the white populations of the 
United States [Muir et a l ., 1988]. The reasons for these racial and 
geographical differences remain today largely unknown, but it is 
clear that environmental or dietary factors may be aetiologically 
important. Migration studies have indicated that mortality rates 
for prostate cancer in Japanese who become domiciled in United 
States increases to half that of the indigenous American people; 
the age standardised mortality ratio of white Americans to 
Japanese, which normally is 10:1, gradually decreases to 5:1 in 
the first generation and to 1.4:1 in the second [Haenzel &  
Kurihara, 1968]. This evidence emphasises the relevance of 
environmental as opposed to racial factors in the aetiology of 
human prostatic tumours.
Studies on the relationship between diet and risk for 
prostate cancer appear of special interest, since nutrition may 
well influence the hormone balance, especially of steroids. The 
finding that prostate cancer occurs at higher frequency in 
Western countries, where there is the greatest per capita  food
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consumption, suggests an association between calorie intake and 
cancer development [Howell, 1974]. In particular, populations at 
high risk of prostate cancer show a higher proportion of animal 
fat intake with respect to those at low risk [Armstrong &  Doll, 
1975]; furthermore, a positive association between relative risk 
and fat consumption has been observed in different ethnic 
groups of Hawaii, having different incidence of prostate cancer 
[Heshmat et a l ., 1985]. In a prospective study on Japanese men, 
a significant increase of age standardised death rate of prostatic 
cancer (from 4.9 up to 11.8) was found in subjects at diet rich in 
milk, meat and eggs, as opposed to a low intake of green and 
yellow vegetables [Hirayama, 1979]; the author suggested that 
vitamin A, present in the vegetables, may confer some degree of 
protection from development of prostate cancer. It  is worth 
mentioning here that incidence of prostate cancer in Japan is 
today markedly increasing, approaching that of United States and 
Western Europe; this has been ascribed to the Westernization of 
Japanese dietary patterns. In a recent case controlled study on 
one hundred Japanese men with prostate cancer, Oishi et al. 
[O is h i et a/., 1988] have revealed that low daily intake of 
betacarotene and vitamin A is associated with an increased risk 
(respectively, 2.13 and 1.94); the same is true for frequent intake 
of bread (2.4 relative risk), which is considered typical of 
Westernized diets.
Although it has been reported that diets relatively high in 
meat and fat intake produce an increase of plasma androgens, it 
is still unclear whether or not different dietary habits may
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directly affect the hormonal micromilieu of steroid target tissues, 
such as prostate.
1.3 .3 . C ircu lating  androgens
I f  the potential role of plasma oestrogens in breast cancer 
development is still unclear, an even greater uncertainty applies 
to circulating androgens and carcinoma of the prostate.
As for oestrogens, the free fraction of plasmatic androgens 
represents only a minor proportion (less than 3%) of the total, 
while a 30 to 40% is bound to albumin and the remaining to SHBG 
[Vermeulen et a l ., 1971]; the latter has a much higher affinity for 
testosterone than for oestradiol, but only a limited capacity of 
steroid binding [Vermeulen & Verdonck, 1968].
Measurements of serum concentration of testosterone have 
failed to demonstrate convincing abnormalities in prostate cancer 
patients [British Prostate Study Group, 1979; Ghanadian, 1982]. 
This riddle is yet complicated by the fact that plasmatic 
testosterone is mostly protein-bound [Anderson, 1974] and that 
its concentration is age-dependent [Vermeulen et al., 1972]; 
therefore, studies comparing prostate cancer patients and 
healthy subjects should combine measurement of the free 
fraction of serum testosterone and careful age matching. 
However, there is suggestion that age-related variations in both 
free and protein-bound plasma testosterone may well be 
variable in different groups of subjects, in such a way that 
parallel studies, even after proper age matching, could lead to 
largely conflicting data [Levell et a l ,  1985].
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Various studies have been focusing on plasma 
concentrations of sex steroids, especially testosterone, comparing 
healthy subjects with either BPH or prostate cancer patients. 
Rannikko and Adlercreutz [Rannikko & Adlercreutz, 1983] found 
that serum levels of free E2 are lower in men having prostatic 
carcinoma and in young controls with respect to BPH patients, 
while the mean free T was significantly higher in controls than in 
the other two groups. The authors suggested that the observed 
age-dependent increase of plasma E2 and the resulting higher E2 
to free testosterone ratio in men with BPH may play a protective 
role against prostate cancer. On the other hand, Hulka et al. 
[H u lka  et a l ., 1987] interpreted the modest depression of serum 
testosterone and E2 found in prostate cancer patients as a result 
of the malignant process rather than a favouring condition. The 
apparent paradox of men with prostatic carcinoma having 
relatively low rather than high plasma testosterone concentration 
has been also supported using isotope dilution techniques [Meikle 
et a l ., 1987]; measurements of plasma androgens, oestrogens, 
SHBG, follicle-stimulating hormone (FSH) and luteinising hormone 
(LH) showed no significant differences between prostate cancer 
patients, their brothers and unrelated controls.
As mentioned above, it is known that black Americans 
have the highest rate of prostate cancer throughout the world 
[Muir et a l ., 1988]. The finding that the 2:1 black-to-white ratio 
in prostate cancer incidence becomes evident around the age 45, 
namely at the earliest appearance of prostatic carcinoma, 
apparently implies that factors responsible for this difference
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may act early in life. To test this presumption, Ross and 
colleagues [Ross et a l ., 1986] embarked on a study of white and 
black college students in Los Angeles, looking at both total and 
free serum testosterone in matched subjects. The authors found 
that adjusted levels of the total and the free fraction of plasma 
testosterone were higher (15% and 13%, respectively) in blacks 
than in whites. However, the percent of free testosterone
increased only by 0.08% (from 2.50% to 2.58%) in the black 
population; in addition, when age was included in the 
multivariate analysis, the mean serum testosterone was virtually 
the same in the two groups. It was concluded that the 15% 
increase of circulating testosterone found in the black population 
could account for the 2:1  ratio in prostate cancer incidence 
between blacks and whites, provided that this increase persists 
with ageing. However, several arguments speak against this
implication. In the first place, there is evidence that the age- 
dependent rise of serum testosterone in prostate cancer patients 
may be due to an increase of the protein-bound component 
[Zum off et al., 1982]. Secondly, more recent studies have revealed 
no significant difference in serum testosterone concentrations 
between young adult Japanese (who represent a low-risk
population) and young adult American whites and blacks [Ross et 
a l . ,  1992]. Similarly, a population-based nested case-control
study on prediagnostic serum levels of both androgens and 
oestrogens, showed no statistically significant difference in 
hormone concentration of subjects who subsequently developed
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prostate cancer with respect to healthy controls, matched for age 
and race [Hsing & Comstock, 1993].
In conclusion, no definitive evidence for a principal role of 
circulating androgens in prostate cancer has been so far 
provided. In this context, it should be pointed out that plasmatic 
levels of androgens may not reflect those of biologically active 
androgen metabolites within prostatic tissues; more, the
contribution of androgens to oestrogen action or their role as 
oestrogen precursors in both normal or diseased human prostate 
gland should also be carefully considered.
1 .3 .4 . P rosta tic  androgens
It  is generally agreed that androgenic stimulation of 
prostate target cells is essentially exerted by DHT; the latter 
originates from the conversion of testosterone through a
5 a-reductase enzyme activity. Although one could expect that
the intracellular concentration of DHT may primarily depend on 
blood supply of circulating testosterone, there is a persuasive 
argument that plasma androgens do not substantially determine 
the intraprostatic steroid patterns; in fact, no correlation has 
been found between plasma and tissue levels of any particular 
steroid, neither in malignant nor in benign human prostate [Klein 
et a l ., 1991]. This evidence emphasises the pivotal role of local 
factors in regulation of intratissue levels of androgens,
particularly of DHT; they include activity of key enzyme systems 
and content of specific, high-affinity sites of androgen binding.
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Formation, accumulation and deactivation of intraprostatic 
D H T are mainly governed by the balance between the 5 a -  
reductase enzyme, which presides over the conversion of 
testosterone to D H T, and the 3 a / 3 p - h y d r o x y s t e r o i d  
dehydrogenase (3a /3p -H S D ), which directs the generation of 
3a/3p-androstanediols (3a/3p-diols). In the regular prostate the 
mean levels of testosterone, DHT and 3a-diol are reported to be 
0.2, 1.6 and 1.7 ng/gr of tissue, respectively.
Early studies, aiming to ascertain differences of 
intraprostatic androgens between normal and hyperplastic 
prostate tissues, suggested that androgen metabolic profiles are 
not dissimilar in the two groups [Morfin et a l ., 1978]. However, 
significantly increased levels of DHT in benign with respect to 
normal specimens were initially reported [Siiteri &  Wilson, 1970]; 
this finding was subsequently confirmed by others [Geller et a l ., 
1976; Hammond, 1978]. In addition, formation of 3 a /3p -d io ls  
appeared to be remarkably reduced in prostatic hyperplasia, the 
ratio of DHT to 3a /3p -d io ls  being significantly increased 
compared to normal tissues [Bruchovsky & Lieskovsky, 1979; 
K rieg  et a l ., 1979]; this evidence substantiated the hypothesis 
that the higher amounts of DHT found in BPH may be a 
consequence not only of an altered 5a-reductase activity, but 
also of an increase in DHT reconversion from 3a/3p~diols. This, 
however, has not been confirmed by others, who found that the 
concentration of 3a-diol is not reduced in BPH tissues [Bartsch et 
a l 1990]. A major concern which has often hampered BPH 
studies is the difficulty to obtain normal prostatic samples for
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comparison with hyperplastic tissues. Walsh and colleagues 
[Walsh et al.y 1983] indicated that DHT levels in human BPH are 
not supranormal provided that specimens are obtained by 
surgery; the authors observed that DH T concentration in normal 
prostatic tissue removed at autopsy, as done in the previous 
studies, is five times less than that present in normal prostates 
obtained from patients who underwent surgery for bladder 
cancer. Therefore, it was concluded that use of autoptic material 
as a source of regular prostate specimens could seriously abridge 
the accuracy of androgen estimate and therefore entangle the 
value of this observation. This, however, does not entirely 
contradict the "DHT" theory or the more recent "oestrogen- 
androgen imbalance" theory, which still maintain convincing 
grounds to be further explored.
Concerning prostatic carcinoma, comparisons of steroid 
concentrations in noncancerous prostates did not show any 
systematic cancer-associated changes [Klein et a l .y 1991]. 
Although a significant decrease of 5a-reductase activity has been 
previously reported, leading, as expected, to significantly 
increased tissue levels of testosterone, DHT levels appeared to be 
not reduced in the malignant prostate [Bartsch et a l 1990; Klein 
et a l.y 1991]. This evidence induced Geller and coworkers [Geller 
et al., 1984] to postulate that, in spite of a lower 5a-reductase, 
DH T accumulation may still occur in prostate cancer tissues 
mainly because of nuclear AR binding; the authors found that 
DHT tissue content is related to both degree of differentiation of 
the tumour tissue and duration of patients' response to endocrine
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therapy, thus representing an useful pointer of the androgen- 
responsiveness of a given prostatic carcinoma. It would imply 
that quantitatively unchanged and functionally intact AR are 
present in prostate cancer tissues, but this has been not 
unequivocally demonstrated. Some studies have failed to find 
such an association between histology and AR content of prostate 
cancer [Trachtenberg et a l., 1982; van Aubel et a l ., 1985], even 
though nuclear AR have been proposed as a better prognostic 
indicator [Ghanadian et a l ., 1981]. Several methodological and 
biological elements may critically influence the results of AR 
assay in prostatic tissues and therefore jeopardise any clear 
interpretation of the existing data. However, since intraprostatic 
DHT concentration is far exceeding (10 to 20 times) that of AR, it 
seems unlikely that nuclear binding alone may account for D H T  
accumulation in prostate tumours. In this respect, other local 
non-steroidal components, including peptide growth factors and 
stromal contribution, could act in combination with enzymatic 
activities and protein binding to generate the actual D H T amount 
within individual prostates.
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2. Steroid Function in Target Tissues and Cells
2.1 . The Steroid  R eceptor Su perfam ily: S tru ctu re  and
F u n c tio n
Our knowledge on molecular mechanisms of steroid 
hormone action has been enormously expanding in the last 2 0  
years, especially since molecular biology techniques became 
available. This led to the description of a wide family of 
receptors, called the steroid receptor superfamily, where steroid 
receptor proteins represent only a moiety of a much larger group 
of distinct molecules. Therefore, it would seem to be more 
appropriate to term them nuclear receptor fa m i ly , to indicate 
that they primarily act via nuclear events. This family in fact 
includes also the receptors for thyroid hormone T 3 , vitamin D 3 , 
retinoic acid and oncogenes, such as v - e r b  A. The main 
implications concerning structure and function of this class of 
regulatory proteins have been recently surveyed by two 
exemplary reviews [O’Malley, 1990; King, 1992].
2.1.1. The domain structure of receptors
As full cDNAs for all major steroid receptors have been 
cloned and sequenced, it has been possible to precisely define 
their structure. Based on the cDNA data, computer comparisons 
of amino acid sequences showed that several receptor proteins 
share regions of close homology, while other regions reveal
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striking differences. On the other hand, mutational analysis, 
which tests function of genetically altered receptor proteins, 
allowed separate functions to be assigned to specific regions 
(domains) of individual molecules. To date, four major domains 
(steroid binding, DNA binding, nuclear localisation and 
transactivation domains) are commonly identified, having some 
degree of functional overlap; a schematic presentation of the 
receptor domain structure is reported in Figure 1.
Steroid binding domain
This fairly large domain is located at the C terminus of the
receptor molecule. Although some single amino acid changes 
may produce a variable loss of binding [Carson-Jurica et al., 1990; 
Danielson, 1991], the highly conserved structure of this region
suggests that it must remain intact for high affinity ligand 
binding. It is known that androgen, progestin, glucocorticoid and 
mineralcorticoid receptors have a closer ligand specificity than 
the oestrogen receptors (ER); this is reflected in the higher degree 
of homology present within the former group as opposed to that 
existing between the whole group and the ER. It is singular that 
so far the precise role of ligand in the overall steroid receptor 
pathway is still unclear. Earlier studies have indicated specific 
structural-based properties of ligand which seem to be required
for optimal binding and biological activity [King & Mainwaring, 
1974]. However, there is evidence to support the concept that the 
receptor protein contains a pocket which is suited to
accommodate the ligand; it is thought that steroid
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F igu re 1. The nuclear receptor superfamily. Schematic representation 
of the domain structure (A/B to E/F) of steroid receptors and other 
related proteins. The boxed numbers indicate the percent of homology in 
both the DNA-binding (C) and the ligand-binding (E/F) domains using the 
human glucocorticoid receptor as reference point. The numbers to the 
left of each bar represent the number of amino acid residues in that 
receptor. Linear representation (top to bottom) of human receptors for 
mineralcorticoid (MR), progesterone (PgR), androgen (AR), glucocorticoid 
(GR), oestrogen (ER), thyroid hormone (TR), retinoic acid (RAR), vitamin 
D (VDR), oestrogen-related receptors 1 and 2 (ERR1 and ERR2) and the 
orphan receptor chicken pvalbumin upstream promoter (COUP).
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induces conformational changes in the receptor which lead to its 
dimerization, the latter process being presumed to be essential 
for subsequent nuclear processing of steroid-receptor complex. 
Other mechanisms however may also contribute to steroid- 
receptor interaction dynamics, including dissociation of heat 
shock proteins [Catelli et a l ., 1990] and protein phosphorylation 
[Carson-Jurica et a l ., 1990].
D N A  binding domain
This important region contains particular amino acid sequences 
which are primarily responsible for specific recognition of the 
cognate steroid response elements (SRE) in the genomic DNA  
adjacent to target genes. Although the structure of this domain 
manifests close homologies, being highly conserved (40 to 90%) 
among different receptor classes, subtle differences in amino acid 
sequences determine the gene specificity of a given receptor 
protein. Of special interest are the so called "zinc fingers", which 
consist of stretches of about 25 amino acids each containing four 
cysteine residues disposed in such a way that they form a loop or 
finger to hold one molecule of zinc [Evans, 1988; Beato, 1989]; 
steroid receptors have two such zinc fingers in the DNA binding 
domain. The first (N-terminal) finger is thought to contain 
primary information for specific nucleotide binding in the major 
groove of the DNA helix; the second may stabilise the receptor- 
DNA complex by ionic interactions with phosphate groups in the 
DNA backbone [O'Malley, 1990; Parker & Bakker, 1991]. The 
relevance of this region to the specificity of DNA binding has
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been dram atically  demonstrated by dom ain-swapping  
experiments, where the interchange of DNA binding domains of 
the glucocorticoid receptors (GR) and ER produced stimulation of 
glucocorticoid sensitive genes by oestradiol and viceversa [Green 
& Chambon, 1991].
Nuclear localisation domains
Two additional sets of amino acids C-terminal to the DNA binding 
domain have been indicated as site of nuclear localisation signals, 
since mutations of these sequences may vary the subcellular 
localization of the receptor [Guichon et al., 1989]. Two such 
domains have been identified in the GR, while the ER contains 
only one. This region may be relevant to the intracellular 
distribution of the unliganded receptor. In fact, it has been 
suggested that presence of cytoplasmic GR may be due to the 
second localization domain, while other steroid receptors, having 
one domain only, are mostly nuclear [Picard et al., 1990].
Transactivation domains
Molecular data support the existence of at least two different 
regions, located at both sides of the DNA binding domain, which 
may markedly influence the overall competence of the receptor 
mechanism [Fawell et al., 1990; Tasset et al., 1990]. These regions 
have been defined as transactivation domains, implying that a 
target gene is regulated by a receptor protein which represents a 
product of a different gene. Although transactivation domain(s)
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appear necessary for transcriptional activation, the latter process 
seems to require the combination of all the receptor 
compartments (DNA binding, ligand binding, dimerization, etc.).
2.1 .2 . The steroid response elem ents (SR Es)
Structure and function of target genes for steroid hormones 
have been investigated as appropriate methodologies became 
available. These genes contain short (about 15 base pairs) 
nucleotide sequences, generally located within their 5? flanking 
region upstream to the start site of transcription, which are 
called steroid (SRE) or hormone (HRE) response elements. The 
SRE consists of two half-sites of about 6 nucleotides having a 
dyad axis of symmetry (inverted repeats or palindromic 
sequences) around a few central base pairs of random 
composition [O'Malley & Tsai, 1992]. Androgen, progestin, 
glucocorticoid and mineralcorticoid receptors share similar SREs, 
while the oestrogen response element (ERE) differs from the 
former by a two-base-pair change in the middle of each half-site. 
Steroid receptors bind to the respective SRE as dimers, with an 
affinity (in the nanomolar order) adequate to influence 
transcription [Tsai et al., 1988]. Once bound, the receptor dimer 
may associate with another dimer (or transcription factor) at an 
adjacent SRE site to establish a more stable complex, having a 
much higher binding affinity (dissociation constant (Kd) 
approximately 10_11M) [Tsai et al., 1989].
The most distinctive point of SRE is that they commonly 
belong to a category of genetic cis elements called enhancers or,
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in only limited cases, silencers, depending on whether they 
stimulate or inhibit transcription. The SREs are separated from 
the transcription start site by a DNA segment which may be 
rather long; it is thought that this DNA portion can form loops so 
that SRE and RNA initiation sites become juxtaposed.
The finding that receptor proteins can bind to any DNA led 
to postulate a "search and find" model, where the receptor, 
thanks to weak associations with non-specific sequences, glides 
along the DNA strand until it arrives at the specific SRE site for 
high affin ity  binding [Yamamoto, 1985]. A lternative ly , 
unliganded receptors may be at or near the specific DNA site at 
all times, ready to bind the ligand and form an active complex, as 
it happens with the T3 receptor [Damm et a l ., 1989].
Recently, much attention has also been drawn on the 
interaction of receptor with other nuclear proteins. It has been 
observed that the difficulty encountered in the past to produce 
specific transcriptional activation by addition of ligand to a cell- 
free system was mainly due to the lack of additional protein 
factors, distinct from receptor and RNA polymerase [Kalff et al.,
1990]. An example is given by the regulation of the collagenase 
gene by glucocorticoids. Binding of a protein complex, named 
A P I, to an enhancer sequence similar to, but distinct from, HRE 
appears to be the principal mechanism of activating collagenase 
gene trasncription. The API binds to DNA as a dimer, consisting 
of either two oncogenes, j u n  and f o s , or two subunits of j u n  
[Gutman & Wasylyk, 1991]. It is possible that monomers of both 
GR and j u n  associate, giving rise to inactive heterodimers.
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Therefore, cross-talk between A P I and nuclear receptor 
dynamics by heterodimer formation may depict unsuspected 
ways by which different signalling pathways can influence each 
other.
2.1 .3 . The orphan receptors
One of the most intriguing observation on the steroid 
receptor superfamily of related genes is represented by its 
unexpected large size and by the disparate nature of its 
members. After cDNAs for the major steroid receptors have been 
cloned and sequenced, screening of DNA libraries by cross- 
hybridisation using cDNA probes revealed a large number of 
receptoroids, not corresponding to any known receptor molecule. 
These proteins have been termed orphan receptors as they still 
wait for both ligand and function. The existence of two such 
molecules was firstly reported by Evans and associates [Giguere 
et a l ., 1988] who termed them ERR (oestrogen-receptor related) I 
and II. Since then, a number of orphan receptor sequences have 
been published, none of them having a recognised function. It is 
not compulsory that all these putative receptors have a ligand 
and exert a precise functional role, but this is likely for at least 
some of them since they are expressed in cells as full-processed 
cytoplasmic messenger RNAs [O'Malley, 1990]. An interesting 
member of this singular family has been recently discovered by 
Wang et al. [Wang et a l 1987]. This factor promotes initiation of 
transcription of the chicken ovalbumin gene by RNA polymerase 
and has therefore been called COUP-TF (chicken ovalbumin
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upstream promoter-transcription factor). It contains surprising 
homologies with other members of the nuclear receptor 
superfamily in both DNA and ligand binding domains. Probably, 
the most relevant feature of COUP-TF is that for the first time a 
promoter regulatory protein is recognised as a legitimate 
component of the receptor superfamily, where only enhancer 
regulatory factors have been thus far included.
It is exciting to speculate, as insinuated by Bert O’Malley,
that orphan receptors may have endogenous ligands and that
these ligands may act as indigenous hormones to the specific 
target cells. I f  this is true, a new scenario will open up, where 
presence of intracrine regulatory systems may have a crucial role 
in the functional control of the cell.
2.2. Sites of Steroid Binding
In the early sixties, the synthesis of radiolabeled 
oestrogens allowed to better investigate the mechanism of 
hormone action at target tissue level. In particular, Glascock and 
Hoekstra [Glascock & Hoekstra, 1959] documented a selective 
accumulation of tritiated hexoestrol in reproductive organs of 
immature goats and sheep. Further, Folca et al. [Folca et a l ,
1961], after administration of labeled hexoestrol to women 
having advanced breast cancer, found that patients whose 
tumours showed a remarkable uptake of radioactive oestrogen 
had a favourable response to subsequent adrenalectomy. The
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availability of labelled oestradiol having high specific activity 
enabled Jensen and Jacobson to demonstrate that radioactivity 
concentrated almost exclusively in tissues which were commonly 
thought to be targets for oestrogen action [Jensen & Jacobson,
1962]. Subsequently, Mobbs [Mobbs, 1966] showed that the 
uptake of tritiated oestradiol by DMBA-induced rat mammary 
cancer tissues is much higher in oestrogen-dependent tumours 
than in those having an independent growth. Similarly, in vitro 
binding of labeled oestradiol was observed only in breast tumour 
specimens from either rats [Terenius, 1968] or patients [Jensen et 
a l . y 1967] who responded to endocrine treatment. A ll these
findings, albeit indirect, indicated that target tissues would 
contain specific components which selectively bind oestrogens.
The first direct evidence for ER in target tissues has been 
provided by Toft and Gorski [Toft & Gorski, 1966] who isolated 
and characterised ER proteins from the rat uterus. The vast
majority of earlier reports on ER were based on the sucrose
density gradients studies. This procedure permits separation of 
different receptor forms by centrifugation through concentration 
gradients of a sucrose solution, the sedimentation constant (i.e. 
the rate of sedimentation per unit gravitational field) of a 
receptor protein being expressed in Svedberg (S) units. Using 
this approach, two major ER forms have been identified, having 
sedimentation constants of about 4S and 8 S, depending on the 
ionic strength of extraction and fractionation buffer. The 8 S form 
was usually isolated at low ionic strength, while the 4S form may 
dissociate from the 8 S form using ionic strength of buffer
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approaching 0 .4M  KC1 [W itt l if f  et al., 1972]. Current 
understanding is that the 4S "salt-extracted" receptor represents 
activated, DNA-bound receptor and that the 8 S form coincides in 
the inactive receptor-heat shock protein complex (see later).
The first demonstration of high affinity binding proteins for 
androgens dates back to 1969, when Fang et al. [Fang et a l ., 1969] 
revealed the presence of a cytoplasmic component (named a -  
protein) of the rat ventral prostate, having a sedimentation 
coefficient of 3.5S, which was able to bind D H T following 
administration of labeled testosterone to animals. Concurrently, 
Mainwaring [Mainwaring, 1969] and Unhjem et al. [Unhjem et al., 
1969] documented the presence of another cytoplasmic protein, 
binding specifically DHT, with a 8 S coefficient. Both proteins have 
been thought to represent different forms of the same receptor 
molecule, the 8 S component being presumably the result of 
aggregation of smaller subunits [King & Mainwaring, 1974].
2.2 .1 . H eterogeneity of steroid binding sites
It is well recognised that steroid hormones bind to sites in 
the target cells other than the specific receptor. This binding has 
been generally ascribed to contamination by serum albumin or 
a-fetoprotein  [M ichel et al., 1974]. However, presence of 
cytoplasmic low-affinity binding sites for oestrogens, which 
cannot be accounted for contamination, was originally reported 
by Clark and associates in the rat uterus [Eriksson et al., 1978; 
Markaverich & Clark, 1979]. The authors in fact identify type I 
and I I  sites of oestradiol binding, the former being characterised
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by high affinity (Kd < 0.5-1.0 nM) and low capacity (1 
pmol/uterus) of hormone binding, the latter by greater (four 
fold) concentration values and by an affinity for oestradiol which 
is about 40 times lower (Kd > 20 nM) than that of type I sites. It 
has been observed that type I I  sites are responsible for up to 
50% of the oestrogen bound in the rat uterus [Peck et al., 1973]. 
The precise role for these secondary sites is still obscure. They 
may serve as storage proteins to accumulate biologically 
available steroid in target cells. A second class of low-affinity 
sites of oestrogen binding has also been described in the nuclei of 
uterine cells. These nuclear type I I  sites have a much lower 
affinity (Kd form 10-30 nM) and a greater capacity of oestradiol 
binding. Markaverich and Clark [Markaverich & Clark, 1979] 
observe that high levels of type I I  sites are maintained by a 
single injection of oestradiol for as long as 72 h, while type I sites 
rapidly decline to basal levels by 24 h. The absence of nuclear 
type I I  sites from organs such as pituitary and hypothalamus, 
which do not grow in response to oestrogens, suggests that these 
sites may be involved in growth stimulation of target tissues by 
oestrogens [Kelner & Peck, 1981].
Multiple binding sites for other steroid hormones have also 
been reported, suggesting that they represent a general feature 
of steroid receptor proteins. Our laboratories have reported the 
presence of both type I and II  androgen binding sites in both 
benign hyperplasia and cancer of the human prostate 
[Castagnetta et al., 1992a]. This evidence confirms previous data
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obtained either in vivo [Pertschuk et a l ., 1985] or in vit ro  
[Turcotte et a l ., 1988].
There is sufficient consensus that type I sites are 
commonly identified at Kd values in the range of 10' 11 to 10_1°M  
[Hawkins et al., 1980; W ittliff, 1984], while type I I  receptors are 
generally confined to Kd in the nanomolar order. However, 
several receptor studies, based on radioligand binding assay, use 
higher ligand concentration ranges and reveal Kd values which 
may be reasonably interpreted as defining type I I  sites only. In 
this respect, the value of type I and II  sites of oestrogen binding 
is not merely conceptual, but it holds a functional significance. In 
fact, numerous studies have indicated that only type I ER 
correlate to both prognosis and response to endocrine therapy of 
human breast and endometrial cancer patients [Barnes et al., 
1979; Leake et a l , 1981; W ittliff, 1984; Castagnetta et al., 1987a; 
C astagnetta  et a l ., 1989b]. This is especially true when the 
assessment of a functional receptor status is addressed by 
measuring ER and progesterone receptors (PgR) in both cytosols 
and nuclei [Thorsen, 1979; Castagnetta et a l ., 1983; Leake &  
Habib, 1987; Castagnetta et al., 1987b].
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2.3. M odels for Steroid Action
Historically, most of the current knowledge on steroid 
hormone action derived from studies carried out in the late 
1950s at the laboratories of Gerald Mueller and Elwood Jensen
[M u e lle r et a l , 1958], suggesting that oestrogens may complex 
with an intracellular protein and therefore play a role in 
regulating nuclear function of a target cell by interacting directly 
with its genetic apparatus. In the subsequent years much effort 
has been made to elucidate the mechanism of action of steroids.
2.3.1. The old model
The classic "two-step" model originated from the early 
work of Gorski [Gorski et a l ., 1968] and Jensen [Jensen et a l ., 
1968]. It states that the native unliganded receptor is located in 
the cytosol and that, after binding to steroid, the hormone- 
receptor complex is translocated to the nucleus to bring about a 
nuclear response. This model was first developed for oestrogens, 
but therefore extended to other steroid hormones [Liao & Fang, 
1969; O'Malley et a l , 1970; Rousseau et a l , 1973]. It was mainly 
based on the observation that homogenates of oestrogen target
tissues (such as uterus, pituitary, oviduct, etc.) from immature or 
ovariectomised animals contained unoccupied ER mostly in the 
cytosolic fraction, while very little unliganded receptor was
found in the nucleus [Shyamala & Gorski, 1969]. In addition,
after administration of labelled oestrogen, the majority of 
radioactivity was found in the nucleus as hormone-receptor
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complex, with a corresponding loss of cytoplasmic receptor 
[Gorski et al., 1968; Jensen et al., 1968].
The phenomenon by which the empty receptor acquires a 
high affinity for nuclear component as a consequence of steroid 
binding has been named activat ion.  In the case of ER, this process 
has been shown to be accompanied, in the rat uterus, by an 
increase in the sedimentation constant from 4S to 5S [Notides &  
Nielsen, 1974]. The activation of the unoccupied receptor is 
thought to represent a temperature-dependent phenomenon,
being obtained in vitro by incubation of target cell cytosols with
hormones at 20-37 °C; use of low temperatures (0-4 °C) gives rise 
to non-activated steroid-receptor complexes, which do not bind 
nuclear elements. The temperature-dependent step has been also 
referred to as t r a n s f o r m a t i o n , indicating that this process 
converts the receptor into a transformed form having higher 
affinity for polyanions like DNA, RNA and proteins [Yamamoto &  
Alberts, 1972]. Gschwendt and Kittstein [Gschwendt & Kittstein, 
1980] proposed to restrict the term a c t i v a t i o n  to the rise in 
nuclear affinity of receptor and to use the term t ran s fo rm a t io n  to 
illustrate the change in the sedimentation coefficient. Contrary to 
oestrogens, activation of other steroid hormone-receptor 
complexes does not involve an increase of the sedimentation 
constant. In the case of androgens, activation of DHT-receptor
complex is followed by a decrease of the sedimentation rate from
3.8S to 3.0S [Liao, 1975]. The same is true for PgR complex of 
both hamster [Chen & Leavitt, 1979] and rabbit [Saffran et a l ,  
1976].
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2 .3 .2 . The equilibrium  m odel
The terms cytosol and cytoplasm have been very often 
mistakenly confused. The cytosol (or soluble) fraction commonly 
derives from a rough cellular disruption (like homogenisation) 
and consists of all soluble components of sheared cells, including 
some nucleoplasmic proteins and various components loosely 
attached to insoluble structures. Sheridan and colleagues 
[S heridan  et a l ., 1979], in a very elegant experiment series, 
suggested that, on the basis of a comparison between 
autoradiographic and biochemical dilution studies, the 
unoccupied steroid receptors are distributed in equilibrium  
between nuclear and cytoplasmic compartments. The authors 
showed that use of aqueous or non-aqueous methods to measure 
both soluble and nuclear receptor dramatically changed the 
results of assay; in fact, the non-aqueous procedure mainly 
preserved the receptor in the nuclear pellet, while using the 
aqueous approach receptor was recovered mostly in the soluble 
fraction [Sheridan et a l ., 1981]. This was true either for ER or PgR. 
On this basis, Martin and Sheridan [Martin & Sheridan, 1982] 
proposed that, in intact target cells, the unoccupied steroid 
receptors are partitioned in equilibrium between nucleus and 
cytoplasm according to the free water content of each cell 
compartment. Further to this model, several concurrent reports 
contributed to severely challenge the old translocation model. 
Siiteri et al. [Siiteri et a l ., 1973] found that, in the immature rat 
uterus, both the 4S and 5S ER forms could be detected at all
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times in the nucleus after two hours exposure to oestrogen; the 
authors suggested that the activation process takes place in the 
nuclear compartment and that it may well require the presence 
of DNA to occur. Zava and McGuire [Zava & McGuire, 1977] 
proposed that, in MCF7 human mammary cancer cells, the 
unoccupied ER is located in the nucleus; similarly, McCormack 
and Glasser [McCormack & Glasser, 1980] observed that in 
dispersed uterine cells in culture the amount of empty receptor 
recovered from the nuclear fraction was much higher than 
expected. Finally, thyroxin and 1,25-dihydroxy vitamin D 
receptors were found to be nuclear proteins, irrespective of the 
presence of ligand [Oppenheimer et a l , 1976; Walters et a l ., 
1980].
2.3 .3 . The plasm a m em brane m odel
Originally, Pietras and Szego [Pietras & Szego, 1979] showed 
that homogenisation of uterine cells in hypotonic buffers 
produced evidence of cytosol ER, while use of buffers containing 
0.25M  sucrose led to the recovery of unoccupied receptors 
mostly from the particulate fraction. On this basis, the authors 
postulated that oestrogen is captured by plasma membrane- 
associated receptors and that the oestrogen-receptor complex is 
therefore internalised by pinocytosis and transferred to the 
nucleus via lysosomes. However, some experimental work has 
indicated that, in a physiological state, steroid uptake by target 
cells is a nonsaturable process, not limiting to the specific 
receptor binding [Muller & Wotiz, 1979], This would imply that
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the cellular transport of steroid is not a primary factor, 
regardless of the subcellular localization of receptor. In this 
respect, the affinity of steroid for the lipidic component of 
plasma-membrane may be relevant only to the intracellular 
diffusion and transit of hormone.
2.3.4. The new model
Despite the above disparate observations, the concept of 
the old model was in force until mid 1980s, when two separate 
lines of investigation provided convincing evidence that steroid 
receptor is a nuclear protein at all time whether or not the ligand 
is bound.
Welshon and associates [Welshons et a l ., 1984] applied a 
cell enucleation technique to examine the intracellu lar 
localization of ER. Using centrifugation-cytochalasin B-induced 
enucleation the authors separated cytoplasm from the nucleus of 
the GH 3 cells, a clonal cell line originated from a rat pituitary 
tum our [Tash jian  et a l ., 1970]. The latter, follow ing
homogenisation procedures, has been found to contain cytosolic
ER, which incur nuclear translocation after exposure to oestrogen 
[Haug et al., 1978]. Enucleation technique gives rise to cytoplasm- 
derived element, called cy top last ,  and to the remainder of the 
cell, named nucleoplast , which contains the nucleus and a rim of 
cytoplasm. Both structures are surrounded by a plasma 
membrane and can be reunited to yield a viable cell [Veomett et 
al . ,  1974]. The cytoplast fraction of the enucleated GH3 cells
consistently exhibited low levels of unoccupied ER, whilst the
INTRODUCTION
majority of receptor was recovered from the nucleoplast fraction, 
namely from a combination of cells lacking variable amount of 
cytoplasm and a few whole cells. In particular, the receptor 
content of cytoplasts represented approximately 1 0 % of that 
found in the whole cells plus nucleoplast fraction.
The subcellular localization of steroid receptors has also 
been investigated using immunocytochemistry. Early studies 
documented the presence of unoccupied ER in the cytosol fraction 
of human breast tumour tissues [Greene & Jensen, 1982; Raam et 
a l ., 1982]. Originally, Greene and colleagues reported on a new 
set of monoclonal antibodies raised against the ER purified from 
the MCF7 human mammary cancer cell line [Greene, 1984]. The 
antibody specificity ranged from recognition of the human ER 
only, to cross-reactivity with a variety of both mammalian and 
avian oestrogen receptors. Using these antibodies, a positive 
staining was found exclusively in nuclei of hormone-responsive 
tissues, including human breast tumours and uterus, and rabbit 
uterus [King & Greene, 1984]. The apparent divergence between 
this evidence and the aforementioned immunocytochemical 
studies has been ascribed to the use of polyclonal antibodies, or 
to unsuitable fixation and sectioning techniques in previous 
reports. Other studies have demonstrated the presence of 
unoccupied PgR in the nucleus of both mammalian tissues 
[Perrot-Applanat et al., 1985] and in the chick oviduct [Gasc et al., 
1984]. However, worth mentioning, Gasc and colleagues observed 
that while two polyclonal antibodies (IgG-G3 and IgG-RB) showed 
nuclear localization of PgR, a monoclonal antibody (BF4) reacted
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with a component of the 8 S cytosolic receptor moiety, which 
seemed to be either cytoplasmic or both cytoplasmic and nuclear 
[Gasc et al., 1984]. Immunocytochemical studies on GR have 
revealed either cytoplasmic or cytoplasmic plus nuclear 
immunoreactivity in target cells [Govindan, 1980; Papamichail et 
a l ., 1981; Antakly & Eisen, 1984]. Androgen receptors (AR) have 
been also localised in nuclei of both rat and human prostate using 
monoclonal antibodies [Chang et a l ., 1989]; however, Demura and 
associates [Demura et al., 1988] detected immunocytochemically 
AR in both cytoplasm and nucleus of benign and malignant 
human prostate, although the receptor specificity of the 
monoclonal antibody used was not reported.
Contrary to the plasma-membrane model, neither 
enucleation nor immunocytochemical studies have confirmed 
presence of oestrogen binding on the surface of target cells.
On the basis of the bulk of data coming from both 
enucleation of intact cells and immunocytochemistry of ER, a new 
model for steroid hormone action was designed [Gorski et al., 
1984; Gorski & Hansen, 1987]. In this model, oestrogen diffuses 
passively into the target cell, crosses the cytoplasm and reaches 
the nucleus, where the unoccupied ER is thought to reside 
immobilised through association to structural nuclear element(s). 
After high affinity binding of oestrogen to a specific site of the 
receptor, the resulting complex incurs a dramatic conformational 
change which is believed to be the "one and only" essential step 
of the primary cellular response to oestrogens [Gorski & Hansen, 
1987]. This rearrangement induces a variation in the affinity of
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receptor for nuclear components, allowing increase and/or 
decrease in the expression of an assortment of tissue-specific 
genes, which eventually leads to modification of the cell 
physiology [Yamamoto, 1985].
The site of steroid receptor synthesis is mostly the
cytoplasm; since this seems to be a rather continuous process,
which can be modulated by a variety of factors, it is reasonable 
to expect that some receptors are normally found in the soluble 
fraction of target cells.
An interesting contribution to this subject comes from 
studies on the dynamics of AR in prostate cells. Hiipakka and
Liao [Hiipakka & Liao, 1984], based on isotope-chasing
experiments, suggested that the AR recycling is a slow process 
which occurs between chromatin-bound and cytosolic forms. The 
authors observed that incubation of minced ventral prostate 
from castrate rats with actinomycin D and 3'-deoxyadenosine (3’- 
dA), which selectively inhibit transcription and processing of 
newly synthesised RNA, produces opposite results. In fact, in the 
presence of actinomycin D, the AR complex appeared to be 
trapped as a chromatin-bound form, while, using 3'-dA, the level 
of cytosolic AR complex increased with a concomitant decrease of 
the chromatin-bound form to a minimum [Hiipakka & Liao, 
1988a]. Armed with this evidence, Liao and associates have 
proposed a model by which steroid-receptor complexes and 
ribonucleoproteins may interact to mutually facilitate their 
release from the nucleus; continued association of receptors to 
newly transcribed RNA could also assist the utilisation of RNA
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into the cytoplasm [Hiipakka & Liao, 1988b]. This would imply 
that some the cytoplasmic receptor may also derive from  
recycling of the steroid-receptor complexes which have moved to 
cytoplasm from nucleus in conjunction with RNA as part of a 
processing mechanism.
In conclusion, unless unequivocal evidence of subcellular 
localization of steroid receptors becomes available, it appears 
hazardous to neglect any indication coming from the steroid 
action models proposed thus far. Rather, it seems appropriate to 
point out with Jack Gorski that "we are still unable to present a 
cogent and detailed model of steroid hormone action at molecular 
level".
2.4. H eat Shock Proteins
The heat-shock phenomenon was originally discovered in 
the fruit fly D ro so p h i la  and described as the massive synthesis of 
a small number of proteins (heat shock proteins, hsps) in 
response to a few degrees rise above the normal growth 
temperature (for a review see [Lindquist &  Craig, 1988]). This 
phenomenon is today known to be common to most organisms, 
both prokaryotic and eukaryotic. The pattern of heat-induced 
proteins varies greatly, but three major species can be identified 
on the basis on their molecular mass: the 80-90, the 60-75 and 
the 15-30 kDa proteins. Although initially identified on the basis 
of their specific induction during the cellular response to heat
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shock, hsps are also induced under a variety of other stress 
conditions and, more, most of them are normally present in 
substantial amount in unstressed cells. Therefore, the terms "heat 
shock proteins" and "stress proteins", which have been in turn 
proposed to describe this relatively large class of molecules, both 
appear inappropriate and "hsps" will be used simply to describe 
the family.
The relevance of hsps to the cell physiology is still debated, 
but it is widely accepted that they all share protein folding and 
chaperone functions with a larger family of proteins that have 
been highly conserved during evolution (reviewed by [Gething &  
Sambrook, 1992]).
The interest for steroid receptors-hsps interactions 
originated from the observation of Toft and Gorski [Toft &  Gorski, 
1966] that cytosolic ER of the rat uterus sedimented at 9S in 
sucrose gradient centrifugation analysis. Subsequently, all steroid 
receptors were found to sediment as 8-1 OS (untransformed) 
complexes in steroid-free cells, while they were recovered 
mainly as 4S (transformed) forms in the presence of the specific 
hormone [Sherman, 1984]. In the late 1970s the composition of 
the 9S complexes was carefully investigated, leading to the 
evidence that both progesterone and glucocorticoid  
untransformed receptor complexes contain a major protein 
component of approximately 90 kDa [Puri et al., 1982; Housley &  
Pratt, 1983]. The latter was hence identified as the 90-kDa heat 
shock protein, hsp90 [Sanchez et a l ,  1985; Schuh et al., 1985]. In 
the last decade, the appreciation that hsp90 is not the only
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receptor-associated protein has clearly emerged. Rather, data 
coming from several studies suggest that other hsps complex to 
unliganded steroid receptors and that the 9S form is a core unit 
of a larger structure [Pratt et a l ., 1992].
2.4 .1 . Hsp association  to steroid receptors
At least three different hsps (hsp90, hsp70, hsp56) have 
been found to associate with steroid receptors in large 
heterocomplexes. These complexes, however, are commonly 
present in cell cytosol regardless of the presence of receptors 
[Perdew & Whitelaw, 1991].
H s p 9 0
This is an ubiquitous, conserved protein which is present in 
re lative ly  high amount in eukaryotic unstressed cells 
[Schlesinger, 1990]. It complexes to several steroid receptors, 
including ER, PgR and GR [Pratt, 1987]. There is convincing 
evidence that hsp90 interacts with the hormone-binding domain 
(HBD) of the GR, although it is still unclear whether HBD includes 
a minimal hsp90 binding site or a diffuse region of the domain is 
involved [Pratt et a l ., 1988]. In addition, the ER HBD has been 
found to be necessary but not sufficient for hsp90 binding, 
indicating that other contact sites out of the HBD (probably 
including the DNA-binding domain) are required for association.
It has been proposed to subdivide the steroid receptor 
superfamily into three classes according to different properties of 
hsp90 binding. Class I includes the receptors for thyroid
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hormone, retinoic acid and vitamin D. The unliganded receptors 
in this class are not recovered from the cell in association to 
hsp90, but bind tightly to nuclear structures requiring high salt 
conditions to be extracted [Dalman et al., 1990; Dalman et a l .,
1991]. By contrast, receptors in classes I I  (GR and 
mineralcorticoid receptors, MR) and I I I  (ER, PgR, AR) give rise to 
stable associations with hsp90. However, while class I I  receptors 
require hsp90 for high-affinity steroid binding, class I I I  
receptors are retained in nuclear "docking" complexes where 
they incur specific conformational changes for hormone binding 
independent of hsp90 [Pratt, 1993].
Several studies suggest that hsp90 behaves as a dimer, 
with a stoichiometry of two molecules to each molecule of 
receptor [Minami et al., 1991]. Murine hsp90 is composed of two 
distinct isoforms which represent products of two different genes 
[Mendel &  Orti, 1988]. It has been postulated that GR interact 
more directly with one of the two hsp90 molecules, giving rise to 
an asymmetrical GR-hsp90 complex [Lefebvre et al., 1989]. 
Interestingly, the only study available on the stoichiometry of 
ER-hsp90 association indicates that, contrary to both GR and PgR 
heterocomplexes, the 9S ER heterocomplex consists of a dimer of 
the hormone-binding protein coupled to a dimer of hsp90 
[Redeuilh et a l ., 1987]. This could be a reflection of the presence 
of a strong dimerization site in the HBD of ER, which is thought to 
be required for DNA binding.
Mendel et al. [Mendel et al., 1986] revealed that exposure 
of intact mouse thymoma cells to glucocorticoid causes the
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dissociation of the GR from the 90-kDa protein. This evidence was 
confirmed later by Denis and associates [Denis et al., 1988] who 
demonstrated that, during this temperature-dependent process, 
GR proceeds from a non-DNA-binding state towards a DN A - 
binding form. Although this phenomenon has been examined in 
detail only for GR, it seems likely the both adrenocorticoid sex 
steroid receptors undergo comparable changes follow ing  
dissociation from hsp90.
H s p 7 0
This hsp family consist of either constitutive or inducible 
proteins which share common properties, such as ATP-binding. 
They have been in turn implied as catalysts of protein assembly 
and shown to possess protein unfoldase activity, which is 
relevant to protein transport across plasma membranes. The first 
report of an association between hsp70 and steroid receptors 
dates back to 1984, when Wrange and coworkers [Wrange et a l ., 
1984] isolated a 72-kDa protein linked to GR in the rat liver. 
Recently, hsp70 has been shown to represent an important 
component of steroid receptor heterocomplexes reconstituted in 
rabbit reticulocyte lysate system (see below) and its unfoldase 
activity is reputed to be an essential requirement for hsp- 
receptor complex assembly [Hutchison et al., 1992]. Additionally, 
Sanchez et al. [Sanchez et a l ., 1990a] suggested that hsp70 may 
also play a role in the transit of steroid receptors across nuclear 
membrane.
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H s p 5 6
Since its first recognition as a 59-kDa component of rabbit PgR, 
ER, AR and GR heterocomplexes [Tai et a l ., 1986], hsp56 has met 
an increasing interest for several reasons. In first place, it was 
shown to be immuno-adsorbed jointly with hsp90 and hsp70 in 
the rat uterus cytosol. It was therefore proposed that these three 
proteins are associated with each other to form a cytosolic
complex independent of the presence of receptor [Sanchez et al., 
1990b]. Secondly, hsp56 has been recognised as a member of the 
immunophilin proteins, which bind immunosuppressive agents, 
such as cyclosporin A and FK506 [Tai et al., 1992]. Although
nomenclature of this protein has generated some confusion 
because of the diverse molecular weights reported in different
species, it is now clear that the receptor-associated 54-59 kDa 
proteins coincide with hsp56 and that the latter is a novel,
moderately abundant heat-shock protein [Sanchez, 1990].
Hsp 27
As for hsp56, a group of small proteins, in the range of 24-30 
kDa, have been reported to be involved in cellular 
thermotolerance and response to a miscellany of both growth and 
differentiation factors. In particular, recent studies have revealed 
that the 28-kDa protein found in MCF7 human mammary cancer 
cells is the same as the oestrogen-regulated 24-kDa protein and 
the mammalian hsp27 [Faucher et al., 1993]. Hsp27 has been 
shown to be phosphorylated in response to various stress 
conditions, including heat [Zhou et al., 1993]. However, there is
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some suggestion that phosphorylation at serine residues 82 and 
78, which respectively represent a major and a minor 
phosphorylation site of the molecule, may activate hsp27 
functions linked to growth signalling pathways in unstressed 
cells [Landry et a l ., 1992]. In addition, hsp27 has been shown to 
behave itself as a serine kinase phosphoprotein, which is likely to 
be involved in a major signal transduction cascade [Zhou et a l ., 
1993]. Interestingly, immunological evidence has indicated that 
oestrogen-regulated hsp27 and the ER-associated 29-kDa protein 
(p29) are the same molecule [Ciocca & Luque, 1991]. The p29 
phosphoprotein was previously characterised as a cytosolic 
component of both breast and endometrial cancer tissues which 
is quantitatively and qualitatively related to ER but not to other 
steroid receptors or other binding proteins [King et a l ., 1987]. It 
was proposed that p29 represents a non-hormone-binding 
component of the receptor mechanism which complexes to ER 
under certain conditions, such as treatment with ammonium 
sulphate [Cano et al.y 1986]. This would suggest that hsp27 is 
another component of larger cytosolic complexes of hsps. 
However, this comparison appears to be unrewarded since 
p29/hsp27 has been found almost exclusively in ER positive 
tissues, whilst larger hsps (hsp90, hsp70) are encountered also in 
hormone-insensitive cells, regardless of the presence of steroid 
receptors. Although several points favour the idea that hsp27 is 
implicated in the oestrogen action, it is still doubtful whether this 
protein participates in the processes of association and
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dissociation of ER heterocomplexes, or it is rather related to the 
receptor activation (dimerization?) and DNA binding phenomena.
2 .4 .2 . M odels for receptor heterocom p lex  assem b ly
The evidence that several hsps exist in large complexes, 
irrespective of the presence of both steroid receptors and ligands, 
suggests that these proteins may interact in a spatially organised 
and temporally co-ordinated manner [Pratt, 1993]. Recently, it 
has became possible to reconstitute purified receptors into 
heterocomplexes by means of an enzymatic system in rabbit 
reticulocyte lysate [Denis & Gustafsson, 1989]. Using this system, 
the GR heterocomplex formed appeared to be functionally 
identical to the native non-DNA-binding 9S complex. This 
heterocomplex was also found to consist of other proteins in 
addition to both hsp90 and hsp70. This was true for both PgR 
and GR, the former including p23 [Smith et a l ., 1992], the latter 
containing hsp56 [Hutchison et a l ,  1993]. It has been suggested 
that steroid receptors might associate with a preformed complex 
in the lysate, which includes several hsps. In this respect there 
is evidence for an essential role of hsp70 in the receptor 
association with hsp90. In fact, Smith et al. [Smith et al., 1992] 
reported that pretreatment of the lysate with a monoclonal 
antibody raised against hsp70 inhibited hsp90 binding to PgR. An 
elemental multistep model has been recently proposed for GR
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F igu re 2. Model for heterocomplex assembly. A hypothetical multistep 
model for glucocorticoid receptor (GR)/heat shock proteins (hsps) 
heterocomplex formation is illustrated. Initially (step 1), the folded GR 
binds to a preformed hsp complex consisting of two molecules of hsp90 
and one molecule each of hsp56 and hsp70. The latter subsequently 
catalyses the unfolding of the GR hormone binding domain (HBD) 
through its intrinsic unfoldase activity, allowing the GR to acquire a high 
affinity steroid-binding conformation which is further stabilised via  
hsp90 (step 2). Dissociation of the steroid-free GR from hsp complex is 
accompanied by refolding of the HBD and possible recycling of the GR 
into another heterocomplex assembly process (step 3).
(Adapted from [Pratt, 1993 #296}).
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heterocomplex assembly (see Figure 2). In this model hsp90 and 
hsp70 behave as a tandem unit, where hsp70 recognises the 
folded state of receptor and favours an ATP-dependent process
which allows the receptor to associate with the complex (step 1). 
Then, hsp70 causes the unfolding of the receptor HBD (step 2), 
with a subsequent hsp90-mediated stabilisation of the unfolded 
receptor in a high-affinity steroid-binding state (step3). Finally, 
high salt dissociation of the hormone-free heterocomplex is 
paralleled by refolding of the receptor HBD and loss of the 
steroid-binding conformation. Hsp90 role seems therefore
devoted to maintain the receptor HBD in a metastable, partially 
unfolded state. In this respect, the steroid receptor
heterocomplexes may retain receptors during transit to and
within the nucleus. These complexes may therefore act as 
"transportosomes", wherein receptors remain "docked" until 
specific hormone binding triggers their dissociation [Pratt, 1993].
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3 .  Steroid Formation and Metabolism
3 .1 . S tero id o g en etic  P athw ays
All steroid hormones are of basically similar structure and 
share common biosynthetic pathways, although relatively minor 
chemical changes lead to striking diversities in their biochemical 
activity. In this respect, steroid-producing organs - specifically 
the adrenal gland, ovary, testis and placenta - which are 
endowed with key enzyme activities of steroidogenesis, are 
characterised by more or less complete blocks at certain reaction 
sites so that the compound preceding the block represents the 
major secretory product of a single tissue.
As illustrated in Figure 3, the basic structure of steroids is 
represented by a perhydrocyclopentanephenanthrene nucleus, 
which is composed of three 6 -carbon rings (A, B and C) and one 
5-carbon ring (D). This molecule contains 6 centres of asymmetry 
and may give rise to 64 possible isomers, some of which are 
inactive, through changes in the position of only one substituent. 
The A, B and C rings are not planes, but they commonly assume a 
"chair" conformation; aromatisation of the ring A to form a ring of 
the benzene type changes its conformation to a flat structure.
The basic building block in steroidogenesis is represented 
by cholesterol, a 27-carbon atoms molecule (see Figure 3), whose 
basic structure is called cholestane. Apart from the placenta, all 
steroidogenic tissues can actively synthesise cholesterol from the
8 6
F igu re 3. Basic structure of steroid hormones. All steroids derive from 
the 27 carbon molecule of cholesterol (here illustrated) through a series 
of enzymatic reactions which eventually lead to formation of corticoids, 
and the three sex steroid classes (progestins, androgens, oestrogens). 
These share the perhydrocyclopentanephenantrene nucleus, consisting 
of three 6-carbon rings (A, B and C) and one 5-carbon ring (D).
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two-carbon molecule of acetate, even if  the major resource 
remains the blood supply. Sex steroids are subdivided into three 
main classes, according to the number of carbon atoms they 
possess (see Figure 4). The 21-carbon series includes corticoids 
and progestins, and the basic structure is the pregnane nucleus. 
The 19-carbon series corresponds to all androgens and is based 
on the androstane nucleus, whereas the oestrogens are 18-carbon 
steroids, based on the oestrane nucleus.
During steroidogenesis, the number of carbon atoms 
progressively reduces from cholesterol to the various steroid 
hormones which are in turn synthesised. This process involves 
several enzymatic reactions which produce cleavage of a side 
chain (desmolase reaction), conversion of hydroxyl groups into 
ketones or viceversa (dehydrogenase reaction), addition of OH 
groups (hydroxylation), formation or reduction of double bonds 
respectively by removal or addition of hydrogens.
The first metabolic step, which occurs in the mitochondria 
and requires NADPH and molecular oxygen, is represented by the 
conversion of cholesterol into pregnenolone (3p-hydroxy-pregn- 
5-en-20-one). This step involves hydroxylation at both the C20 
and C22 positions (20- and 22-hydroxylase enzymes), with 
subsequent cleavage of the side chain (20,22-desmolase). Once 
pregnenolone is formed, further steroid synthesis may follow two 
alternative pathways, namely either the A5 -3(5-hydroxysteroids  
or the A4 -3-ketone pathway. The former (the A 5 pathway) 
proceeds through the 17-hydroxypregnenolone and the 
dehydroepiandrosterone (DHA), the latter (the A4 pathway) by
8 8
F igu re 4. The three classes of steroid hormones. Steroids are divided 
into 3 main groups depending on the number of carbon atoms they 
possess: the 21-carbon series, including corticoids and progestins, the 
19-carbons series, including all androgens and the 18-carbon series, 
represented by oestrogens.
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way of progesterone and 17a-hydroxyprogesterone. In the A4 
pathway, two enzyme activities govern the conversion of 
pregnenolone to progesterone: the 3(3-h y d r o x y  s te r o id
dehydrogenase and the A4-5 isomerase; they transform the 
3-hydroxyl to a ketone group and transfer the double bond from 
the 5-6 to the 4-5 position. Once the A4-5 ketone is formed, 
progesterone is hydroxylated at the 17 position to yield 
17a-hydroxyprogesterone, which represents the immediate 
precursor of the C l9 series of androgens. Following peroxide 
formation at C20 and epoxidation of both the C l9 and C20 
carbons, the side chain is split off to produce androstenedione. 
Intervention of the 17(3-hydroxysteroid dehydrogenase (17P H S D ) 
determines the reduction of the 17-ketone to the 17p-hydroxyl 
androgen testosterone. Either androgen (androstenedione and 
testosterone) can be rapidly converted by microsomal enzymes 
to the corresponding C l8 phenolic steroid oestrogens (oestrone 
and oestradiol) in a process referred to as aromatisation. This 
process includes hydroxylation of the angular 19-methyl group, 
followed by loss of the 19-carbon as formaldehyde and 
aromatisation of the A ring (dehydrogenation). Alternatively, in 
the A5 pathway, pregnenolone can be directly converted to the 
A5-3p-hydroxy C19 steroid DHA through 17a-hydroxylation and 
subsequent desmolase cleavage of the side chain. However, 
irrespective of the precursor source, C19 A4 -3-ketone substrates 
may proceed to oestrogen formation, as indicated above. The 
latter aromatisation step mainly takes place in the ovary, but
90
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also, though to a lesser extent, in both testis and the adrenal 
gland.
3 .2 . Local M etabolism
Although the main circulating sex steroids, namely 
testosterone in man and oestradiol or oestrone respectively in 
pre- or post-menopausal woman, may act directly on target 
tissues, peripheral metabolism frequently gives rise to 
biologically active metabolites which may assume an important 
role in regulation of both normal and malignant cell growth. 
Much attention has been drawn in recent years to pathways of 
steroid formation and degradation, including conjugate steroids, 
in peripheral target tissues, especially human breast and 
prostate. In particular, key enzyme activities have been isolated 
and purified, their genes have been sequenced and possible 
regulatory mechanisms have also been explored. This has 
allowed a better understanding of basic rules which determine 
the actual levels of active hormones in target cells in different 
conditions, including cancer.
3 .2 .1 . O estrogens
Unlike the C19 and C21 steroids, the metabolism of 
oestradiol is primarily oxidative, the main pathway being the 
oxidation at C17p position to yield oestrone (E i) (see Figure 5). 
This conversion, like that of testosterone to androstenedione, is
F ig u re  5. Pathways of oestradiol metabolism. The metabolism of 
oestradiol in target tissues primarily includes the reversible conversion 
to oestrone via the 17p-hydroxy steroid dehydrogenase (17PHSD) 
enzyme. This is commonly followed by two mutually exclusive reactions, 
which consist of hydroxylation at the C16a or at C2 positions, to yield 
respectively 16a-hydroxyoestrone or 2-hydroxyoestrone. The former 
may be further converted by 17pHSD to oestriol, the latter can also be 
metabolised by catechol-O-methyltransferase to its methoxy derivative 
2-methoxyoestrone. Possible direct formation of oestriol from oestradiol 
is also considered (hatched line).
O
es
tr
ad
io
l 
O
es
tro
ne
 
2-
hy
dr
ox
yo
es
tr
on
e
INTRODUCTION
a
9
eou•«»*
0>o>%Xo
La
’O
JS■a
VO
o
•  mmU*-»
C/3
O
92
INTRODUCTION
the only freely reversible reaction (E2 originates from Ei in the 
reductive pathway), and is governed by the 17PHSD enzyme 
system. It is commonly followed by two mutually exclusive 
pathways which consist of hydroxylation at the C l6 a or at C2 
positions, to give respectively 16a-hydroxyoestrone (1 6 a O H E i) or 
2-hydroxyoestrone (2 0 H E i) .  The former may be further 
converted by 17PHSD to oestriol (E3 ), the latter can also be 
metabolised by catechol-O-methyltransferase (C O M T) to its 
methoxy derivative 2-methoxyoestrone (2M eO Ei) .
The concept that oestrogens, like testosterone, may need to 
be converted to biologically active derivatives for full expression 
of hormone action was first introduced by Fishman and Norton 
[Fishman & Norton, 1975]. The authors suggested that 2- 
hydroxylated oestrogens (catecholoestrogens, CCE) may well 
mediate the parent hormone's action, having properties distinct 
but relevant to the physiology or pathophysiology of a target 
organ. Today, it is recognised that CCE can be generated by at 
least three distinct microsomal, P450-mediated enzymatic 
functions, namely 2-, 4- and 2/4-hydroxylases, which produce 
both 2- and 4-hydroxy derivatives of either E2 or E ] . These 
hydroxylase activities appear to be independently expressed and 
differentially regulated in several target tissues [Weisz, 1991].
As already discussed (see 1.2.4.), while the oestrogenic 
potency appears to be reduced by 2 -hydroxylation, it may be 
preserved or even enhanced by hydroxylation at the C4 position. 
This could be also ascribed to the slower rate of dissociation of 
4 0 H E 2  from the oestrogen receptor (ER), although the biological
93
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significance of such a prolonged association remains to be 
clarified. Interestingly, the 2/4-hydroxylase enzyme, which 
appears to be the only hydroxylase activity expressed in human 
breast organoids, has been found to be dependent on the 
availability of organic hydroperoxide (OHPs) [Bui & Weisz, 1988]. 
CCE, like other hydroquinones, represent suitable substrates for 
redox cycling, by which potentially mutagenic free radicals are 
generated [Liehr et al., 1986]. Such a process, while using OHPs, 
also generates them through the lipid peroxidation caused by 
free radicals. It has been proposed that, in the presence of both 
oestrogens and appropriate P450, the availability of OHPs may 
initiate a viscious cycle where peroxide-dependent CCE formation 
may provide further fuel for redox cycling by generation of free 
radicals and the resulting maintenance of OHPs supply [Weisz, 
1991]. This cascade, however, would occur only in the case that 
cellular mechanisms protecting against oxidative damages have 
been overwhelmed. Such a system could support the potential 
role of oestrogens as either initiators or promoters of cancer.
3 .2 .2 . A ndrogens
In some androgen target tissues, such as prostate, 
seminiferous tubules, epididymis and some cutaneous regions, 
circulating testosterone is commonly converted into its 
biologically active derivative 5a-dihydrotestosterone (D H T )  
through a 5a-reductase enzyme system. This reductive pathway 
is an essential step as androgen action on development and 
growth of these tissues can be elicited. DHT has long been
94
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recognised as the principal intranuclear androgen in human 
prostate and skin [Anderson & Liao, 1968; Gomez &  Hsia, 1968]. 
D H T may be in turn converted by means of the 3 a /3  0 -  
hydroxysteroid dehydrogenase (3 a /3 0 H S D ) to 3 a - or 30- 
androstanediols, which exhibit an androgen potency even 
greater than that of testosterone in specific target tissues [Wilson 
& Walker, 1969; Ito & Horton, 1971]. On the other hand, 
testosterone can be converted to A4-androstenedione (oxidative  
pathway) through the 170HSD enzyme system. The latter, as far 
as androgen metabolism is concerned, presides over the crosslink 
between the oxidative and the reductive pathways (see Figure 6 ). 
Androstenedione is generally considered to behave as a weak 
androgen, mainly because it lacks the hydroxyl group at the 17 
position. It is commonly metabolised to its 5a-reduced derivative 
androstanedione (5a-androstan-3,17-dione) by means of the 5a -  
reductase enzyme activity and further deactivated to either 
androsterone or its epimer epiandrosterone respectively by the 
action of 3a or 30HSD. Alternatively, androstenedione can be 
reduced to the 5p-androstanedione and subsequently degraded 
to etiocolanolone. The latter, together with androsterone and 
epiandrosterone, are thought to represent catabolic products (17- 
ketosteroids) having very little (if any) androgen potency. They 
can be readily eliminated, mostly with urine but also with bile, 
following conjugation with glucuronic or sulphuric acids in liver 
and, to a lesser extent, in kidney. These metabolites may be also
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F ig u re  6. Pathways of androgen metabolism. Both reductive and 
oxidative pathways are illustrated. In the former, testosterone is 
converted to dihydrotestosterone (DHT) via the 5a-reductase (5a-Red) 
enzyme; DHT can be in turn metabolised to 3a/30-androstanediols 
(3a/3p-diols) through the 3oc/3p-hydroxysteroid dehydrogenase enzyme 
(3a/3pHSD). In the latter, testosterone is oxidised to androstenedione 
via the 17p-hydroxysteroid dehydrogenase (170HSD); androstenedione 
can be further converted to 5a-reduced metabolites of the 17keto series, 
including 5a-androstanedione (5a-Adione), androsterone and its epimer 
epiandrosterone (EpiA), through 5aRed and 3ot/3pHSD enzymes. As cam 
be seen, the 170HSD activity presides over the cross-link between  
reductive and oxidative pathways of androgen metabolism.
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converted to their 17p-hydroxy derivatives, to give rise to either 
3a  or 3p androstanediols.
3 .2 .3 . Steroid  conjugates
Metabolism of blood-borne steroid hormones also includes 
their conjugation to form extremely polar water-soluble 
derivatives, such as sulphates and glucuronides. This metabolism 
produces steroid conjugates which can be freely eliminated 
through urine and/or bile. There is still some question as to 
whether these polar metabolites serve other biological functions. 
In the past, the enzymic reactions which control formation of 
steroid conjugates were assumed to be the sole prerogative of 
intrasplancnic organs, such as liver and kidney. However, it has 
been observed that these reactions may well occur also in 
peripheral target tissues and cells [Pack & Brooks, 1970; Buirchell 
& Hahnel, 1975].
Sparse experimental evidence indicated that other forms of 
steroid conjugates, which are even less polar than the free parent 
hormones, exist. In particular, formation of acetate and fatty acid 
esters of testosterone was documented in rat mammary and 
brain homogenates [King et al., 1964; Kishimoto, 1973]. Although 
this was first ascribed as an artifact of in vitro incubation, more 
recent reports have consistently revealed the presence of 
endogenous hydrophobic steroid derivatives, especially  
oestrogens, termed lipoidal steroids.
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Oestrogens
There is convincing evidence that ovaries may secrete both 
oestradiol and oestrone either as free steroids or as sulphate 
esters [Giorgi, 1967]. Oestrogen sulphates represent the major 
form of circulating oestrogens during the menstrual cycle [Nunez 
et a l .y 1977], in postmenopausal women [Roberts et a l ., 1980; 
W yllie  et al.y 1984; Kyprianou & Isaacs, 1989a] and in the human 
foetal life [Pasqualini &  Kind, 1986]. Firstly Robbins and Lipman 
[Robbins & Lipman, 1957] discovered that specific enzyme 
activities (sulphotransferases or sulphokinases) may catalyse the 
transfer of a sulphate group to a variety of substrates, including 
hormones, from the so-called "active sulphate". This compound, 
commonly termed PAPS, was shown to consist of a high energy 
phosphosulphate group esterified (through the phosphate) at the 
5 '-p o s itio n  of 3 '-phosphoadenosine. The steroid  
sulphotransferases represent a class of enzymes which includes 
both 3p-hydroxysteroid [Adams & Edwards, 1968] and oestrogen 
[Adams, 1967] sulphotrasnferases. Presence of oestrogen 
sulphurylation activity was initially reported in both bovine 
adrenal gland [Adams & Poulos, 1967] and porcine uterus [Pack 
& Brooks, 1974]. Concomitant experimental evidence indicated 
that human mammary carcinoma tissues contain steroid 
sulphokinase enzyme activities [Adams, 1964]. In particular, Dao 
and Libby [Dao & Libby, 1971] demonstrated that steroid 
sulphurylation is significantly correlated with both prognosis and 
response to horm one-ablative manoeuvres, such as 
adrenalectomy, in late-stage breast cancer patients. The authors,
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comparing dehydroepiandrosterone (DHEA) and 17P-oestradiol 
(E 2 ) as substrates for tumour sulphotransferases, found that a 
lower ratio of DHEA sulphate (DHEA-S) to E2 sulphate is 
associated with a poor prognosis and response to adrenalectomy. 
In addition, Leung and colleagues [Leung et a l ., 1973] showed a 
close correlation between levels of oestrogen sulphurylation and 
content of cytosolic ER in human primary breast tumour tissues. 
This original observation was confirmed by ensuing studies 
where high sulphotransferase activity was found almost 
exclusively in ER positive/progesterone receptor (PgR) positive 
human breast cancer tissues [Adams et a l ., 1979; Pewnim et al., 
1980; Wilking et a l ., 1980; Tseng et al., 1983] and cells [Adams et 
a l . ,  1990]. Similar results have been obtained in human 
endometrium, where both sulphotransferase and 17|3HSD enzyme 
activities were found to be under progesterone control [Tseng &  
Liu, 1981; Brooks et al., 1983].
The finding that circulating oestrone sulphate (E]S) may be 
readily transformed into free oestradiol in both mammary 
[Wilking et al., 1980] and uterine [Pack & Brooks, 1970] tissues 
indicates that E]S may act as oestrogen precursor in target cells 
containing the enzyme activity necessary to hydrolyse it 
(sulphatase). The same applies also to plasma DHEA-S [Prost et 
a l . ,  1984]. Sulphatases are membrane-bound enzymes which, 
contrary to what observed with sulphokinases, do not appear to 
be significantly correlated with either ER or PgR status of human 
breast tumours [Prost et al., 1984]. However, studies on cultured 
mammary cancer cells have shown that labelled E]S is largely
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hydrolysed in hormone-dependent cell lines (MCF7, T47D) to 
produce free oestradiol, whilst this conversion is significantly 
lower in hormone-independent (MDA-MB231, M DA-M B436) cells 
[Pasqualini et a l ., 1990].
Overall, the above studies support the concept that 
peripheral target tissues, such as breast and endometrium, may 
actively hydrolyse circulating steroid sulphates to yield 
biologically active oestrogens. The latter can be in turn 
sulphurylated to provide a storage pool which may contribute to 
maintain elevated intracellular oestrogen in hormone-dependent 
tissues, even in absence of an adequate blood supply of steroids.
In 1977 Hochberg and colleagues reported on the isolation 
of a new class of steroid conjugates, called lipoidal steroids 
[Hochberg et a l ., 1977]. These nonpolar derivatives were first 
identified in the bovine adrenal cortex as naturally occurring 
metabolites of the A 5-3 (3-hydroxysteroids, pregnenolone, 
dehydroisoandrosterone and 1 7 a -h y d ro x y p re g n e n o lo n e  
(reviewed by [Hochberg & Lieberman, 1980]). More recently, 
hydrophobic derivatives of oestradiol have been found to be 
produced by human breast tumour tissues [Schatz & Hochberg, 
1981] and human mammary cancer cells in culture [Adams et a l ., 
1986]. They mainly consist of long-chain fatty acids esterified to 
oestradiol at the 17(3 position [Abul-Hajj, 1982]. Fatty acid esters 
of the adrenal-derived oestrogen 5-androstene-3p, 17(3-d io l 
(A5Adiol) have been also identified in human breast cancer cells 
[Adams et al., 1990]. Perhaps, the most important feature of 
these alkyl esters of steroids resides in their superior biological
1 0 0
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potency, as opposed to the polar steroid conjugates which have 
very weak or null hormonal activity. In this respect, lipoidal 
oestrogens represent the endogenous analogs of synthetic esters 
of oestrogens which have been used for decades as long-acting 
hormonal drugs. Lipoidal oestrogens are in fact resistant to 
metabolism and capable of producing a prolonged stimulation of 
sensitive cells.
Among all the oestrogen conjugates, lipoidal oestradiol 
(L E 2 ) is the only to maintain a full oestrogenic potency. Several 
experimental observations have strengthened the assumption 
that LE2 may be involved in the oestrogen-primed function at 
target tissue level. In this respect, is there possible that this 
nonpolar steroid is itself oestrogenic or that it plays a role in the 
oestrogen action by affecting the intracellular equilibrium  
between oestradiol and oestrone.
Androgens
The significance of androgen conjugates was initially recognised 
in the early 1930s, when acid hydrolysis of human urine was 
found to release compounds which stimulate capon comb growth 
[Adler, 1934]. Subsequent studies demonstrated that adrenal 
DHEA-S is an important precursor of the 5a-reduced androgen 
conjugates in urine [van de Wiele et al., 1963]. In addition, after 
intraveous administration of labelled testosterone to 
experimental animals, both androstanediols and androsterone 
were detected in the urine mostly as glucuronides and sulphates 
[Mauvais-Jarvis et al., 1968].
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Conjugated androgens commonly include glucuronide and 
sulphate conjugates of DHT, androsterone and androstanediol. 
Although both 3a and 3|3 forms of androstanediol exist, little or 
no 3P-reduced androgens are being found in serum or urine after 
administration of labelled testosterone or DHT [Mahoudeau et a l ., 
1971]. Formation of glucuronide and sulphate androgens can 
take place at the 17-carbon position of D HT, the 3-carbon 
position of androsterone and at either the 3- or the 17-carbon 
position of androstanediol. It must be also pointed out that the 
parent unconjugated steroids are readily interconverted and that 
this process has been shown to occur not only in the liver but 
also in peripheral target tissues, such as skin and prostate [Gomez 
& Hsia, 1968]. Chung and Coffee [Chung & Coffey, 1978] 
investigated formation of androgen glucuronides in minces of 
both normal and hyperplastic human prostate after incubation 
with testosterone. The authors found that testosterone 
glucuronide predominates in normal tissues, while D H T  
glucuronide prevails in hyperplastic tissues.
Although the more obvious concept is that androgen 
conjugation represents merely a process for hormone inactivation 
and excretion, the likelihood that androgen conjugates could 
serve as reservoir for back conversion to biologically active 
metabolites is still claimed. The latter possibility has recently 
received some support from the evidence that human genital 
skin contains sulphatase activity [Kaufman et a l ., 1990]. Huot 
and Shain [Huot & Shain, 1988] indicated that both normal 
AXC/SSh rat ventral prostate and clonally derived AXC/SSh rat
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prostate cancer cells actively metabolise either oestrone sulphate 
or oestrone glucuronide to oestrone, whilst neither normal nor 
neoplastic prostate cells have the ability to convert DHEA-S to 
DHEA. However, both benign and malignant human prostate 
tissues have been shown to possess steroid sulphatase enzymes, 
including those which preside over the production of free DHEA  
by cleavage of DHEA-S [Klein et a l ., 1988]. The same authors 
observed that cancerous prostatic tissues retain substantial 
3a/3pH S D  activity, which yields androstenedione from DHEA, 
concluding that human malignant prostate may be able to use at 
least androstenedione as substrate for direct production of 
biologically active androgens. Interestingly, aromatase activity 
also has been found in human prostate [Stone et al., 1986]. In 
this context, the finding that tamoxifen counteracts the 
stimulatory effect of DHEA on growth of MCF7 human breast 
cancer cells [D i Monaco et al., 1991] appears to be worth 
mentioning. This evidence suggests that DHEA effects may be also 
mediated via aromatisation of this androgen to oestrone or 
oestradiol. The likelihood that prostate tumour cells could use 
circulating androgens (specifically DHEA or its sulphate) to 
produce intraprostatic oestrogens through the aromatase 
pathway deserves attention, especially as oestrogens may have a 
role in both benign and aberrant growth of the human prostate.
1 0 3
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3.3 . P eripheral Uptake and M etabolism  o f Steroids
Although the blood supply is assumed to be the major
source of tissue steroids, the ability of peripheral target tissues, 
such as breast and prostate, to withdraw circulating steroids, to 
accumulate them against gradient and to give rise to biologically 
active metabolites, once again emphasises the cardinal 
importance of local microenvironment in driving the overall 
metabolic function of individual tissues. A dditionally , 
mechanisms which are involved in the regulation of such a
complex apparatus of enzymatic activities are likely to be 
dependent on local factors; the latter may direct the metabolic 
fate of steroids based on the actual cell requirement rather than 
on the potentially available steroids from circulation. This has 
recently led Labrie [Labrie, 1991] to introduce the new concept
of "intracrinology", signifying the intracellular processes relevant
to the hormonal control of a target tissue, as opposed to 
endocrinology as the central homeostasis of the whole endocrine 
system. This scenario is even more intimate to the neoplastic 
condition, where diffusible trophic factors are prim arily  
responsible for growth control of target cancer cells, especially in 
the hormone-refractory disease.
3.3 .1 . O estrogen uptake and m etabolism  in hum an breast
Biosynthesis of active oestrogens by breast tissues 
commonly includes transformation of plasma-derived steroid 
precursor, such as androgen and oestrone sulphate, into
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oestradiol. The mechanisms involved in the local production of 
oestrogens in breast tumour tissues have been investigated using 
tissue homogenates, tissue cultures and animal models. Three 
main enzyme systems have been identified: the aromatase, the 
sulphatase/sulphokinase and the 17PHSD.
A ro m a ta s e
The process by which an androgen precursor is converted to 
oestrogens is called aromatisation. Concerning human breast 
tissues, this process is mostly represented by transformation of 
circulating androstenedione to E] through the aromatase. Most of 
our knowledge on the enzymology of this transformation comes 
from studies on the human plancental aromatase. This enzyme 
complex consists of two protein components, a flavoprotein 
NAPH-cytochrome P-450 reductase and a member of the 
cytochrome P-450 gene superfamily known as aromatase P-450 
[Thompson & Siiteri, 1974]. The aromatisation of the steroid 
aliphatic A ring into an aromatic ring is unique in biology and is 
exemplified only in the oestrogen biosynthesis [Fishman, 1988]. 
This reaction is completely stereospecific and involves the loss of 
both the C l9 methyl group and the ip and 2p hydrogens, while 
those at la  and 2a positions are retained. It is conceivable that 
this precise sequence cannot be accomplished in one single step, 
but is rather achieved by three separate hydroxylation processes. 
However, it is still uncertain whether three different enzymes or 
one enzyme having three distinct catalytic sites are involved.
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Aromatisation of androgens to yield oestrogens occurs in 
several sites in the human, mainly the ovaries in woman and the 
testes in man; quite importantly, however, this reaction may also 
take place in other tissues, such as prostate and fat. Presence of 
aromatase activity has been repeatedly documented in both 
normal and tumour breast tissues [M iller et a l ., 1982; Santen, 
1986; Vermeulen et a l ., 1986; James et a l ., 1987]. The proportion 
of aromatase-containing tumours is ranging between 60 and 85% 
[M iller, 1986; Lipton et al ., 1987], the measured activity being 
comparable or higher than that found in other peripheral tissues 
[A b u l-H a jj  et a l ., 1979]. Aromatase enzyme has been also
detected in breast fat [Perel & Killinger, 1979], as well as the 
adipose tissue from other body sites [Grodin et al., 1973].
While in premenopausal women the major source of 
oestrogen is represented by the ovary, in postmenopause 
conversion of circulating androstenedione, mostly of adrenal 
origin, to Ei could substantially contribute to the oestrogen 
content of tumour breast tissues. This assumption has been 
questioned by several investigators who claimed that kinetic 
characteristics of the aromatase enzyme make this route a 
relatively unimportant contributor to intratumour oestrogen 
[Bradlow, 1982; Tilson-Mallet et al., 1983]. As already discussed, 
however, results from in vitro assay of enzyme activities should 
be taken with caution since they may not precisely predict i n 
vivo events. Using precise isotopic kinetic techniques in vivo, 
Santen and coworkers calculated that the rate of aromatisation of 
androstenedione to E i ranged from 0.5 up to 10% in
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postmenopausal women [Santen, 1988]. In an elegant 
experiment series, James and colleagues [James et a l ., 1990] 
observed that, following simultaneous infusion of 3H - 
androstenedione and 14C-oestrone to postmenopausal breast 
cancer patients, the aromatisation route appeared to be the major 
biosynthetic pathway of oestrogens in some but not all cases. On 
the other hand, the observation that plasma levels of E2 in 
patients with advanced breast cancer are substantially reduced 
by administration of 4-hydroxy-androstenedione, a potent 
"suicide" inhibitor of aromatase, clearly speaks in favour of the 
view that aromatase is an important source of endogenous 
oestrogen [Coombes et al ., 1984].
Conflicting reports exist on the relationship between the 
extent of the aromatase activity and the ER status of breast 
tumours. Most studies failed to find a significant association [Li 
& Adams, 1981; Tilson-Mallet et a l ., 1983], whereas others 
detected even higher aromatase activity in the receptor negative 
tissues. However, Miller and O'Neill [Miller & O'Neill, 1987], using 
the technique of product isolation, showed a statistically 
significant tendency of aromatase to associate with the presence 
of oestrogen receptors. Similarly, Vermeulen and colleagues 
[Vermeulen et a l ., 1986] reported a positive correlation of 
aromatase activity and the receptor content of breast tumours. 
In addition, patients whose tumours contain detectable levels of 
aromatase are more likely to respond to anti-aromatase 
treatment, particularly aminoglutethimide [M iller & O’Neill, 
1989].
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An exciting piece of evidence comes from studies of O'Neill 
and M iller [O'Neill & Miller, 1987]. They found that adipose 
tissue derived from breast tumours exhibits significantly higher 
aromatase activity with respect to breast fat taken from women 
having benign breast disease. Furthermore, the authors 
compared aromatase levels in adipose tissue from the periphery 
of each breast quadrant of twelve consecutive mastectomy 
samples from patients having breast cancer. Interestingly, the 
highest level of aromatase activity was constantly found in the 
quadrant which contained clinically manifest tumour, whilst the 
quadrant with the lowest activity never showed macroscopic 
tumour. This evidence lends itself to some conjecture. Although 
fat from breast quadrants bearing tumour might have the 
highest aromatase activity because of microscopic tumour 
involvement, no neoplastic foci could be demonstrated in the fat 
adjacent to that taken for aromatase assay. Rather, it has been 
suggested that breast tumours may secrete polypeptide factors 
which can in turn induce or stimulate the aromatase activity in 
the surrounding adipose tissue [Simpson & Mendelson, 1989]. 
Alternatively, a regional increase of aromatase activity could 
represent a pre-cancer condition, whereby locally increased E2 
concentration may lead to malignant growth at that site. The 
authors concluded that, irrespective of any possible explanation, 
this evidence suggests that breast tumour development is 
associated with significant changes of steroid metabolism in the 
local environment.
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Sulphatase/Sulphokinase
Another important source of oestrogen for peripheral target 
tissues is provided by circulating E iS . During the human 
menstrual cycle, plasma levels of E iS  are 5 to 10 times those of 
unconjugated oestrogens (E i and E2 ), while E iS  represents the 
major circulating oestrogen in the postmenopausal age. 
Remarkable amounts of EjS are being found in mammary cancer 
tissues [Hawkins et a l ., 1985]; correspondingly, several reports 
have indicated that both sulphatase and sulphokinase enzymes 
are present in human breast tumours [Prost et al., 1984; Santner 
et a l ., 1984]. Therefore, there is appropriate background to 
assume that sulphate and unconjugated oestrogens are in a 
continuous equilibrium in breast cancer cells.
Sulphatase enzyme appears to be rather ubiquitous, being 
found in adipose, benign and cancerous human breast tissues 
[Hawkins et al., 1985]. Similarly, sulphokinase activity can be 
detected in several types of breast samples, although different 
forms of the enzyme appear to be present [Adams et al., 1979].
Hydrolysis of EiS to Ei through breast sulphatase may 
represent a major route by which intracellular E i, once produced, 
is further converted to E2 by the 17pHSD activity. There is 
evidence that sulphatase levels in human breast tumour tissues 
are much higher than those of aromatase [Santner et al., 1984; 
S a n tn er et al., 1986]. Although the substrate affinity of 
sulphatase is lower than that of aromatase, the amount of 
oestrogen formed via the sulphatase pathway is about ten times 
greater than that produced through aromatase [Santner et al.,
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1984]. In order to ascertain whether or not the sulphatase 
pathway holds a biological significance, Santner and colleagues 
[Santner et a l ., 1986] measured the effects of both EiS and E2 on 
colony formation of NM U rat mammary tumour cells (which are 
both oestrogen- and prolactin-dependent). At 10_8M, EiS induced 
an increase of number of colonies which was comparable to that 
obtained after exposure to 1 0 10M E2 ; similarly, 10_6M  E iS  
produced about the same effect as 10*8M  E2 . In addition, Santen 
[Santen, 1986] observed that rats bearing N M U  mammary 
tumours experience a complete tumour regression after 
castration, while intact animals double tumour size over a period 
of 14 days; using an Alzet mini-pump as delivery system for 
steroid hormones, the author found that castrated rats exhibited 
a reappearance of tumour following infusion with either 100 
nmol/hour E2 or 1000 nmol/hour EiS. The latter was shown to be 
converted to E2 in this system. This evidence clearly supports the 
view that circulating E iS  may behave as a biologically active 
oestrogen, provided that the target cell retains the enzyme 
apparatus which is required to yield free E i and hence to 
convert it to E2 .
Further complements to this issue come from in vitro 
studies. Initially, Vignon and associates [Vignon et a l ., 1980] 
demonstrated that MCF7 human breast cancer cells convert E iS  
to Ei and that this pathway is responsible for the oestrogenic 
effect of EjS on protein synthesis. More recently, Pasqualini et al. 
[Pasqualini et a l ., 1990] indicated that different oestrogen-3- 
sulphates (E]-3S, E2-3S and E3 -3 S) may exert important biological
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effects on several mammary cancer cells in culture, while 
oestrogen-17-sulphates appear to be inactive. Presumably, cells 
may actively hydrolyse sulphates at the C3 but not the C17 
position. In addition, after 24 hours incubation with 3H -E iS , most 
of precursor is converted to unconjugated E 2 in hormone- 
dependent cell lines (MCF7, T47D), whilst very little conversion 
(if any) occurs in hormone-independent mammary cancer cells 
(M D A -M B 231 and M D A -M B 436). It  was concluded that 
sulphatase activity seems to be strictly related to the hormonal 
status of cells. Previous in vivo studies, however, did not show 
any significant association of sulphatase activity to the oestrogen 
or PgR status of the tumour or to the hormonal status of breast 
cancer patients [Prost et al., 1984]. Additionally, reasonable 
uncertainty remains on whether hydrolysis of EiS and DHEA-S is 
governed by one single enzyme or two separate sulphatase 
activities are involved. Studies on MCF7 human breast cancer 
cells documented that these reactions are mediated by different 
enzymes, having distinct kinetics [Maclndoe et a l .y 1988]. 
Parenthetically, the same authors found that DHEA-S significantly 
inhibits, in a non-competitive fashion, the hydrolysis of 
physiological EiS in intact MCF7 cells.
As reported above (see 3.2.3. Steroid conjugates: 
Oestrogens),  breast tumour tissues and cells contain sulphokinase 
activity, though at levels by one order of magnitude lower than 
sulphatase. High sulphating activity has been found to be 
invariably associated with oestrogen receptor positive tumours, 
whereas receptor negative ones commonly have much lower
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activity [Pewnim et a l ., 1980]. This observation has been
confirmed by studies on mammary cancer cell lines [Adams et al., 
1988b], where 3-sulphates of both E2 and Ei represented the
major products of E2 metabolism in oestrogen receptor positive 
MCF7 and ZR75-1 cells, while production of oestrogen sulphates 
in receptor negative cells MDA-MB231 and M D A -M B 330 was
either significantly lower or not detectable. This evidence, 
combined to the finding that oestrogen sulphates do not bind to 
oestrogen receptors, insinuates that the sulphokinase enzyme 
and the receptor may be functionally related.
17 p-hydroxysteroid-dehydrogenase (17/5HSD )
The 17(5 HSD enzyme system is responsible for the 
interconversion of E2 and E i, and for that of testosterone and
androstenedione and DHEA and A5androstenediol. However, data
gained with the human placental 17pHSD have indicated that the 
affinity for E2 is much higher than that for testosterone, the Km 
values being 10 pM  and 250 pM , respectively [Luu-The et al., 
1990a]. This enzyme activity is also normally present in several 
other tissues, including testis, kidney, liver, skin and ovary. Its 
inherent complexity is also mirrored in the presence of multiple 
enzyme forms, having distinct co-factor requirements, kinetics of 
reaction and subcellular distribution [Pollow et al., 1977]. In 
addition, the equilibrium between E2 and E i, that is to say 
between the reductive way (E i-- -> E 2 ) and the oxidative way (E2 - 
- -> E i) ,  has been shown to vary between in vitro [Bonney et al., 
1983a] and in vivo [McNeill et al., 1986a] conditions.
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In postmenopausal women, breast tumour tissues show an 
invariably higher (up to 20  times) E2 concentration with respect 
to Ei [James et a l ., 1986]; conversely, E i is the predominant 
circulating steroid at that age. This evidence strongly suggests 
that some mechanisms would either permit E2 accumulation in 
breast tumours or increase the intratumour conversion of E i to  
E 2 . James and associates [James et a l ., 1990], using infusion of 
radiolabelled oestrogens in postmenopausal breast cancer 
patients before surgery, observed that administration of either 
3H -E 2 or 3H -E i produced intratumour levels of E2 which always 
exceeded those of E i. This indicates that the preferred metabolic 
route of radioactive oestrogens was towards E2 . Furthermore, the 
authors showed that the proportion of intratumour E2 was 
significantly related to the plasma levels of DHEA-S, suggesting 
that the latter steroid could in some way modulate the direction 
of E2 metabolism in breast tissues. This assumption is 
corroborated by the evidence that some adrenal androgens, 
including A5-androstenediol, DHEA and its sulphate, may inhibit 
in a noncompetitive manner the 17(3HSD activity of both human 
breast and endometrium [Bonney et a l ., 1983b]. On the other 
hand, induction of 17pHSD activity (oxidative way) by progestins 
has been documented in human endometrium and in normal 
breast cells in culture [Tseng & Gurpide, 1975; Prudhomme et a l ., 
1984]. In the latter, however, the progestin-induced stimulation 
of the Ei formation seems to occur exclusively in the presence of 
the same E2 , suggesting that an oestrogen-priming effect is
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prerequisite for progestin action on 17PHSD activity in normal 
human breast [Mauvais-Jarvis et a l ., 1990].
Circumstantial data from the literature indicate that 
17pHSD levels in breast tumour tissues are related to the stage of 
disease. Beranek et al. [Beranek et a l ., 1985] showed that the 
extent of 17pHSD activity in breast fat of women having breast 
cancer is positively and significantly associated to the size of the 
tumour. Furthermore, Miller and O’Neill [Miller &  O’Neill, 1989] 
reported a significantly higher 17PHSD activity (oxidative way) in 
breast fat from patients whose tumours have colonised axillary 
lymph nodes, as compared to node-negative patients. Therefore, 
it would seem that a more advanced stage of disease (in terms of 
both tumour size and nodal involvement) and a poorer prognostic 
expectation are associated with a raise of 17PHSD activity in 
breast fat.
Additional interest comes from studies of Vermeulen and 
Deslypere [Vermeulen & Deslypere, 1989]. The authors found 
that 17pHSD activity (both directions) is remarkably higher in ER 
positive than in ER negative human mammary cancer; however, 
the oxidative pathway (E2 - - -> E i)  was always prevailing with 
respect to the reductive pathway (E ]-- -> E 2 ) in both ER positive 
and negative tumours. This would lead to E\  accumulation in 
tumour tissues, irrespective of the receptor status. Thus, we are 
facing a seeming paradox in that the significantly and 
consistently higher E2 concentration found in ER positive breast 
tumour tissues [van Landeghem et a l ., 1985a; Thijssen et al.,
1986], as well as the greater Ei content observed in ER negative
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ones [Abul-Hajj, 1979] do not match the supposed prevalence of 
the oxidative way of 17PHSD (favouring Ei accumulation) in these 
tissues. Once again, the lack of correlation between levels of 
endogenous oestrogens and both extent and direction of key 
enzyme activities of oestrogen metabolism is rather 
disappointing. However, it ought to be emphasised that, from a 
methodological standpoint, measurement of such a complex and 
dynamic structure as an enzyme system using crude extract and 
classical enzymology approach is doubtless far more artificial and 
puzzling than the quantitation of individual steroids in tumour 
tissue homogenates. Relevant points arise from studies on E2 
metabolism in vitro in human oestrogen-responsive and 
unresponsive mammary and endometrial cancer cells. Several 
groups [Castagnetta et a l ., 1986b; Adams et a l ., 1988b; Pasqualini 
et a l ., 1990; Carruba et al., 1994] have in fact found a significant 
association between the ER status of cells and their metabolic 
behaviour, in that ER-positive hormone responsive cells favour 
the reductive pathway of 17pHSD leading to E2 accumulation, 
while ER-negative non-responsive cells favour E2 oxidation to E i. 
This pattern has been consistently shown in our laboratories 
using variable incubation times with physiological concentrations 
of labelled E2 or Ei used as precursors and subsequent HPLC 
analysis to separate and identify radioactive steroid metabolites 
[Castagnetta et al., 1991a]. This procedure, which is highly 
sensitive and reproducible, allows us to simultaneously measure 
multiple enzyme activities of both oestrogen and androgen 
metabolism in intact cultured cells; it also allows us to evaluate a
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wide spectrum of steroid metabolites as either conjugated 
(sulphates and glucuronides) or unconjugated compounds. Kinetic 
parameters relevant to the main enzyme activities of steroid 
metabolism have proved to be far from those assessed using 
classical enzymology, suggesting that the latter approach is 
unlikely to predict the factual enzyme function in vivo.
Preliminary observation has also suggested that 17pH S D  
activity may substantially change in different types of breast 
tissues [Santner et a l ., 1986]. Both membrane-bound and soluble 
activities have been shown to occur in breast fat and glandular 
tissue [Tait et al., 1989]. In particular, different soluble forms, 
three in the adipose tissue and two in the glandular tissue of 
human breast, have been encountered. James and colleagues 
[James et al., 1990] embarked on a study of both soluble and
membrane 17pHSD forms in normal and tumour breast tissues 
and cells. Both adipose and glandular breast specimens revealed 
at least two different soluble activities, having molecular weights 
of 30 and 70 kDa and markedly distinct substrate and/or co-
factor requirements. Using Sephadex G-200 chromatography, in 
the presence of E2 as substrate and NAD or NADPH as co-factor,
the authors found that the 30-kDa form is predominant in both
breast adipose tissue and isolated stromal cells, whereas in MCF7 
and T47D human epithelial mammary cancer cells the 70-kDa 
form prevails. Both C l9 and C21 steroids, including DHEA-S and 
progesterone, significantly inhibited the 30-kDa enzyme activity, 
whilst they did not affect the higher molecular weight form. On 
the other hand, kinetic analysis of the membrane-bound 17PHSD
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activity, revealed that in normal and cancerous breast tissues the 
K m for E2 ranged from 1 to 5 pM , while a lower affinity (K m of 
25-40 pM ) enzyme was present in the membrane fraction of both 
fibroblasts and epithelial MCF7 or T47D cancer cells. The addition 
of conditioned medium from cultures of breast fibroblasts to 
MCF7 cells induced a significant increase in the conversion of E i 
to E2 (reductive way), with a corresponding rise in the activity of 
the soluble 30-kDa form of the 17(3HSD, while very little effect on 
the oxidative direction (E2 - - - > E i)  was seen. In summary, the 
above evidence indicates that at least two major forms of both 
soluble and membrane-bound 17pHSD exist and that these two 
forms can be distinguished on the basis of molecular weights, 
substrate affinity and specificity, co-factor requirements. In 
addition, the 30-kDa form seems to be susceptible to a variety of 
stimuli, while the 70-kDa form appears to be refractory to these 
factors. Interestingly, the 30-kDa form is likely to correspond to 
the 17(iHSD reductive activity, while the precise functional role of 
the 70-kDa form is more obscure. It might be that the latter form 
governs the oxidative 17|3HSD pathway or that it presides over 
C19 steroid oxo-reductive pathways. A molecular biology 
approach has recently allowed isolation of two distinct 17pHSD  
mRNAs [Poutanen et al., 1992] and two "in tandem" human 
17pHSD genes, located on chromosome 17, have been sequenced 
[Luu-The et a l ,  1990b]. All this body of evidence supports the 
view that 17pHSD is a complex of multiple enzyme moieties 
having different kinetics, cellular localisation and regulatory 
function of E2 metabolism.
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3 .3 .2 .  E n zy m e s  o f  an d ro g e n  m e ta b o l i s m  in h u m an  
p r o s t a t e
It has long been recognised that DHT accumulates in nuclei 
of prostate target cells and that androgenic regulation of prostatic 
cell function is principally mediated through D H T binding to 
specific receptor sites [Anderson & Liao, 1968; Bruchovsky &  
Wilson, 1969]. Since DHT is not a significant product of either 
gonadal or adrenal secretion, it is clear that local metabolism is 
primarily involved in the androgen action. Therefore, studies of 
the enzyme functions which influence intracellular D H T levels 
may hold a striking interest, especially in the view that both 
benign hyperplasia and cancer of the human prostate remain, at 
least in part, under endocrine control (for a review see [Griffiths 
et a/., 1991]).
Unfortunately, several aspects lim it the biological 
interpretation of the in vitro enzyme analysis. First of all, there 
is evidence that distinct enzyme forms, having different 
properties and subcellular localisation, may exist in either normal 
or pathological human prostate [Rennie et a l.y 1983; Hudson,
1984]. In second place, the quantitative estimates of the enzyme 
kinetic data (K m and V max) are currently carried out under 
conditions that are optimised to yield maximum conversion rates. 
This condition largely differs from physiological environment of 
pH, temperature, co-factor, substrate concentration, and enzyme 
inhibitors, in vivo. For prostate studies, it has been proposed that, 
given the generally low substrate concentration compared to the 
observed K m, the velocity of the reaction is directly proportional
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to and therefore better expressed by the ratio V max/K m [Krieg et 
al., 1983].
Sulphatase
As already discussed for oestrogen metabolism in human breast 
tumour tissues (see 3.3.1.: Sulphatase!Sulphokinase),  this enzyme 
complex catalyses the cleavage of steroid sulphates, such as 
DHEA-S and E iS . It is normally present in various human 
peripheral tissues, including liver, lung, brain, endometrium and 
placenta. Early studies have documented that human prostate 
may readily hydrolyse both DHEA-S and EiS [Farnsworth, 1973; 
Carlstrom et a l ., 1980] and therefore use these steroid precursors 
for further conversion to biologically active metabolites of both 
androgens and oestrogens. However, some question remains on 
whether cleavage of DHEA-S or E iS is governed by one or two 
different enzyme activities; some authors concluded that one 
only enzyme is involved [Klein et a l ., 1989], but the diverse Km 
(p M ) and V m a x  (nmol/h/mg DN A ) values therein reported 
(respectively, EiS: 8.7 and 47.4; DHEA-S: 4.3 and 8.4) suggest 
otherwise. Since plasma levels of both DHEA-S and E iS  are 
elevated and the ratio V max/ K m for this enzyme activity is 
comparatively high in prostatic tissues, even low uptake by 
prostatic cells could substantially contribute to the intratissue 
pool of unconjugated steroids. Indeed, higher tissue content of 
both DHEA and Ei with respect to plasma levels has been found 
in human prostate [Bartsch et al., 1986]. It is still unclear,
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however, whether these steroids act as precursors or may exert a 
direct effect on prostate cell function.
3 f t -hydroxy st ero id -dehydroge nasel A4>5 - is o m e r  ase 
This isomerase enzyme complex is commonly present at high 
activity in steroidogenic organs. It presides over conversion of 
both DHEA to androstenedione and A5Adiol to testosterone. 
Firstly, Harper and colleagues [Harper et al., 1974] detected 
isomerase activity in human prostate, although the extent of 
reaction was very low. More recent studies [Bartsch et al., 1990], 
using HPLC separation of steroid metabolites, showed that human 
BPH tissues convert DHEA to androstenedione in the presence of 
N A D  as co-factor. However, the low isomerase activity  
consistently found in both normal and pathological human 
prostate suggests that this reaction is rate-limiting.
5 a - re d u c ta s e
With no doubt this enzyme system holds a central role in the 
androgenic regulation of both regular and diseased prostate. It 
was first described by Farnsworth and Brown [Farnsworth &  
Brown, 1963] and subsequently found mainly in the nuclear 
membrane fraction of prostatic tissues [Houston et al., 1985; 
B ruch ovsky  et al., 1988]. It converts A4 -steroids, including 
testosterone and androstenedione, to the respective 5a-reduced  
derivatives, i.e. DHT and 5a-androstanedione (5a-Adione).
The intracellular DHT concentration is primarily regulated 
by the 5a-reductase enzyme in conjunction with the 3a/3(3H S D ,
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which catalyses the reduction of DHT to 3a and 3p-diols. These 
two enzyme systems have been shown to possess significantly 
higher V max/K m ratio values than all other enzymes involved in 
prostatic androgen metabolism [Bartsch et a l ., 1990].
Previous studies on castrated rats treated for two weeks 
with silastic implants releasing testosterone, androstenedione or 
DHT, revealed that, regardless of the androgen infused, prostate 
tissues always contained high levels of DHT [Bartsch et a l ., 1983]. 
This suggests that androgen metabolism in rat prostate is almost 
exclusively directed towards D H T and that other enzyme 
activities (e.g. 17PHSD) concur in this process. Both epithelial and 
stromal components of the prostate may significantly contribute 
to DH T formation, the 5a-reductase activity being found to be 
evenly distributed between the two compartments [Sirett et a l ., 
1980; Bolton et a l ., 1981].
The question whether or not alterations in DHT formation 
and degradation are involved in development of both BPH and 
prostatic carcinoma may be properly addressed by studies 
comparing androgen metabolism and content in normal, 
hyperplastic and cancerous prostatic tissues. In the past, these 
studies have been crucially hampered by the complication of 
obtaining suitable specimens of normal prostate. Further, the 
evergrowing practice to use transurethral resectomy, instead of 
open surgery, as palliative, disobstructing manoeuvre in prostate 
cancer patients has made it hard to get undamaged cancer 
samples of appropriate size. Nonetheless, a number of studies 
have investigated either DHT content or 5a-reductase activity in
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BPH and prostate cancer tissues as opposed to regular prostate.
c
Unfortunately, results from these studies are largely at variance.
DHT levels were earlier reported to be significantly (3 to 4 
fold) higher in BPH than in normal human prostate [Geller et al., 
1976; Hammond, 1978; Morfin et a l ., 1978; Isaacs et al., 1983]. 
This evidence, however, was subsequently challenged by Walsh 
and colleagues [Walsh et al., 1983], who did not find a 
supranormal tissue content of this androgen in hyperplastic 
prostate. If  correct, this finding would suggest that, in spite of 
the reduction of circulating testosterone with increasing age, DHT  
levels in BPH remain unaltered through a compensatory increase 
of the 5a-reductase activity. The latter possibility, however, is 
still debated. By contrast, more recent reports [Bruchovsky et al., 
1988; Bartsch et al., 1990] documented that normal and 
hyperplastic prostate exhibit comparable levels of 5a-reductase  
activity. It should be pointed out that this apparent discrepancy 
may well derive from methodological pitfalls. In fact, while some 
earlier studies used conditions which approximate the in vivo 
state (fresh prostate tissue slices unsupplemented with pyridine- 
nucleotide co-factors), others measured enzyme activities in 
more artificial environments (tissue homogenates supplemented 
with NADPH as co-factor), which do not allow function of the 
regulatory mechanisms existing in intact cells and the utilisation 
of endogenous co-factors. Bartsch and colleagues [Bartsch et al.,
1987] claimed that, since 5a-reductase activity found in BPH 
tissues was similar to that observed in normal prostate, 
differences in DHT concentration between the two groups should
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be better ascribed to other age-related events. In particular, it 
has been suggested that androgen receptors could be responsible 
for increased nuclear "trapping" of DHT in BPH, postulating that 
at that site DHT is protected from further metabolism since the 
3a/3pH S D  is mainly located outside the nucleus [Bartsch et a l .,
1990]. This assumption, however, is rather unlikely since either 
D H T concentration (in the order of pmol/mg DNA) or extent of 
5 a-reductase activity (in the order of nmol/h/mg DNA) are far 
exceeding the androgen receptor content (in the order of 
fmol/mg DNA) of BPH tissues.
There is overall consensus that 5a-reductase activity is 
distinctly decreased in human prostatic carcinoma with respect 
to both normal and hyperplastic tissues [Bartsch et a l ., 1990; 
Klein et al., 1991]. This phenomenon may be also a reflection of 
either the preponderance of epithelial cancer cells having 
comparatively low enzyme levels or the process of de­
differentiation leading to loss of 5a-reductase activity. More 
importantly, however, overall decrease of 5a-reductase in 
prostate cancer tissues may be the outcome of reduced enzyme 
activity in intracarcinomatous stromal cells, wherein substantial 
amounts of 5a-reductase are located. This issue has been 
recently approached by Klein et al. [Klein et al., 1991], who 
measured hydroxyproline concentration to approximately 
quantify the stromal contribution to the overall tumour volume. 
Although a significantly decreased hydroxyproline content was 
found in prostate cancer tissues with respect to surrounding 
benign areas, this reduction was too small to account for the
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remarkable differences observed between 5a-reductase activity 
of benign and malignant samples. More, epithelial and stromal 
compartment revealed parallel contribution to the overall losses 
of this enzyme activity in prostate tumours. Surprisingly, in spite 
of the decrease of 5a-reductase, unchanged or even higher D H T  
concentrations have been found in malignant with respect to 
benign prostate tissues [Bartsch et a l ., 1990; Klein et a l ., 1991]. On 
the other hand, intratumour testosterone levels were 
significantly higher than in nonmalignant prostate. This finding 
has been interpreted once more as a consequence of D H T  
accumulation in nuclei of prostate cancer cells through binding to 
intact androgen receptors. However, the same uncertainty 
manifested above for BPH also applies here.
This conflicting body of evidence is further complicated by 
the fact that human prostate might contain several types of 5a - 
reductase isoenzymes [Rennie et a l ., 1983]. Martini and associates 
[M a r t in i et a l ., 1990] demonstrated that ageing decreases 
conversion of testosterone to DHT in the rat prostate, without 
altering the production of 5a-reduced derivatives of the 17-keto 
series, namely 5a-Adione and androsterone (A ), from A 4- 
androstenedione (A 4 Ad). In addition, the authors found that 
administration to rats of 4-hydroxy-4-androstene-3,17-dione 
(40H -A ), an inhibitor of both 5a-reductase and aromatase 
prostatic enzymes, significantly reduces formation of the 17-OH 
series metabolites (DHT and 3a/3p-diols), while the 5a-reduction  
yielding the derivatives of the 17-keto series is even increased. 
The latter observation was further corroborated by the finding
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that, using A4Ad as labelled precursor in either presence or 
absence of 40H -A , the conversion to 5a-reduced metabolites of 
17-keto series was not significantly inhibited. Therefore, it was 
concluded that rat prostate may contain two distinct 5 a -  
reductase isoenzymes, having differential sensitivity to both 
ageing and 40H-A .
Presence of two separate 5a-reductases in nuclei of 
prostatic stromal and epithelial cells has been recently reported 
[Hudson, 1987]. The apparent Km values for stromal enzyme 
were found to be 10 -fold higher than those of the epithelial form, 
indicating that the latter has greater substrate affinity; on the 
contrary, stromal activity exhibited V max values up to 5 times 
those observed for the epithelial enzyme, suggesting that either 
stromal 5a-reductase activity has higher velocity of substrate- 
enzyme complex degradation or its tissue concentration is 
greater. Support to the possibility that different forms of 5 a -  
reductase activity coexist in the epithelial compartment itself 
comes from recent in vitro studies carried out in our laboratories 
on human prostate cancer cell lines. Incubation of hormone- 
responsive LNCaP cells with tritiated testosterone used as 
precursor yielded comparatively high DHT formation (reductive 
pathway), also accompanied by production of A4Ad and 5a -  
reduced compounds of the 17-keto series (5a-Adione and A). By 
contrast, androgen nonresponsive PC3 cells, under exactly the 
same experimental conditions, metabolised a high proportion of 
testosterone mainly to A4Ad, with a consequent conversion to 
both 5a-Adione and A (oxidative pathway), while no detectable
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DHT formation was observed [Castagnetta et a l ., 1994]. This 
pattern was consistently obtained between 24 and 96 hours 
incubation. This evidence indicates that LNCaP and PC3 cells, 
although both possess 5a-reductase activity, preferentially turn 
testosterone metabolism to the reductive or the oxidative 
pathway, namely towards DHT or A4Ad formation, respectively. 
This suggests that at least two distinct 5a-reductase isoforms 
exist and that they may be differently expressed or regulated in 
these cell lines.
A ro m atase
Although it has been suggested that oestrogens may participate 
in the pathogenesis of prostate diseases, including BPH and 
cancer, patterns of oestrogen formation and metabolism in the 
human prostate are still uncertain. Since levels of circulating 
oestrogens in the older male are about one hundred times lower 
than those of testosterone, it seems more likely that prostatic 
tissues use androgen blood supply for local oestrogen production. 
Therefore, attention has been drawn to the presence of 
aromatase enzyme in the prostate. Thus far, however, results 
from several studies are highly controversial in this respect 
[Smith et al., 1982; Stone et al., 1986]. Nonetheless, more recent 
reports have readdressed this issue using new, accurate 
methodologies. Fishman [Fishman, 1988] observed that normal 
human prostate actively aromatises A4Ad to yield both E] and E2 
and that this activity is substantially increased in BPH tissues. 
Correspondingly, Martini and colleagues [Martini et al., 1990]
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evaluated aromatase activity in pools of human BPH tissue 
homogenates using the amount of tritium released in the aqueous 
phase as a measure of the conversion of lp -3H-androstenedione  
to E i . The authors found that this enzyme activity is present at a 
significant rate in BPH tissues, with an affinity which is lower 
than that reported for other tissues (rat brain, human placenta). 
Moreover, BPH aromatase proved to be highly sensitive to 40H - 
A, which is known to inhibit the aromatisation process in 
placental microsomes [Brodie et a l ., 1987].
These data reinforce the view that androgen-derived 
oestrogens may basically contribute to the hormonal 
microenvironment of prostatic tissues and therefore be 
potentially important in development of pathological entities.
17  p-hydroxy steroid dehydrogenase
Presence of 17|3HSD activity has been earlier reported in both 
normal [Acevedo & Goldzieher, 1965a] and diseased [Acevedo &  
Goldzieher, 1965b] human prostate gland. It is mainly located in 
the microsomial fraction of prostate epithelial cells, although is 
also present in the stromal compartment. This enzyme complex, 
other than governing E2 and Ei interconversion, directs the 
crosslink between oxidative and reductive pathways of androgen 
metabolism. In the reductive side, it converts some 17- 
ketosteroids, including DHEA, androstenedione and E i, to the 
respective 17p-hydroxy derivatives, namely A 5 A d io l ,  
testosterone and E2 . It is worth noting that cleavage of both 
DHEA-S and EiS, followed by 17p-reduction to yield respectively
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A5Adiol and E2 , eventually lead to formation of oestrogenic 
steroids, suggesting that this pathway is mainly involved in 
regulation of oestrogen milieu in the prostate. In a recent study, 
Tunn and colleagues [Tunn et a l ., 1993] determined the kinetic 
parameters of the 17PHSD enzyme complex in testosterone and 
A4Ad interconversion in epithelial and stromal compartments of 
normal and hyperplastic human prostate. Both Km and V max 
values obtained are in favour of the presence of a heterogeneous 
enzyme system, with a relative prevalence of the reductive side 
(A 4Ad— >testosterone) of the reaction, particularly in BPH 
stroma. At this site the balance of this reversible transformation 
is thus potentially shifted towards testosterone. However, since 
the capacity of the conversion is much lower than that of other 
prostatic enzymes, such as 5a-reductase, it remains unclear 
whether testosterone formation from A 4Ad s ign ifican tly  
contributes to the intraprostatic levels of this androgen, in vivo.
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4 .  Peptide Growth Factors
4.1. Peptide Regulatory Factors (PRFs)
The term PRFs describes a class of peptide signalling factors 
which share certain basic properties: (a) low molecular weight 
(usually below 80 kDa); (b) specific high-affinity cell surface 
receptors; (c) short or intermediate range of action at very low 
concentration (10 -9 to 10_11M) (d) involvement in the control of 
cell differentiation and/or proliferation. For clarity, these "growth 
factors" would be kept apart from cytokines, which are 
commonly defined as a subset of peptides having 
immunoregulatory effects. However, this distinction is becoming 
blurred since many cytokines have been shown to affect also 
growth of non-immune cells.
PRFs are commonly thought to play a central role in the so- 
called paracr ine  and autocrine  regulation [Sporn & Todaro, 1980], 
as opposed to the endocrine control of cell growth and 
differentiation exerted by circulating hormones (see Figure 7). In 
the p a ra c r in e  and autocr ine  loops, PRFs act respectively on the 
immediate vicinity cells or upon the producing cells themselves. 
The autocr ine  model was initially proposed as a mechanism by 
which transformed cells may escape the growth dependence on 
exogenous supply of both hormones and growth factors. 
However, it is now clear that many normal cell types produce 
PRFs that can actively regulate their own growth and
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Figure 7. Models for cell growth control. Different mechanisms by 
which hormones or polypeptide growth factors regulate growth of target 
cells are illustrated. In the endocrine mode of action, hormones are 
produced by cells in distant organs and act upon target cells following 
delivery into the bloodstream. In  the paracrine  and autocrine loops, 
peptide growth factors act respectively on the immediate vicinity cells or 
upon the producing cells themselves. Two additional models are here 
depicted. The juxtacr ine  model involves cell-cell contacts whereby 
growth-regulating signals are primed through binding of membrane 
growth factors to specific cell surface receptors on adjacent cells. The 
intracrine model describes the intracellular mode of action of indigenous 
regulatory molecules which are produced and act inside the cell.
INTRODUCTION
ENDOCRINE
♦  ♦
PARACRINE JUXTACRINE
AUTOCRINE INTRACRINE
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differen tia tion . A dd itionally , there is evidence that 
autostimulatory signals may act w ith in  the cellu lar 
compartments where protein synthesis occur. This has led to 
introduce the term "intracr ine"  to describe the intracellular mode 
of action of regulatory molecules produced inside the cell. An 
example comes from the "orphan receptors" (see 2.1.3.), namely 
from intracellular binding proteins that may interact with 
endogenous, as yet unknown, ligands as potential intermediaries 
in the functional control of the cell. Furthermore, cell-cell 
contacts, such as attachment to the extracellular matrix, may 
imply growth-regulating signals which are mediated through 
specialised cell adhesion molecules and their specific cell surface 
ligands [Liotta, 1986]. Overall, this bidirectional regulation can be 
described as "juxtacrine", indicating that intercellular connections 
may prime growth regulatory mechanisms through the 
filamentous system of the cytoskeleton.
In many instances, PRFs represent m ultifunctional 
molecules, having a range of biological effects [Sporn & Roberts,
1988]. Two main events generally occur. Firstly, post-receptor 
signalling pathways (see 4.3.) produce a variation of gene 
expression; in the second place, ligand-receptor complexes are 
internalised and degraded, leading to down-regulation of the 
receptor function.
This dogma, however, has been recently challenged by the 
suggestion that some PRFs may also act directly at specific 
nuclear sites [Burwen & Jones, 1987]. Another important concern 
is that the effects of individual PRFs are crucially dependent on
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the background set by other signalling molecules; this implies 
that a target cell would integrate the assortment of signals
received to yield a response coherent with its context. In 
addition, different PRFs may have divergent or additional effect 
on the same signalling pathway. The matter is further 
complicated by the indication that some PRFs can down-regulate 
other unrelated receptors (a process termed transmodulation) 
[Zachary & Rozengurt, 1985] or induce the production of other 
PRFs [Balkwill, 1989]. Overall, this makes much more difficult to 
predict confidently the net effect of specific PRFs.
In terms of cell biology, the cancer phenomenon can be 
described as a disorder of the cell social behaviour in
multicellular organisms. This could reflect errors in external
regulatory signals or a subversion of intracellular control
mechanisms at genetic level. These two apparently opposed
views coincide in that any alteration in the cellular genome
organisation causes a distortion of the recognition of and
response to external signals regulating cell growth and 
differentiation. In this framework, PRFs studies might contribute 
to the understanding of processes responsible for the appearance 
of a transformed phenotype.
Abnormalities of both PRFs production and membrane 
receptors may well lead to disorders of cell growth. Various
experimental systems have documented that immortalised cell 
lines secrete substantial amounts of PRFs in their culture medium 
and that this activity may enhance cell proliferation via an
a u to c r in e  loop [Sporn & Roberts, 1985]. The "conditioned”
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medium obtained from these cultures has also been shown to 
promote growth of cells of totally unrelated lineages or even 
induce, at least transiently, a transformed phenotype in some 
nonmalignant cells in culture [Derynck, 1988]. On the other hand, 
any increase of number and/or affinity of specific cell surface 
receptors may result in an enhanced response to locally available 
PRFs. In addition, structural alterations may give rise to a 
constitutively active form of the receptor (e.g. truncated 
receptor) in the absence of ligand [Weiner et a l ., 1989]. It is also 
conceivable that the intracellular signalling cascade may be 
altered in such a way that cellular response to normal
concentrations of PRFs is exaggerated or that cell is locked in a 
continuous proliferative state in absence of external signals 
[Robertson, 1988]. This would effect the ability of cells to grow 
in vitro on minimal requirements of both medium an serum.
Finally, cells may escape a negative growth control normally 
exerted by some PRFs through loss of specific membrane
receptors or block of the inhibitory signal at some later point 
[Roberts et a l ., 1988].
4.2. The Epidermal Growth Factor (EGF) Family
Although the first description of EGF activity dates back 
over 30 years, the subsequent attempts to ascertain its precise
biological role and mechanism of action have remained mostly 
fruitless. In the early 1960s, when Rita Levi-Montalcini and
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Stanley Cohen were investigating the control of nerve cell 
development and growth [Levi-Montalcini &  Cohen, 1960], they 
found that snake venom containing phosphodiesterases, added to 
tumour cell extracts to exclude involvement of nucleic acids, 
exhibited itself a nerve growth factor-like activity. This evidence 
eventually led Cohen [Cohen, 1962] to describe this activity in 
mouse submaxillary gland extracts as responsible for premature 
eyelid opening and incisor eruption ("tooth-lid factor”) when 
injected into neonatal mice. The present name EGF first appeared 
few years later, when Cohen [Cohen, 1965] documented that this 
m olecule also promotes epidermal p ro life ra tion  and 
keratinisation in organ cultures of embryonic skin. Following 
optimisation of both isolation and purification procedures, 
sufficient amount of mouse EGF (mEGF) was then available to 
determine its primary sequence [Savage et a l ., 1972]. It was 
found to consist of 53 amino acids, with an approximate 
molecular weight of 6054, and to contain six cysteine residues. 
The latter represent the sites of three disulphide bonds, 
specifically located between Cys6-Cys2o, Cysi4 -Cys3 i and Cys34- 
C ys 4 2 , which create three main peptide loops [Savage et al., 
1973]. A ll these three bonds seemed to be required for full 
biological potency of EGF [Taylor et al ., 1972].
Concomitantly, independent studies led to the purification 
of urogastrone, a substance which proved to be effective in 
treatment of experimentally induced ulcers in dogs, from urine of 
pregnant women (at low frequency of ulcers) [Gregory, 1975]. 
Subsequent comparative analysis of amino acid compositions
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persuaded Gregory to conclude that urogastrone was the human 
homologue (hEGF) of mEGF.
Initially, De Larco and Todaro [De Larco &  Todaro, 1978] 
reported that retroviral transformation of 3T3 fibroblasts with 
the Moloney sarcoma virus was associated with the release into 
the culture medium of a mitogenic substance which was referred 
to as "sarcoma growth factor" (SGF). Further studies revealed that 
SGF consisted of two distinct components, termed transforming 
growth factor a (TGFa) and p (TGFP). The former was found to be 
structurally homologous to EGF and characterised by binding to 
EGF receptor, the latter potentiated the clonal effects of TGFa on 
growth of normal rat kidney (NRK) cells, in culture. Subsequently, 
rat TGFa was purified from conditioned media of feline sarcoma 
virus (FeSV)-transformed cells and its amino acid sequence 
determined [Marquardt et a l ., 1984]. TGFa is a 6 -kDa polypeptide 
whose 50 amino acid primary structure displays homology to 
EGF; this includes preservation of the six cysteine residues and 
the resulting three disulphide bonds, with some additional 
conservation most notably in the third loop.
More recent reports have deduced the primary sequence of 
EGF from other species, including rat, guinea-pig and pig 
[Simpson et a l ., 1985; Pascall et a l ., 1991]. Comparison of the 
known EGF sequences points to some interesting clues (see Figure 
8 ). Firstly, the six cysteine and other amino acid (Gis, G36, Y 37 , 
G 39 , R41 and L47) residues are invariant. Overall, there is 50% 
homology among EGF sequences, the most highly conserved 
region being extended from Ser9 throughout Glu24 . In addition,
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both N and C termini appear to be unimportant for biological
activity, while a core of (4-48)EGF in all species would be 
sufficient in this respect. Similarly, TGFa sequence is very highly 
conserved in different species (human, rat, bovine) and shows 
33-44% homology with EGF (see Figure 8 ).
Apart from the different species-specific subtypes, it is 
now clear that both EGF and TGFa belong to an extended family 
of related proteins which share the invariant spacing of six 
cysteine residues and the ability to bind and activate the EGF 
receptor. For instance, the newly discovered amphiregulin,
isolated from conditioned medium of MCF7 cells treated with 
phorbol ester, was found to be structurally and functionally 
related to both EGF and TGFa [Shoyab et a l ., 1989]. The same was 
true for other two proteins, the Schwannoma-derived growth 
factor [Kimura et a l ., 1990] and the heparin-binding EGF-like 
growth factor [Higashiyama et al., 1991]. Furthermore, a series of 
poxvirus growth factors show considerable (25-30%) homology to 
EGF. They include vaccinia virus growth factor (VGF) [Reisner,
1985], myxoma virus growth factor (M VGF) [Upton et al., 1987], 
molluscum contagiosum [Porter & Archard, 1987] and Shope
fibroma virus growth factor (SFGF) [Chang et al., 1987].
Additionally, the EGF structural motif is also encountered in a 
variety of proteins not formally classified as PRFs, as well as in 
an assortment of distant species. This amazing array of naturally 
occurring EGF-like domains makes it difficult to imagine a 
satisfactory interpretation of their functional role. They could 
represent sequence motifs used to generate a number of similar
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Figure 8 . Amino acid sequence alignment of epidermal growth factor 
receptor (EGFR) ligands. Several members of the EGF family or related 
factors which are known to activate EGFR are included from both 
human and other species. Conserved residues (notably cysteine 
residues) are boxed. Hu, human; Mo, mouse; Rt, rat; Gp, guinea pig; Pg, 
pig; Ho, horse; Rb, rabbit; Bo, bovine; VGF, vaccinia virus growth factor; 
MVGF, myxoma virus growth factor; SFGF, Shope fibroma virus growth 
factor; AR, amphiregulin; HB, heparin-binding EGF-like growth factor.
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protein structures, vestigial copies of an ancestral gene product 
devoid of any actual function or common precursors for as yet 
unknown growth factors.
4.2 .1 . B iosynthetic  routes
Early reports indicated that several high molecular weight
(9, 28, 30 and 74-kDa) forms of EGF exist [Taylor et a l ., 1974;
Frey et a l , 1979]. More recently, with the advent of recombinant 
DNA technology, it has been revealed that EGF mRNA is 
approximately 4750 base pairs and that it encodes a large
precursor (called preproEGF) of 1217 amino acids (128-kDa) 
[Gray et a l ., 1983; Scott et a l., 1983]. Correspondingly, cloning of 
rat cDNAs showed that TGFa is encoded by a 4.8-kilobase mRNA 
that includes a short 5’ untranslated region of 150 nucleotides, a 
long 3' untranslated region of approximately 3900 nucleotides 
and an intermediate coding region in between [Lee et a l ., 1985a; 
Blasband et a l ., 1990]. The latter sequence encodes a precursor 
(termed proTGFa) 159 or 160 amino acids long.
The first 25 amino acids from the N terminus of the
preproEGF are thought to behave as a "pre-signal" sequence. The 
mature (1-53)EGF is represented by residues 976-1029 of the 
precursor, although the latter remarkably includes seven more 
repeating EG F-like domains with some degree (20-40% ) 
homology to EGF [Scott et a l ., 1983]; interestingly, the most 
conserved region in these EGF-like segments corresponds to the 
29-37 span in the "authentic" (1-53)EGF. The extreme C terminus 
of preproEGF shows a 20 amino acid hydrophobic region
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(residues 1039-1058), down-sequence from the "authentic" EGF 
by just ten residues. It has been suggested that this motif acts as 
a transmembrane domain, in a alpha helical conformation, whose 
function is to arrange the bulk of the precursor as a membrane- 
bound glycoprotein having both carbohydrate and EG F-like  
domains on the external surface of the cell membrane [Scott et 
a l., 1985]. Although the most obvious concept is that EGF, under 
this form, is available to extracellular protease activities for local 
cleavage of the mature EGF, it is intriguing to speculate that 
preproEGF may even directly participate in cell-to-cell or cell-to- 
extracellular matrix interactions while it is held within the cell 
membrane. Using an EGF mini-gene expression system, it has 
been shown that the membrane-anchored form of EGF is capable 
of stimulating EGF receptors on adjacent cells [Dobashi & Stern,
1991].
By analogy, proTGFa has been shown to contain both a 
signal peptide and a second extremely hydrophobic region 
having the characteristics of a transmembrane domain [Derynck 
et a l ,  1984]. It has been therefore suggested that proTGFa is an 
integral membrane glycoprotein from which the mature growth 
factor is cleaved through the action of an elastase-like enzyme on 
alanine-valine bonds at both termini. As postulated for 
preproEGF, these membrane-spanning precursor forms may 
provide a mechanism whereby growth factor action can be 
limited to adjacent cells or, alternatively, behave as cell 
recognition or adhesion molecules. There is recent convincing 
evidence that proTGFa binds to and activates EGF receptor on
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adjacent cell surfaces, leading to immediate downstream signal 
transduction [Brachmann et a l ., 1989; Wong et al., 1989]. In 
addition, this intracellular signalling cascade has been found to 
result in the stimulation of DNA synthesis and transformation of 
NRK cells [Blasband et a l ., 1990].
4.2.2. Tissue distribution and functional implicat ions
The enormous literature concerning structural and 
functional features of both EGF and TGFa has been recently 
surveyed by two excellent reviews [Fisher &  Lakshmanan, 1990; 
Prigent & Lemoine, 1992]. Although very often studies on 
intratissue EGF have been constrained by the low levels of either 
immunoreactive EGF or EGF mRNA, several reports have 
immunohistochemically or biochemically detected significant 
amounts of EGF in a range of human tissues [Kasselberg et a l ., 
1985; Kajikawa et a l ., 1991]. Apart from submandibular salivary 
gland, these include different sites of the gastrointestinal tract, 
anterior pituitary, bone marrow, mammary gland, uterus, ovary 
and placenta.
The possibility that TGFa could be detected also in normal 
tissues was realised soon after its discovery [Roberts et al., 1981]. 
Significant levels of either TGFa or its transcript have been found 
mainly in normal self-renewing epithelial tissues (e.g. skin and 
gastrointestinal tract) [Derynck et al., 1984]. In addition, TGFa  
mRNA has been identified in epithelial cells from various body 
sites, including anterior pituitary [Samsoondar et a l., 1986], skin 
keratinocytes [Coffey et a l , 1987], female genital tract [Kommoss
141
INTRODUCTION
et a l ., 1990], brain [Wilcox & Derynck, 1988] and others. There is 
today a great deal of evidence suggesting that TGFa is implicated 
in the process of normal development. Earlier reports showed 
that relatively high levels of TGFa mRNA are present in crudely 
dissected rat foetuses at days 8 and 9 of gestation [Lee et a l ., 
1985b]. Subsequent in situ hybridisation, however, revealed 
that this evidence was mainly a result of contaminating maternal 
decidua, rather than a contribution of the embryo itself [Han et 
a l . y 1987]. Interestingly, TGFa expression in decidual tissues 
displayed an apparent gradient, the highest levels being found in 
the immediate proximity to the embryo. Since both decidua and 
embryo tissues contain EGF receptor [Chegini & Rao, 1985], it is 
conceivable that maternal TGFa may stimulate decidual growth 
and embryonic development respectively via autocrine and/or 
paracrine mechanisms.
4.2.3. Biological effects and cancer growth
Both in vivo and in vitro studies have demonstrated that, 
apart from growth regulation, EGF may have profound effects on 
mechanisms involved in differentiation, motility and function of 
target cells. For instance, implants of EGF pellets induced 
formation of ductal end buds in mouse mammary gland and 
superseded oestrogen and progesterone requirement for normal 
development of mammary stem cell layer [Coleman et a l 1988]. 
Several reports also indicate that EGF may have a role in the 
central nervous system [Fallon et a l ,  1984]. In particular, EGF has
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been shown to support growth of cultured telencephalic neurones
from the rat brain [Morrison et a l ., 1987].
T G F a  has been shown to stimulate cell migration 
[Barrandon & Green, 1987], angiogenesis [Schreiber et a l ., 1986] 
and bone resorption [Stern et a l ., 1985]. Additionally, TGFa  
stimulates both growth and migration of keratinocytes in wound 
healing [Schultz et a l ., 1987]
Most of our present knowledge of the effects of both EGF 
and TG Fa is based on in vitro studies. The range of either
epithelial or mesenchymal cultured cells which are influenced by
EGF and TGFa is astonishing. Although obvious care should be 
placed in extrapolating the role of these growth factors in normal 
and malignant cell growth in vivo, the pleiotrophic action of EGF 
and TG Fa in vitro  suggest a myriad of functions of these 
molecules in vivo. However, it should be emphasised that net 
effects may be both dependent on the availability of adequate 
EGF receptor and related to interaction with both hormones and 
other growth factors. In particular, it is known that bombesin,
PDGF and TGFp act in synergy with either EGF or TGFa [Rozengurt,
1986].
Insofar as cancer cell growth is concerned, there is
evidence that TGFa is involved in malignant transformation,
while this association is less clear for EGF.
Overproduction of both TGFa and its mRNA has been
observed in transformed cultured cells [Derynck et a l 1987] and 
in several human solid tumours, including breast [Barrett-Lee et 
a l ., 1990] and prostate [LLoyd et al., 1992]. Transfection of NRK
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or mouse mammary epithelial cells with TGFa plasmids may 
produce fu ll transformation, as assessed by anchorage- 
independent growth and tumourigenicity in nude mice 
[W a ta n a b e  et a l ., 1987; Shankar et a l ., 1989]. However,
concurrent overexpression of EGF receptors may be required for 
TGFa-induced transformation of 3T3 fibroblasts [Di Marco et a l .,
1989].
Although the potential role of EGF in neoplastic 
transformation is still obscure, there is a large body of literature 
supporting a tumour promotional activity for EGF (reviewed by 
[Stoscheck & king, 1986]). Elevated expression of EGF has been 
found in a large proportion (6 8 %) of prostatic tumours [Fowler et 
a l ., 1988], while high levels of EGF-like activity have been 
described in breast, endometrial and ovarian carcinomas 
[Bauknecht et a l , 1989]. Some earlier work [Kurachi et a l.y 1985] 
suggested that EGF has a likely role in the onset and subsequent 
growth support of mouse mammary tumour.
Most importantly, however, the overall involvement of EGF 
and TGFa in the induction, promotion and progression of 
malignant cells from endocrine target tissues (such as breast and 
prostate) should be considered in a much wider context where 
the combined action of these and other peptide growth factors 
with steroid hormones has to be carefully taken into account. 
There is good evidence that production of both EGF and TGFa are 
under control of oestrogens and androgens respectively in human 
breast and prostate tumour tissues and cells (for pertinent 
reviews see [Lippman & Dickson, 1989; Griffiths et a l ., 1991]).
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4.3 .  The T r a n s fo r m in g  G ro w th  F a c t o r  (3 (T G F P )  
S u p e r f a m i l y
The main reason why research on TGFp has attracted so 
fervid scientific excitement in the last two decades mainly lies in 
some characteristics unique to this peptide family. Firstly, unlike 
many other growth factors, TGFps are largely expressed by a 
variety of both normal and transformed cells. Secondly, there is 
an exceptionally high conservation of TGFps structure in several 
species. Finally, TGFps have been implicated in a range of 
biological activities, including embryonic development, tissue 
remodelling, inflammation and wound repair, angiogenesis, 
immune response, apart from control of cell proliferation 
(reviewed by [Roberts & Sporn, 1990]). In this respect, TGFps can 
be considered the prototype of multifunctional signalling 
molecules.
T G F p  was first described as a factor capable of inducing 
colony formation of NRK fibroblasts in soft agar in the presence 
of EGF and originally referred to as sarcoma growth factor, SGF 
[De Larco & Todaro, 1978]. Since similar activities were found in 
acid-ethanol extracts of several tumour cells, the name was 
changed to "transforming growth factor" [Roberts et al., 1980]. It 
was subsequently revealed that the original SGF activity was 
composed by two entirely different peptides, which were hence 
termed TGFa and TGFp [Anzano et a l ,  1983].
Today, it is known that TGFps belong to a multi-gene family 
of related peptides which share 30 to 40% amino acid homologies
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and conservation of 7 cysteine residues. These peptides include 
inhibins and activins [Ying, 1988], Mullerian inhibitory substance 
[Josso & Picard, 1986], bone morphogenetic proteins [Wozney et 
a l ., 1988], D ro so p h ila  decapentaplegic protein [Panganiban et al.,
1990], the mouse Vgr-1 gene product [Lyons et al., 1989a] and 
the GDF-1 factor [Lee, 1990]. It has been suggested that many of 
these peptides act in orchestrated patterns during the embryonic 
development [Lyons et al., 1989b], but the broad range of the 
biological activities exerted suggest that they are important 
components of several basic cellular processes.
The cellular and molecular biology of TGFp has been 
extensively reviewed by recent symposia, to which the reader 
may rely on for reference*.
4.3.1. Biosynthesis and structure
Initially, TGFp (TGFpi) was purified to homogeneity from 
human platelets and placenta, partly sequenced and finally  
cloned from a human placental cDNA library [Derynck et a l .,
1985]. These studies revealed that TGFp was a disulphide-linked 
homodimer of 25 kDa, composed of two monomers of 112 amino 
acids each (12.5 kDa). Further studies, however, showed that 
monkey kidney BSC-1 cells released in their culture medium a
* Transforming Growth Factor-Bs. Chemistry, Biology and Therapeutics, 
K.A. Piez & M.B. Spom (eds). Annals of the New York Academy of Science,
volume 593, 1990 (379pp).
Clinical Applications of TGF-B. G.R. Bock & J, Marsh (eds). Ciba Foundation
Symposium 157, Wiley , Chichester, 1991 (254pp).
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TGFp-related molecule, having negative autocrine growth effects 
[Tucker et al., 1984]; this factor was later isolated and found to 
be identical to a second form of TGFp, called TGFp2 , which had 
been previously isolated from bovine bone [Seyedin et al., 1987] 
and human glioblastoma cells [Wrann et a l ., 1987]. It was 
therefore clear that at least two different TGFp forms (the 
original TGFpi and TGFP2) exist. In the past few years, three 
more TGFp species have been cloned by low stringency 
hybridisation from mammalian (TGFP3) [Derynck et a l ., 1988], 
chicken (TG FP4) [Jakowlew et al., 1988] and frog (TGFP5 ) 
[Kondaiah et a l., 1990] cDNA libraries. Overall, there is 70-80%  
homology in the different TGFp monomers, with a complete 
preservation of the 9 cysteine residues throughout, while the 
sequence of each mature TGFp type is very highly conserved (98- 
100%) between species. TGFpi, 2 and 3 have been found to share 
most of their activities, while the biological significance of the 
other two forms remains to be established. A ll these three 
human isoforms are thought to exist prevalently as homodimers; 
however, biologically active heterodimers, consisting of one 
chain each of TGFPi and TGFp2 , have been found in porcine 
platelets [Cheifetz et al., 1987] and it would be not surprising if  
this were also true for human TGFps.
T G F p i is synthesised as a larger 391 amino acid precursor 
(p re p ro T G F p  1) of which the sequence of the mature TGFpi 
monomer comprises the C-terminal end region. Similarly, TGFp2 
and TGFp3 derive from precursor forms respectively of 414 and 
412 amino acids, the mature forms being represented by
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disulphide-bond homodimers of 24 kDa [ten Dijke et a l ., 1990]. 
However, only 30% homology occurs in the proregion of these 
different precursors. Analysis of Chinese hamster ovary (CHO) 
cells transfected with TGFpi precursor cDNA revealed that both 
mature and precursor forms of TGFPi are held in a protein 
complex (90-110 kDa), which consists of preproTGFpi, the pro- 
region of TGFPi precursor and the mature TGFPi [Gentry et a l .,
1987]. The proregion of the precursor form includes three main 
potential sites of glycosylation (Asn 82, Asn 136, Asn 176) which 
are thought to be essential for TGFpi processing and secretion 
[Miyazono & Heldin, 1989; Sha et a l ., 1989]. In particular, the 
first two glycosylation sites contain mannose-6 -phosphate (M -
6P) residues which may capacitate the precursor to bind to M-
6P/insulin-like growth factor I I  cell surface receptors [Purchio et 
a l . ,  1988]. This suggests that preproTGFPi may function 
differently from the mature peptide and that it may be delivered 
to lysosomes where its proteolytic cleavage occurs. Glycosylation 
sites have been found also in other TGFp precursor types, 
specifically three in TGFp2 , four in TGFp3 and one in TGFp4 . 
Interestingly, all TGFp precursor forms, apart from TGFP2 , show 
an Arg-Gly-Asp (RGD) sequence proximal to the cleavage site 
which is thought to represent a recognition motif for extracellular 
matrix receptors of the integrin fam ily [Ruoslahti &
Pierschbacher, 1987].
An important feature of several TGFps is that they exist in 
many tissues as high molecular weight latent complexes, which 
can be activated by transient acidification or proteolytic
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treatment [Lyons et a l., 1988; Pircher et a l ., 1988]. Latent TGFPi 
(L -T G F P i)  complex has been purified from human platelets and 
structurally characterised [Miyazono et al., 1988]. Under non­
reducing conditions it displays a molecular weight of 210 kDa 
and is found to consist of at least three distinct components (13, 
40 and 125-160 kDa, respectively) using reducing conditions. 
The 13-kDa component represents the TGFPi monomer, while the 
40-kDa component corresponds to the N-terminal remnant of the 
precursor, lacking the hydrophobic signal sequence (residues 1 - 
29). The third 125-160-kDa component is a novel subunit, 
distinct from previously described proteins, which has been 
termed TGFpi-binding protein (TGFp i-BP). The assembly of these 
components to yield the 210-kDa L-TGFPi complex includes a 
series of disulphide bonds which bridge them each other; a 
tentative model is illustrated in Figure 9. As can be seen, the 
complex consists of a mature TGFPi homodimer noncovalently 
associated to a dimeric form of the 40-kDa N-terminal remnant 
of the TGFpi precursor (latency-associated peptide, LAP). The 
latter is disulphide-linked to the TGFpi-BP which is most likely 
monomeric. Recombinant TGFPi, 2 and 3 have been shown to 
occur as smaller latent complexes (approximately 105 kDa) which 
lack TGFpi-BP; this indicates that LAP is sufficient for latency 
[Brown et al., 1990].
There is a subtle perplexity on the relationship existing 
between the TGFp precursor forms, on one hand, and the latent 
TG FP complex on the other. To my best knowledge, there is no
1 4 9
INTRODUCTION
evidence in the literature on how these two entities relate each 
other, curiously authors tend rather to keep them separated.
TG Fp-LA Ps are peptides consisting of approximately 300 
amino acids that, likewise their parent precursors, contain at 
least three potential N-glycosylation sites and some RGD  
sequences (see Figure 9). The presence of these peculiar domains 
suggests that LAPs, alone or in complexes, may interact with 
specific cellular binding proteins different from the TGFp 
receptors.
An interesting complement to this issue comes from the 
analysis of TGFp i-BP. The latter is a 125-160 glycoprotein which 
has been found to contain multiple EGF-like repeats [Miyazono et 
al . ,  1988]. Similarly, TGFpi-BP purified from human foreskin 
fibroblasts showed a 64% of its sequence to be occupied by 16 
EGF-like fragments and by three copies of a distantly related 
eight-cysteine motif [Kanzaki et al., 1990]. The functional role of 
TG Fpi-B P remains to be clarified. Addition of TGFpi-BP does not 
inhibit TGFpi binding to its own receptor, suggesting that it is not 
required for latency. However, TGFp i-BP may stabilise the latent 
complex or take part in the biosynthesis and processing of the 
mature TG FPi. Additionally, free TGFpi-BP forms have been 
shown to occur in some cell types, including human platelets. 
This evidence, combined to the peculiar structure of this large 
protein (including multiple EGF-like motifs), suggests that it may 
also participate in vivo to processes unrelated to the TGFp action.
Finally, the active forms of TGFp can also be bound and 
inactivated by a 2 -macroglobulin (a 2 M ), a serum protease
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F ig u re  9. Latent transforming growth factor-pi (TGFpi) complex. 
In this schematic representation a mature TGFPi homodimer is 
disulphide-bonded to a dimeric form of the 40-kDa N-terminal remnant 
of the TGFPi precursor (the so called latency-associated peptide, LAP). 
The latter is also linked by disulphide bonds to a relatively large protein, 
the TGFpi-binding protein (TGFpi-BP) which is monomeric. Presence of 
three potential N-glycosylation sites (GS) and some Arg-Gly-Asp (RGD) 
sequences in the LAP molecule is also indicated (for details see text). 
(Modified from [Miyazono, 1991 #297])
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inhibitor [Huang et al., 1988]. TGF|3-a2M complexes have been 
found in serum [O'Connor-McCourt & Wakefield, 1987], but is still 
unclear whether these complexes function like carriers to release 
bioactive TGFp at relevant target sites or a2M  acts locally as a 
scavenger for undesirable TGFp activity, in vivo.
4.3.2. Biological  activity
In an imaginative description, Sporn and Roberts [Sporn &  
Roberts, 1988] have represented the biological activity of TGFp 
and other growth factors, like symbols or letters in an alphabet
of a biological regulatory language, is always contextual. Indeed, 
TG Fp is a pointed example of multifunctional signalling peptide 
working in the intricate network of communication between and 
within cells.
It must be pointed out, however, that the multiplicity of
TG F p  actions is also based on the balance of the different TGFp
isoforms in individual tissues. Although most in vitro  assays 
showed nearly equivalent activity of the three human TGFp 
isoforms, the evidence that in certain systems one isoform 
exhibits effects several times greater than the others indicates 
that isoform switching may have significant consequences at 
specific target sites. In addition, TGFps themselves have been 
shown to participate in the differential regulation of TGFp
isoform expression. For instance, Bascom and colleagues [Bascom 
et al., 1989a] have documented that in murine AKR-2B cells TGF- 
Pi down-regulates expression of the mRNA for both TGFP2 and 
TG FP 3, while TGFP2 up-regulates expression of all TGFp mRNAs.
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This differential regulation finds its molecular basis in the 
different location of the TGFp genes (chromosomes 19, 1 and 14 
respectively for TG FPi, 2 and 3) and, especially, in the very 
different character of their 5' flanking regions [Roberts et al., 
1991].
Perhaps, the most striking effects of TGFps are those on cell 
growth and differentiation and on extracellular matrix formation. 
Both of them are relevant to many other TGFp actions, including 
embryogenesis, angiogenesis, inflammation and tissue repair, 
immune response, bone remodelling and cartilage formation.
Epithelial differentiation and growth inhibition 
Inhibition of epithelial cells is often paralleled by their terminal 
differentiation. While TGFpi potently inhibits growth of rat 
intestinal, mink lung and human bronchial epithelial cells in the 
presence or absence of mitogens, it concomitantly induces their 
differentiation [Massui et al.y 1986; Kurokawa et a l., 1987].
Both TG Fpi and TGFp2 are the most potent growth 
inhibitors known for a wide range of cultured cells, including 
epithelial, endothelial and many myeloid cells [Bascom et al., 
1989b]. All the three human TGFp species intensely inhibited 
growth of keratinocytes by inducing a reversible growth arrest in 
the Gi phase of the cell cycle [Shipley et al., 1986; Graycar et a l., 
1989]. Since keratinocytes have specific cell surface receptors for 
TG F ps, release remarkable amounts of TGFp into the culture 
medium and respond to addition of TGFp, it has been proposed 
that TGFpi acts in this context as a negative autocrine growth
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regulator. Although TGFpi does not seem to interfere with early 
events produced by other peptide growth factors, such as the EGF 
induction of the c-fos proto-oncogene, EGF stimulation of DNA  
synthesis is prevented by addition of TGFPi in the late G i, 
namely long after early EGF-induced events have occurred [Like 
& Massague, 1986]. Furthermore, TGFPi inhibits entry of the cell 
into the S phase when added at any time up to the G i /S  
boundary [Pietenpol et a l ,  1990a]. Subsequent studies have 
indicated that TGFPi participates in a growth inhibitory pathway 
which involves the proto-oncogene c - m y c  and the protein 
product (pRb) of the retinoblastoma tumour suppressor gene. It 
is known that early c - m y c  induction is necessary for the 
recruitment of quiescent cells into the Gi phase [Bascom et al., 
1989b]. Knock-out of the c - m y c  gene using antisense 
oligonucleotides intensely inhibits proliferation of mouse 
keratinocytes [Pietenpol et a l., 1990b]. However, unlike other
immediate early genes, elevated c-myc  expression persists over 
the Gi and during the S phases of the cell cycle [Coffey et a l ., 
1988]. Interestingly, addition of TGFPi to EGF-stimulated mouse 
keratinocytes at any point of the Gi phase or during the early S 
phase rapidly reduced expression of both c - myc  transcript and 
protein [Moses et al ., 1991]. It was proposed that TGFPi action is 
mediated via a protein that interacts with a specific cis element 
of the 5' regulatory region of the c - m y c  gene, leading to 
inhibition of the transcriptional initiation of this gene [Pietenpol 
et al., 1990b]. Further studies have indicated that this protein 
component is likely to correspond to pRb. The latter is 105-kDa
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cell cycle regulatory factor, having presumptive growth 
suppressor activity, which is differentially expressed in multiple 
phosphorylated forms throughout the different cell cycle phases 
[De Caprio et a l ., 1989]. The underphosphorylated forms prevail 
during G i and in the growth-arrested state, while 
hyperphosphorylated forms are encountered in the S and G2/ M  
ph ases. On this basis it has been suggested that
underphosphorylated pRb is responsible for growth suppression 
and that TGFp 1 may prevent further scheduled pRb
phosphorylation, leading to cell arrest in the late Gi [Laiho et a l ., 
1990a]. In addition, it has been demonstrated that 
underphosphorylated pRb associates with transforming proteins 
of several DNA tumour viruses, such as large T antigen (TAg) of 
the SV40 [De Caprio et a l ., 1988], E1A of adenovirus [Whyte et a/., 
1988] and E7 of human papilloma virus -16 [Dyson et al., 1989]. 
This association has been shown to result in a block of the growth
suppressive activity of pRb [De Caprio et al., 1988] and in the
prevention of the inhibitory effect of TG Fpi on both cell 
proliferation and c- myc  expression [Pietenpol et a l ., 1990a]. A 
model has been therefore proposed whereby T G F p i-in d u c ed  
growth suppression is mediated by the repression of the c - m y c  
gene via pRb (see Figure 10).
Extracellular matrix formation
The action of TGFp on many cell types, both normal and 
neoplastic, commonly implies the up-regulation of several cell 
adhesion molecules [Massague, 1990]. In particular, TGFP
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F ig u re  10. Model for transforming growth factor pi-induced growth 
inhibition. TGFpi is thought to activate the protein product (pRb) of the 
retinob lastom a tum our suppressor gene by preventing its  
hyperphosphorylation during the cell cycle. Underphosphorylated pRb 
interacts with a specific cis element of the 5' regulatory region of the 
c-myc gene, leading to inhibition of the transcriptional initiation of this 
cellular oncogene [Pietenpol, 1990b #298]. The latter has been shown to 
be necessary for the recruitment of quiescent cells into the Gi phase 
[Bascom, 1989 #299}. Therefore, TGFpi could induce a repression of 
the c-myc gene through activation of pRb, leading to the observed 
growth arrest of cells in the late Gi phase of the cell cycle. This 
assum ption is also supported by the evidence that association of 
underphosphorylated pRb with transforming proteins of several DNA 
tumour viruses, such as large T antigen (TAg) of the SV40, E1A of 
adenovirus and E7 of human papilloma virus-16, results in a block of the 
growth suppressive activity of pRb and in the prevention of the 
inhibitory effect of TGFPi on both cell proliferation and c-myc expression 
[Pietenpol, 1990a #300].
(Modified from [Moses, 1991 #301]).
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increases the expression of genes encoding for both fibronectin 
and different types of collagen [Ignotz & Massague, 1986], as well 
as production of other extracellular matrix components, including 
tenascin, osteonectin, thrompospondin, etc. [Massague, 1990]. In 
addition, TGFp down-regulates expression of various collagenase- 
like enzymes [Kerr et a l ., 1988], but increases the synthesis of 
proteolytic inhibitors, such as plasminogen activator inhibitor- 1 
(PA I-1) [Laiho et a l ., 1986]. The likely net effect is represented 
by an accumulation of extracellular matrix, as observed 
following intradermal administration of TGFp [Roberts et a l .,
1986]. TGFp has also been shown to control the expression of the 
repertoire of the integrin family of cell-extracellular matrix and 
cell-cell adhesion receptors [Heino et a l ., 1989]. Thus, TGFp may 
dramatically affect the adhesive behaviour of the cell and 
therefore be primarily involved in those processes wherein cell 
migration, homing and settlement are essential.
Other activities
The developmental role of TGFps is supported by its spatial 
and temporal expression in the developing embryo. For instance, 
in the mouse developing palate, TGFp3 mRNA is expressed very 
early in the medial edge epithelial cells, while TGFpi mRNA  
expression emerges in the same cells at a slightly later stage; in 
contrast, T G F p 2 mRNA is confined to mesenchymal cells 
[Fitzpatrick et a l ., 1990].
In the bone remodelling process TGFp potently stimulates 
chemotaxis, proliferation and terminal differentiation of
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committed osteoblasts [Noda & Camilliere, 1989], while it inhibits 
osteoclast formation and activity [Chenu et al., 1988]. In this 
context, however TGFp synergises with other locally produced 
factors; these include the osteoinductive factor (OIF) and a family 
of related proteins called bone morphogenesis proteins (BMP) 
[Wozney et al., 1988]. Recently, it has been documented that 
oestrogens stimulate TGFp production in bone cells [Komm et al.,
1988]. The value of this evidence is twofold. Firstly, it may 
explain why menopausal oestrogen withdrawal also results in 
osteoclastic bone resorption and reduced bone formation. In 
second place, the finding that TGFPi is an oestrogen-regulated 
growth factor in human mammary cancer cells [Knabbe et al.,
1987] and that it produces an increased cell adhesion via up- 
regulation of extracellular matrix, may provide a background for 
the well known propensity of breast tumours cells to metastasise 
to bones. Similarly, production of TGFp2 by human prostatic 
adenocarcinoma cells [Danielpour et al., 1989] may be implicated 
in complex mechanisms whereby osteoblastic metastases are 
preferentially formed during prostate tumour progression.
T G F p  has also marked negative effects on the immune 
system, in that it inhibits thymocyte proliferation and opposes 
the action of some immunoregulatory agents, such as interleukins 
[K e h r l et al., 1986]. By contrast, TGFp is chemotactic to 
macrophages, stimulates their function [Wahl et al., 1987] and 
has been shown to promote angiogenesis [Roberts & Sporn, 1990].
The latter activities seem to be essential for TGFp action in 
tissue repair. It is worth noting here that wound healing and
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cancer share common molecular and cellular mechanisms, as in: 
"a wound is a tumour that heals itself" [Haddow, 1972] and 
"tumours are wounds that do not heal" [Dvorak, 1986]. Wound 
healing is a complex but orderly process of repair which involves 
several processes, e.g. inflammation, cell migration and 
proliferation, synthesis of extracellular matrix, angiogenesis and 
tissue remodelling [Peacock, 1984]. Intuitively, TGFp is a likely 
candidate to actively participate in wound repair since it
regulates many of these processes. In animal models, TGFp 
increases the rate of healing and the breaking strength of the
repaired tissue and enhances angiogenesis and consequent blood 
flow to dermal wounds directly or indirectly through local
release of other growth factors (reviewed by [Amento & Beck, 
1991]).
4.4. The Platelet-Derived Growth Factor (PDGF)
The PDGF is an ubiquitous peptide growth factor having 
potent mitogenic activity on a number of both normal and 
transformed cells. Its discovery is directly linked to studies on 
serum as a necessary growth requirement for cultured cells. 
Originally, it was noted that several cell types, notably 3T3 
fibroblasts and smooth muscle cells, grew in culture medium 
supplemented with serum (i.e. the soluble fraction of clotted 
blood), but their proliferation rate was markedly reduced in 
presence of plasma (namely the non-cellular fraction of the
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whole blood). The evidence that normal growth could be restored 
by supplementing plasma with an extract of platelets (which 
break down during blood clotting) clearly indicated that these 
cells contained a major growth factor for 3T3 and smooth muscle 
cells and eventually lead Ross and colleagues [Ross et al., 1974] to 
baptise it as platelet-derived growth factor.
4.4.1. Structure, isoforms and coding genes
After valorous attempts (because of the very low  
concentrations found in the starting material), human PDFG  
(hPDGF) was finally purified to homogeneity from platelets 
[H e ld in  et al., 1979]. It was found to be a homodimer of 
approximately 30 kDa, consisting of two different peptide chains, 
denoted A and B, respectively of 16,000 and 14,000 molecular 
weight. The dimer is highly disulphide-bonded, both within and 
between each chain, by a total of 16 cysteine residues, with a 
60% homology between the A and B chains. The latter are 
encoded by two different genes, localised on different 
chromosomes. The A-chain gene contains at least 7 exons 
spanning 22-24 kilobases of genomic DNA and is located on the 
proximal long arm of chromosome 7 [Betscholtz et al., 1986]. It 
generates three different mRNAs (1.9, 2.3 and 2.8 kb) which are 
thought to give rise to various forms of the A-chain. The gene for 
B-chain corresponds to the c-sis proto-oncogene, the cellular 
homologous of the viral oncogene encoded by simian sarcoma 
virus (SSV) [Doolittle et al ., 1983]. The different chromosomal 
localisation of the two genes justified the evidence that PDGF was
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secreted by cell types other than platelets as biologically active 
homodimers of the individual chain. These PDGF isoforms (PDGF- 
AA and PDGF-BB) were respectively identified in SSV- 
transformed cells [Owen et a l ., 1984] and in a human 
osteosarcoma cell line [Heldin et a l., 1986].
4.4.2. Mitogenic action, transformation and function i n 
v i v o
Early studies showed that PDGF alone was unable to 
properly stimulate DNA synthesis by cultured 3T3 fibroblasts, 
unless platelet-deprived plasma was supplemented [Pledger et 
a l ., 1978]. This clearly indicated that PDGF synergises with other 
plasma-borne factors, some of which were shown to have 
insulin-like activity (somatomedins) [Stiles et a l ., 1979]. It is now 
recognised that PDGF acts, jointly with other growth factors like 
EGF and fibroblast growth factor (FGF), as a "competence” factor 
in the first part of the Gi cell cycle phase; other factors 
(particularly the somatomedin insulin-like growth factor I, IG F-I) 
act later in the G\  phase as "progression" factors. Both 
"competency" and "progression" steps are required to allow the 
quiescent (Go) cells to enter the Gi phase and to proceed along 
until the restriction point of the late Gi is reached [Pledger et a l ., 
1978]. It has been shown that PDGF produces an early induction 
of cellular proto-oncogenes, such as c-fos and c-m yc , suggesting 
that this effect is necessary for progression of cells through the 
cell cycle (reviewed in [Stiles, 1983]).
Many diploid cells have been found to produce both PDGF 
chains. On this basis, it has been postulated that PDGF may play
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a role in the pathophysiology of a number of tissues. Smooth 
muscle cells and placental cytotrophoblasts actively synthesise 
PDGF and contain specific cell surface receptors; this suggests that 
PDGF may function as an autocrine regulator for both vessel wall 
and placental growth [Seifert et a l ., 1984; Nilsson et a l.y 1985]. By 
contrast, endothelial cells and activated macrophages produce 
PDGF but fail to respond to it since they lack PDGF receptors [Di 
Corleto & Bowen-Pope, 1983; Martinet et a l.y 1986]; this would 
imply that PDGF act on the neighbouring cells in a paracrine 
fashion.
Equally, expression of both A and B-chain mRNAs or 
production of PDGF-like activity have all been observed in a 
variety of human tumour cell lines (reviewed by [Ross et a l.y 
1986]). While lineages derived from mesenchymal neoplasias and 
gliomas produce and respond to PDGF, carcinoma and leukaemia 
cells do not express PDGF receptors but secrete PDGF, suggesting 
that a paracrine regulation of the surrounding stromal cells could 
be in force.
The functions of PDGF in vivo extend over a wide range of 
biological effects (for a review see [Antoniades, 1991]). Either the 
hPDGF heterodimer or the two PDGF homodimers are potent 
mitogens and chemoattractants for a number of diploid cells, 
including fibroblasts, arterial smooth muscle cells and 
osteoblasts. In addition, PDGF enters important aspect of cellular 
metabolism, such as protein, lipid and prostaglandin synthesis. 
Finally, it appears to be involved in the pathophysiology of some
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important processes, like mammalian embryogenesis, wound 
healing and osteogenesis, fibrosis and atherosclerosis.
4.5. The Insulin-Like Growth Factors (IGF)
IGFs are a structurally related fam ily of circulating 
peptides having profound effects on both growth and 
differentiation of many cell types. The term IGFs was originally 
introduced to denote their 50% homology to the proinsulin. They
were initially discovered as a growth hormone (GH)-dependent
serum factor which stimulates in vitro sulphation of cartilage
proteoglycans [Salmon & Daughaday, 1957]. Subsequently, it was 
found that they may act in endocrine, paracrine and/or autocrine 
fashion and that, unlike most peptide growth factors, circulate in 
blood bound to various specific binding proteins (reviewed by
[Froesch et a l.y 1985; Baxter, 1986]).
4.5.1. Structure and molecular biology
Two major IGFs, termed IGF-I and IG F-II, have been thus 
far identified and characterised [Rinderknecht &  Humbel, 1978a; 
Rinderknecht & Humbel, 1978b]. IGF-I and I I  are single chain
polypepdtides respectively of 70 (M r 7649) and 67 (M r 7471)
amino acids which share 60-70% homology each other. In
comparison to proinsulin, the sequence homology is confined to 
both A and B domains, while the connecting C peptides are
different, being shorter in IGFs (8-12 amino acids with respect to
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35 in the proinsulin); furthermore, both IG F-I and I I  have an 
additional C-terminal D domain of 6 -8  amino acids. This is, 
however, an overly simplistic picture. Several larger and smaller 
variants of the parent IG F-I and I I  have been in fact isolated 
from disparate sources, including human tissue extracts and body 
fluids, or predicted on the basis of cloning studies [Herington,
1991]. The physiological significance of these relatively low 
abudant forms remains to be established
In the last five years, molecular biology techniques have 
allowed to determine cDNA sequences, mRNA transcripts, 
genomic structures and chromosomal localisation of the genes 
encoding for both IGF-I and I I  (reviewed by [Daughaday &  
Rotwein, 1989]). The IGF-I gene has been recently sequenced and 
subsequently denominated IG F-IA  [Rotwein et a l ., 1986a] It was 
found to encode the complete amino acid sequence (B, C, A and D 
domains) plus a N-terminal 5' signal sequence and a 3' sequence 
of 105 nucleotides encoding a C-terminal extension (the E 
peptide) of 35 amino acids. Later, Rotwein [Rotwein, 1986b] 
identified a second human IGF-I cDNA (termed IGF-IB) having a 
longer (77 amino acids) E peptide chain. This double expression is 
probably a product of an alternative splicing of the primary 
mRNA transcribed from a single IGF-I gene. The latter is located 
on the long arm of the chromosome 12 and consists of five exons, 
the IGF-IA being derived from exons 1, 2 3, and 5, the IGF-IB  
from exons 1,2, 3 and 4. Four major mRNAs have been identified 
in both rat and human tissues. Their size ranges from 0.8 up to 
7.5 kb, mostly depending on the length of the 3' untranslated
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region [Murphy et a l ., 1987]. Expression of IGF-I mRNAs occurs in 
both adult and foetal tissues, where it appears to be under 
control of GH and other hormonal factors; e.g. oestrogens have 
been shown to markedly increase the IG F-I mRNA levels in the 
rat uterus [Murphy & Friesen, 1988]. Characterisation of both 
human and rat IG F-II genes revealed that they are located on the 
short arm of chromosome 11, adjacent to the related insulin gene 
[Bell et a l , 1985]. Structural analysis indicated that, differently 
from the IGF-I gene, the human IG F-II gene is composed of eight 
exons, of which the first five are non-coding sequences 5’ to the 
signal peptide, while exons 6, 7 and 8 encode for IG F-II. As with 
IG F-I, multiple forms of IG F-II mRNA have been identified, 
ranging from 2 to 6 kb in size, in both foetal and non-hepatic 
adult tissues [de Pagter-Holthuizen et al., 1988]. Contrary to IGF- 
I, GH is only a minor regulator of IG F -II expression, while 
developmental status seems to be of utmost importance.
4.5.2. IGF binding proteins
A distinctive feature of IGFs is that these polypeptide 
growth factors circulate bound to specific, high-affinity binding 
proteins (IGFBPs). This evidence, however, has been recently 
found to be common to other growth factors, e.g. PDGF [Raines et 
al . ,  1984]. The IGFBPs compose a family of related polypeptides 
which have been recently cloned and characterised. At least five 
different IGFBPs have been so far identified [Baxter & Martin, 
1989a]. IGFBP-1 has been cloned as a 25-28 kDa protein having 
equivalent binding affinities for IG F-I and II  [Brewer et a l .,
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1988], while IGFBP-2 was originally isolated from BRL-3A foetal 
rat liver cell line and subsequently found to be a non­
glycosylated protein of 35 kDa which binds IG F -II with higher 
affinity than IG F-I [Binoux et a l ,  1982]. The IGFBP-3 has been 
shown to participate in the major circulating IGFBP complex, the 
150 kDa acid-labile, GH-dependent binding protein [Baxter &  
M artin, 1989b]. This complex consists of the IGFBP-3  
glycosylated protein, detected as a characteristic doublet of 40 
and 43 kDa on SDS-PAGE, an acid-labile component (ALS) of 84 
kDa and IGF-I or II. It seems that ALS combines to a pre-formed 
IGFBP-3/IGF complex and that IGFBP-3 cannot bind to ALS in the 
absence of IGF. More recently, two additional IGFBPs (4 and 5) 
have been isolated and cloned, but their biological signicance and 
mechanisms of regulation are still unknown.
Comparison of the individual amino acid sequences 
indicates that all known IGFBPs share marked conservation 
throughout different species (particularly rat and human) and 
striking homology (over 50%) one to another. Conserved residues 
are generally clustered in the N and C termini, all the 18 
cysteines being preserved at both sites. IGFBP-1 and 2 show a 
peculiar RGD (Arg-Gly-Asp) sequence in the C-terminal domain 
and IGFBP-3 and 4 also contain electrostatically comparable 
sequences. This feature, which is common to other growth factor 
precursors and associated proteins (see also 4.3.1.), is of special 
interest since it seems to represent a recognition motif for 
extracellular matrix receptors of the integrin family [Ruoslahti & 
Pierschbacher, 1987]. It is still unclear whether IGFBPs act
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indirectly by influencing IGF action or they have a functional role 
as such. In the first instance IFGBPs, which bind both IG F-I and 
I I  in a stoichiometric manner, may increase the half-life and 
reduce the clearance of IGFs from circulation [Cohen & Nissley, 
1976], However, whether IGFBPs lim it the IG F access to 
extravascular space or they rather enhance IGF delivery and 
availability to target tissues (? via RGD) remains to be clarified. 
Alternatively, IGFPBs might be involved in paracrine/autocrine 
functions, also independent from the IGF action.
4.5.3. Biological activity
The IGFs feature a wide spectrum of biological effects on 
many tissues and cells, in vitro (reviewed by [Froesch et a l ., 
1985; Baxter, 1986]). These effects are only assumed to take 
place in vivo, because relevant studies have been crucially 
hampered in the past by the difficulty in obtaining adequate 
supply of IGFs. The effects of IGFs, especially IG F-I, on cell 
proliferation appear to be cell cycle-dependent. In fact, they 
require prior exposure to other "competence" factors, such as 
PDGF or FGF, to allow the cell to cross the Go/Gj boundary (see 
also 4.4.2.). In this respect, IG F -I has been defined a 
"progression" factor, whose potent mitogenic effects eventually 
lead to a rapid increase in DNA synthesis [Stiles et a l ., 1979]. If  
cell proliferation is at steady state or is unrealisable, IG F-I may 
act as a powerful stimulator of cellular differentiation, as it 
occurs in the ovarian granulosa cells [Hutchinson et a l 1988], 
IGF-I has been shown to stabilise specific mRNAs in Balb/C 3T3
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cells, suggesting that it may increase the abundance of labile 
mRNAs and proteins by preventing their degradation [Zumstein 
& Stiles, 1987].
4.6. Growth Factor Receptors
The myriad of biological effects induced by peptide growth 
factors mostly depends upon their interaction with specific, high- 
affinity cell membrane receptors. Binding of a growth factor to its 
cognate receptor on the external surface of the cell triggers a 
cascade of intracellular events which eventually leads to 
stimulation of DNA synthesis.
The molecular analysis of known growth factor receptors 
reveals that they fall into defined categories having distinct 
structural and functional peculiarities. They include simple 
transmembrane receptors, as in the tyrosine kinase, the 
serine/threonine kinase, the tyrosine phosphatase and the 
multichain "cytokine" families, or the unrelated G-protein 
associated seven-helical domain class of receptors, called 
serpentine receptors.
4.6.1. The tyrosine kinase family
Although addition or removal of phosphate groups 
normally occur on either threonine or serine residues, binding of 
specific growth factors, such as EGF, PDGF or IGF-I and II, to their 
cell surface receptors leads to rapid phosphorylation of the
1 6 8
F igu re  11. The tyrosine kinase family of growth factor receptors (for 
details see text).
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tyrosine residues of a particular set of cellular proteins. 
Structural analysis has revealed that the tyrosine kinase activity 
is located within the intracellular domain of the receptor (see 
Figure 11) and that ligand binding is required for 
phosphorylation of specific substrates, including the receptors 
themselves and a number of key intracellular regulatory 
enzymes.
The E G F  receptor (EGFR)
The availability of large amounts of pure EGF and the use of the 
squamous carcinoma cell line A431, which overexpresses EGFR, 
has made possible the purification of this receptor [Wrann & Fox, 
1979]. Both cDNA sequence and genomic structure of EGFR have 
been determined [Ullrich et a l ., 1984; Haley et a l ., 1987].
The EGFR is a 170 kDa (1186 amino acids) single chain 
membrane glycoprotein consisting of three separate domains: a 
621 amino acid extracellular domain which is responsible for EGF 
binding and contains a high proportion of cysteine residues 
clustered in two distinct regions; a hydrophobic 23 amino acid 
transmembrane region; and a 542 amino acid intracellular region 
containing a highly conserved tyrosine kinase domain.
The extracellular domain comprises about one half of the 
entire EGFR sequence and is thought to interact with EGF on a 
stoichiometric basis. Bajaj and colleagues [Bajaj et a l ., 1987] have 
proposed a model for tertiary structure of this domain (see 
Figure 12). It includes two large variable regions (L I and L2), 
each L subdomain being followed by one small cysteine-rich
170
F ig u r e  12. The epidermal growth factor receptor (EGFR). This 
schematic representation exemplifies the EGFR domain composition. 
According to a recent model for the tertiary structure of EGFR, the 
external domain (621 amino acids) includes two large variable regions 
(LI and L2), each followed by one small cysteine-rich region (SI and S2 ). 
The short hydrophobic transmembrane domain (23 amino acids) 
continues in a composite intracellular domain (542 amino acids). This 
consists of a tyrosine kinase region (reported in black) and a further 250 
amino acid tail at the C terminus containing specific tyrosine residues 
(Y 992, Y 1068, Y 1148, Y 1173) w hich serve as receptor  
autophosphorylation sites. The two threonine residues (Thr654 and 
Thr669) and the serine residue (Ser671) in between the transmembrane 
and the kinase domains represent phosphorylation sites for other growth 
factor-stimulated kinases, leading to a negative regulation EGFR 
activity.
(Adapted from [McDonald, 1989 #302]).
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region (S I and S2). Compact folding of both L and S subdomains, 
also involving formation of disulphide bonds, confers stability to 
the structure and might account for the unusual resistance of this 
receptor domain to proteases.
The transmembrane domain of EGFR is a highly 
hydrophobic region containing a stretch of basic residues at the 
cytoplasmic end which may serve as a "stop" sequence to anchor 
the polypeptide chain to the plasma membrane. Since 20 amino 
acids are enough to cross the 30 A cell membrane, it is thought 
that this 24 amino acid domain forms an a-helix .
The cytoplasmic domain of the EGFR can be roughly 
subdivided in a 50 amino acids intracellular space, a 250 amino 
acid tyrosine kinase domain and a further 250 amino acid tail at 
the C terminus. The latter region contains three major tyrosine 
residues (Y1068, Y1148, Y1173) which serve as receptor
autophosphorylation sites [D o w n w a r d  et a l ., 1985], although 
additional site(s) (Y992) have been recently reported [Walton et 
a l . ,  1990]. The autophosphorylation process appears to be 
relevant to procure maximum biological activity of the receptor 
[Helin et al., 1991]. The tyrosine kinase region is featured by the 
presence of an ATP binding site and a catalytic site that controls 
phosphoryl transfer to tyrosine residues of specific intracellular 
proteins (see below). The smaller bridging region in between the 
transmembrane and the kinase domains is also functionally 
important since it includes at least two threonine residues 
(Thr654 and Thr669) that can be phosphorylated by other 
growth factor-stimulated kinases, leading to a negative
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regulation of ligand-induced tyrosine kinase activity and 
receptor internalisation [Lin et a l ., 1986; Northwood et a l ., 1991]. 
These phosphorylation sites, jointly with an additional serine 
residue (Ser671) in the same region, may provide a mechanism 
whereby the same EGF or other growth factors (notably PDGF) 
may down-modulate the EGFR activity [Heisermann et a l ., 1990].
The EGFR is naturally present at around 104 -1 0 5 sites/cell 
on the membrane of normal cells, while some transformed cells 
overexpress EGFR (106 -107 sites/cell). It is widely accepted that 
EGF binding induces receptor aggregation in clusters on the cell 
surface. The most likely model foresees that ligand-receptor 
interaction occurs mainly at the two large subdomains (L I and 
L2) of the extracellular region of the receptor through 
hydrophobic contacts. This may cause dramatic conformational 
changes in both the ligand and the receptor and probably 
produce intermolecular allosteric effects which eventually lead to 
receptor dimerization [Schlessinger, 1988]. This would bring the 
tyrosine kinase domains of two receptor monomers into close 
proximity allowing reciprocal phosphorylation and activation. 
Further to ligand binding, the EGF-receptor complex is captured 
by clathrin-coated pits and internalised within 30 minutes. This 
leads to lysosomal receptor degradation, with negligible receptor 
recycling. Since full signal transduction takes much longer (8  
hours), the cell must therefore initiate an active synthesis of 
EGFR to avoid receptor depletion at its surface. Although 
endocytosis and degradation of the receptor are ligand-induced 
processes, they do not seem to affect the biological activity of
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EGFR; in fact, substances that inhibit either receptor degradation 
or formation of the coated pits respectively leave the EGF- 
induced mitogenic response unchanged [Savion et al., 1980] or 
even increase it [Maxfield et al., 1979].
The P D G F  receptors (PDGFR)
PDGF receptors have been found on the membrane of most 
mesenchymal connective-tissue-forming cells, whilst they have 
not been observed on epithelial or arterial endothelial cells. 
Initial work postulated the presence of a single class PDGF 
receptor which was first described as a 180 kDa transmembrane 
glycoprotein with an external PDGF-binding domain and an 
intracellular region containing a split tyrosine kinase domain 
[Huang et al., 1982]. Subsequent studies, using pure recombinant 
PDGF isoforms, revealed that this receptor, called PDGFR-p, binds 
to PDGF-BB and hPDGF heterodimer respectively with high and 
lower affinity, while it does not recognise the PDGF-AA  
homodimer [Hart et a l ., 1988]. The latter binds instead to a 
second receptor form, termed PDGFR-a, which is also able of 
binding the two other PDGF isoforms [Heldin et al., 1988]. Cloning 
studies revealed that PDGFR-p is synthesised as a 160 kDa 
precursor that mature to the 180 kDa glycoprotein [Keating &  
Williams, 1987], while the PDGFR-a derives from a 140 kDa 
precursor which is converted to a 170 kDa mature form 
[Claesson-Welsh et al., 1989]. The a  and p receptor forms share 
about 40% homology each other and have been found to be 
products of two separate genes. It has become increasingly
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evident that PFGFR-a and p represent distinct receptor subunits 
that are brought together by one of the three PDGF isoforms 
[S e ifert et a l ., 1988]. The receptor subunits are thought to be 
"floating" within the cell plasma membrane and to acquire a 
stable dimeric conformation following binding to a PDGF isoform. 
The a-subunit can bind any PDGF chain (A or B), while the P- 
subunit can bind only the B chain; as a result, PDGF-BB will
bind any combination of the two receptor subunits ( a a , ap, pp), 
PDGF-AB will bind to either aa  or ap receptors and PDGF-AA can 
bind solely to the a a form [Seifert et al., 1988]. Since several cell 
types differentially express a and p subunits, the mitogenic 
effects of PDGF w ill depend upon the presence of adequate 
amount of individual PDGF isoforms and, especially, on the 
relative number of the different receptor subunits on the cell 
surface.
The extracellular region of both PDGF receptors contains 
five immunoglobulin-like domains, suggesting that they are 
related to the immunoglobulin superfamily. At the intracellular 
end, PDGF receptors show a tyrosine kinase domain split into two 
parts by a variable-length insertion sequence with little or no 
homology to other kinases. Interestingly, deletion of this insert 
sequence produces a mutated form of receptor which retains the 
kinase activity, but is unable to transduce the mitogenic signal 
[Escobedo & Williams, 1988]. Phosphorylation of several tyrosine 
residues of the intracellular domain of the receptors occurs as a 
result of PDGF binding and is thought to be important for signal 
transduction [Ek et al., 1982]. Cell surface PDGF receptors have a
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half-life of approximately 3-4 hours which decreases to 30 
minutes following PDGF binding and receptor aggregation. Once
formed, PDGF-receptor complex is internalised within 1-2 
minutes in endosomes and subsequently degraded into
lysosomes, the breakdown products of PDGF being found in the 
extracellular space after 15-30 minutes.
The I G F  receptors (IGFR)
Response of target cells to IG F-I and I I  is mediated by three 
distinct receptor types, precisely the type I and I I  IGFR and the 
insulin receptor. High homology exists between the type I and
insulin receptors, while the type I I  receptor is structurally and
functionally unrelated [Rechler & Nissley, 1986]. The type I IGFR 
is a 300 kDa complex which results from a heterotetrameric 
arrangement of two dimers each consisting of disulphide-bonded 
ap subunits (see Figure 11). The two a subunits are responsible 
for IGF binding and are extracellular, being linked by disulphide 
bonds to the p subunits. The latter cross the cell membrane with 
a shorter N terminal tail in the extracellular space and a 
cytoplasmic region which contains the tyrosine kinase domain 
[Nissley & Rechler, 1984]. Autophosphorylation of the type I IGFR 
itself has been shown to occur at three main phosphorylation 
sites (Y1146, Y1150 and Y 1151) and is reputed to be involved in 
the signal transduction process [Czech, 1989]. There is a high 
degree of functional specificity for the type I receptor binding, 
the relative affinities being IG F -I> IG F -II» in s u lin , whilst the
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insulin receptor binds insu lin>IG F-I> IG F-II [Nissley &  Rechler,
1984].
In contrast, the type I I  IGFR is quite different from both 
type I  and insulin receptors in that it consists of a monomeric 
glycosylated polypeptide of 260 kDa which lacks either tyrosine 
kinase activity or phosphorylation sites. It binds IG F -II with 
greater affinity than IGF-I, but does not recognise insulin at all. 
Recently, cloning of type I I  receptor has revealed that it is 
identical to the cation independent mannose 6 -phosphate (M -6 P) 
receptor [Tong et a l ., 1987]. The receptor is mostly extracellular, 
with a very short cytoplasmic tail, and is composed of 15 repeats 
of the M -6P binding subunit. The type I I  IGF receptor seems to 
behave as a multifunctional protein, capable of binding not only 
IG F-II and M -6P, but also other peptides such as the latent TGFpi 
[Purchio et a l>  1988] (see also 4.3.1.). The role of type I I  
receptors in mediating the IGF-induced mitogenic action is 
unclear. Although most studies have indicated that this effect is 
mediated solely by type I receptors, there is increasing evidence 
that the type I I /M -6 P receptors may be implicated in specific 
pathways of signal transduction, like via the GTP-dependent 
coupling proteins [Nishimoto et a l , 1989].
Other receptors
Two member of the human proto-oncogene e r b B family are 
worthy of mention here. Both c -e rb B -2  and c -e rb B -3  proto­
oncogenes have been identified probing human genomic libraries 
with the w -e rb B oncogene from the avian erythroblastosis
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retrovirus [Yamamoto et al., 1986; Kraus et al., 1989]. The latter 
encodes for a truncated version of EGFR (the QBlAy~erbB protein) 
having a short N-terminal tail of 61 amino acids and lacking also 
the 32 amino acid residues at the C-terminal end of the receptor, 
which contains the major autophosphorylation sites of EGFR [Beug 
et al., 1988]. However, it has been shown that the \ - e r b B  protein 
retains intrinsic tyrosine kinase activity and that it incurs 
autophosphorylation at as yet unknown sites [Kris et al., 1985]. 
In contrast, the predicted structure of both human c-e rb B -2  and 
c -e rb B -3  protein products revealed colinearity with most of the 
EGFR sequence, with an extracellular region arranged as a pocket 
to accomodate a putative polypeptide ligand [Coussens et al.,
1985]. A remarkable degree of homology is present between the 
two proto-oncogene products and with EGFR, mostly within the 
tyrosine kinase domain (respectively 82 and 60% with respect to 
EGFR). The c-erbB-2  protein has been also referred to as HER-2 
based on its similarity with the h u m an  E_GF receptor; it 
represents the human counterpart of the rat neu  protein, the 
product of an oncogene associated with neuroblastomas 
[Schechter et al., 1984].
The potential role of both c -e rb B -2  and c -e rb B -3  in the 
transmission of a mitogenic signal is obscure. There is however 
evidence that activation of the EGFR may produce EGFR/c-erfrB-2 
heterodimers and result in cross-phosphorylation of the c -e rb B -2  
protein in cells that express both receptors [King et al., 1988]. In 
this respect, the EGFR and c-erbB-2  may act in a synergistic 
fashion to induce transformation of rodent cells, although it
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seems likely that tyrosine kinases of the two receptors may 
recognise either common or separate, specific substrates. On the 
other hand, the potential role of c -erbB-3  in transduction of a 
mitogenic signal is presently unknown; however, expression of 
c -erbB-3  transcripts has been detected in both human mammary 
M DA-MB361 and squamous A431 carcinoma cell lines, being 
seemingly restricted to cells of epithelial or neuroectodermal 
origin [Plowman et a l , 1990].
4.6.2. The TGFp receptors
Many cell types express on their membranes multiple 
binding sites for TGFp, having distinct affinity for the different 
T G F p  isoforms (reviewed by [Massague et a l ., 1990]). Four 
different cell surface binding proteins have been thus far 
identified, having the high affinity and specificity characteristics 
pertinent to physiologically significant receptors [Segarini, 1991]. 
They have been termed TGFp receptor type I, I I ,  I I I  (or 
betaglycans) and IV  (see Figure 13).
The type I and II  receptors share common characteristics. 
Both are glycoproteins of approximately 53 and 70-85 kDa, 
respectively, and contain complex N-linked carbohydrate. They 
exhibit a 10 to 2 0 -fold decreasing affinity of T G F P i> T G F p 2 
binding and are ubiquitously distributed in an assortment of 
both normal and transformed cells from different species, 
including human. Nevertheless, peptide mapping studies have 
documented striking diversities in the ligand-binding domain of 
these two receptor forms [Cheifetz et a l ., 1986]. Interestingly,
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F igure 13. Transforming growth factor-P (TGFp) binding proteins. This 
diagram illustrates the four TGFP receptor forms so far identified. Both
type I (53 kDa) and II (75 kDa) receptors are thought to mediate the 
TGFp-induced growth inhibition and up-regulation of the extracellular 
matrix components. The betaglycan (type III) receptor (280 to 330 
kDa) is an integral membrane proteoglycan containing a core unit of 
approximately 110-120 kDa which binds both TGFPi and TGFP2 with 
equal affinity; it may have a role in presentation of TGFp to functionally 
active receptors or in its delivery to the extracellular space. The type IV 
receptor has been recently isolated from GH3 rat pituitary tumours 
cells; its functional role is presently unknown.
(Modified from [Massagu6 , 1990 #64]).
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studies on chemically induced TGFP-resistant mutants derived 
from mink lung epithelial cells (M vlLu) have revealed that class 
R mutants, which have selectively lost expression of functional 
type I  receptors, become totally insensitive to all known TGFp 
effects, including growth suppression and extracellular matrix 
formation [Boyd & Massague, 1989]. While this suggested that 
type I  receptors are primarily involved in the TG F p-spec ific  
transmembrane signalling, a cognate role for the type I I  receptor 
was initially reputed unlikely. However, studies on recently 
established cell clones where type I and I I  receptors are 
simultaneously altered, indicated that either receptor is involved 
in signal transduction, possibly as component of a single receptor 
complex [Laiho et a l ., 1990b].
The type I I I  receptor is a high molecular weight complex of 
280 to 330 kDa on SDS-PAGE which has been termed betaglycan 
[Andres et al., 1989]. It is present on the cell surface of a variety 
of cell types, although its distribution is not as broad as that of 
type I and I I  receptors. The most distinctive feature of 
betaglycan resides in its heterogeneous composition: it is an 
integral membrane proteoglycan consisting of a 200 kDa 
glycosaminoglycan (GAG) chain component and a 10 kDa N-linked 
glycans bound to a core unit of approximately 110-120 kDa 
[Cheifetz et al., 1988a]. The 200 kDa component is a hybrid of 
two GAGs, heparan sulphate and chondroitin sulphate [Segarini & 
Seyedin, 1988], which do not bind TGFp and are not required for 
functional expression of the receptor on the cell surface [Cheifetz 
& Massague, 1989]. The core unit is responsible for TGFp binding
181
INTRODUCTION
that, contrary to type I and I I  receptors, occurs at equal affinity 
for both TGFPi and TGFp2 . A soluble form of betaglycan which 
lacks membrane anchor has been found in serum, extracellular 
matrices and in the culture medium of several cell types [Andres 
et a l ., 1989]. Although most TGFP effects are commonly thought 
to be mediated solely by type I and I I  receptors, whether and 
how betaglycan is implicated in TGFp action remains to be 
established.
The type IV  receptor has been recently isolated from GH3 
rat pituitary tumours cell as a binding protein that associates 
with other members of the TGFp superfamily, such as inhibin and 
activin [Cheifetz et al.y 1988b]. Its functional role is presently 
unknown, but it seems conceivable that it mediates TGFpi and 
inhibin/activin regulation of FSH release by the pituitary.
Unfortunately, the signalling cascade downstream of TGFp 
interaction with cell surface receptors is ill-defined. After 
receptor binding, TGFp is rapidly internalised and degraded by 
lysosomal enzymes [Massague & Kelly, 1986], but it is unclear 
whether this represents an essential step for T G F p -in d u ced  
changes. Some experimental evidence suggested that TGFp may 
activate several intracellular signalling pathways, including 
protein kinase C (PKC), phosphatidylinositol and GTP-dependent 
binding proteins (see below), but there is no indication that this 
activation is directly dependent on TGFp binding to its receptors.
182
INTRODUCTION
4.7. Post-Receptor  Signalling Pathways
4.7 .1 .  Tyrosine  k inase-assoc iated  pathways
As previously described (see 4.6.1.), several growth factor 
receptors (including EGFR, PDGFR and IGFR) contain a cytoplasmic 
domain having intrinsic tyrosine kinase activity.
A search for selected proteins which are thought to be 
likely candidates for physiological tyrosine kinase substrates 
revealed that, following binding of PDGF to cell surface receptors, 
a number of cellular proteins are phosphorylated on tyrosine 
within seconds. Most of these proteins may be phosphorylated 
directly by the PDGFR tyrosine kinase, becoming physically 
attached to the receptor as a consequence of its dimerisation and 
autophosphorylation (see Figure 14). Notably, four distinct 
proteins have been found to associate with the tyrosine kinase 
domain of the PDGFR: the phospholipase C (PLC), the phosphatidyl 
insositol 3-kinase (PI-3K), the pp60src encoded by the src proto­
oncogene and the ras GTPase activating protein (ras-GAP). 
Activation of this protein set results in a generation of small 
molecules, called second messengers, which are potent mediators 
of signals dispatched to distant sites in the cell. They include the 
quintessential second messenger cyclic AMP (cAMP), cyclic GMP 
(cGMP), inositol triphosphate (IP 3), diacyl glicerol (DAG) and 
calcium ions (Ca2+).
As illustrated in Figure 14, after the cytoplasmic domain of 
PDGFR undergoes autophosphorylation, the PLC is activated and 
produces cleavage of the phosphatidyl inositol 4,5-diphosphate
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F ig u re  14. Tyrosine kinase receptor signalling pathways. PDGF- 
induced post-receptor pathways are here exemplified. After ligand- 
induced PDGFR dimerization and autophosphorylation, subsequent 
activation of phospholipase C (PLC) produces cleavage of the 
phosphatidyl inositol 4,5-diphosphate (PIP2) into diacyl glycerol (DAG) 
and inositol triphosphate (IP3). The latter causes a rise of intracellular 
calcium (Ca2+) levels which in turn induces the stimulation of various 
cellular enzymes and concurs with DAG in the activation of the protein 
kinase C (PKC). On the other hand, liganded PDGFR stimulates the 
phosphatidyl inositol 3-kinase (PI-3K) activity, that adds phosphates to 
the ring of phosphoinositol at position 3, yielding an active product (PI- 
3P) which is thought to play an important role in the cell growth cycle.
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(P IP 2 ) into IP3 and DAG [Wahl et a l ., 1989]. The IP3 diffuses 
through the cytoplasm and causes release of Ca2 + from 
membranous storage compartments where it is usually 
sequestered by binding to a specific receptor located on the 
endoplasmic reticulum; the resulting rise of the intracellular 
calcium in turn induces the activation of various cellular 
enzymes. In addition, IP 3 may enter a number of metabolic 
pathways, including further phosphorylation to yield IP4 , IP5 and 
IP 6 or dephosphorylation to inositol from which phosphatidyl 
insositol can be resynthesised. On the other side, DAG combines 
with Ca2 + in the activation of another key growth-regulating 
enzyme, the protein kinase C (PKC, see Figure 14), which 
phosphorylates both serine and threonine residues on dozens of 
target proteins. Another consequence of PD G FR  
autophosphorylation is the stimulation of the IP-3K activity (see 
Figure 14); the latter adds phosphates to the ring of 
phosphoinositol at position 3, yielding an active product which is 
thought to play a crucial role in the cell growth cycle [Coughlin et 
a l ., 1989].
The pp60v_src is the aberrant protein product of the avian 
Rous sarcoma virus (RSV), the very first oncogene product 
identified [Collett et a l , 1978]. It is a membrane protein kinase 
which phosphorylates selected tyrosine residues on both its own 
molecule and a panel of unrelated proteins. Its normal cousin, the 
pp60c_src, also has a kinase activity which conversely is latent 
until activated by various external stimuli, including PDGF 
binding.
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The ras-GAP is a multifunctional protein which represents 
a site of crosstalk between the PDGFR and the ras signalling 
pathway, one of the most important growth regulatory circuitries 
in the cell. This protein is required for the activation of GTPase 
belonging to the ras family of membrane-associated G-proteins 
[E llis et a l ., 1990]. The ras protein, termed p21ras, exists in two 
states, active and inactive, which shift one to another 
respectively through alternative binding of GTP and GDP 
nucleotides. The inactive, GDP-bound p21ras is proded to release 
the captive GDP molecule by ligand-activated growth factor 
receptors through as yet unknown mechanisms. Once released, 
GDP is immediately substituted by a GTP molecule via a GDP/GTP 
exchange factor, causing the switch of p21ras to an active state. 
The latter, however, persists a few seconds since GTP is rapidly 
transformed into GDP by loss of a phosphate and therefore 
p 2 1 ras again acquires an inactive mode. In contrast, the mutant 
oncogenic p21ras has lost the ability to convert GTP into GDP, 
hence maintaining a prolonged excited state and behaving as a 
lasting source of growth-stimulatory signals.
Association of all these four putative protagonists of post­
receptor signalling pathways with the cytoplasmic domain of 
tyrosine kinase receptors appears to involve a short sequence of 
around 100 amino acids (termed SH2: src hpmology-2.) which is 
capable of recognising phosphorylated tyrosines and the 
surrounding residues on the insert region of the split kinase 
domain of PDGFR or more distal autophosphorylated sites in 
other growth factor receptors [Koch et a l ., 1991]. Once created,
186
INTRODUCTION
receptor phosphotyrosines attract and bind these proteins 
through the SH2 domain, producing their activation via either 
phosphorylation or subtle changes in protein folding (see Figure 
15).
4.7.2. The protein kinase C (PKC)
The PKC represents a multigene family of closely related 
membrane serine/threonine protein kinases [Nishizuka, 1984]. 
Structural analysis has revealed that different PKCs share a 
number of conserved domains [Nishizuka, 1988]. In particular, 
the N terminus of the molecule contains a C l region, which is 
thought to be responsible for enzyme inhibition, and a C2 region, 
which confers calcium-dependence to PKC. It is of interest to note 
that in the presence of DAG the calcium levels required for PKC 
activation drop to those normally found within the cell, with a 
consequent induction of PKC activity and phosphorylation of a set 
of cellular proteins. The involvement of PKC in the transduction 
of mitogenic signals is outlined by the evidence that the phorbol 
esters, potent mitogens for quiescent cells, act as non- 
metabolisable analogues of DAG, causing an unrelenting 
stimulation of PKC activity and a likely priming of mechanisms 
controlling the entry of the cell from G1 into the S cell cycle 
phase. However, identification of potential substrates for PKC 
activity has been difficult. One interesting clue is that PKC 
phosphorylates membrane receptors, such as the EGFR, inducing 
a loss of binding affinity and a consequent inhibition of the EGFR- 
linked tyrosine kinase activity [Lin et a l ., 1986].
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F igu re  15. The SH2 proteins. The physical association of phosphatidyl 
insositol 3-kinase (PI-3K), phospholipase C (PLC), pp60v'sr (src) and 
ras-GAP (GAP) proteins with the cytoplasmic domain of tyrosine kinase 
receptors is shown. These four putative components of post-receptor 
signalling pathways contain a short sequence of around 100 amino acids 
(termed SH2: src homology-2; marked in face-bold) which is capable of 
recognising phosphorylated tyrosines and the surrounding residues on 
the insert region of the split kinase domain of PDGFR or other growth 
factor receptors, but that ignores the partner receptor if  the critical 
tyrosine residues are not phosphorylated. Once phosphotyrosines are 
created, the receptor will attract and bind these proteins, producing their 
activation via either phosphorylation or subtle changes in their protein 
folding.
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Overall, it appears that phopshorylation of specific amino 
acid residues on selected proteins is a cardinal process in growth 
signalling pathways wherein both tyrosine and serine/threonine 
kinases concur to activate multiple cellular substrates. Using this 
simple mechanism, an extraordinary array of intracellular 
’’molecular switches" can be turned "on" and "off" in seconds, 
allowing the cell to maintain continuously a social behaviour.
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5 .  Cancer of the Human Prostate
5.1. Prostatic Carcinoma: A D ifficu lt Case
Unlike both oestrogen and progesterone receptors in breast 
and endometrial cancer, the use of androgen receptors both as 
prognostic indicators and predictors of response of prostate 
cancer patients to endocrine treatment has been crucially 
hampered by either methodological pitfalls in the assay or the 
heterogeneous composition of most tumour tissues; the situation 
is further complicated by developmental and functional features 
inherent in the human prostate gland that make it highly 
heterogeneous in nature. Secondly, little is known on the 
mechanisms whereby such tumour types invariably tend to 
progress from an endocrine towards a hormone-refractory status. 
Continued growth of prostate cancer is achieved through intricate 
pathways where steroid hormones and other polypeptide growth 
factors act directly or in a paracrine/autocrine fashion in the 
growth control of cancer cells, but also serve as mediators of 
ce llu la r interactions between stromal and ep ithe lia l 
compartments as like as with the extracellular matrix. Finally, 
insensitivity of androgen-independent tumour growth to 
endocrine manoeuvres is also reflected in the failure of androgen 
ablation to induce programmed cell death, as it is seen in 
hormone-dependent prostatic epithelial cells. A more complete 
knowledge of all the above processes may well help to design
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new effective treatments which would encompass the diverse 
susceptibility to conventional therapies developed by prostate 
cancer cells during tumour progression.
5.1.1 .  Epidemiological  background
Incidence of prostate cancer varies greatly throughout the 
world, being the highest in the black population of the United
States and the lowest in the Asian populations of China and India 
[Zaridze et al., 1984]. The Western European countries range 
between the upper and the mean position, with Norway, Sweden 
and Switzerland having the highest rates. Epidemiological data 
(reviewed by [Griffiths et al> 1987]) give an alarming idea on the 
dimensions of the problem: in the United States more than 
90,000 new cases of prostatic cancer present annually, resulting 
in approximately 26,000 deaths each year [Sondik, 1988]. 
Overall, statistical data also indicate that during the last decade 
incidence rates have been dramatically rising worldwide, to such 
a point that prostate cancer has become the most prevalent 
cancer and the second principal cause of cancer death in man
[Carter & Coffey, 1990]. However, mortality rates for prostate 
cancer are remarkably lower than the incidence rates and the
increasing prevalence of this tumour type is accompanied by a 
smaller increase in deaths [Zaridze et al., 1984].
It is recognised that the human prostate has a uniquely
high occurrence of latent microcarcinomas. This is of interest, 
since autopsy studies have revealed that prevalence of latent 
carcinomas appears to be associated with the mortality rates of
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clinical prostate carcinoma [Breslow et al., 1977]. It has been 
postulated that tumour initiation does not differ in populations 
having high or low mortality rates, but that geographical 
differences in both prevalence of latent prostatic cancer and 
mortality rates could be ascribed to a diverse weight of tumour 
promoting factors.
5.1.2.  M orphofunctional  implicat ions
The heterogeneous composition of both normal and 
diseased human prostate is well established. Evidence coming 
from anatomy or embryological studies suggests that the prostate 
gland is composed of distinct regions having different functional 
activity and sensitivity to both androgens and oestrogens. 
Initially, McNeal proposed that the prostate gland contains three 
major glandular regions, the central zone (CZ), the transition zone 
(T Z ) and the peripheral zone (PZ), and some important 
nonglandular areas concentrated in the anteromedial portion of 
the gland [McNeal, 1972]. These different regions can also be 
separated topographically. In fact, the TZ together with 
periurethral glands surround the urethra proximal to the 
veromontanum and represent the ’’inner" prostate, while the CZ 
and PZ comprise the remainder of the gland, the "outer" prostate. 
Comparative anatomy studies on primates also support this view, 
in that the cranial and caudal prostatic lobes of the rhesus 
monkey appear to be homologous to the human CZ and PZ, 
respectively [Blacklock & Bouskill, 1977]. It is noteworthy that 
human BPH mostly derives from the TZ, whilst prostate cancer
193
INTRODUCTION
typically originates in the PZ and may subsequently spread to 
both the CZ and the periurethral region. Additionally, foci of 
intraductal dysplasia, a prostatic lesion that is thought to be 
premalignant [McNeal, 1986], have been found to associate with 
PZ microcarcinomas [McNeal, 1993]. Although prostate tumours 
may occasionally originate from TZ, either histological or clinical 
features of these tumours point to the possibility that their 
biological potential is different from the PZ tumours [Blacklock, 
1982; McNeal, 1992].
This histological distinction is not merely instructive, but 
holds a precise functional significance. For instance, significantly 
higher tissue concentrations of DHT have been documented in the 
periurethral than in the outer prostate [Siiteri &  Wilson, 1970]. 
Furthermore, presence of cytosol androgen receptors (AR) has 
been more frequently revealed in the PZ region (71%) with 
respect to periurethral tissue (39%) from both benign and 
malignant human prostate [Bowman et a l ., 1986].
Another major concern pertains to the procedures routinely 
used to obtain prostate cancer specimens suitable for AR assays. 
Since transurethral resection (TUR) is currently performed with 
increasing frequency in place of retropubic prostatectomy, it has 
been argued that the heat generated by the cutting loop of 
resectoscopes may seriously deteriorate the AR content of the 
resected chippings [Kyprianou et al., 1986]; however, this 
problem can readily be encompassed by selecting large 
uncharred specimens [Bowman et a l ., 1985]. In addition, studies 
recently carried out in our laboratories have suggested that TUR
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specimens represent suitable material for receptor studies, 
provided that only cutting current is employed, while the 
coagulating current is confined to the final part of the resection 
[Castagnetta et al., 1991b]. It should be emphasised that, due to 
the uneven distribution of AR throughout normal and diseased 
human prostate, sampling condition during TUR or other bioptic 
manoeuvres may critically influence the outcome of biochemical 
and biological assays. Based on normal anatomy, specimens taken 
from the beginning of TUR would correspond to the periurethral 
region, while the most peripheral part of the resection is most 
likely to be PZ tissue; further, perineal or transrectal biopsy will 
initially encounter the PZ and subsequently the CZ region. This, 
together with the undoubted regional and histological variation 
in both steroid receptor content and hormone sensitivity of 
prostatic tissues, implies that results from morphological and 
biochemical studies should be also interpreted by the light of the 
different areas sampled.
5.1.3. Molecular biology of androgen action
It is universally recognised that conversion of circulating 
testosterone into its biologically active derivative DH T represent 
an essential step for androgen action in prostate tissues. High 
affinity binding of DHT to intracellular AR primes a sequence of 
events that eventually lead to changes in the expression of a 
specific set of androgen-responsive genes.
The human AR belongs to the steroid receptor superfamily 
(see 2 .1 .), a section of a larger multigene family of ligand-
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inducible trans-acting regulatory factors [Parker, 1986]. It is a 
110 kDa protein encoded by a single gene that spans over 90 
kilobases and is located on the chromosome X  [Lubahn et a l ., 
1988]. The human AR gene consists of 8 exons, of which one large 
exon gives rise to the N-terminal domain of the receptor and 5 
exons divide out the sequence coding for the hormone-binding 
domain [Brinkmann et a l ., 1989].
Studies on the main secretory protein of the rat ventral 
prostate, the prostate binding protein (PBP), have provided a 
significant insight into the androgenic interaction at genetic level. 
The PBP (also referred to as prostatein) is a tissue-specific 
glycoprotein consisting of three polypeptides (C l, C2 and C3) 
encoded by three highly homologous genes [Parker et a l ., 1982]. 
Its synthesis is profoundly depressed by castration and can be 
restored after androgen administration [Heyns et a l ., 1977]. The 
homology existing between the DNA-binding domain of AR and 
that of other steroid receptor classes accounts for the fact that AR 
recognise hormone response elements (HRE, see 2.1.) specific to 
glucocorticoids or progestins in the tyrosine aminotransferase 
(TA T) gene [Denison et a l ., 1989] and the M M TV  long terminal 
repeat region [Ham et al ., 1988]. Similarly, the PBP genes contain 
putative androgen response elements which are responsible for 
androgenic modulation of their expression [Rushmere et al 
1987]. Androgen-responsive genes also include those encoding 
for secretory proteins that are being used to monitor prostatic 
disease, specifically the acid phosphatase [Yeh et a l 1987] and 
the kallikrein-like prostate specific antigen [Digby et a l ., 1989].
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A deeper knowledge of mechanisms whereby androgens 
regulate expression of responsive genes directly involved in the 
growth control of prostatic cells appears essential for evolution of 
both basic and clinical research relevant to the malignant human 
prostate.
5.1.4. Multifarious growth regulation
Androgens are thought to be necessary for prostate 
development and maintenance of both cell number and 
functional activity in the adult gland. However, a direct role for 
androgens in the control of growth of prostatic cells is still 
questionable. Androgen-dependence of both pre- and post-natal 
development of the prostate is illustrated by the evidence that 
administration of testosterone to immature male rats produces 
an accelerated prostatic development [Berry &  Isaacs, 1984], 
whilst deficiency of either AR or the 5a-reductase enzyme 
results in a rudimental prostate or in its complete absence 
[Imperato-McGinley, 1984]. In addition, the presence of 
androgenic steroids preserves the normal size of the adult gland 
through a balance between cell renewal and cell death, although 
exogenous androgens do not induce its enlargement. However, it 
has been suggested that other controlling factors are required for 
accomplishment of androgen-promoted proliferation of prostatic 
cells [Bruchovsky et a l , 1975].
There is substantial evidence that steroid hormones other 
than androgens may be significantly involved in the growth 
control of normal or pathological human prostate. In the first
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place, oestrogens have been implicated in the development of 
BPH, while their role in human prostate cancer is still debated 
(see [G riffiths et al., 1989]). Previous work indicated that 
oestrogens may exert a direct effect on the proliferative activity 
of prostate epithelial cells, an action which has its unique 
morphological counterpart in the so-called "squamous 
metaplasia" [Bern, 1963]. Further studies have shown that 
oestradiol, alone or synergizing with androgens, may be relevant 
to the genesis of both benign prostatic hyperplasia and prostatic 
carcinoma [Wilson, 1980; Wilding, 1992]. This has led to the 
hypothesis of androgen-supported oestrogen-enhanced  
stimulation of prostate epithelium as an essential requirement to 
overcome factors that normally limit cell proliferation [Leav et 
a l . ,  1989]. Additionally, high affinity oestrogen binding sites 
have been identified in normal, benign and cancerous human 
prostatic tissues [Murphy et a l ., 1980; Ekman et al., 1983]. In 
particular, immunocytochemical studies have revealed that 
oestrogen receptors are mostly located in the stromal 
compartment of prostatic tissues, arguing that stromal cells may 
represent the primary site of oestrogen action in the prostate 
[Chaisiri &  Pierrepoint, 1980]. This view has been further 
supported by the finding that oestrogens apparently lack 
mitogenic activity on cultured prostatic epithelium [Eaton & 
Pierrepoint, 1982]. However, several in vitro studies have shown 
that oestradiol stimulates growth of androgen-dependent LNCaP 
human prostate epithelial cancer cells at levels comparable or
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even greater than those observed after androgen administration 
[Schuurmans et a l ., 1988a; Sonnenschein et a l ., 1989].
Although a role for glucocorticoids in the pathogenesis and 
progression of human prostate cancer has not yet been defined, 
their implication in prostate growth and function is suggested 
[G riffiths et al.y 1979]. Glucocorticoid receptors (GR) have been 
found in both rat and human prostatic tissues; their presence 
may account for the glucocorticoid stimulation of prostatic 
epithelial cells observed in vitro [M c K e e h a n  et a l ., 1984].
Glucocorticoids seem to counteract some prostate processes 
induced by castration, such as weight loss and decrease of PBP 
secretion. This suggests that glucocorticoids may assume an 
important role when androgen regulation of prostatic tissues is in 
some way impaired.
The conviction that androgens could not be solely
responsible for prostatic cell proliferation has stimulated
research on the possible involvement of diffusible local factors in 
both normal and aberrant prostate growth. A number of
prostate-derived growth factors have been identified in human 
BPH and prostate tumour tissues and isolated from prostatic 
secretions [Parrish et al., 1984; Matuo et a l ., 1987]. In particular, 
substantial amounts of EGF-like activity have been detected in 
human prostatic tissues and fluids [Elson et a l ., 1984; LLoyd et 
a l ., 1992]. Additionally, presence of EGFR has been documented in 
both human and rat ventral prostate. In the latter, androgens
down-regulate expression of EGFR, suggesting that castration may 
result in EGFR induction and consequently prevent prostatic
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regression [Traish & Wotiz, 1987]. In contrast, synthesis of EGFR 
is stimulated by androgens in LNCaP human prostate epithelial 
cancer cells [Schuurmans et al., 1988a]; this evidence directly 
hints at the likely implication of prostate stromal compartment in 
the epithelial EGFR regulation by androgens. Studies on human 
prostate cancer have revealed an inverse relationship between 
EGFR and AR, with a developing prevalence of high versus low 
affinity sites of EGF binding in poorly differentiated tumours 
[Davies & Eaton, 1989].
Several human prostate cancer cells in culture synthesise 
and release into the culture medium polypeptide growth factors. 
In particular, DU 145 and PC3 cells produce PDGF-AA and PDGF- 
BB, in spite of the absence of specific cell surface receptors 
[Sitaras et a/., 1988]. Furthermore, the effects of peptide growth 
factors on proliferation of prostate tumour cell lines have been 
investigated. Notably, either growth stimulation by EGF and TGFa 
[Eaton et a l , 1988] or inhibition by TGFp [Wilding et al., 1989a] 
have been observed.
Unfortunately, very little information exists on the 
interaction between steroid hormones and peptide growth factors 
in the regulation of prostatic cancer cell proliferation and 
function. A clearer understanding of these processes, in either 
androgen-responsive or androgen-independent states, appears 
fundamental to appropriately address expanding areas of basic 
research and for development of new growth factor-based 
therapies for human prostate carcinoma.
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5 .1 .5 .  M esenchym al-ep i the l ia l  in te ra c t io n s
The potential role of mesenchymal-epithelial interaction in 
the development of both BPH and cancer of the human prostate 
was in itia lly  realised at histomorphological level by the 
pioneering studies of Franks [Franks, 1956]. Later on, using an in 
v itro  model, Franks and colleagues observed that DNA synthesis 
in prostatic epithelial cells depends on the presence of adjacent 
stromal and myoepithelial cells [Franks et a l ., 1970].
In the more recent years, this area of investigations has 
been dominated by the impressive work of both Gerald Cunha's 
and Leland Chung's groups (for relevant reviews see [Cunha et 
a l 1987] and [Chung et al ., 1991]).
In the first place, Cunha and colleagues indicated that the 
balance between stromal and epithelial compartments is 
essential for direction of prostate development and growth. Using 
elegant procedures, the authors separated the endodermal 
urogenital sinus (UGS), from which prostate epithelial outgrowths 
(prostatic buds) originally emerge, into mesenchyme (UG M ) and 
epithelium (UGE) and found that the amount of UG M  present is 
primarily responsible for the final size of the adult gland [Chung
& Cunha, 1983]. In addition, increase of prostatic growth in situ
was observed when UGM or intact UGS were grafted directly into 
the prostate of intact adult male rats [Chung et a l ., 1984].
It has been proposed that a tight interaction exists between 
neuroendocrine networks residing primarily in the mesenchyme 
and key enzymes of androgen metabolism basically located in the
epithelium of the human prostate [Chang & Chung, 1989; Higgins
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& Gosling, 1989]. The role of mesenchyme as a mediator of 
androgen action upon prostatic epithelium has been established 
in mesenchyme and epithelium tissue recombination  
experiments using mice affected by testicular feminization (Tfm) 
syndrome. In the latter condition, the external genitalia are 
feminized and the prostate completely fails to develop as a 
consequence of defective or absent androgen receptors [Ohno, 
1977]. Four possible combinations of Tfm or wild-type UGM  and 
UGE were grafted into intact male hosts to achieve a physiological 
androgenic milieu. Prostatic morphogenesis occurred only in the 
presence of the wild-type U G M , whilst no prostatic 
differentiation was seen using Tfm UGM, irrespective of the 
epithelium type (Tfm or wild-type UGE) used [Cunha et a l ., 1980]. 
The androgen-dependent formation of prostate observed using 
the wild-type UGM  and Tfm UGE combination indicates that 
androgen action would be mediated by receptor-positive stromal 
cells, since Tfm epithelium remains AR-negative throughout 
prostate induction [Shannon & Cunha, 1984]. Additionally, using 
this combination, androgen-induced DNA synthesis was found to 
be equivalent to that obtained in completely wild-type prostates, 
supporting the view that androgens regulate a variety of 
epithelial features via androgen-induced mediators of stromal 
origin [Cunha & Chung, 1981]. This assumption is also supported 
by the fact that androgens stimulate DNA synthesis in epithelial 
prostatic tissue in organ culture only in the presence of stroma, 
whereas androgen-induced growth of cultured isolated epithelial 
cells is not yet established [Sandberg & Kadohama, 1980].
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In a recent model system, m orphologically and
biochemically well characterised prostatic fibroblast and 
epithelial cell lines derived from both embryonic and adult 
prostate glands have been inoculated together in vivo or co­
cultured in vitro [Camps et a l ., 1990]. Results obtained so far
appear noteworthy. Firstly, coinoculation of athymic mice with a 
rat foetal UGM cell line (rUGM) and androgen-independent PC3 
human prostate epithelial cancer cells resulted in rUG M  
stimulation of PC3 tumour growth in the male mice; this suggests 
that androgen-sensitive growth can be induced in androgen- 
unresponsive epithelial cells by interaction with relevant 
mesenchymal cells [Chung et a l ., 1991]. In the second place, the 
marginally tumourigenic LNCaP human prostate cancer cell line 
can be stimulated to form carcinomas in the male athymic mice 
by the concomitant inoculation of non-tumourigenic prostate or 
bone fibroblasts; in contrast, LNCaP cells did not form tumours in 
either castrated male or female hosts [Gleave et a l ., 1991].
Additionally, conditioned media from cultured bone and prostate 
fibroblasts remarkably enhanced growth of LNCaP in vitro. This 
evidence indicates that normal fibroblasts may accelerate
prostate epithelial tumour formation in the presence of an
androgenic microenvironment and that this action is likely to be 
mediated by diffusible, paracrine growth factors.
5.1.6. Cell apoptosis: a self-program to die
In the past the concept of cell death was mistakenly
identified as a pathological process, termed necrosis, whereby the
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cell dies because of physical or chemical external injuries. This 
"accidental" cell death typically tends to assume specific 
morphological and biochemical characteristics, also depending on 
the causative agent. However, further investigations made clear 
that a morphologically distinct, spontaneous form of cell death 
occurs naturally in several tissues under various conditions. In 
the early 1970s, Kerr and coworkers [Kerr et al., 1972] christened 
this physiological process of cell death as apoptosis, from the 
ancient Greek word describing the falling off of leaves from trees 
or petals from flowers. The fact that cell death is spontaneously 
occurring generated the idea that it is self-programmed and led 
to introduce the term "programmed cell death" as an alternative 
expression to name this process (reviewed by [Schwartzman &  
Cidlowski, 1993]).
In the last two decades an increasing number of reports 
have indicated that programmed cell death occurs in 
phylogenetically distant organisms during embryonic and foetal 
development, tissue differentiation and growth. Furthermore, 
addition or removal of appropriate regulatory factors induces 
apoptosis in many hormone- and growth factor-responsive 
tissues, including prostate, breast, uterus, thymus, adrenal cortex. 
It is also known that apoptosis occurs in several human tumours 
spontaneously or in consequence of treatment; examples include 
breast cancer, prostate cancer, leukaemias, pancreatic cancer and 
many others.
In the programmed cell death a certain number of specific 
signals activate the cell to undergo an energy-dependent
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mechanism of death or, by paraphrasing, the cell commits suicide 
without any apparent reason in an otherwise friendly  
microenvironment, as opposed to the cell which is murdered by 
its hostile milieu in the case of necrosis. Activation of the 
programmed cell death may depend upon either the presence of 
a specific inducer (e.g. glucocorticoids in the thymocyte death 
[Wyllie, 1980]) or the loss of a normally active repressor (as 
when reduction of serum ACTH leads to cell death in the zona 
reticularis of the adrenal gland [Wyllie et a l ., 1973]). Once
activated, programmed cell death proceeds along an orderly 
sequence of morphological and biochemical events which 
ultimately lead to an irreversible degradation of genomic DNA  
and cell fragmentation. The structural changes that eventually 
lead to cell death are rather stereotypic and initially consist of 
loss of cell junctions, condensation of nucleus and cytoplasm, and 
chromatin coalescence into one or several large masses; this is 
followed by nuclear breaking and cellular rupture into numerous 
membrane-bound smooth-surfaced fragments, called apoptotic 
bodies, which contain a variety of morphologically intact 
cytoplasmic organelles and some nuclear fragments. The 
apoptotic bodies are subsequently phagocytosed and rapidly 
digested by the nearby macrophages or epithelial cells.
Androgen withdrawal induces specific biochemical and 
molecular changes in the normal prostate which finally lead to 
cell death. After castration, the levels of serum testosterone 
dramatically fall below 2 % of normal controls; as a consequence, 
prostatic DHT also drops to less than 5% of intact controls, leading
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to both variation in the nuclear AR function and a novel 
expression of genes encoding for a specific set of proteins. These 
genes include the testosterone-repressed prostate message-2  
(TRPM-2) gene [Montpetit et al., 1986], the Ca2+ responsive c-fos 
[B uttyan  et a l ., 1988] and the c -m y c  [Quarmby et a l ., 1987] 
protooncogenes, the hsp70 gene [Buttyan et al., 1988] and the 
TGF(3 gene [Kyprianou & Isaacs, 1989a]. Initially, castration- 
induced apoptosis of prostatic cells involves enzymatic 
degradation of genomic DNA into fragments consisting of 
nucleosomal oligomers lacking intranucleosomal breaks. This DNA  
fragmentation is due to the activation of a Ca2+/M g 2+-dependent 
endonuclease, induced by the increase of intracellular calcium 
levels further to androgen ablation [W yllie et al., 1984]. The 
process of DNA degradation is complete one day only after 
castration and it appears to be an irreversible commitment step 
for viable cells to die [Kyprianou et al., 1991]. The importance of 
perturbation of cellular calcium homeostasis in the prostatic cell 
death is first of all suggested by the evidence that a rapid, 
sustained increase of intracellular calcium is the earliest 
detectable event in cells undergoing apoptosis. More importantly, 
the artificial rise of intracellular calcium concentration by means 
of calcium ionophores (such as A23187) or ionomycin induces 
prostatic cell death [Martikainen & Isaacs, 1990]. Conversely, 
comparison of castrated rats receiving prostate implants of either 
placebo or nifedipine, a calcium channel blocker, showed that 
castration-induced prostatic involution is significantly slower in 
the nifedipine-treated rats than in the placebo-treated group
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[Martikainen & Isaacs, 1990]. During days 2-7 after castration, an 
increasing expression of specific genes is seen in the involuting 
rat ventral prostate. In particular, the TRMP-2 mRNA appears 2 
days after castration and peaks at a 400-fold level at day 4 
[Montpetit et a l ., 1986], while TGFJ3 mRNA increases by
approximately 1 0 -fold since the first day and is maximally 
expressed (about 40-fold) by 4 days postcastration [Martikainen 
et a l , 1990]. Similarly, mRNA for the c-myc protooncogene raises 
up to 6 -fold in the regressing prostate, apparently as a
component of a cascade induction of c-fos, c-m yc  and hsp70
transcripts [Buttyan et a l ., 1988].
Basically, tumour growth depends upon the balance of cell 
division and cell death, a greater cell proliferation being required 
for continued neoplastic growth. Therefore, effective treatments 
could be designed aiming to either reduce the rate of cancer cell 
proliferation or augment the rate of cell death, eventually leading 
to a negative balance in favour of cell death and to the involution 
of the tumour. Since most of the presently available 
chemotherapeutic agents act on proliferating cancer cells, the 
effectiveness of cancer therapy will be greater in tumours having
high proliferation rates. However, in the presence of a low rate of
cell death, it is highly unlikely that chemotherapy could lessen 
the proportion of dividing cells below that of dying cells, also 
because the maximum tolerated therapeutic intensity is 
generally not high enough to achieve a significant reduction of 
cell proliferation [Schackney et a l ., 1978]. Therefore, in order for 
chemotherapy to be effective the rates of both cell proliferation
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and death in a given tumour must be high [Tubiana & Malaise, 
1975], An additional obstacle comes from the fact that currently 
used cytotoxic drugs affect only proliferating (cycling) cells, while 
cells in a quiescent state (Go) or cells dividing late after exposure 
to the chemotherapeutic agents may repair the damage 
undergone and survive the treatment. Thus, a major hope is to 
develop new pharmacological therapies which can k ill cancer 
cells regardless of their cell cycle state. This is exactly what 
occurs in the normal rat prostate following androgen ablation. In 
the intact adult male the supply of circulating androgens is 
enough to retain rates of cell proliferation and death in 
equilibrium, avoiding either overgrowth or involution of the 
gland. Since the proportion of dividing cells in the normal adult 
prostate of intact male rats is approximately only 2 % per day, a 
2 0 % increase of the daily rate of cell death caused by androgen 
ablation, coupled to the decrease of cell proliferation, will result 
in the fact that after 7 days castration over 70% of the rat 
prostatic cells have died [Isaacs, 1984]. This clearly indicates that 
the cell death induced by androgen ablation mostly involves non­
dividing, Go cells.
Coming to human prostate cancer, the vast majority of 
patients experience an often dramatic, beneficial response to 
androgen ablation therapy; unfortunately, most of them 
subsequently develop a hormone-refractory disease where any 
second-line antiandrogen treatment is ineffective, no matter how 
aggressively given [Eaton & Griffiths, 1990]. There is convincing 
evidence that this failure is a reflection of the heterogeneous
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composition of primary prostate tumours, wherein androgen- 
dependent and -independent cancer cells are likely to coexist 
well before any endocrine treatment is initiated [Isaacs & Coffey, 
1981].
Several experimental data confirm the assumption that 
programmed cell death is activated also in androgen-dependent 
prostate tumour cells following androgen ablation. In this 
respect, the case of transplantable PC82 human prostatic cancer 
cell line is enlightening [Kyprianou et a l ., 1990]. When PC82 cells 
are grafted into intact male nude mice they give rise to actively 
growing tumours. I f  the host mice undergo castration, the 
proportion of dividing cells in the PC82 population decreases 
about 7-fold, while the rate of cell death increases up to 11-fold, 
so that the tumour rapidly regresses. At the molecular level, 
these changes are paralleled by DNA fragmentation and by the 
increasing expression of both TRPM -2 and TGFp genes. 
Conversely, if  exogenous androgens are administered to the 
castrated mice, DNA degradation ceases, TRPM-2 and TGFp 
transcripts decline to pre-castration levels and tumour growth 
resumes.
Unfortunately, androgen-independent prostatic cancer cells 
have lost the program of cell death in response to androgen 
ablation. However, using a panel of cell lines derived from the 
Dunning R3327 androgen-independent prostate tumours, it has 
been shown that these cells retain the major part of the 
pathways leading to programmed cell death. For instance, 
treatment in vitro of the Dunning AT-3 cell line with non-
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androgenic ablative agents inducing a "thymine-less death" 
causes the induction of the TRMP-2 gene and the activation of 
the Ca2 +/ M g 2 + -dependent endonuclease with the resulting 
fragmentation of genomic DNA [Kyprianou & Isaacs, 1989b]. Once 
again, a crucial shortcoming of this type of anticancer drug is that 
they require cell proliferation to be effective. Thus, although 
apoptosis can readily be induced in androgen-dependent prostate 
cancer cells by androgen ablation and proliferating androgen- 
independent cells can be controlled using the presently available 
cytotoxic agents, the key aspect remains the management of 
quiescent androgen-independent cell clones. In this respect, 
development of non-androgenic (growth factor-based?) 
strategies able to activate the pathways of programmed death in 
nondividing androgen-independent prostate tumour cells is 
awaited.
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6. Aims of Thesis
The main goal of the present thesis was to explore the 
activity of both sex steroid hormones and transforming growth 
factors a and p in the regulation of growth and metabolism of 
prostate cancer cells, in vitro.
To this end, three human prostate tumour cell lines, LNCaP, 
DU145 and PC3, each having distinct status of steroid sensitivity, 
have been used as model systems.
The effects of both androgens (T and DHT) and oestradiol on 
cell growth rates have been weighed, also in relation to 
mechanisms responsible for accomplishment of hormone action. 
In addition, status and content of steroid receptors (AR and ER) 
has been determined using multiple approaches, including ligand 
binding assay, immunocytochemical assay, reverse transcriptase- 
PCR of mRNAs, and through immunofluorescent staining of the 
hsp27, which appears to be quantitatively and qualitatively 
related to a functional ER machinery.
Growth response of prostate cancer cells to either TGFa or 
TG F(3 i has been assessed in different experimental conditions. 
Furthermore, presence of membrane receptor sites for both EGF 
and TGFp has been evaluated using radioreceptor assay and, for 
EGFR, Western blot analysis. Expression of endogenous EGF, TGFa 
and TGFp i has also been estimated by immunofluorescent 
staining.
2 1 2
Analysis of rates and direction of steroid metabolism has 
been carried out through incubation of cultured cells with 
labelled steroid precursor (T or E2 ) and reverse phase-HPLC 
estimation of both precursor degradation and product's 
formation. Possible paracrine influence of either TGFa or TGFpi 
on the extent of both individual reactions and overall reductive 
and oxidative pathways of either metabolism have also been 
inspected.
The results have been used as the basis for models of 
hormone-sensitive and insensitive prostate cancer, allowing 
suggestions of how new therapies might be devised.
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1.  Mater ia ls
1.1. In Vitro Systems
1.1.1. Cell lines
LNCaP.FGC (passage 19), DU145 (passage 59) and PC3 
(passage 16) human prostate cancer cell lines all were purchased 
from the American Type Culture Collection (Rockville, MD).
The LNCaP cell line (Figure 16A) was originally established 
from a lymph node metastasis of a human prostatic 
adenocarcinoma [Horoszewicz et a l ., 1980]. Cultured cells grew in 
monolayers loosely attached to the surface of plastic culture 
dishes, with a mean population doubling time of 60 h. Early 
studies showed that LNCaP cells contained specific androgen- and 
oestrogen-binding proteins in the cytosol; nuclear androgen 
receptors were also detected [Horoszewicz et a l ., 1983]. In 
addition, cells responded in a dose-dependent manner to DHT, 
with a parallel rise in the production of the prostatic acid 
phosphatase. Karyology studies revealed that this cell line is 
aneuploid, having a wide range (33 to 91) of chromosome 
number, at least 7 different marker chromosomes and a modal 
number of 76 chromosomes after 32 months growth in vitro;
The DU145 cell line (Figure 16B) was originated from a 
brain lesion of a human metastatic prostatic carcinoma [Stone
et al.,  1978]; the brain metastasis was described as a
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; moderately differentiated adenocarcinoma tissue, with foci of 
poorly differentiated cells. The DU 145 cells were reported to be 
an apparently non hormone-sensitive cell line, growing as 
isolated islands in culture with an average doubling time of 34 h. 
Karyotype analysis at transfer 57 revealed that cells were 
aneuploid, having a hypotriploid modal chromosome number 
(64), several minute chromosomes and 3 marker chromosomes.
The PC3 cell line (Figure 16C) were derived from a 
vertebral metastasis of a poorly differentiated human prostatic 
carcinoma [Kaighn et a l , 1979]. Cultured PC3 cells were described 
as having epithelial-like morphology, with numerous grape-like 
aggregates of loosely attached viable cells. Growth of cells was 
insensitive to a variety of factors, including DHT, EGF, FGF and 
insulin, with a population doubling time of approximately 33 h. 
Chromosome studies at passage 17 showed a bimodal frequency 
distribution of chromosome number in the subtriploid range, 
with two major peaks at 60 and 69 chromosomes. In addition, 
subsequent karyotypic analysis demonstrated that chromosomes 
2, 3, 5, 15 and Y were consistently missing, while at least 11 
different marker chromosomes were observed [Ohnuki et al., 
1980].
1.1.2. Cell culture
For routine maintenance, cells were grown in RPMI-1640  
medium, containing 5 p^g/ml phenol red and supplemented with 
10% foetal calf serum (FCS), 2 mM L-glutamine and antibiotics 
(100 U l/m l Penicillin, 100 pg/ml Streptomycin, 0.25 p g /m l
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Amphotericin B) - all from GIBCO BRL (Uxbridge, Middlesex, UK). 
Cells were harvested using trypsin:EDTA (1:5 v/v, GIBCO BRL) 
and subcultured at 1:4 to 1:5 ratio in 100 mm plastic dishes 
(Costar Italia srl, Milan) at 37°C in a humidified atmosphere of 5 % 
C O 2 in air. Both culture medium and cells were routinely tested 
for mycoplasma contamination using either infusion in 
mycoplasma broth and enriched nutrient agar or Hoechst 33258 
fluorescent staining method. For all experiments cells having a 
narrow range of passage number were used (LNCaP = 21-24, 
DU 145 = 61-63, PC3 = 18-20).
1.2. Antibodies and Antisera
The D5 antibody and the human ER cDNA were kindly 
provided by R.J.B. King (Guildford University, UK) and by P. 
Chambon (Strasbourg, F), respectively.
Neutralising antibody against TGFBi (rabbit, polyclonal) was 
purchased from British Biotechnology Ltd. (Abingdon, UK).
Polyclonal (rabbit, BG48) antibody against EGF receptor was 
generously supplied by W. Gullick (ICRF, Oncology Group, 
London).
Monoclonal antibodies against EGF, TGFa and TGFPi were 
purchase from Oncogene Science Ltd (Manhasset, NY).
Fluorescent (F ITC  conjugate) anti-mouse IgG (sheep) and 
anti-rabbit IgG (donkey) antisera were kindly supplied by SAPU 
(Carluke, Scotland).
ADDENDUM
The id e n t i t y  o f  LNCaP cells was also assessed by  
im m unocytochem ical assay of PSA, in  both standard conditions 
and fo llow ing PSA stimulation by l , 2 5 (OH)2 D3 (v itam in  D3 ).
| (Skowronski et al., Endocrinology 1993, 132: 1952-1960 )
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2 .  Experimental  Procedures
2.1. Growth Studies
Growth rates of LNCaP, DU145 and PC3 human prostate
tumour cell lines were measured in routine RPM I medium
supplemented with 10% FCS. Cells ( l-5 x l0 4) were seeded onto
6 -well tissue culture plates (9.5 cm2, Costar) and left undisturbed
for 24 h. Thereafter, cells were grown up to 12 days with a 
medium change every 3 days. DNA estimation was performed as 
described later in this section (see 2.10.) at day 2, 4, 6 , 8 , 10 and 
12 on triplicate wells for each observation time. The average 
population doubling time was calculated by dividing the logio of 
the average DNA content per well by the logio2.
2.2. Radioligand Binding Assay of AR and ER
Steroid receptor (AR and ER) content and status of human 
prostate cancer cells was determined by means of radioligand 
binding assay, as extensively described elsewhere [Castagnetta et 
a l ., 1987a; Castagnetta et a l., 1992a]. Cells (70-80% confluent), 
growing in 162 cm2 plastic flasks (Costar) in routine medium, 
were harvested and pelleted by centrifugation at 120xg for 5 
minutes at 4°C. The cell pellet was then washed twice in ice-cold 
PBS-A (170 mM NaCl, 3.4 mM KC1, 2 mM Na2P 0 4, pH 7.4), 
resuspended in 4 ml of HED buffer (10 mM Hepes, 1.5 mM EDTA, 
0.5 mM Dithiothreitol, pH 7.4) and gently teflon-glass 
homogenised for 2 x 10 sec bursts at a setting of 600-800 rpm on
2 2 1
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a Potter S cooling system homogeniser (B.Braun Biotech GmbH, 
Germany). As routinely carried out in our laboratories for both 
ER and AR assay in either breast or prostate tissues [Castagnetta 
et a l 1987a; Castagnetta et al., 1992a], cell homogenates were 
spun at 800xg for 5 min at 4°C to separate the soluble 
(supernatant) from the nuclear (pellet) cell fraction. The 
supernatant was further centrifuged at 2000xg for 5 min at 4°C 
to remove cell debris; the nuclear pellet was subsequently 
washed three times in ice-cold buffered saline (10 mM Hepes, 
150 mM NaCl, pH 7.4) and resuspended to the original volume in 
the same saline. Aliquots (150 p i) of each cell fraction were 
therefore incubated overnight at 4°C against increasing 
concentrations (from 0.1 up to 5 nM) of radioligand, namely 
[ 1 7 a -m eth y l-3H]mibolerone j for AR
and [2,4,6,7-3H] 17|3-oestradiol for ER. In the case of AR, a 100 
fold excess of unlabeled mibolerone was used to measure 
displacement of androgen binding; a constant concentration 
( 1 0 '7M ) of cold triamcinolone acetonide was also used to hamper 
mibolerone binding to glucocorticoid receptors. In the case of ER, 
a 100 fold excess of unlabeled diethylstilbestrol (DES) was used 
for competition studies; in addition, a 1 00  fold excess of 
unlabeled synthetic androgen methyltrienolone (R1881) was 
used to measure possible displacement of oestradiol binding from 
AR. After incubation, DCC absorption and filtration methods were 
used to separate bound from unbound ligand in soluble and 
nuclear fraction, respectively. For the soluble fraction, each tube 
was mixed for 15 min with 0.5 ml of DCC (0.15% w/v Charcoal,
2 2 2
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0.0015% w/v Dextran) suspension in HES buffer (10 mM Hepes, 
1.5 mM EDTA, 250 mM Sucrose, pH 7.4) to strip the unbound 
radioligand. Samples were centrifuged at 3000xg for 5 min at 
4°C. One ml aliquots of the resulting supernatant were counted 
in a LS1801 P-counter (Beckman Inc., Irvine, CA, USA) using 
Ready Gel™ (Beckman) as scintillation cocktail. For the nuclear 
fraction, 100  pi aliquots of the nuclear suspension were filtered 
through Whatman GF/C glass fiber filters (Whatman Ltd., 
Maidstone, UK) using a Millipore apparatus (Millipore SpA, Milan, 
Italy), the unbound ligand being washed out using saline. Filters 
were then removed, dried overnight at room temperature and 
counted for radioactivity. All the experiments to measure AR and 
ER cell contents were done in triplicate. Binding data were finally 
processed as described below.
2.3. Analysis and Expression of Receptor Data
Receptor data from both saturation and competition studies 
were analysed and processed using Scatchard analysis and a 
modification (©OncoLog 2.2) of a least-square fit routine [Leake 
et a l ., 1987], run on an IBM -PC, yielding both dissociation 
constant (Kd) and concentration values (fmol/ml homogenate); 
the latter were expressed either as fmol/mg protein or DNA or as 
number of sites per cell, for any cell compartment. Data were also 
analysed using a model for one or two binding sites, depending 
on the best fit achieved. Protein and DNA cell contents were 
determined using the Bradford [Bradford, 1976] and the modified 
Burton methods [Katzenellenbogen &  Leake, 1974], respectively.
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2.4. Reverse Transcriptase-PCR of AR
Expression of AR mRNA in LNCaP, DU 145 and PC3 cells was 
examined using reverse transcription of cellular RNA and PCR 
amplification of the reaction products. Cells grown in 100 mm cell 
culture dishes (56 cm2, Costar) until 80-90% confluent were 
washed twice with PBS-A and lysed directly on dishes using 3 ml 
of RNazol™ B (Biotecx Lab., Houston, TX). Cell lysates were 
therefore harvested and total RNA extracted according to the 
recommendations of the supplier.
The precipitated RNA was dissolved using 100 p i of 
diethylpyrocarbonate (DEPC)-treated water and heated to 60 °C 
for 15 minutes to ensure complete solubility. In order to avoid 
contamination of genomic DNA, RNA preparations were diluted to 
a final concentration of 1 pg/ml and aliquots (1 p i) incubated 
with 10U DNase I (GIBCO BRL) for 15 minutes at room 
temperature. Digestion was terminated by the addition of 1 pi of 
20 mM EDTA and DNase I heat inactivated by incubation at 65 °C 
for 15 minutes. Reverse transcription was performed using a 
modification of the Superscript preamplification system (GIBCO  
BRL) methodology. Briefly, 1 pi of random hexamers (50 ng/pl) 
was added to each digest; samples were then mixed gently and 
heated to 70 °C for 10 minutes. After cooling on ice for 5 minutes, 
one set of RNA duplicates received 8 pi of the reaction cocktail, 
consisting of 3 pi DEPC-treated water, 1 pi of lOx reaction buffer 
(200 mM Tris-HCl - pH 7.4, 500 mM KC1, 25 mM MgCl, 1 mg/ml 
bovine serum albumin, BSA), 1 pi of 10 mM deoxynucleotides
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triphosphates (dNTP) mix, 2 pi of 0.1M dithiothreitol (DTT), 1 pi 
of Superscript I I  RT (200 U/pl). The second set of duplicates 
received the same reaction cocktail, except one pi more DEPC- 
treated water instead of Superscript I I  RT. After gentle mixing, 
all samples were incubated at 45 °C for 50 minutes and the 
reaction terminated by heating to 70 °C for 15 minutes. Excess 
RNA was eliminated through incubation for 20 minutes at 37 °C 
with 1 pi RNase H (2U/pl, Boehringer, Mannheim, Germany). PCR 
conditions used were a modification of those previously reported 
by others [Allen et a l.y 1992]. Shortly, the amplification reaction 
was carried out in a total volume of 100 pi containing the reverse 
transcribed cDNA, 10 pmol (1 pM ) each of the 24-mer 5'- 
GCTGTGAAGGTTGCTGTTCCTCAT-3' as sense primer and the 24- 
mer 5 -TCCAGAATCTGTTCCAGAGCGTGC-3’ as antisense primer, 
lOx PCR buffer (100 mM Tris-HCl - pH 9.0, 500 mM KC1, 1.0% 
(w/v) Triton X-100), 10% (v/v) dimethylsulphoxide (DMSO), 5U 
Taq-DNA-polymerase (Promega, Madison, W I). PCR was carried 
out using a Hybaid Omnigene thermocycler in 40 cycles, each 
comprising 45 seconds at 93 °C, 1 minute at 60 °C and 1 minute 
at 72 °C. The primer set used identifies a 280 bp target locus 
from nucleotides 229 to 508 of exon 1 of the human AR gene 
(HUM ARA, GenBank; accession number M21748), which includes 
a unique, highly polymorphic CAG trimeric repeat (short tandem 
repeat, STR) encoding 11-31 glutamine residues.
Aliquots (16 pi) of PCR products were electrophoresed for 2 
h at 50 W through a 2% agarose gel containing lx  TBE buffer (89 
mM Tris-borate, 89 mM boric acid, 2 mM EDTA, pH 8.0). The gel
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was then stained with 1 jig/ml ethidium bromide for 20  minutes 
at room temperature, destained in water by 2x15 minutes 
washes and finally photographed using a Polaroid land camera 
on a long wave UV light box.
2.5. Immunocytochemistry of ER and PgR
Presence of both ER and PgR was investigated in LNCaP,
DU 145 and PC3 cells by a modification respectively of ER-ICA
and PgR-ICA methods, using the commercially available Abbott 
(Divisione Diagnostici, Rome, Italy) kits. Cells were grown in 
routine medium directly onto 2-well Lab-Tek® Tissue Culture 
Chamber Slides™ (Nunc, Naperville, IL ) until 60-80% confluent. 
Medium was aspirated off, cells washed twice in ice-cold PBS-A 
for 5 minutes and fixed for 10 minutes at 4°C using 3.7% (v/v) 
formaldehyde solution in PBS (150 mM NaCl, 10 mM Na2HPC>4 , 
2.0 mM K H 2PO 4 , pH 7.4). After 5 minutes rinse in PBS at 4°C, 
wells were exposed for 4 minutes to methanol and for 3 minutes 
to acetone at -20°C, with two subsequent rinses in PBS for 5 
minutes. Non-specific binding sites were blocked through 
incubation of slides with goat serum for 2 0  minutes in a
humidified chamber at room temperature. The excess of blocking
serum was then removed and slides incubated for 24 h at 4°C 
with the primary rat monoclonal anti-ER or anti-PgR antibodies 
(0.1 pg/ml). Parallel control wells received normal rat IgG under 
identical conditions. After 2 washes of 5 minutes in ice-cold PBS, 
slides were incubated in a humidified chamber at room 
temperature with the bridging antibody (goat anti-rat) and then
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exposed to the rat PAP-complex, each step being for 30 minutes. 
Slides were washed twice as before and the solution of the 
chromogen substrate (diaminebenzidine, DAB) added for 15 
minutes under the above conditions. After 5 minutes washing 
under gentle running of distilled water, all slides were 
counterstained for 10 minutes with 0 .2 % (w/v) ethyl green in 
O .IM  sodium acetate buffer (pH 4.0). Finally, slides were rinsed 
in distilled H 2O, air dried and, after 2x1.5 minutes dips in butanol 
and 3X2 minutes dips in xylene, mounted using the Eukitt®  
mounting medium (Bio-Optica, Milan, Italy). Abbott ER-ICA and 
PgR-ICA control slides were simultaneously processed and used 
as positive controls. For each condition, 100 randomly selected 
fields from at least 3 different slides were analysed. Analysis of 
the receptor staining was performed using the quantitative 
oestrogen/progesterone analysis application (release 2 .0 ) for 
CAS™200 Image Analyser (Becton-Dickinson Italia SpA, Milan), 
which automatically yields percent of positively stained nuclei 
and measures the intensity of staining (positive stain); the latter 
was defined as the summed optical density for the positive 
receptor nuclear area over the summed total optical density of all 
the nuclei expressed as a percentage. Percentage values of <30%, 
from 30 to 60% and >60% respectively identified weak, moderate 
and strong stain intensities.
2.6. Reverse Transcriptase-PCR of ER
Presence of ER mRNAs in prostate cancer cell lines was 
investigated using reverse transcriptase-PCR, as recently
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established in our laboratories [Pfeffer et al., 1993]. Cells grown 
to near confluence in 100 mm cell culture dishes (56 cm2, Costar) 
were washed twice with PBS-A, lysed directly on dishes in 3 ml 
of RNazol™ B (Biotecx Lab., Houston, TX ) and harvested using a 
rubber policeman. Total RNA was extracted from ZR75-1, MCF7 
and M DA-M B231 mammary carcinoma cell lines and from 
prostate cancer cells according to the manufacturer's protocol 
(see Section 2.4.). One pg RNA of each cell line was reverse 
transcribed at 42°C for 45 minutes using 25 pmol (2.5 pM ) of a 
15-mer antisense primer downstream of the region to be 
amplified and avian myeloblastosis virus reverse transcriptase 
(Boehringer, Mannheim, Germany) in PCR-buffer (10 mM Tris- 
HC1 pH 8.3, 1.5 mM MgCl2, 50 mM KC1, 0.005% Tween-20, 0.005% 
Nonidet P-40, 10 mg/ml gelatin) containing the dNTP at 10 mM  
each. cDNA was used for amplification without further 
purification. PCR was carried out with Taq-DNA-polymerase 
(Promega, Madison, W I) using 25 pmol (2.5 pM ) each of the 24- 
mer 5'-CATAACGACTATATGTGTCCAGCC-3' (nucleotides 937-962, 
exon 3) oestrogen receptor cDNA sequence [Greene et a l ., 1986] 
as sense and the 24-mer 5’-AACCGAGATGATGTAGCCAGCAGC-3' 
(nucleotides 1596-1572, exon 6 ) as antisense primers in 30 
cycles at 65°C, 72°C and 94°C of 30 sec each. The amplification 
products were then electrophoresed on a 1.4% agarose gel, 
photographed under UV-illumination and blotted onto nylon 
membranes by alkaline transfer [Ausubel et a l ., 1994]. For 
Southern hybridisation experiments, a human oestrogen receptor 
cDNA, generously gifted by Pierre Chambon (Strasbourg, France),
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was cut from pSG5 plasmid, radiolabelled with 32P by random- 
primed labelling (Boehringer) and used as a probe following 
standard procedures [Ausubel et al., 1994].
2.7. H sp27 Im m unostain ing
Immunofluorescence of the 27 kDa HSP27, which is 
reported to be qualitatively and quantitatively related to ER in 
several human tissues [King et al., 1987], was also used as a 
possible index of functional ER. To this end cells grown directly 
onto 8 -well Lab-Tek® Tissue Culture Chamber Slides™ (Nunc, 
Naperville, IL )  were fixed at -20 °C for 15 min in 
acetone:methanol (1:1, v/v). Cells were then incubated for 30 min 
at room temperature with 10% (v/v) sheep serum (SAPU, 
Carluke, Scotland) in PBS to suppress non specific binding. After 
5 washes in BSA/PBS (0.1%, w/v), cells were incubated for 2 h at 
room temperature in presence of a monoclonal (mouse) D5 
antibody (1:100) raised against a ER component purified from 
human myometrium [Coffer et al., 1985]; duplicates wells 
received PBS/BSA only. After incubation, cells were washed 5 
times as before and specific binding of D5 antibody visualised 
through a second step FITC-conjugated anti-mouse antiserum 
(1:40). Following 2 h incubation at room temperature in the dark, 
cells were washed, the plastic upper chambers removed and 
slides coverslip-sealed using Acquamount (BDH, Dorset, UK) 
mounting medium. Immunofluorescence was visualised within 
24 h using a Leitz Orthoplan fluorescent microscope.
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2 . 8 .  P reparation  o f  D ialysed , H eat-In activa ted , D extran  
Coated Charcoal Treated-FCS (DHICT-FCS)
One hundred ml aliquots of FCS were dialysed (12 kDa 
molecular weight cut-off) for 48 hours at 4°C against 4x1 litre 
changes of HBSS Hank's modified buffer (1.3 mM CaCl2, 5.4 mM  
KC1, 0.5 mM MgCl2, 0.5 mM MgS04, 137 mM NaCl, 4 mM NaHC03, 
0.4 mM NaH2P0 4 , pH 7.2). The dialysed serum was transferred to 
a glass container and heat inactivated at 56 °C for one hour in a 
water bath. The serum was then cooled to 4°C and added to a 
pellet of dextran coated charcoal (DCC: 0.25% (w/v) Charcoal,
0.0025% (w /v) Dextran) previously suspended in PBS. The 
solution was stirred at 4°C for 45 minutes and then centrifuged 
at 10,000xg for further 45 minutes at 4°C. The supernatant was 
finally filtered through 0.22 pm filters (M illipore SpA, Milan,
Italy) to ensure sterility.
2.9. S tero id  R esponsiveness
To examine growth response of human prostate tumour 
cells to various concentrations of either androgens (DHT and T) or 
oestrogen (E 2 ), cells were cultured for a week in RPMI medium 
supplemented with 10% DHICT-FCS, with medium changes every 
72 h. Subconfluent cell monolayers were rinsed twice in PBS-A, 
harvested by trypsinisation and seeded onto 6 -well tissue
culture plates (9.5 cm2, Costar) at a density of 5-10 x 104
cells/well in routine medium. After 24 h (day 0), cells were 
washed twice with PBS-A and medium replaced with phenol
red-free RPM I medium, supplemented with 10% DHIC T-FC S, 
containing increasing concentrations (from 10-11 up to 10_7M ) of
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T, DHT or E2 in ethanol (0.1% final concentration); control wells 
received vehicle (ethanol, 0.1%). At day 3, medium was removed 
and replaced with fresh medium as before. After 6 days, medium 
was discarded and DNA estimation performed as described 
below.
In separate experiments, PC3 cells were exposed to E2 
(1 x 1 0 ' 11 up to lx lO _7M) in presence or absence of a anti-TGFBi 
neutralising antibody (chicken, polyclonal; N D 50 = 2-3 jig /m l;  
British Biotechnology, Oxon, UK) at a final concentration of 9.2 
pg/ml; parallel wells were incubated with the anti-TGFBi 
antibody alone, control wells received vehicle (ethanol, 0 . 1%) 
only. After different incubation times (24, 72, 144 h) medium 
was discarded and DNA content measured as hereafter described.
2.10. DNA growth assay
Estimation of the DNA cell content was performed using a 
Hoechst 33258 microassay, as extensively described elsewhere 
[Leake & Habib, 1987]. Briefly, cells from growth studies or 
hormone responsiveness or T G F a /T G F B i (see below, 2.16.) 
experiments were washed twice with PBS-A. Cells were then 
solubilised for 30 minutes at 37 °C in 3 ml of pre-warmed 0 .2 % 
(w /v) sodium dodecyl sulphate (SDS) in ETN buffer (10 mM  
EDTA, 10 mM Tris+HCl, pH 7.0). Aliquots (100 pi) of each sample 
were then transferred to RT-30 test tubes to which 3 ml of ETN  
buffer containing Hoechst 33258 (100 ng/ml) and RNase A (5 
ng/ml), were added. Tubes were thoroughly vortexed and 
incubated for 30 minutes at room temperature in the dark.
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Fluorescent enhancement at 450 nm was finally measured 
through a Hitachi Perkin-Elmer MPF-24 fluorescent spectro­
photometer (Perkin-Elmer, Norwalk, CT), using an excitation 
wavelength of 360 nm and both slit widths at 5 nm. Cell DNA  
content was finally calculated on a calibration curve constructed 
using stock DNA solution. Using this method DNA content and 
cell number have been shown to be linearly correlated [Leake & 
Habib, 1987].
2.11. Tritiated  Thym idine Uptake
Separate experiments were carried out in order to assess 
whether or not growth stimulation of LNCaP cells by oestradiol is 
mediated through ER. Cells were grown for a week in RPMI 
medium supplemented 10% charcoal treated-FCS (CT-FCS) and 
then seeded onto 6 -well tissue culture plates (9.5 cm2, Costar) at 
a density of 2 x l0 5 cells/well in phenol red-free RPM I medium 
plus 5% CT-FCS. Cells were left undisturbed for 48 h and then 
additioned with 0.01, 1 or 100 nM oestradiol with or without 100 
nM IC I-182,780, a pure synthetic antioestrogen [Wakeling et al., 
1991]. Parallel wells were exposed to IC I-182,780 alone; control 
wells received vehicle (ethanol 0.1%) only. Cells were then 
incubated for 6  days, with a medium change at day 3. After the 
incubation period, [methyl-3H]Thymidine (specific activity 248 
GBq/mmol, Du Pont de Nemours Italiana SpA, Milan) was added 
(74 KBq/well) in RPMI for 6 h. After the pulse, medium was 
discarded and cells were fixed in methanol for 10  minutes at 
-20°C to minimise cell losses. Cells were then rinsed twice with
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PBS-A and washed three times using 2 ml of ice-cold 10% 
trichloroacetic acid (TCA) for 10 minutes. Cell monolayers were 
subsequently solubilised using 1 ml of 0.1% SDS in 0.3N NaOH and 
duplicate aliquots (400 pi) of acid-precipitable material from SDS 
solution were counted for incorporated radioactivity in a 8 - 
counter after acidification using 10% (v/v) acetic acid. A ll 
experiments were performed in triplicate.
2.12. Northern Blot Analysis of TG Fpi mRNA
Specific experiments were carried out to investigate TGFBi 
mRNA expression and possible regulation by E2 in PC3 cells. Cells 
were grown to near confluence in 10 -cm plastic dishes in routine 
medium. After two washes with PBS-A, cells were trypsinised 
and plated at appropriate densities in 75 cm2 tissue culture 
flasks. After 24 h, medium was replaced with serum-free, phenol 
red-free RPM I medium, supplemented with 20 pg/ml transferrin 
(Sigma-Aldrich, Milan, Italy) and 400 pg/ml BSA fraction V  
(Sigma-Aldrich), containing 10"11 to 10_7M E2 in ethanol (0.1%); 
duplicate flasks received ethanol only. After varying incubation 
times (6 , 24 and 72 h), cell monolayers were washed three times 
with ice-cold PBS and lysed directly into the culture flasks using 
3 ml/dish of RNAzol™ B (Biotecx Laboratories, Houston, TX); RNA 
was therefore extracted from cells fo llo w in g  the 
recommendations of the supplier (see Section 2.4.). Ten pg of 
total R N A  were electrophoresed in 3 -(N -m o rp ho lino ) 
propanesulphonic acid (MOPS) buffer at 30 volts for 16 h in a 
cold room through a 1 .2 % agarose gel containing 6 .6 %
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formaldehyde. The filters were hybridised using DNA probes to 
human TGFBi (British Biotechnology) consisting of chemically 
synthesised single stranded oligonucleotides. The latter were a 
cocktail of antisense sequences complementary to exons 6 , 7A 
and 7B. Probes were end-labelled by T4-Polynucleotide Kinase 
using y[32P]-dATP. Hybridisation was carried out at 60 °C for 16 
h in 1M NaCl, 50 mM Tris-HCl (pH 7.5), 10% Dextran Sulphate, 1% 
SDS. Filters were subsequently washed for 5 min at room 
temperature in 2x standard saline citrate (SSC) and for 15 min at 
60 °C in 2x SSC/0.1% SDS. Filters were finally autoradiographed 
for 20 h at -70 °C using Kodak X-OMAT AR film.
2.13. Growth Factor Binding Studies
Presence of high affinity binding sites for both EGF and 
T G F (31 in prostate cancer cells was assessed by means of 
radioreceptor assay. Cells were seeded onto 24-well plates at a 
density of 5x l0 4 cells/well in routine medium. After overnight 
incubation in a 5% CO2 atmosphere at 37 °C, cells were washed 
three times with PBS and grown to near confluence in RPMI 
medium with 1% FCS. Cells were then washed three times using 
PBS/BSA (0.1% w/v) and incubated for 2 hours at 25 °C in 200 pi 
binding buffer (RPM I without phenol red and FCS, with 0.1% 
BSA) containing 300 pM 125I-EGF or 100 pM 125I-TG FB i (Du Pont 
de Nemours Italiana SpA, Milan) plus various concentrations of 
unlabeled growth factor (EGF = 0.15 to 40 nM; TGFBi = 2 pM to 20 
nM); ranges of cold EGF or TGFBi were selected according to 
previous binding studies on prostate tumour tissues and cells
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[Traish & Wotiz, 1987; Schuurmans et a l ., 1988a; Wilding et a l.y 
1989a]. Separate wells were used for DNA and protein 
estimation. After four washes with ice-cold PBS/BSA, cells were 
solubilised for 30 minutes at 37 °C using 500 pi of SDS (0.1% 
w/v). Duplicate aliquots of the cell lysates were finally counted 
in a gamma-counter (LKB, Surrey, UK). Results of quadruplicate 
experiments were processed using Scatchard analysis and a least 
square fit routine, as described above (see Section 2.3.).
2.14. Immunofluorescence of EGFR, EGF, TG Fa and TGFpi 
Expression of both EGFR and endogenous EGF, TGFa and 
TGF(3i in LNCaP, DU 145 and PC3 prostate cancer cell lines was 
studied using fluorescent immunostaining. Cells were seeded onto 
8 -well Lab-Tek® Chamber Slides™ (Nunc Inc., Naperville, IL ) at a 
density of 2 x l0 4 cells per well and left undisturbed at 37 °C in a 
humidified CO2 incubator for 24-48 hours. Excess culture medium 
was then aspirated and cells washed three times with PBS-A. 
Cells were fixed at -20 °C for 10 minutes using acetone:methanol 
(1:1, v/v) and air dried. To suppress non specific binding, cells 
were incubated for 30 minutes at room temperature with 10% 
(v/v) sheep serum (SAPU, Carluke, Scotland) in PBS. Following 
incubation, cells were washed five times using 0.1% (w/v) BSA in 
PBS. The latter was removed and aliquots (200 p 1/well) of
primary antibodies appropriately diluted (EGF-R 1:200; EGF and 
T G F a 1:7; TGFBi 1:200) using PBS/BSA, were added. To assess non 
specific fluorescence, duplicate wells received PBS/BSA only. The 
slides were incubated for 2 hours at room temperature in a
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hum idified chamber. Following incubation, the primary 
antiserum was aspirated and cells washed five times as before. 
Aliquots (200 p i) of FITC fluorescent secondary antibodies 
(SAPU), diluted 1:100 using PBS/BSA, were then added to each 
well and incubated for 2 hours in a humidified chamber in the 
dark. After incubation, cells were washed again five times, the 
plastic upper chambers were removed and coverslips sealed on 
slides using Acquamount (BDH, Dorset, UK) mounting medium. 
Finally, immunofluorescence was visualised within 24 hours 
using a Leitz Orthoplan fluorescent microscope.
2.15. Western Blot Analysis of EGFR
The expression of EGFR in prostate cancer cell lines was also 
investigated using western blot analysis. Cells grown in 162 cm2 
plastic flasks (Costar) were washed twice with ice-cold PBS, 
harvested in 10 ml PBS using a rubber policeman and 
transferred to 12 ml centrifuge tubes. Cells were then pelleted by 
centrifugation at lOOOxg for 10 minutes at 4 °C. The cell pellet 
was washed twice with 1 ml PBS and lysed using 1 ml lysis 
buffer (50 mM Tris-HCl - pH 6 .8 , 150 mM NaCl, 5 mM EDTA, 
Nonidet P-40 0.5% v/v, 1 mM phenylmethylsulphonylfluoride, 
PMSF). After gentle resuspension, cell lysates were transferred to 
eppendorf polytubes, left on ice for 1 h and centrifuged at 
lOOOxg for 20 minutes at 4 °C. To the resulting supernatant was 
added 200 pi sample buffer (62.5 mM Tris-HCl - pH 6 .8 , 5% w/v 
glycerol, 2% w/v SDS, 0.001% bromophenol blue), and the mix 
was boiled for 3-5 minutes and briefly cleared by centrifugation.
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Aliquots (50 p i) of the supernatant were used for protein 
estimation using the Lowry method [Lowry et a l ., 1951]. Samples 
were loaded at a concentration of 10 to 2 00  pg protein.
Polypeptides were resolved by a 12% SDS/polyacrylamide 
gel electrophoresis (SDS/PAGE) in Tris/Glycine buffer (25 mM  
Tris, 192 mM Glycine, 0.1% w/v SDS) using a MiniSub-Cell™  
apparatus (Bio-Rad Italiana, Milan) set at a constant current of 
40-60 milliamperes (ma) until the bromophenol blue tracker dye 
was 0.5 cm from the bottom of the gel. Where appropriate, gels 
were stained for protein in 0 .1% (v/v) coomassie brilliant blue 
R250, 50% (v/v) methanol and 10% (v/v) acetic acid for 1 h at 
room temperature; the molecular weight (M W ) of the resolved 
polypeptides was determined by calibration with a set of protein 
markers (myosin, M W  200,000; a2-macroglobulin, M W  170,000; 
phosphorylase B, M W  97,400; glutamate dehydrogenase, M W  
55,400; lactate dehydrogenase, MW  36,500) run on parallel lanes 
of the same gel. Destaining was accomplished by repeatedly 
washing the gels with 50% methanol (v/v) and 10% acetic acid 
(v /v ). Proteins resolved by SDS/PAGE were transferred 
electrophoretically onto nitrocellulose membrane (Hybond N) in 
transfer buffer (25 mM Tris, 192 mM Glycine, 0.01% w/v SDS, 
20% v/v methanol, pH 8.3) using a Bio-Rad Trans-Blot™ cell at a 
constant current of 400 ma for 3 h or 40 ma for 16-20 h. In 
order to verify the quality of transfer and to mark the positions 
of molecular weight standards, blots were stained for 5 minutes 
with 0.1% (w/v) Amido Black dissolved in 45% (v/v) methanol 
plus 10% (v/v) acetic acid and destained using 90% (v/v)
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methanol/2% (v/v) acetic acid. Following transfer, blots were 
blocked through incubation with 10 ml TBST buffer (10 mM Tris- 
HCl - pH 8.2, 150 mM NaCl, 0.05% v/v Tween 20) containing 2% 
(w/v) non-fat dry milk for 1 h at room temperature. The blots 
were then washed five times using TBST for a total of 1 h and 
incubated with the BG48 anti-EGFR primary polyclonal antibody 
(1:200 dilution in TBST) for 16 h at 4 °C. After five washes as 
before, specific binding was revealed through addition of 0 .1  
pCi/ml [125I]-Protein A in TBST and incubation for 1-2 h at room 
temperature. After incubation, removal of the unbound 
radiolabel was achieved by a further five washes in TBST. 
Finally, blots were air dried and exposed for one week to Kodak 
X-omat S film with intensifying screens at -70 °C.
2.16. T G F a and TGFB Dose-Response Experiments
The effects of either TGFa or TGFpi on growth of LNCaP, 
DU145 and PC3 cells have been compared. Cells growing in log 
phase were seeded onto 6 -well tissue culture plates (Nunc) at a 
density of 2 x l 0 5 cells per well in routine culture medium to 
parallel experimental conditions used for the EGFR binding assay. 
After 24 hours, increasing concentrations of either TG Fa (from
0.5 to 50 ng/ml) or TGFBi (from 0.05 to 5 ng/ml) were added. 
After a further 24 or 48 hours incubation, medium was discarded 
and DNA estimation carried out as described before (see Section
2.9.).
Additional experiments were designed to inspect response 
of cells to either growth factor in the presence of steroid-
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deprived, dialysed FCS, namely under experimental conditions 
identical to those used for hormone responsiveness studies. Cells 
in the exponential growth phase were harvested and plated on 
6 -well tissue culture plates (Costar) at a density of l -2 x l0 5 
cells/well in routine culture medium. After 24-48 h, medium was 
removed and substituted with phenol red-free RPM I medium 
supplemented with 10% D H IC T-FC S , containing various 
concentrations of TGFa (0.5-50 ng/ml) and TGFBi (0.05-5 ng/ml) 
(day 0). Cells were then incubated for 48 h or, after a medium 
change at day 3, for 6 days. Following incubation, medium was 
discarded and DNA cell content measured as described in Section
2.9.
2 .17 . Steroid  M etabolism
Methodological approach and procedures used to measure 
metabolic pathways of steroids in in vitro systems have been 
previously established and optimised [D'Agostino et a l ., 1984; 
D'Agostino et a l ., 1985; Castagnetta et a l ., 1986c]. Cells growing in 
log phase were harvested by trypsinisation, counted in a 
hemocytometer and plated onto 60 mm cell culture dishes at a 
density of 0 .5 -2x l06 cells/dish. After 24-48 h, cells were washed 
twice with PBS-A and the medium substituted with FCS-free, 
phenol red-free RPMI medium, in order to avoid any interfering 
factor that might modify the metabolic ability of cells. After a 
further 24 h, medium was replaced with the same experimental 
medium containing l-1 0 x l0 9M  radioactive testosterone ([1,2,6,7- 
3H(N)]testosterone; specific activity: 92.1 Ci/mmol; DuPont de
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Nemours Italiana SpA, Milan) or oestradiol ([6 ,7-3H]oestradiol; 
specific activity: 48 Ci/mmol; DuPont de Nemours) as precursors. 
The latter were both periodically checked and purified using 
high-performance liquid chromatography (H PLC ) prior to 
experimental use. Following either 24 or 72 h incubation, 
medium was transferred to sterile plastic tubes (C ostar® , 
Cambridge, M A) and stored at -80°C until analysis; to prevent 
oxidation of hydroxylated oestrogen metabolites, 1 mM ascorbic 
acid was added to the medium when appropriate. Cells were 
washed three times using PBS-A and solubilised in 3 ml of 0.1% 
SDS at 37°C for 15-30 minutes. Aliquots (100 p i) of the cell 
lysates were therefore used to estimate D N A  content, as 
previously described (see 2.9.).
For time-course experiments, triplicate dishes of PC3 cells 
( 2 x l 0 6 cells/dish) were incubated in the presence of 50 nM  
tritiated T  for 30 min, 2, 8 and 24 h, under exactly the same 
experimental conditions. Medium and cells were then processed 
as described above. In addition, separate experiments were 
carried out to measure conversion rates of labelled  
androstenedione (6 x l0 _6M, [4-14C ]a n d ro s t-4 -e n e -3 ,17-d ione; 
specific activity: 55 mCi/mmol; DuPont de Nemours) in PC3 cells 
after 24 h incubation; both experimental conditions and 
analytical procedures used were identical to those herein 
described for both testosterone and oestradiol metabolism.
A ll the experiments were done in triplicate.
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2.17.1 . Extraction procedures
The procedures used for extraction and subsequent HPLC 
analysis of both androgens and oestrogens are summarised in 
Figure 17. Steroid extraction was carried out on the incubation 
medium, since it has been shown that the steroid profile of the 
surrounding medium accurately reflects any steroid metabolism 
by the intact celL [Castagnetta et al., 1986b]. To prevent loss of 
radioactivity, all the glassware was precoated prior to sample 
manipulation with 4 pg of the same radioinert steroid. One ml 
aliquot of medium was transferred to a scintillation vial to assess 
the total radioactivity (TR) processed per ml. Steroid extraction 
was performed in glass vials on 1 ml aliquots of the incubation 
medium using 10 ml of diethyl ether for androgens or 10 ml of 
diethyl ether:acetone (9:1, v/v) for oestrogens. To facilitate 
androgen extraction, the pH was raised to approximately 10.0 by 
addition of 20 pi of 2M sodium hydroxide, since this increases the 
preferential partitioning of free androgen metabolites in the 
ether phase. Samples were thoroughly mixed by gentle shaking 
in a water-bath at 4°C for 30 minutes and then left standing for 
5-10 minutes. The aqueous phase was transferred to separate 
glass tubes and freeze dried in a SVC100H Speed Vac®  
evaporator-concentrator (Savant Instruments Inc., Farmingdale, 
N Y ) for about 2 h. The dried extracts were resuspended using 
970 pi of acetate buffer (0.75 M, pH 5.0), containing 30 p i of 
Glusulase enzyme mixture (DuPont Co., Wilmington, DE) and 
incubated at 37°C for 18 h to hydrolyse steroid conjugates 
(sulphates and glucuronides). Following incubation, samples were
241
F igu re 17. Flow diagram of procedures used for steroid extraction and 
chromatographic separation. The chart summarises the methodologies 
used for extraction of either free or conjugate steroids (androgens and 
oestrogens) from the incubation medium of prostate cancer cells in  
steroid metabolism experiments (for full details of methodologies see 
Materials and Methods: 2.17.).
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MEDIUM
I
E x t r a c t i o n
Oestrogens:
1 mM ascorbic acid  
d ie thy l etheriacetone (9:1) 
E2-precoated vials
CELLS
lysed  w ith  0.1% SDS
\
Fluorim etric  
DNA assay
Androgens:
4m M  NaOH  
d ie thy l ether 
T-precoated vials
E ther phase
N2 stream  dried-
Acetone resuspension
N2 stream  dried
E xtract
Acetonitrile resuspension
Extracted rad ioactiv ity  
Count C l (as fro m  2) 
Count C2 (as fro m  4)
Aqueous phase
freeze  d ried
E nzym atic hydrolysis
Glusulase (Helix Pomatia) 
p H  5.0 acetate bu ffe r 0 .75M  
3 7  °C fo r  18 h
I
E xtraction
(as in 1)
-  E ther phase  
Aqueous phase
Adhering  
rad ioactiv ity  
Count A2
20 fil injected 
to  RP-HPLC analysis 
UV and Radiom etric d etection  
"on line"
Non-extracted  
rad ioactiv ity  
Count B
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transferred to glass vials and extracted again as before: the 
resulting aqueous phase was read for non-extracted radioactivity 
(B), while the ether phase was processed as hereafter described 
to extract hydrolysed steroids. The two ether phases (free and 
hydrolysed steroids) were evaporated co dryness under gentle 
nitrogen stream at 42°C in a water-bath, resuspended three 
times with 2 ml acetone and transferred to separate tubes to be 
desiccated again as before; the empty vials from both ether 
phases received 10 ml of scintillation cocktail (Ready Gel™, 
Beckman) which was then counted for radioactivity adhered to 
walls (A l and A2) in a P-counter (Beckman Instruments Italia, 
Milan). The dried extracts were finally stored at -20°C until 
chromatographic analysis. Extracts of either free or hydrolysed 
steroids were resuspended in 30 pi of a mixture consisting of 20 
pi acetonitrile and 10 pi acetic acid 0.2M in the case of androgens, 
or 10 pi acetonitrile, 10 p i acetic acid and 10 p i equilin (500 
pg/m l) used as internal standard, in the case of oestrogens. 
Twenty pi of the resulting solution were used for HPLC analysis 
(see below), while 5 pi were read in a p-counter to measure the 
radioactivity respectively extracted for each steroid fraction (C l 
and C2). The extraction efficiency was finally calculated as 
follows:
Extraction Efficiency = —— x  -^----------
*  (C l+ C 2 )x 6  + (A1 + A 2 + B)
2 4 3
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2.17.2. Chromatographic Analysis
Extracted steroids were chromatographically analysed in 
reverse phase (RP)-HPLC, using a Beckman model 324 HPLC
system equipped with an UV detector (model 160), set at 280 nm 
or 214 nm respectively for oestrogens and androgens, and with 
an "on-line" Flo-One/beta (model IC) three-channel radioactive 
detector (Radiomatic Instruments, High Wycombe, UK). The latter 
allows to detect simultaneously signals coming from two separate 
radioactive counting channels (i.e. for 3H and 14C radioisotopes, at 
efficiencies of 42% and 81%, respectively, under stopped-flow 
conditions) and from the UV detector. Steroids were separated 
under isocratic condition using an Ultrasphere ODS (Beckman) 
column (250x4.6mm I.D ., 5pm particle size), thermostated at
20°C . An optimised m obile phase, consisting of 
acetonitrile:tetrahydrofuran:0.05M citric acid (31:9:60, v/v) or of 
acetonitrile:0.05M citric acid (45:55, v/v), at a flow rate of 1 
ml/minute, was used to separate respectively androgen and 
oestrogen metabolites in a total analysis time of approximately
30 minutes. Identification of individual metabolites was achieved 
by simultaneous UV evaluation of cold steroid standards; relative 
retention times (RRT) for authentic androgens and oestrogens are 
reported in Table 1. Radiometric detection was performed using a 
1 ml flow cell and Ready-Flow I I I  (Beckman) as scintillation 
mixture at a flow rate of 3 ml/min. Routine data integration was 
achieved by a Flo-One/beta FIB  IC program (Radiomatic, Tampa, 
FL) and computed in net cpm, after correction for both sample 
residence time and background subtraction (40 and 70 cpm
2 4 4
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Table 1. Trivial names, abbreviations and relative 
times (RRT) of authentic steroid standards in reverse 
performance liquid chromatography (RP-HPLC)
retention
phase-high
Trivial Name Abbreviation RRT Id. No.
Androgens  (A)
16 ah ydroxy-testosterone 16aOH-T 0.35
19hydroxy-androstenedione 190HA 0.44
Androstenediol A5Adiol 0 .96
T e s to s te ro n e T (i.s.) 1 .0 0 (1 )
Androstenedione A4 Ad 1.18 (2 )
3|3-androstanediol 3p-diol 1.28
Dehydroepiandrosterone DHEA 1.36
Epiandrosterone EpiA 1.58 (3 )
Dihydrotestosterone DHT 1.66 (4 )
3a-androstanediol 3a-diol 1.75 (5 )
5a-androstanedione 5a-Adione 2.09 (6 )
Androsterone A 2.41 (7 )
Oestrogens (B)
Oestriol E3 0 .22
16a-Hydroxyoestrone 16aOHEi 0.35 (1 )
2-Hydroxy oestradiol 20HE2 0.43
4-Hydroxyoestradiol 40HE2 0 .47
2-Hydroxyoestrone 20HEi 0.55
4-Hydroxyoestrone 40HEi 0.65
Oestradiol E2 0 .70 (2 )
4-Methoxyoestradiol 4MeOE2 0 .76
2-Methoxyoestradiol 2MeOE2 0 .86 (3 )
E q u ilin Eq (i.s.) 1 .0  0
Oestrone Ei 1.09 (4 )
4-Methoxyoestrone 4MeOEi 1.21
2-M ethoxy oestrone 2MeOEi 1.33
RP-HPLC analysis: Ultrasphere-ODS column; mobile phases used: 
A=Acetonitrile:Tetrahydrofurane:0.05M citric acid (31:9:60, v/v); 
B=Acetonitrile:0.05M citric acid (45:55, v/v). Flow rate: 1 ml/min.
i.s.: internal standard; Id. No.: peak identification number.
2 4 5
All experim ents, unless otherwise indicated, w ere performed 
three times, each tim e in trip licate (N=9), using 6 -w e ll tissie 
culture plates. Statistical analysis was carried out through tte 
InStat™  GraphPad Software (version 2.01) run on a Macintosh 
LCii computer. This statistical package autom atically tests tte 
assumption of equal variances w ith in  and between data groups 
through an F-test, allowing appropriate use of parametric or nor- 
parametric tests to compare population means or medians.
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respectively for 3H and 14C). Both precursor degradation and 
formation of metabolic products were finally expressed either as 
percentages of conversion rate (%CR), i.e. as the percent of total 
radioactivity recovered, or as pmol/ml for any incubation time.
2.18. Studies on M odulation of Steroid  m etab o lism  by 
T G Fa and TGFpi
These experiments were specifically designed to explore 
possible modulation of rates and direction of steroid metabolism 
by both TGFa and TGFp in human prostate cancer cells, 
maintaining exactly the same experimental conditions used in 
studies on steroid metabolism. To this end, cells (0 .5 -lx l0 6) were 
incubated for 72 h in phenol red-free, FCS-free RPMI medium 
containing the radioactive steroid ( l - 5 x l O ’ 9M  tritiated  
testosterone or oestradiol) in presence or absence of either TGFa  
or TGFPi, at the dose of 50 and 5 ng/ml, respectively. These dose 
levels were selected on the basis of the maximum effect 
observed on cell proliferation yields. After incubation, cells and 
medium were processed and analysed as described in the 2.15. 
chapter.
2 .19 . S ta tistics
The two-tailed Student's t test, the F test and the 
Spearman correlation test (all 95% confidence limits) were used 
for statistical comparisons.
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EXPERIMENTAL
1. GROWTH CHARACTERISTICS
Growth curves of prostate tumour cell lines are shown in 
Figure 18. Overall, population doubling times, as calculated 
during the log phase growth (i.e. days 4 to 6 over a 12 days 
observation interval), was approximately 36 h for LNCaP  
(passage 23), 23 h for DU145 (passage 62) and 32 h for PC3 
(passage 19) cells.
The DNA content of the three cell lines ranged approx im a te ly  
from  30 to 60 pg DNA/cell.
2. STEROID RECEPTORS
2.1. A ndrogen R eceptors (AR)
2.1 .1 . L igand binding assay
The presence of both soluble and nuclear sites of androgen 
binding in human prostate cancer cell lines has been assessed by 
means of radioligand binding assay. Dissociation constant (Kd) 
and concentration values of AR in either cell fraction are shown 
in Table 2. Overall, Kd values fell well below the cut-off value of 1 
nM (ranging from 0.10 and 0.37 nM), ensuring that purely type I 
(high affinity, limited capacity) androgen binding sites were 
identified [Castagnetta et a l ., 1992a]. In addition, presence of 
both soluble and nuclear type I I  (lower affinity, greater capacity) 
AR was also revealed. Typical Scatchard plots of type I and I I
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F ig u re  18. Growth curves of human prostate cancer cells. Mean 
population doubling times were 36 h for LNCaP, 23 h for DU145 and 
32 h for PC3 cells, as calculated in the exponential growth phase (days 4 
to 6). Values represent mean ±SD (bars) of triplicate wells. For 
methodological details see text (Material and Methods: 2.1.).
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Table 2. Type I androgen receptor content of LNCaP, DU 145 
and PC3 human prostate cancer cell lines.
Soluble Fraction Nuclear Fraction
Kd (nM) Fmol/mg DNA Kd (nM) Fmol/mg DNA
LNCaP 0.37 372.5 0.18 69.1
±0.11 ±183.5 ±0.05 ±13.0
DU 145 0.24 334.3 0.22 84.0
±0.09 ±194.2 ±0.09 ±17.9
PC3 ND ND 0.10 44.1
±0.02 ± 5 .5
Values represent mean ±SD of triplicate assays. Kd = dissociation 
constant; ND = not detectable.
AR in LNCaP and DU145 cells (soluble and nuclear) and in PC3 
cells (nuclear only) are shown in Figures 19 to 21.
In the soluble fraction, LNCaP and DU 145 cells exhibited 
similar mean levels of type I AR (see Table 2); this was also true 
when receptor concentrations were expressed as site number per 
cell j(13 ,922 ±5,142 vs 13,294 ±5,794) or as fmol/mg cytosol 
protein (14.8 ±7.3 vs 14.3 ±8.3). Type I I  AR were detected in 
both LNCaP and DU145 cells, with mean Kd and concentration 
values respectively of 5.6 nM and 108.6 fmol/mg protein in 
LNCaP and of 7.3 nM, and 124.2 fmol/mg protein in DU145 cells. 
Neither type I nor type I I  AR were detectable in the soluble 
fraction of PC3 cells.
2 5 0
Figure  19. Ligand binding assay of androgen receptor (AR) in LNCaP 
cells. Typical Scatchard plots of both soluble (top) and nuclear (bottom) 
androgen binding are shown. Presence of two sites of androgen binding 
was determined according to the significantly better (P<0.05, F test) fit 
achieved for the two-sites model. Each data point was performed in 
triplicate. Kd = dissociation constant, BpM = bound picomolar, B/F 
bound over free. For methodological details see text (Materials and 
Methods: 2.2. and 2.3.).
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Figure 20. Ligand binding assay of androgen receptor (AR) in DU145 
cells. Typical Scatchard plots of both soluble (top) and nuclear (bottom) 
androgen binding are shown. Presence of two sites of androgen binding 
was determined according to the significantly better (P<0.05, F test) fit 
achieved for the two-sites model. Each data point was performed in 
triplicate. Kd = dissociation constant, BpM = bound picomolar, B/F 
bound over free. For methodological details see text (Materials and 
Methods: 2.2. and 2.3.).
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F igure 2 1 . Ligand binding assay of androgen receptor (AR) in PC3 cells. 
A typical Scatchard plot of nuclear androgen binding is shown. No 
detectable AR were found in the soluble fraction. Presence of two sites of 
nuclear androgen binding was determined according to the significantly 
better (P<0.05, F test) fit achieved for the two-sites model. Each data 
point was performed in triplicate. Kd = dissociation constant, BpM = 
bound picomolar, B/F bound over free. For methodological details see 
text (Materials and Methods: 2 .2 . and 2.3.).
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As regards the nuclear fraction, all three cell lines 
displayed the presence of type I receptors, the highest 
concentration being found in DU 145 and LNCaP cells (3,419 ±728  
and 2,666 ±502 sites/cell, respectively), the lowest in PC3 cells 
(1,572 ±196 sites/cell). Nuclear type I I  androgen binding sites 
were also found in all cell lines, with Kd values ranging from 3.3 
up to 6.8 nM and binding site concentrations of 155.7. to 798.2 
fmol/mg DNA.
It is noteworthy that while LNCaP and DU 145 cells show 
both soluble and nuclear type I AR, the absence of detectable AR 
from the soluble fraction of PC3 cells seems to indicate an 
impaired receptor machinery [Castagnetta et a l., 1990]. However, 
DU 145 cells, which contain apparently functional AR, failed to 
grow in response to either T or DHT (see below: 3.1.).
2 .1 .2 . R everse transcriptase-PC R  (RT-PCR)
Inspection of human AR mRNA expression in LNCaP, DU145 
and PC3 prostate tumours cells was accomplished by means of 
reverse transcriptase-PCR system. This approach allows 
identification of very small amounts of specific messenger RNAs 
through reverse transcription and subsequent amplification of 
the reverse-transcribed DNA.
Using a primer set consisting of a sense and an antisense 
primer corresponding to a sequence in exon 1 of the human AR 
gene (HUM ARA, nucleotides 229 to 508), DNA amplification gave 
rise to one single PCR product of the expected length (around 
280bp) in all the three cell lines. As shown in Figure 22, agarose
2 5 4
F igu re 2 2 . Reverse transcriptase-polymerase chain reaction (RT-PCR) 
of androgen receptors in  human prostate tum our cells. E th id ium  
bromide-stained 2% agarose gel of amplification products obtained from 
one pg of to ta l RNA in  presence or absence of reverse transcriptase 
(RT). A ll RNA samples were treated w ith  DNase I  prior to reverse 
transcription. The reference ladder is expressed in  base pairs (bp). Lane 
1: 123 bp ladder; lane 2 : DU145 +RT; lane 3: DU145 -RT; lane 4: LNCaP 
+RT; lane 5: LNCaP -RT; lane 6 : PC3 +RT; lane 7: PC3 -RT; lane 8 : 123 
bp ladder.
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gel electrophoresis of the amplification products revealed the 
presence of a strong band in each cell line, with minor diversities 
in the relative mobility; the latter is likely to be a reflection of 
the highly polymorphic STRs present in exon 1. Although the 
semiquantitative nature of PCR does not permit any conclusive 
inference, scrutiny of the ethidium bromide-stained agarose gel 
indicates that, given the same amount of starting template (1 pg 
of total RNA for each cell line), LNCaP cells yielded the greatest 
amount of the amplification product, while DU 145 and PC3 cells 
respectively showed intermediate and lower levels of expression. 
Additionally, possible contamination by genomic DNA was 
eliminated by treatment of the RNA preparations with DNase I 
and double-checked by omitting the addition of reverse 
transcriptase (Superscript I I  RT) in duplicate RNA preparations. 
The absence of any detectable amplification product from 
samples not receiving Superscript I I  RT (see Figure 22) clearly 
demonstrates that no genomic DNA is present and that, therefore, 
PCR products derive exclusively from the extracted RNA.
2.2. O estrogen R eceptors (ER)
2 .2 .1 . L igand binding assay
ER content and status of human prostate cancer cell lines 
were evaluated by means of the radioligand binding method. 
Presence of both type I and type I I  sites of oestrogen binding 
was documented in the soluble and nuclear fractions of LNCaP
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cells. In PC3 cells, the soluble fraction did not show any 
detectable oestrogen binding site, while presence of both type I 
and type I I  ER was revealed in the nuclear fraction. By contrast, 
neither soluble nor nuclear oestrogen binding was revealed in 
DU145 cells. Kd and concentration values for type I ER in LNCaP 
and PC3 cells are reported in Table 3. As can be seen, Kd values 
were below the cut-off of 0.55 nM (range of 0.16 to 0.49 nM), 
indicating that type I (high affinity, limited capacity) ER are 
detected in both soluble and nuclear compartments [Castagnetta 
et a l., 1987a; Castagnetta et a l., 1992b]. Figures 23 (A and B) and 
24 respectively illustrate typical Scatchard plots and saturation 
curves for type I ER in LNCaP (soluble and nuclear) and PC3 
(nuclear only) cells.
Table 3. Type I oestrogen receptor content of LNCaP and PC3 
human prostate cancer cell lines.
Soluble Fraction Nuclear Fraction
Kd (nM) Fmol/mg DNA Kd (nM) Fmol/mg DNA
LNCaP 0.49 2123 0.25 328.1
±0.05 ±368.1 ±0.03 ±48.2
PC3 ND ND 0.16 118.8
±0.04 ± 2 2 .3
Values represent mean ±SD o f trip lica te  assays. Kd = dissociation 
constant; ND = not detectable.
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F igu re 23A. Ligand binding assay of oestrogen receptor in the soluble 
fraction of LNCaP cells. Typical Scatchard plot (top) and tracer ligand 
saturation curve (bottom) of oestrogen binding. BpM = bound picomolar; 
B/F = bound over free. ■  = total, •  = specific, A = non-specific binding of 
tritiated oestradiol, as calculated from competition studies using a 1 0 0  
fold excess of unlabelled diethylstilbestrol. Each data point was 
performed in triplicate.
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F igu re  23B. Ligand binding assay of oestrogen receptor in  the nuclear 
fraction of LNCaP cells. Typical Scatchard plot (top) and tracer ligand 
saturation curve (bottom) of oestrogen binding. BpM = bound picomolar; 
B/F = bound over free. ■  = total, •  = specific, ▲ = non-specific binding of 
tritia te d  oestradiol, as calculated from competition studies using a 100 
fold excess o f unlabelled diethylstilbestro l. Each data point was 
performed in  triplicate.
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F igu re  24. Ligand binding assay of oestrogen receptor in the nuclear 
fraction of PC3 cells. Typical Scatchard plot (top) and tracer ligand 
saturation curve (bottom) of oestrogen binding. BpM = bound picomolar; 
B/F = bound over free. ■  = total, •  = specific, ▲ = non-specific binding of 
tritiated oestradiol, as calculated from competition studies using a 1 0 0  
fold excess of unlabeled diethylstilbestrol. Each data point was 
performed in triplicate.
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In LNCaP cells, the soluble fraction displayed type I 
receptor concentrations ranging from 1,814 to 2,531 fmol/mg 
DNA, with a mean number of 79,755 ±2 ,657 binding sites/cell, 
corresponding to 51.3 ±3.9 fmol/mg cytosol protein. The nuclear d 
fraction revealed a much lower type I ER content (ranging from 
275.5 up to 370.0 fmol/mg DNA); this was also true when ER 
concentrations were expressed in terms of site number/cell 
(mean value of 13,737 ±1,158). In PC3 cells, no detectable type I 
ER were found in the soluble fraction. In the nuclear fraction, PC3 
cells showed lower type I ER fmolar concentrations (in the range 
of 96.4-132.3 fmol/mg DNA) than LNCaP cells, with a mean 
number of 4,037 ±556.3 sites/cell.
Type II  ER were also found in both cell fractions of LNCaP 
cells and in the nuclear compartment of PC3 cells (see Table 4).
Table 4. Type I I  oestrogen receptor content of LNCaP and PC3 
human prostate cancer cell lines.
Soluble Fraction Nuclear Fraction
Kd (nM) Fmol/mg DNA Kd (nM) Fmol/mg DNA
LNCaP 7.24 11784.8 7.02 1942.2
±0.30 ±3867.2 ±0.35 ±513.0
PC3 ND ND 4.42
±0.87
848.9
± 2 2 3 .7
Values represent mean ±SD of triplicate assays. Kd = dissociation  
constant; ND = not detectable.
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In LNCaP cells, soluble type II receptors exhibited mean Kd and 
concentration values respectively of 7.2 ±0.3 nM and 11,785 
±3,867 fmol/mg DNA (equivalent to 391.4 ±135 .4  fmol/mg  
protein); the nuclear fraction showed similar Kd values (meanly 
7.02 ±0.35 nM), but a much lower type I I  ER content, the mean 
concentrations being 1,942 ±513 fmol/mg DNA. The PC3 cells 
exhibited slightly lower type II nuclear ER content (ranging from 
854.8 to 2,053.3 fmol/mg DNA) and Kd values (range of 3.5 to 4.6 
nM), while no detectable type II binding was found in the soluble 
fraction.
2.2.2. Immunocytochemistry of ER and PgR
Immunocytochemical assay for both ER and PgR in human 
prostate cancer cells was carried out using the commercially 
available ER-ICA and PgR-ICA kits (Abbott) and subsequent 
quantitative image analysis through the CAS™ 200 Image 
Analyser (Becton-Dickinson Italia SpA, Milan). As illustrated in 
Figure 25, LNCaP cells stained positively for both ER and PgR, the 
percent of positive nuclei being 66% and 59%, respectively. The 
intensity of staining was consistently strong (positive stain over 
80% for both ER and PgR), with a coefficient of variation lower 
than 15% for either receptor. On the other hand, PC3 cells 
displayed very low ER positivity (see Figure 26), with about 25% 
of positive nuclei having a weak to moderate degree of staining 
(48% positive stain), while all cells were PgR-negative. The 
DU145 cells proved negative for both ER and PgR.
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F igu re 25. Immunocytochemistry of oestrogen (ER) and progesterone 
(PgR) receptors in  LN C aP hum an prosta te  cancer cells. A l  
LN C aP /E R . B l  LNCaP/PgR (x40 f in a l m a g n ifica tio n s ;.
Immunocytochemical assay o f both ER and PgR was carried out using a 
m odification respectively of ER-ICA and PgR-ICA Abbott k its . Cells 
were incubated for 24 h a t 4°C w ith  prim ary monoclonal anti-ER or anti- 
PgR monoclonal antibodies and the reaction v isualised th rough a 
peroxidase-anti peroxidase (PAP) system using the diaminobenzydine as 
chromogen substrate.
C Negative control, receiving 0.1 pg/ml normal rat IgG (x40) .
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F igu re 26. Immunocytochemistry of oestrogen receptors (ER) in PC3 
prostate cancer cells (x40 final magnification). Immunocytochemical 
assay of ER was carried out using a modification of the ER-ICA Abbott 
method. Cells were incubated for 24 h at 4°C with primary monoclonal 
anti-ER monoclonal antibody and the reaction visualised through a 
peroxidase-anti peroxidase (PAP) system using the diaminobenzydine as 
chromogen substrate.
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2.2.3. Reverse transcriptase-PCR (R T-PC R )
Presence of mRNAs for ER in prostate tumour cells was 
investigated through reverse transcription and PCR amplification 
of total RNA extracted from LNCaP, DU145 and PC3 cells, using 
the breast cancer cell lines ZR75-1 and MCF7 as positive and 
M DA-M B231 as negative controls. Southern hybridisation was 
also used to confirm identity of the amplification products. For 
PCR amplification, an ER cDNA was used as template, with a sense 
primer corresponding to a sequence in exon 3 and an antisense 
primer corresponding to a sequence in exon 6. PCR products 
obtained from either mammary or prostate cancer cell lines were 
separated on a 1.4% agarose gel, as shown in Figure 27 (left 
panel). As determined by comparison with the <J>x-HaeIII marker 
fragments, two major bands of 659 and 323bp were observed in 
ZR75-1, MCF7, LNCaP and PC3 cells, whereas no detectable 
amplification product was found in the oestrogen non responsive, 
ER-empty MDA-MB231 cell line nor in DU 145 prostate cancer 
cells (not shown). Results from Southern hybridisation analysis, 
using the complete ER-cDNA as a probe, revealed hybridisation of 
the two major bands and some minor bands in between (Figure 
27, right panel). The 659bp band corresponds well to the 
expected length (nucleotides 937 to 1596 of the ER sequence) of 
a normal ER mRNA. The 323bp band originates from a variant 
ER mRNA, lacking the entire exon 4; this variant, which is a likely 
product of alternative splicing, has recently been isolated and 
characterised from human breast cancer cell lines in our 
laboratories [Pfeffer et a l ., 1993]. The bands of intermediate
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F igu re 27. Reverse transcriptase-polymerase chain reaction (RT-PCR) 
of oestrogen receptors in LNCaP and PC3 prostate cancer cells. Left 
panel. Ethidium bromide staining of agarose gel electrophoresis of PCR 
amplification products obtained from one jig total RNA: lane 1 = ZR75-1; 
lane 2 = MCF7; lane 3 = MDA-MB231; lane 4 = LNCaP; lane 5 = PC3 
cells; lane 6 = reverse transcription-PCR of a RNA-free control sample. 
Marker lane = <|)x-174-HaeIII digest fragments (length given in base 
pairs). Right panel. Southern blot analysis of the PCR-amplified DNA 
from the left panel. Samples were hybridised using a 32P-labelled human 
oestrogen receptor cDNA as a probe.
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length are of unknown origin, although one amplification product 
shows a length compatible with a putative variant messenger 
lacking exon 5 which would also be amplified by the primer set 
used; using a nested primer set with an antisense primer in exon 
4, a single band was observed in all cases (not shown). Although 
reverse transcriptase-PCR is by no means precisely quantitative, 
the relative amount of the ER messengers was reproducibly 
different in the cell lines studied. Equivalent expression of both 
ER mRNAs was observed in the two oestrogen responsive 
mammary cancer cell lines and, though at lower levels, in the 
androgen sensitive LNCaP cells. In contrast, both mRNAs 
appeared to be expressed in far lower but detectable amounts in 
androgen non-responsive PC3 cells. Under the same conditions, 
no reaction could be detected in the oestrogen non-responsive 
human breast cancer cell line MDA-MB231; therefore, expression 
of the ER mRNA in PC3 cells is clearly significant.. Moreover, 
digestion of the reaction products by the restriction enzyme Hind 
I I I ,  which cuts once in the amplified region (ER exon 4), yielded 
identical fragments of the expected size (not shown).
2.3 . Im m unostain ing of the 27 kDa H eat Shock P rotein  
( h s p  2 7 )
Immunofluorescence of the 27 kDa hsp27, which has been 
reported to be qualitatively and quantitatively correlated to ER 
in several human tissues [King et al., 1987], was used as an 
indication of functional ER in human prostate cancer cells. 
Immunostaining was obtained using a D5 monoclonal antibody 
raised against hsp27 and visualised through a FITC-conjugate
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secondary antiserum. A positive staining was revealed in both 
LNCaP and PC3 cells, whilst DU145 were hsp27-negative. In 
LNCaP, the majority (over 85%) of cells showed an intensive 
stain, mostly located in the cytoplasm, which was consistently 
strong (see Figure 28, top). Conversely, PC3 cells displayed a 
positive staining mainly occurring in nuclei, although some 
cytoplasmic staining was also present (see Figure 28, bottom), 
percent of positive cells was lower than that seen in LNCaP cells 
(approximately 50%), with minor discrepancies in stain intensity. 
Control wells from either cell line not receiving primary D5 
antibody stained very poorly, indicating that hsp27 staining was 
specific.
3. HORMONE RESPONSIVENESS
3.1. R esponse to Androgens
In order to evaluate the effects of either T or DH T on 
growth of human prostate cancer cell lines, cells were grown for 
6 days in RPMI medium supplemented with 10% DHICT-FCS in 
the presence of increasing concentrations of androgens and the 
growth response measured as the DNA content of exposed cells 
with respect to controls. Using such stringent experimental 
conditions, growth of both DU145 and PC3 cells was minimally 
affected by any dose of T and DHT used (see Figure 29, top and 
centre respectively). The effects of T and DH T on growth of 
LNCaP cells are shown in Figure 29, bottom. As can be seen, both
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F ig u re  28. Immunofluorescence of the 27 kDa heat shock protein 
(hsp27) in human prostate cancer cells. Top: LNCaP cells; Bottom: PC3 
cells. Expression of hsp27 was visualised using a D5 primary monoclonal 
antibody and a secondary step FITC-conjugated antiserum (x50 final 
magnifications).
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F igu re  29. Androgen response of human prostate cancer cells. DU145 
(top), PC3 (centre) and LNCaP (bottom) cells growing in RPMI medium  
supplem ented with 1 0 % DHICT-FCS were exposed for 6  days to 
in crea sin g  concentration  (from 0.01 up to 100 nM) of 
dihydro testosterone (DHT) and testosterone (T). Values represent 
mean ±SD (bars) of triplicate experiments. *P<0.03 and **P<0.004 with 
respect to control (Student's t test, 95% confidence limits).
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0.01 and 1 nM doses of either T or DHT produced a slight, not 
significant decrease of the cell growth. However, DNA content of 
LNCaP cells significantly increased following addition of 
lx lO _10M T or DHT (respectively 30.2% and 33.8% above control, 
P<0.03). Higher doses of either androgen produced a progressive 
reduction (from 19.4 up to 58.8%) in DNA content of this cell line, 
which was highiy significant at both 10-8 and 10_7M  doses 
(P<0.004).
3.2. R esponse to O estradiol
The effects of E2 on growth of LNCaP, DU 145 and PC3 cells 
were investigated under exactly the same experimental 
conditions used for androgens. As illustrated in Figure 30, 
growth of androgen responsive, AR-positive LNCaP cells was 
significantly stimulated by the addition of E2 (peak of 65.8% at 1 
nM; P=0.009). Conversely, a highly significant inhibition of cell 
proliferation was seen at 100 nM E2 dose (40%, P=0.006).
In contrast, growth of DU 145 cells was totally unaffected by 
any E2 concentration used (see Figure 30).
Surprisingly, androgen unresponsive, AR-negative PC3 cells 
displayed a significant, dose-related inhibition of growth, with a 
maximal effect at 10'7M E2 (55.2% with respect to control, 
P c lO -6; see Figure 30 and, in more detail, Figure 31 A); this effect 
was also significant at lower (even at 0.01 nM) E2 doses and 
became evident after 72 h at concentrations higher than 1 nM E2 
(not shown). It is noteworthy that this negative growth 
regulation is cognate to that observed in PC3 cells after addition
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F igu re 30. Oestrogen response of human prostate cancer cells. LNCaP, 
DU145 and PC3 cells growing in KPMI medium supplemented with 10% 
DHICT-FCS were exposed for 6  days to increasing concentration (from 
0.01 up to 100 nM) of 17p-oestradiol (E2). Values represent mean ±SD 
(bars) of triplicate experiments. Degrees of significance (P) with respect 
to controls: LNCaP: 1 nM <0.01,100 nM <0.006. PC3: 0.01 nM <0.0002, 
0.1 and 1 nM <0.00002, 10 nM <0.0006, 100 nM <10-6 (two-tailed  
Student’s t test, 95% confidence limits). No significant differences were 
found for DU145 cells at any E2 concentration used.
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F igure 31. Growth effects of oestradiol and anti-TGFPi antibody in PC3 
cells. Cells growing in RPMI medium supplemented with 10% DHICT- 
FCS were exposed for 6  days to (A) increasing concentration (from 0.01 
up to 100 nM) of 17p-oestradiol (E2) or (B) anti-TGFPi (Ab) antibody 
(9.2 pg/ml) ±E2 (0.01,1 and 100 nM). Values represent mean ±SE (bars) 
of triplicate experiments.(A): *, P<0 .0 0 0 2 ; ***, P<0.0006**; P<0.00002; 
****, P<0.00001. (B): *, P<0.00001; **, P<0.0001; ***, P<0.008 (two- 
tailed Student’s t test, 95% confidence limits). No significant difference 
was found in comparison of Ab+100 nM E2 with respect to control 
(P=0.435).
EXPERIMENTAL
1 0 0
90
ou
c
o
U  "3  
£
80
f iO)u
ImOJ
Ch
^  70
z
Q  
W  60
50
40
0 . 01  0.1  1 10
O es trad io l  C on cen tra t io n
100
(n M )
350
300
iS 250
c
©
U "S £ 200
o
-  § 1 5 0
O) wo
S3 100  
eu
50
0
AntiTGFB (Ab) E2 0.01 nM+Ab E21 nM+Ab E2100 nM+Ab
2 7 3
EXPERIMENTAL
of 1 ng/ml TGFBi (54.4% of control), under exactly the same 
experimental conditions (see below). In order to test whether the 
E 2 -induced growth inhibition could be mediated via TGFp, PC3 
cells were incubated with a polyclonal antibody which 
neutralises the biological activity of TGFBi. Exposure to the anti- 
TGF(3 antibody produced a large increase of growth of PC3 cells, 
which was near 300% of control after 6 days; this effect was 
opposed by the addition of E2 (10-11 to 10_7M ), being almost 
completely reversed at the dose of 100 nM (see Figure 3 IB).
3.3 . T ritia ted  Thym idine Uptake
Separate experiments were carried out in order to ascertain 
whether or not E2 -induced effects on growth of LNCaP cells are 
mediated via its own receptor. 3H-thymidine incorporation was 
measured in LNCaP cells pre-cultured for a week in steroid- 
deprived medium. As shown in Figure 32, after 6 days exposure 
to different E2 concentrations (0.01, 1 and 100 nM), with or 
without addition of the pure antioestrogen IC I-182,780, growth 
of LNCaP cells was significantly increased in presence of all E2 
doses, with a peak stimulation of over 120% above control at the 
0.01 nM dose (P<0.00001). Simultaneous addition of 100 nM  
IC I-182 completely abolished the E2 -induced growth stimulation 
at any oestradiol concentration, while IC I -182 itself did not 
affect cell proliferation yields. These results seemingly contradict 
those obtained measuring DNA content of LNCaP cells exposed for 
6 days to E2 in RPMI medium supplemented with 10% DHIC T- 
FCS, whereby 1 nM E2 only singificantly stimulated cell
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F ig u re  32. Effects of oestrogen and anti-oestrogen ICI-182,780 on 
tritiated thymidine uptake by LNCaP cells. Cells were exposed for 6  
days in steroid-deprived medium to increasing concentrations of E2 
±ICI-182 or to ICI alone; cell proliferation was measured through a 6  h 
pulse of 3H-thymidine as described in the Materials and Methods 
section (see 2 .1 1 .). Values represent mean dpm ±SD (bars) of triplicate 
experiments. *P<0.00001, two-tailed Student's t test (95% confidence 
limits).
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proliferation. This apparent discrepancy, however, could be
ascribed to the different experimental conditions used (10%  
DHICT-FCS vs 5%  CT-FCS as RPMI supplements).
3.4. Northern Blot Analysis of TG Fpi mRNA
Aiming to verify the likelihood that E2 inhibits growth of 
PC3 cells through induction of TGFBi, PC3 cells were exposed to 
different E2 concentrations for various intervals (from 6 up to 
72 h) and possible effects on TGFBi mRNA investigated through
Northern blot analysis. Results from 72 h experiments are shown 
in Figure 33a. As it can be seen, the ethidium bromide staining of 
ribosomal RNA revealed less amount of total RNA loaded on lanes 
3 and 4 of gel (respectively, 1 and 100 nM E2 ). The relative level 
of TGFBi mRNA is shown in Figure 33b. Although lanes 3 and 4 
apparently contained less amounts of TGFBi mRNA, no significant 
difference was observed between controls (lane 1) and E2 0.01, 1 
and 100 nM (lanes 2, 3 and 4, respectively) when carefully 
compared to the ethidium bromide picture. This was also true at
shorter incubation times (6 and 24 h, not shown). Human
fibroblasts (lane 5) used for comparison showed higher level of 
TGFBi mRNA expression.
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F igu re  33. Northern blot analysis of transforming growth factor-pi 
(TGFPi) messenger RNA in PC3 cells: effects of oestrogen. Cells were 
incubated with increasing concentrations of oestradiol (from 10'11 up to 
10'7M) in serum-free medium for 72 h prior to RNA extraction. Ten jig of 
total RNA were loaded onto each lane and blots probed against a 
cocktail of specific TGFpi oligonucleotides, (a) Staining with ethidium  
bromide of ribosomal RNA is shown to verify the amount of total RNA 
loaded on gel. (b) Autoradiograms of blots hybridised with TGFPi probes. 
Lane 1 represents a control sample receiving vehicle only (ethanol 
0.1%); the effects of 100 nM, 1 nM and 0.01 nM oestradiol are shown in  
lanes 2, 3 and 4, respectively. RNA from normal human fibroblasts is 
shown in lane 5.
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4. GROW TH FACTOR RECEPTORS AND CONTENT
4.1. Growth Factor Receptors
Radioreceptor assay of either EGF-R or TGFp-R in prostate 
tumour cell lines was carried out through incubation with 1251 - 
EGF or 125I-T G F 6 i in the presence of increasing concentrations of 
unlabeled growth factor.
Results of Scatchard analysis of EGF-R content of the three 
cell lines are reported in Table 5.
Table 5. Epidermal growth factor receptor levels in LNCaP, 
DU 145 and PC3 human prostate cancer cell lines.
Kd (nM) Fmol/mg P Sites/cell
LNCaP 0.16 107 43,046
±0.06 ±11 ±3,444
DU145 0.32 541 187,654
±0.09 ±67 ±6,011
PC3 0.17 392 99 ,200
±0.03 ±3 6 ±4,415
Values represent mean ±SD of quadruplicate experiments. 
Kd = dissociation constant; P = protein
All LNCaP, DU145 and PC3 cells exhibited high affinity binding 
sites for EGF, with Kd and receptor concentration values ranging
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from 0.16 to 0.32 nM and from 43,046 to 187,654 sites/cell, 
respectively. Although presence of low affinity EGF binding sites 
in human tumour tissues and cells has been previously reported 
by others [REFS], no clear evidence for lower affinity sites of EGF 
binding in the prostate cancer cell lines studied was obtained. As 
can be seen in Table 5, EGF-R concentrations appeared, however, 
much higher in the DU 145 cells, being respectively two and four 
times greater than in PC3 and LNCaP cells. Scatchard plots of 
EGFR in the three cell lines are illustrated in Figure 34.
Presence of high-affinity TGFBi receptors was revealed in 
both DU145 and PC3 cells (for respective Scatchard plots see 
Figure 35), whilst no detectable high-affinity site of TGFBi 
binding was found in LNCaP cells. DU 145 cells showed mean 
concentration values of 45.9 ±4.1 fmol/mg protein, corresponding 
to 3,023 ±376 binding sites/cell, with a Kd of 7.9 ±2.5 pM. PC3 
cells displayed higher receptor content, with mean values of 95 
±8 fmol/mg protein (corresponding to 4,745 ±732 sites/cell) and 
a Kd in a lower picomolar range (4.5 ±0.6 pM). In addition, low 
affinity sites of TGFBi binding were found in DU145 cells (see 
Figure 35, top), with mean Kd and concentration values of 91.1 
±15.8 pM and 16,959 ±1,189 sites/cell, respectively.
4.2. Im m unofluorescence for EGFR, EGF, TG Fa and TG Fpi
Presence and expression of EGF-R, EGF, TGFa and TGFBi in 
LNCaP, DU145 and PC3 cells was investigated through fluorescent 
immunocytochemical staining using specific antibodies, either 
monoclonal or affinity-purified polyclonal, raised against the
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F igu re  34. Radioreceptor assay of epidermal growth factor receptors 
(EGFR) in human prostate cancer cells. Scatchard plots of specific high 
affinity EGF binding in LNCaP (top), DU145 (centre) and PC3 (bottom) 
cells are shown. Each data point was performed in quadruplicate. Both 
dissociation constant (Kd) and concentration values are reported in  
Table 5. r: LNCaP=0.881, DU145=0.998, PC3=0.906. BpM = bound 
picomolar, B/F bound over free. For methodological details see text 
(Materials and Methods: 2.13.).
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F igu re  35. Radioreceptor assay of transforming growth factor-Pi 
(TGFp) receptors in human prostate cancer cells. Scatchard plots of 
high affinity TGFp binding in DU145 (top) and PC3 (bottom) cells are 
shown. DU145: Kd=6.9 pM; 2,925 sites/cell; r=0.978. PC3: Kd=4.1 pM; 
4,526 sites/cell; r=0.981. Presence of low affinity TGFp sites in DU145 
cells is also illustrated: Kd=84.9 pM; 15,863 sites/cell; r=0.936. Each 
data point was performed in quadruplicate. BpM=bound picomolar, 
B/F=bound over free.
B/
F 
B
/F
EXPERIMENTAL
High
affinity0,20-
Low
affinity
62 4 50 1
BpM
0,30
0,24“
0,18-
0,12“
0,06“
0,00
8 10620 4
BpM
281
EXPERIMENTAL
selected antigens. Specifically bound antibodies were visualised 
by addition of a second step FITC-conjugated antiserum against 
immunoglobulins of the relevant species (rabbit, mouse). Results 
are summarised in Table 6.
Table 6. Intensities of immunofluorescent stain for growth 
factor (GF) and growth factor receptor (GFR) content of human 
prostate cancer cells.
GF/GFR
EGFR EGF TGFa TGFpi
LNCaP ++ + ++ (+ )
DU 145 +4+ -H- 44+ ND
PC3 (+ ) ND (+ ) +
ND = not detectable. (+) = weakly positive.
Intensive stain for EGF-R (Figure 36A) and TGFa was seen in 
DU145. TGFa stained slightly less in LNCaP cells (Figure 36B); by 
contrast, PC3 cells displayed a weak staining for both TGFa and 
EGF-R. EGF was also detected in both DU145 and LNCaP cells, 
although at lower stain intensity, while PC3 cells were negative 
for EGF expression. TGFBi stained poorly in LNCaP cells and not at 
all in DU 145 cells, but showed a positive stain, though not 
intense, in PC3 cells (Figure 36C). In all cases, the very low levels
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F ig u re  36. Immunofluorescence of grow th factor and grow th factor 
receptors in  prostate cancer cells. The immunofluorescent s ta in ing  o f
(A) EGF-R in  DU145 cells, (B) TGFa in  LNCaP cells and (C) TGF(3i in  
PC3 cells is illu s tra te d  (x50 fina l magnification). Cell monolayers were 
exposed to p rim a ry  polyclonal (EGF-R) or monoclonal (EGF and TGFa) 
antibodies and specific b inding visualised through a second-step FITC- 
conjugate antiserum. Results are summarised in  Table 5.
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of non-specific binding observed substantiated the specific 
nature of staining.
4.3. Western Blot Analysis of EGFR
Expression of cell surface EGF-R in LNCaP, DU 145 and PC3 
cells was also evaluated through Western blotting analysis, using 
a specific polyclonal antibody BG48 raised against the synthetic 
peptide 2E (residues 985-996) and labelling of specific binding 
with [125I]-Protein A. Amido Black staining of blots allowed also 
verification of the quality of transfer and comparison of 
molecular weights with selected standards proteins (not shown). 
As illustrated in Figure 37, autoradiograms showed higher levels 
of EGFR expression in DU 145 cells, intermediate in PC3 and lower 
in LNCaP cells, overall in agreement with Scatchard plot data, but 
partly in contrast to the fluorescent staining. EGFR levels of 
prostate cancer cells were lower than those found in EGFR-rich 
A431 squamous carcinoma cells, but markedly higher than in 
MCF7 human mammary cancer cells.
5. RESPONSE TO GROWTH FACTORS
5.1. Growth response to TG Fa and TGFBi
The effects of various concentrations of both TG Fa and 
T G F B i on growth of prostate cancer cells after either 24 or 48 h 
incubation were firstly assessed on cells grown in routine culture
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Figure 37. Western blot analysis of epidermal growth factor receptor 
(EGFR) in prostate cancer cells. The autoradiogram shows specific 
EGFR binding using the anti-EGFR polyclonal antibody BG48 and 
[125I]-protein A as secondary species labelling. Lane 1: MCF7 cells; lane 
2*. A431 cells; lane 3: D U 145 cells; lane 4: LNCaP cells; lane 5: PC3 cells. 
Sample loading of 200 fig membrane protein for MCF7 cells, 10 fig for 
A431 cells and 100 fig each for DU145, LNCaP and PC3 cells.
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medium in parallel experimental conditions to those used for 
EGF-R and TGFp-R binding studies.
At 24 hours (data not shown), neither LNCaP nor DU145 
cells exhibited growth stimulation in response to increasing 
concentrations (from 0.5 up to 50 ng/ml) of TGFa. In contrast, 
PC3 cells showed a dose-dependent increase (as measured by 
DNA content), reaching a maximum of about 18% above control at 
50 ng/ml dose.
After 48 hours exposure (see Figure 38A), LNCaP cells 
remained insensitive to TGFa at all doses tested; conversely, PC3 
cells showed a more pronounced dose-related increase of growth, 
which was about 36% at the 50 ng/ml dose (P<0.003). DU 145 
cells revealed only a slight rise of DNA content at the dose of 0.5 
ng/ml, whilst the other doses did not affect growth of this cell 
line.
As regards TGFBi, LNCaP cells seemed to be insensitive to 
increasing concentrations (from 0.05 to 5 ng/ml) of this growth 
factor over 24 hours exposure. PC3 cells, on the contrary, showed 
a remarkable decrease of DNA content (25.6% and 23.7% at 1 and 
5 ng/ml, respectively). Similarly, DU145 cells exhibited reduction 
in growth which was very close to that found in PC3 cells, being 
respectively of 24.6% and 22.3% at 1 and 5 ng/ml doses.
After 48 hours exposure (see Figure 38B), the data 
appeared consistent with those obtained at 24 hours. LNCaP still 
exhibited no response to any TGFBi dose, while PC3 cells showed 
a significant decrease of growth with respect to control (maximal 
at the 5 ng/ml dose - 54.5% of control, P<10-6), which was twice
286
F ig u re  38. Growth response of prostate cancer cells to transforming 
growth factor-a (TGFa) and -pi (TGFpi). Cells were grown in routine 
medium and exposed for 48 h to increasing concentrations of either (A) 
TGFa (0.5-50 ng/ml) or (B) TGFpi (0.05-5 ng/ml). Values represent 
mean ±SD (bars) of triplicate experiments. (A): *P<0.03 and **P<0.003;
(B): *P<0.009 and **P<10-6, with respect to controls (two-tailed 
Student’s t test, 95% confidence limits).
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the effect seen at 24 hours. On the other hand, DU 145 cells
displayed a much less pronounced reduction in DNA content 
between 24 and 48 hours, being only 28.2% at 48 hours after the 
same dose of 5 ng/ml (P<0.009).
Additional experiments were carried out to investigate the 
growth effects of both TGFa (10 and 50 ng/ml) and TGFBi (1 and 
5 ng/ml) after 48 h and 6 days exposure using DHICT-FCS
supplemented RPM I medium, therefore under experimental 
conditions identical to those used for evaluating response of cells 
to steroids (androgens and oestrogen) and closer to those used in 
studies on steroid metabolism (see below).
Concerning TG F a, neither 48 h nor 6 days exposures of
LNCaP cells to either 10 or 50 ng/ml significantly affected cell
proliferation (see Figure 39, top). Surprisingly, DU145 cells 
showed a decrease of growth that peaked at 50 ng/ml after 6 
days (25.2% with respect to control; see Figure 39, centre). 
Similarly, PC3 cells lost the growth stimulation seen after 48 h in 
routine medium (35.9% at 50 ng/ml), showing a slight reduction 
(less than 15%) of their DNA content after 6 days exposure at the 
50 ng/ml TGFa dose (see Figure 39, bottom).
Concerning T G F p i, results from both 48 h and 6 days 
experiments confirmed that LNCaP cells are insensitive to this 
growth factor, only a minor decrease of growth (around 15%) 
being found at 5 ng/ml after a 6 days interval (see Figure 40, 
top). At 48 h exposure, the DU 145 cells displayed a decrease of 
growth following addition of 1 and 5 ng/ml TGFPi which was 
equivalent to that seen at the same doses after 48 h in routine
288
F ig u re  39. Growth response of human prostate cancer cell lines to 
transforming growth factor-a (TGFa). LNCaP (top), DU145 (centre) 
and PC3 (bottom). Cells were grown in RPMI medium supplemented 
with 10% DHICT-FCS and exposed for 48 h or 6  days to selected 
concentrations of TGFa (10 and 50 ng/ml). Values represent m^an ±SD 
(bars) of triplicate experiments.
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F ig u re  40. Growth response of human prostate cancer cell lines to 
transforming growth factor-Pi (TGFpi). LNCaP (top), DU145 (centre) 
and PC3 (bottom). Cells were grown in RPMI medium supplemented 
with 10% DHICT-FCS and exposed for 48 h or 6  days to selected 
concentrations of TGFPi (1 and 5 ng/ml). Values represent mean ±SD 
(bars) of triplicate experiments.
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medium; this trend was further confirmed at 6 days incubation, a 
greater inhibition of growth (36.8% with respect to control) being 
observed at the 5 ng/ml dose (see Figure 40, centre). In contrast, 
PC3 cells exhibited a marked lessening (about one half) of the 
effects previously found at 48 h using routine medium at either 
T G F p i dose (1 ng/ml: 17.2% vs 34.1% and 5 ng/ml: 24.8% vs 
45.5% with respect to routine medium conditions). After 6 days 
exposure, PC3 cells showed a further significant decrease of their 
DNA content, with a maximal effect seen at 5 ng/ml (over 68% 
below control, see Figure 40, bottom).
6. STEROID METABOLISM
6.1. A n drogen s
Measurement of multiple enzyme activities of testosterone 
metabolism in human prostate cancer cell lines was carried out 
using physiological concentration of tritium-labelled precursor(s) 
administered to living cultured cells for variable incubation times 
and RP-HPLC separation and identification of radioactive 
androgens.
After 24 h incubation, AR positive LNCaP and DU145 cells, 
on the one hand, and androgen unresponsive, AR-poor, PC3 cells, 
on the other, displayed divergent patterns of testosterone 
metabolism (see Table 7).
2 9 1
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Table 7. Testosterone conversion rates in human prostate 
cancer cells: percent values of undegraded precursor (3H -T ) and 
products formed after 24 h incubation.
3H -T D H T 3a-diol A4 Ad 5a-A dione A EpiA
LNCaP 81.7 1.8 0.87 11.6 3.7 * *
±2.6 ±0.2 ±0.17 ±0.9 ±0.3
DU 145 86.1 6.9 0.76 4.1 1.3 N D N D
±2.8 ±0.7 ±0.12 ±0.6 ±0.4
PC3 11.3 N D N D 60.9 18.3 2.9 6.0
±0.6 ±2.1 ±1.3 ±0.1 ±0.7
Values are expressed as percentages (mean ± SD) of total radioactivity 
detected in triplicate experiments. Cells (0 .5 -lx l06) were incubated with 
l - 2 xlO_9M labelled testosterone as precursor, in FCS free, phenol red free- 
RPMI medium for 24 h and the incubation medium processed as described 
in the Materials and Methods section (see 2.17.). (*) negligible amounts 
occasionally detected in the free fraction only (see Figure 41). ND = not 
detectable. For abbreviations see Table 1.
In fact, as also illustrated in Figures 41 and 42 respectively, 
T remained mostly unconverted in both LNCaP and DU145 cells, 
the percent of labelled T being 81.7 ±2.6 for LNCaP and 86.1 ±2 .8  
for DU145 cells. A relatively high DHT formation was revealed in 
both cell lines, with a higher extent of the reaction in DU 145 
(mean 6.9 ±0.7%) with respect to LNCaP cells (mean 1.8 ±0.2%); a 
small proportion of 3a-androstanediol (3a-d io l) was also seen at 
a nearly equivalent extent (0.87 and 0.76%) in both cell lines.
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F igu re  41. Typical HPLC profile of androgen metabolism in LNCaP 
cells. Cells (lxlO 6) were incubated with lxlO'8M tritiated testosterone 
for 24 h and both precursor degradation and product formation analysed 
through RP-HPLC and radioactive detection. Crude cpm values were: 
(1) T, 309,983; (2) A4Ad, 48,608; (3) EpiA, 1,971; (4) DHT, 4,298;
(5) 3a-diol, 2,592; (6 ) 5a-Adione, 13,686; (7) A, 2,006. For abbreviations, 
relative retention times and peak identification number see Table 1, 
Androgens.
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F igu re  42. Typical HPLC profile of androgen metabolism in DU145 
cells. Cells (5x10s) were incubated with 5xlO'9M tritiated testosterone 
for 24 h and both precursor degradation and product formation analysed 
through RP-HPLC and radioactive detection. Crude cpm values were:
(1) T, 162,694; (2) A4Ad, 5,167; (4) DHT, 21,895; (5) 3a-diol, 5,783;
(6 ) 5a-Adione, 2,859. For abbreviations, relative retention times and 
peak identification number see Table 1 , Androgens.
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Conversely, the production of androstenedione (A4Ad) and its 5a- 
reduced derivative 5a-androstanedione (5a-Adione) was greater 
in LNCaP (respectively, 11.6 and 3.7%) than in DU145 cells 
(respectively, 4.1 and 1.3%). Occasionally, negligible amounts of 
both androsterone (A ) and its epimer epiandrosterone (EpiA) 
were found in LNCaP cells (see Figure 41).
In contrast, PC3 cells exhibited high conversion rates of T, 
the percent of unconverted precursor being only 11.3 ±0.6 after 
24 h. Formation of metabolic products preferentially followed 
the oxidative way, with a remarkable conversion of T  to A4A d 
(60.9 ±2.1% ) and a consequent formation of the 5 a -re d u c e d  
derivatives of the 17-keto series, 5a-Adione, A and EpiA (Figure 
43). Overall, these three androgen metabolites accounted for 
more than 27% of total radioactivity detected by 24 h.
The prevalence of the oxidative pathways of androgen 
metabolism in this cell line was further confirmed by 
experiments using 14C-labelled A4Ad as labelled precursor (see 
Figure 44). In fact, the most part (89.6%) of A4Ad remained 
unconverted after 24 h incubation, with a negligible (less than 
1%) formation of T and an appreciable production of the 17-keto 
derivatives 5a-Adione, A and EpiA (overall more than 9% as a 
sum). Although the proportion of 17-keto metabolites formed 
from A4Ad is smaller than that seen after 24 h incubation with 
3H -T  (over 27%), this evidence clearly indicates that the direction 
of androgen metabolism in PC3 cells is totally shifted in favour of 
the oxidative way.
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F igu re  43. Typical HPLC profile of androgen metabolism in PC3 cells. 
Cells (lxlO 6) were incubated with lxlO'8M tritiated testosterone for 24 h 
and both precursor degradation and product formation analysed through 
RP-HPLC and radioactive detection. Crude cpm values were: (1) T, 
28,687; (2) A4Ad, 236,990; (3) EpiA, 29,565; (6 ) 5a-Adione, 81,262;
(7) A, 10,895. For abbreviations, relative retention times and peak 
identification number see Table 1 , Androgens.
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F igu re 44. HPLC profile of androstenedione metabolism in  PC3 cells. 
Cells (2x l06) were incubated for 24 h in  the presence of carbonated 
androstenedione (6xlO '6M) and rates and direction of metabolism 
analysed by means of RP-HPLC and radioactive detection. Crude cpm 
values were: (1) T, 2,322; (2) A4Ad, 216,868; (3) EpiA, 1,962; (6) 5a- 
Adione, 1,838; (7) A, 18,434. For abbreviations, relative retention times 
and peak identification number see Table 1, Androgens.
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Notably, however, a good proportion (range: 43 to 57%) of 
radioactive androgens was present in conjugate form (either 
sulphate or glucuronide) in LNCaP cells, mostly (over 90%) as 
unconverted T. By contrast, no conjugate formation could be 
observed in either DU 145 or PC3 cells, as also confirmed by the 
high percent values of extraction efficiency (87% and 90%
respectively).
Most importantly, no detectable DHT formation (reductive 
pathway) was revealed by 24 h in PC3 cells; as previously 
observed from our laboratories [Castagnetta et a l., 1991c], this 
was also true after longer exposure intervals (72-96 h). In order 
to ascertain whether DHT formation in PC3 cells may occur
earlier and become clandestine because of its rapid conversion to 
5a-Adione via 17BHSD, or to 3a/3p-androstanediols (3 a /3 B -  
diols) via 3a /3pH S D , time-course experiments using shorter 
exposures (30 min, 2, 8 and 24 h) in sequence were set up (see
Figure 45). Again, no measurable DHT or 3a/3B-diols production
was seen at any incubation time, while the prevalence of the 
oxidative pathway, leading to A4Ad formation, was confirmed. In 
fact, T was increasingly converted to A4Ad, an appreciable 
amount (over 8%) of this metabolite being found after only 30 
min incubation. A proportional increase of 5a-Adione was also 
seen at 8 and 24 h. Formation of A4Ad plus 5a-Adione was 
inversely and significantly related to the proportion of 
metabolised T (r=-0.976, P<0.03; Spearman correlation test).
Results from 72 h experiments were confirmatory of those 
obtained after 24 h incubation (see Table 8). In fact, both LNCaP
298
F igu re 45. Time-course of testosterone metabolism in PC3 cells. Cells 
(2x l06) were incubated with 50 nM tritiated testosterone as precursor 
for various intervals (from 30 minutes up to 24 hours) to inspect both 
testosterone degradation and formation of metabolic products. The 
histograms illustrate the proportion of undegraded testosterone (open 
bars) and that of androstenedione (hatched bars) plus 5a -  
androstanedione (black bars) formed against time. No DHT formation 
was observed at any incubation time. Values represent mean ±SD from 
triplicate experiments. For methodological details see text (Materials 
and Methods: 2.17.).
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Table 8. Testosterone conversion rates in human prostate 
cancer cells: percent values of undegraded precursor (3H -T ) and 
products formed after 72 h incubation.
3H -T D H T 3a-diol A4 Ad 5a-A dione A EpiA
LNCaP 55.4 3.3 14.0 14.2 0.5 10.3 2.3
±1.8 ±0.3 ±0.8 ±0.7 ±0.1 ±0.6 ±0.3
DU 145 54.6 13.2 11.0 13.3 2.1 3.1 2.9
±1.1 ±0.6 ±0.8 ±0.8 ±0.4 ±0.2 ±0.3
PC3 2.9 N D N D 46.5 24.8 10.9 14.9
±0.4 ±1.7 ±1.2 ±0.9 ±0.8
Values are expressed as percentages (mean ± SD) of total radioactivity 
detected in triplicate experiments. Cells (0 .5 -lx l06) were incubated with 
l - 2 xlO'9M labelled testosterone as precursor, in FCS free, phenol red free- 
RPMI medium for 72 h and the incubation medium processed as described 
in the Materials and Methods section (see 2.17.). ND = not detectable. For 
abbreviations see Table 1.
and DU 145 cells maintained over 50% of labelled T unconverted, 
while a more pronounced formation of either DHT or 3a-diol was 
observed. These two 5a-reduced metabolites accounted for a 
considerable proportion (LNCaP, 17.3%; DU145 14.2%) of total 
radioactivity detected in both cell lines. On the other hand, 
formation of A4Ad increased noticeably between 24 and 72 h in 
DU145 cells (from 4.1 to 13.3%) and, to a lesser extent, in LNCaP 
cells (from 11.6 to 14.2%), with a consequent rise of 5a-reduced
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metabolites of the 17-keto series (A and EpiA). Despite this, 
production of androgen derivatives through the oxidative way 
(including A4Ad, A and EpiA) never exceeded 30% of radioactive 
androgens in either LNCaP or DU145 cells.
In contrast, PC3 cells showed a further increase of T  
degradation, the proportion of unconverted precursor being only 
2.9% of the total. Formation of A4Ad was remarkable (46.5% ), 
though decreased with respect to 24 h experiments (60.9%). This 
is not surprising in the view of the markedly enhanced 
conversion of A4Ad to its derivatives 5a-Adione (24.8% ), A 
(10.9%) and EpiA (14.9%). These metabolites, in fact, accounted 
for approximately 50% of total radioactivity detected; notably, 
oxidative metabolism produced over 95% of all radioactive 
androgens found in PC3 cells.
A negligible proportion (less than 10%) of conjugate (either 
sulphate or glucuronide) T was occasionally found in LNCaP cells 
after 72 h incubation. Conversely, as in 24 h experiments, no 
conjugate formation could be detected in either DU 145 or PC3 
cells.
6 .2 . O estrogens
Enzyme activities of oestradiol metabolism in human 
prostate cancer cell lines were inspected through incubation of 
cultured cells with a physiological concentration of labelled 
precursor (tritiated E2 ) and RP-HPLC analysis. Similarly to 
testosterone metabolism (see Section 6.1.), divergent patterns of
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oestradiol metabolism were encountered in LNCaP, DU145 and 
PC3 cells.
Table 9. Oestradiol conversion rates in human prostate cancer 
cells: percent values of undegraded precursor (3H -E 2 )  and 
products formed after 24 h incubation.
3H-E2 Ei 16aOHEi 2MeOE2
LNCaP 88.5 ±2.6 10.3 ±0.8 ND 1.2 ±0.3
DU 145 93.2 ±2.1 6.6 ±0.7 ND ND
PC3 6.3 ±0.4 89.6 ±2.9 3.8 ±0.3 ND
Values are expressed as percentages (mean ± SD) of total radioactivity 
detected in triplicate experiments. Cells (0.5-lx l06) were incubated with 
l-2xlO _9M  labelled oestradiol as precursor, in FCS free, phenol red free- 
RPMI medium for 24 h and the incubation medium processed as described 
in the Materials and Methods section (see 2.17.). ND = not detectable. For 
abbreviations see Table 1.
As reported in Table 9 and respectively illustrated in 
Figures 46 and 47, after 24 h incubation both LNCaP and DU 145 
cells maintained the most part of 3H - E 2  unconverted  
(respectively 88.5% and 93.2%), a relatively minor oxidation to Ei 
being observed in both cell lines (10.3% in LNCaP and 6.6% in 
DU 145 cells); additionally, LNCaP cells formed very little 2MeOE2. 
In contrast, PC3 cells (see Figure 48) showed a large conversion 
of E2 to Ei (approximately 90%), with only a small part (less than
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F igu re  46. Typical HPLC profile of oestrogen metabolism in LNCaP 
cells. Cells (lxlO 6) were incubated with lxlO'8M tritiated oestradiol for 
24 h and both precursor degradation and product formation analysed 
through EP-HPLC and radioactive detection. Crude cpm values were: (2 ) 
E2 , 157,778; (3) 2 MeOE2 , 2,244; (4) E i, 18,342. For abbreviations, 
relative retention times and peak identification number see Table 1, 
Oestrogens.
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F igu re  47. Typical HPLC profile of oestrogen metabolism in DU145 
cells. Cells (5x l05) were incubated with lxlO“9M tritiated oestradiol for 
24 h and both precursor degradation and product formation analysed 
through RP-HPLC and radioactive detection. Crude cpm values were:
(2 ) E2 , 19,387; (4) E i, 1,275. For abbreviations, relative retention times 
and peak identification number see Table 1 , Oestrogens.
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F igu re 48. Typical HPLC profile of oestrogen metabolism in PC3 cells. 
Cells (5x l05) were incubated with 5xlO'9M tritiated oestradiol for 24 h 
and both precursor degradation and product formation analysed through 
RP-HPLC and radioactive detection. Crude cpm values were: (1) 
16aO H E i, 2,973; (2 ) E2, 2,450; (4) E i, 68,573. For abbreviations, 
relative retention times and peak identification number see Table 1, 
Oestrogens.
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7%) of the precursor remaining undegraded; interestingly, an 
appreciable amount (3.8%) of 16aO HEi was also found in this cell 
line.
Results of 72 h experiments were largely in accordance to 
those obtained by 24 h (see Table 10).
Table 10. Oestradiol conversion rates in human prostate cancer 
cells: percent values of undegraded precursor (3H -E 2 )  and 
products formed after 72 h incubation.
3H-E2 Ei 16aOHEi
LNCaP 70.6 ±1.8 28.9 ±1.2 ND
DU 145 85.1 ±1.1 14.5 ±0.9 ND
PC3 3.6 ±0.7 85.6 ±1.6 10.5 ±0.8
Values are expressed as percentages (mean ± SD) of total radioactivity 
detected in triplicate experiments. Cells (0 .5 -lx l06) were incubated with 
l-2xlO'9M labelled oestradiol as precursor, in FCS free, phenol red free- 
RPMI medium for 72 h and the incubation medium processed as described 
in the Materials and Methods section (see 2.17.). ND = not detectable. For 
abbreviations see Table 1.
Although, as expected, the extent of Ei formation increased in 
both LNCaP and DU145 cells (28.9% in the former and 14.5% in 
the latter), the most part of 3H - E 2  remained unconverted 
(respectively 70.6% and 85.1%). Conversely, PC3 cells showed a 
further precursor degradation, the proportion of remaining 3H-E2
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being only 3.6%; nonetheless, the proportion of the Ei produced
did not change significantly (85.6% vs 89.6% at 24 h), because of
the marked increase in 16aO H E i formation (up to 10.5% of the
total).
7. M O D U LA TIO N  OF STEROID M ETA BO LISM  BY TG Fa AND  
TGFp
7.1. Testosterone Metabolism
The influence of TGFa and TGFp i on testosterone 
metabolism in prostate cancer cells was initially investigated 
through simultaneous addition of labelled T and a selected 
concentration of the relevant growth factor and incubation for a 
72 h interval.
In LNCaP cells (see Figure 49, bottom), TG Fpi did not 
significantly affect the proportion on unconverted T, whilst TGFa 
reduced it by more than 20%. Both growth factors produced an 
increase of both DHT and 3 a -d io l form ation (reductive  
metabolism), which was approximately 3-fold greater for TGFa  
(35.1% for DHT and 12.5% for 3a-diol). On the other hand, a 
noticeable rise of both A4Ad (21.4%) and its derivatives, including 
A and EpiA (over 80% as sum), was seen following TG Fa  
administration; by contrast, TGFPi induced a decrease of these 
17-keto metabolites that, however, never exceeded 15% from 
control. Overall, comparison of reductive (D H T plus 3a-diol) and 
oxidative (A4Ad and A+EpiA) metabolism in LNCaP cells (see
307
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Figure 49, top) indicated that both TGFa and TGFpi caused an 
extension of the reductive pathways, which was greater for TGFa 
(26.7%) than for TGFpi (15.4%); conversely, TGFa induced a 
remarkable increase (nearly 50%) of the oxidative metabolism, 
while TGFpi slightly reduced formation of 17keto androgens 
(12.2% less than control).
The DU145 cells showed a different picture (see Figure 50, 
bottom). In fact, although neither growth factor substantially 
modified the extent of T degradation, both TGFa and TGFpi 
produced a reduction, though not significant, of DHT formation 
(respectively 5.9% and 10.1%). Conversely, production of A4A d  
was significantly stimulated (respectively 107.3% and 51.7%) by 
either factor, while a much less pronounced increase (15.7%) of 
A+EpiA was found with TG Fpi only. Overall, reductive 
metabolism was substantially decreased by TGFa (23.5% from 
control) and only slightly reduced by TGFpi (6.2%), while both 
growth factors caused an equivalent increase (around 26%) of the 
oxidative metabolism (see Figure 50, top).
Testosterone metabolism was minimally affected by either 
T G F a  or TGFPi in PC3 cells (see Figure 51, bottom). The 21% 
decrease of unconverted T observed with TG Fa is of minor 
importance since in this cell line the proportion of unmetabolised 
precursor after 72 h incubation is very small and, therefore, even 
little variations in T conversion rates may result in apparently 
significant differences of T degradation. Apart from a quite 
limited increase seen in A4 Ad formation with both TG Fa and 
T G F p i, the oxidative metabolism in PC3 cells was unaffected by
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F igu re  49. Effects of TGFa and TGFPi on androgen metabolism in 
LNCaP cells. Selected doses of TGFa (50 ng/ml) and TGFpi (5 ng/ml) 
were added to experimental medium containing lxlO _8M tritiated  
testosterone and cells (lxlO 6) incubated for 72 h. Rates and direction of 
metabolism were subsequently assessed through RP-HPLC and 
radioactive detection. The diagram at bottom shows the percent of 
reaction for any single metabolite detected with respect to control (0 ). 
The chart at the top illustrates the overall influence of either growth 
factor on both reductive and oxidative pathways of androgen 
metabolism, respectively expressed as the sum of (DHT+3a-diol) and of 
(A4Ad+EpiA+A).
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F igu re  50. Effects of TGFa and TGFpi on androgen metabolism in 
DU145 cells. Selected doses of TGFa (50 ng/ml) and TGFpi (5 ng/ml) 
were added to experimental medium containing lx lO ‘8M tritiated  
testosterone and cells (lxlO 6) incubated for 72 h. Rates and direction of 
m etabolism  were subsequently assessed through RP-HPLC and 
radioactive detection. The diagram at bottom shows the percent of 
reaction for any single metabolite detected with respect to control (0 ). 
The chart at the top illustrates the overall influence of either growth 
factor on both reductive and oxidative pathways of androgen 
metabolism, respectively expressed as the sum of (DHT+3a-diol) and of 
(A4Ad+EpiA+A).
Pe
rc
en
t 
di
ff
er
en
ce
 
fro
m 
co
nt
ro
l
EXPERIMENTAL
oIn
aoa
6o
ft)oda>
In
dvouVcu
□  TGFa 
TGFp
Reductive Oxidative
150
□  TGFa 
B  TGFP
100-
50-
0 i v v v |_
;L:
\ \ y y  . \ \
-50 I I
T DHT
 1 1 1-----
3a-d io l A4Ad A+EpiA
3 1 0
F igu re  51. Effects of TGFa and TGFPi on androgen metabolism in PC3 
cells. Selected doses of TGFa (50 ng/ml) and TGFPi (5 ng/ml) were added 
to experimental medium containing l x l 0 8M tritiated testosterone and 
cells (lxlO 6) incubated for 72 h. Rates and direction of metabolism were 
subsequently assessed through RP-HPLC and radioactive detection. 
The diagram at bottom shows the percent of reaction for any single 
metabolite detected with respect to control (0); ND = not detectable. The 
chart at the top illustrates the overall influence of either growth factor 
on both reductive and oxidative pathways of androgen metabolism, 
respectively expressed as the stun of (DHT+3a-diol, i f  any) and of 
(A4Ad+EpiA+A).
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either growth factor, while the reductive metabolism remained 
virtually absent (see Figure 51, top).
7.2. O estradiol M etabolism
The effects of both TGFa and TGFp i on oestradiol 
metabolism in prostate tumour cell lines were also compared.
In LNCaP cells, where only Ei formation was seen after 72 h 
incubation, both TGFa and TGFpi caused a slight increase of the 
proportion of unconverted E2 (11.7% and 4.1%, respectively), with 
a proportional decrease of Ei production (25.4% and 8.4% from 
control: see Figure 52).
A reverse picture was observed in DU145 cells (see Figure 
53, bottom). In fact, either growth factor slightly reduced the 
proportion of undegraded E2 (5.3% and 5.7% for TGFa and TGFpi, 
respectively). However, while TG Fa induced a remarkable 
increase of Ei formation (33.8%), TGFPi caused its reduction 
(9.1%); interestingly, an appreciable amount of E3 (6.2%) was 
found following TG FPi administration. Consequently, the 
reductive metabolism (expressed as the sum of E2 and E3 ) was 
only somewhat altered by both TGFa and TG FPi, whilst the 
oxidative pathway (namely E i formation) was enhanced by TGFa 
and relatively reduced by TGFpi (see Figure 53, top).
Although in PC3 cells, after 72 h incubation, the most part 
E 2 is converted to E i, both TGFa and TG Fpi significantly  
augmented oestradiol oxidation in this cell line (see Figure 54, 
bottom). In fact, either growth factor induced a further 
degradation of E2 (22.7% and 25.1% for TGFa and TG FP i,
3 1 2
F ig u re  52. Effects of TGFa and TGFPi on oestrogen metabolism in  
LNCaP cells. Selected doses of TGFa (50 ng/ml) and TGFpi (5 ng/ml) 
were added to experimental medium containing lx lO _8M tritiated  
testosterone and cells (lxlO 6) incubated for 72 h. Hates and direction of 
m etabolism  were subsequently assessed through RP-HPLC and  
radioactive detection. The diagram at bottom shows the percent of 
reaction for any single metabolite detected with respect to control (0 ). 
The chart at the top illustrates the overall influence of either growth 
factor on both reductive and oxidative pathways of oestrogen  
m etabolism, respectively expressed as the sum of unconverted  
E2+2 MeOE2 and the extent of E i formation.
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F igu re  53. Effects of TGFa and TGFpi on oestrogen metabolism in 
DU145 cells. Selected doses of TGFa (50 ng/ml) and TGFpi (5 ng/ml) 
were added to experimental medium containing lxlO '8M tritiated  
testosterone and cells (lxlO 6) incubated for 72 h. Rates and direction of 
metabolism were subsequently assessed through RP-HPLC and 
radioactive detection. The diagram at bottom shows the percent of 
reaction for any single metabolite detected with respect to control (0). 
The chart at the top illustrates the overall influence of either growth 
factor on both reductive and oxidative pathways of oestrogen  
metabolism, respectively expressed as the proportion of unconverted E2 
and the extent of E i formation.
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F ig u re  54. Effects of TGFa and TGFPi on oestrogen metabolism in  
PC3 cells. Selected doses of TGFa (50 ng/ml) and TGFPi (5 ng/ml) were 
added to experimental medium containing lxlO'8M tritiated testosterone 
and cells (lxlO 6) incubated for 72 h. Kates and direction of metabolism  
were subsequently assessed through RP-HPLC and radioactive 
detection. The diagram at bottom shows the percent of reaction for any 
single metabolite detected with respect to control (0). The chart at the 
top illustrates the overall influence of either growth factor on both 
reductive and oxidative pathways of androgen metabolism, respectively 
expressed as the sum of unconverted E2+16aOHEi and the extent of E i 
formation.
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respectively). This was accompanied by a parallel increase of Ei 
formation (nearly 13% for both factors) and a significant decline 
of 16aO H Ei production (71.3% for TGFa and 64.3% for TGFPi). 
Therefore, reductive E2 metabolism (expressed as the sum of E2 
and 1 6 a O H E i) was remarkably lessened by either TGFa (nearly 
60%) or TGFp 1 (55.1% ), while both factors yielded a
correspondent increase of E2 oxidation to Ei (14.0% and 12.8% 
respectively for TGFa and TGFPi) (see Figure 54, top).
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1. Models for Prostate Cancer Studies
As emphasised in the Introduction (see Section 5.1.1.)* the 
incidence of human prostate cancer has been continuously 
increasing during the last decade, so that prostatic carcinoma has 
become the most prevalent neoplasm and the second principal 
cause of cancer death in man [Carter & Coffey, 1990]. The 
shortage of suitable tools for either screening or early diagnosis 
as well as the limited knowledge on both the aetiology and the 
regulation of development and growth of prostate tumour, 
burden this cancer with a unfavourable prognosis and leave 
clinicians at a loss in the management of patients.
In the past, prostate studies have been critically obstructed 
by two major problems: in the first place, the difficulty in
obtaining suitable tissue specimens; secondly, the lack of 
appropriate in vitro models. Despite the numerous efforts made 
since the early 1970s, the establishment of prostate tumour cells 
in long-term tissue culture has been considerably rare. Initially, 
isolation of prostatic epithelial cell lines from primary prostate 
cancer was complicated by the heterogeneous composition of 
primary lesions and by the objective limitations in achieving
physical separation and identification of the cell type(s) grown in  
v i t r o .  This has led researchers to derive epithelial cells from 
metastatic tissue, where mostly tumour cells are likely to be 
present. Despite this, prostate cancer cell lines provided with a 
genuine pedigree have been rare; for instance, both the early
M A I60 [Fraley et a l., 1970] and the EB33 [Okada &  Schroder,
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1974] prostate tumour cells have been shown to be contaminated 
by the ubiquitous HeLa cervical carcinoma cells. More recently, 
however, the isolation of the DU145 [Stone et a l ., 1978] and PC3 
[Kaighn et a l ., 1979] cell lines, followed by the LNCaP cell line 
[Horoszewicz et a l ., 1980], has allowed investigators to use these 
cells as useful models respectively for hormone-independent and 
hormone-dependent human prostate cancer. Although data from 
cultured prostate epithelial cells should be considered with 
caution, especially because of the lack of a physiological stromal 
compartment, most of the present knowledge on the growth 
regulation of human prostate cancer has been gained with i n 
v i t r o  systems. The use of both conditioned media and 
transplantable prostatic tumour cell lines may partly override 
the intrinsic limits of these systems and provide important 
additional approaches to completion of the understanding of 
malignant prostate development and growth.
2. Steroid Function in Human Prostate Cancer Cells
2.1. Response to steroids
Several studies have explored the effects of steroid 
hormones on growth of cultured human epithelial prostate cells. 
In the present work, using stringent experimental conditions 
(RPM I medium supplemented with 10% DHICT-FCS), LNCaP cells 
show growth response to DHT (33.8% peak stimulation at 10'10M ,  
after 6 days exposure), while DU 145 and PC3 prove to be
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insensitive; this is in agreement to the existing literature [Stone 
et a l ., 1978; Kaighn et a l ., 1979; Horoszewicz et a l ., 1983]. As also 
previously reported by others [Sonnenschein et a l ., 1989], LNCaP 
cells exhibit a significant growth inhibition when exposed to 
higher (10-9 to 10_7M ) DHT concentrations, with a maximum 
decrease of over 58% at 10_7M. This evidence apparently fits 
with the two-step mechanism designed by Sonnenschein group 
on the growth control exerted by androgens on LNCaP cells [Olea 
et a l ., 1990]. In this model, low concentrations (< 1 0 '10M) of either 
androgens or other steroidal compounds (including oestrogens, 
progestins and antiandrogens) induce a growth stimulation of 
LNCaP cells through removal of a putative plasma-born inhibiting 
protein, called androcolyone I (step 1). At higher concentrations 
(> 1 0 _9M ), only androgens trigger a specific AR-mediated effect 
which results in a inhibition of growth of LNCaP cells (step 2). 
However, a recent report documented that growth of a LNCaP 
supersensitive subline (LNCaP-ss) in serum-free medium is 
significantly stimulated by both very low (1 0 '16- 10_14M ) and 
higher (10_9-10-7M ) DHT concentrations [Kirschenbaum et al., 
1993].
Under the same experimental conditions, growth of LNCaP 
human prostatic epithelial cancer cells is significantly stimulated 
by a physiological concentration (1 nM) of oestradiol, while it is 
significantly inhibited at a higher concentration (100 nM) (see 
Figure 30). Contrary to what observed with androgens, where 
this biphasic behaviour has been repeatedly reported by others 
[Berns et al., 1986; Sonnenschein et al., 1989], this inhibition is
3 2 0
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here reported for the first time. Thtese data confirm previous
studies in that the oestradiol-iinduiced increase of LNCaP
proliferation is comparable or eveni ‘greater than that produced 
by androgens [Schuurmans et al’.., 1988a; Sonnenschein et al., 
1989; Iguchi et al., 1990]. Conversely* growth of DU145 cells is 
minimally affected by the addition of any E2 concentration.
Interestingly, E2 shows a clear inhibitory effect on growth 
of human prostate cancer PC3 cells; this is true also at lower 
concentration, within physiological range (see Figure 30 and 
31 A). At higher doses (1 nM or more) this effect becomes 
evident before 6-days exposure. Again, the data in this thesis are 
the first to show that E2 inhibits growth of epithelial prostate
cancer cells is provided; this may represent an alternative 
explanation for the efficacy of the oestrogen therapy in advanced 
prostatic cancer, wherein androgen-independent tumour cells are 
likely to be largely prevalent. Since the early 1940s, the high 
response rates (70-80%) achieved in prostate cancer patients 
using a synthetic oestrogen, the orally active DES, have been
ascribed to the fact that, after DES administration, circulating 
testosterone falls to the levels found in castrates [Turkes et al.,
1988]. Recent experimental data have, however, emphasised that 
intravenous stilbestrol diphosphate, and oestrogens in general, 
may exert a direct cytotoxic effect on prostate tumours which 
could explain the response to oestrogens seen in patients having 
metastatic and otherwise hormone-refractory disease [Ferro,
1991].
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2.2. Steroid receptors
Presence of binding sites for both androgens and oestrogens 
in LNCaP, DU145 and PC3 cells has been investigated using 
multiple approaches.
In the first place, radioligand binding assay reveals that 
both type I (high affinity, limited capacity) and type I I  (lower 
affinity, greater capacity) sites of androgen binding are present 
in soluble and nuclear cell fractions of LNCaP and DU145 cells, 
while PC3 cells exhibit only nuclear type I AR (see Table 2). 
Based on previous experience by others [Thorsen, 1979; Leake &  
Habib, 1987] and our own group [Castagnetta et a l ., 1983; 
Castagnetta et a l ., 1987b; Castagnetta et a l ., 1992a], the absence 
of type I receptors from one cell fraction is likely to denote an 
impaired mechanism of action of steroids. Recently, it has been 
observed that nuclear type I AR are widespread in human 
prostate cancer tissues and therefore their potential value as 
predictors of both prognosis and response to endocrine treatment 
of patients is questionable; the same applies to type I I  AR, that 
are almost ubiquitously distributed in either cell fraction 
[Castagnetta et a l , 1991b; Castagnetta et a l ., 1992a].
Preliminary data obtained using the reverse transcriptase- 
PCR (RT-PCR) system support the results of biochemical assay of 
AR. In fact, using this approach, a portion of exon 1 of the human 
AR gene is amplifiable in LNCaP, DU 145 and PC3 cells (See Figure 
22); this evidence is strongly suggestive of the presence of AR 
mRNA in all three cell lines. Assuming that the same amount of 
template target within the total RNA extracted from cells gives
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rise to equivalent amplification and synthesis of cDNA in the 
three cell lines, the LNCaP cells yield the greatest PCR product, 
with DU 145 and PC3 cells respectively having intermediate and 
lower levels.
While androgen-responsive LNCaP cells are universally
recognised as AR-endowed, though with a point-mutated form of 
AR, conflicting data in the literature exist on the presence of AR 
in androgen independent human prostate cancer cells. Although
radioligand binding assay has been frequently used to measure 
AR content of cultured prostate tumour cells, data concerning
DU145 and PC3 cells are surprisingly sparse. In this study, 
following the original observation of Clark and Peck for oestrogen 
receptors [Clark & Peck, 1979], use of ligand concentrations 
ranging from 0.1 up to 5 nM allows definition of an experimental 
window which covers both type I and at least part of type II  
receptors and therefore enables a proper study of the 
heterogeneity of steroid binding sites. This is of primary concern, 
since clinical data strongly support the view that type I receptors 
are essential intermediaries of steroid hormone action, while the 
potential role of type II  binding sites remains unclear [Barnes et 
a l ., 1979; Leake et a l., 1981; Castagnetta et a l ., 1989b]. Overall,
apart from one report [Veldscholte et a l ., 1990a], most studies 
have used a ligand concentration range (from 1 up to 25 nM) 
such that mainly type II (low affinity, greater capacity) AR are 
highly likely to be identified [Horoszewicz et al., 1983; Berns et 
al . ,  1986; Sonnenschein et al., 1989; Olea et al., 1990]. This 
inconsistency is also reflected in the higher Kd and concentrations
3 2 3
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values of cytosolic AR commonly obtained in LNCaP cells (ranges: 
K d, 0.9-3.2 nM; concentration, 67-920 fmol/mg protein) as 
opposed to those herein reported for type I receptors (ranges: Kd, 
0.23-0.41 nM; concentration 11.3-24.1 fmol/mg protein).
Previous work suggested that either DU 145 or PC3 cells 
lack AR mRNA or protein, although no alteration in the structure 
of androgen receptor gene could be detected [Tilley et al., 1990; 
Trapman et al., 1990]. However, recent studies have documented 
that normal AR mRNA is present, though at low levels, in PC3 
cells [Culig et al., 1993]. In addition, Brolin and colleagues [Brolin 
et al., 1992], comparing cytochemical and biochemical AR assays 
in prostate cancer cell lines, found that, using 
immunohistochemistry, the majority (75%) of DU145 cells was AR 
positive, although they failed to reveal detectable AR sites with 
biochemical techniques.
Soluble and nuclear ER content of prostate tumour cells has 
been investigated by means of radioligand binding assay. Both 
type I and II  ER are present in both cell fractions of LNCaP cells; 
conversely, PC3 cells show presence of both receptor types in the 
nuclear fraction only, while the soluble compartment does not 
display any detectable site of oestrogen binding (see Tables 3 
and 4). The DU 145 cells apparently lack both cytosolic and 
nuclear ER.
Several studies have investigated the steroid receptor 
content of LNCaP cells using the radioligand binding assay 
method. Early work by Horoszewicz and colleagues [Horoszewicz 
et al., 1983] revealed presence of cytosolic oestrogen receptors in
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LNCaP cells. Some inconsistency, however, emerged from further 
studies which failed to detect ER from either nuclear extract or 
cytosol fraction of LNCaP cells [Berns et a l ., 1986; Sonnenschein et 
a l ., 1989]. For this reason, the oestradiol-induced increase of 
LNCaP proliferation has been for years ascribed to the presence 
of a point-mutated form of androgen receptor, having an 
increased affinity for progestagenic and oestrogenic steroids 
[Veldscholte et a l ., 1990a]. In fact, the relative binding affinity 
(RBA) observed for oestradiol ranged from 0.9 up to 4.3% when 
compared to that of the synthetic androgen R1881 [Schuurmans 
et a l ., 1988a; Sonnenschein et a l ., 1989; Veldscholte et a l ., 1990a; 
Veldscholte et a l ., 1990b]. Thus, we are facing a seeming paradox: 
the very low RBA values reported for oestradiol could not, in fact, 
match its remarkable effect on growth of LNCaP cells. The 
present data clearly indicate that both type I (high affinity, 
limited capacity) and type II  (lower affinity, greater capacity) 
oestrogen binding proteins are present in both cell fractions of 
LNCaP cells and that their levels are comparable to those found 
in other oestrogen-responsive cancer tissues [Castagnetta et a l ., 
1987a; Castagnetta et a l ., 1987b] and cells [Lo Casto et a l ., 1983; 
Castagnetta et a l., 1986b]. Besides, our results are consistent 
with the original definition of biochemical and functional features 
relevant to distinct sites of oestrogen binding [Clark & Peck, 
1979] and, more, with the discriminant value of type I ER in both 
breast and endometrial cancer patients [Castagnetta et a l ., 1987a; 
Castagnetta et a l ., 1992b]. It must be pointed out that most of 
previous studies used higher ligand concentrations (from 2 up to
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20 nM) [Sonnenschein et a l ., 1989], even as single point assay 
[Berns et a l ., 1986], so selecting an experimental window which 
does not allow quantitation of high affinity, low capacity binding 
sites.
The expression of ER at the mRNA level in prostate cancer 
cells has been determined using the highly sensitive RT-PCR; the 
combined Southern blot analysis enhances the sensitivity and 
confirms the identity of the amplification products. Using this 
approach, expression of a normal ER mRNA in LNCaP cells and, 
though in far lower amounts, in PC3 cells is illustrated here for 
the first time (see Experimental, Section 2.2.3.; see Figure 27); in 
contrast, no detectable amplification product(s) is seen in DU 145 
cells. Furthermore, a rather abundant expression of a variant ER 
mRNA lacking the entire exon 4 is also observed in LNCaP and at 
much lower extent in PC3 cells. This variant has been previously 
characterised in our laboratories from oestrogen responsive 
mammary carcinoma cell lines, suggesting that it is a likely 
product of alternative splicing [Pfeffer et a l ., 1993]. It is 
noteworthy that this variant is jointly expressed with the normal 
messenger only in ER positive, oestrogen-responsive MCF7 and 
ZR75-1 mammary carcinoma cell lines, whilst both mRNAs are 
absent from ER negative, non responsive M DA-M B231 cells. 
Although RT-PCR does not allow an accurate estimation of the 
relative amount of the ER transcripts, it can be deduced that 
equivalent levels of expression of both normal and variant ER 
mRNA are present in the two oestrogen-responsive mammary 
carcinoma cell lines and in LNCaP cells, whilst PC3 cells show
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much lower amounts of both the amplification products. This 
may account for the apparent lack of ER in the soluble fraction of 
the latter cell line using biochemical assay. However, the fact that 
no reaction product could be observed in the oestrogen non- 
responsive human breast cancer cell line MDA-MB231 under the 
same conditions, clearly indicates that the expression of the ER 
mRNAs in PC3 cells is significant. It is worth mentioning that the 
amplification primers (24-mers) used show 9 and 10 mismatches 
in the androgen receptor sequence and, if they were to give rise 
to any amplification product from that sequence, it should not be 
of the observed length.
Immunocytochemical studies reveal intensive staining of 
LNCaP cells for both ER and PgR (see Figure 25). The latter is 
commonly thought to be an index of a functional oestrogen 
receptor machinery in human breast and endometrial cells, so 
that clinicians have been using it as a helpful discriminant in the 
management of breast cancer patients. On the other hand, ER 
staining was much lower, though appreciable, in androgen non 
responsive PC3 cells and absent in DU 145 cells. These results 
seem at variance with a previous study by Brolin and colleagues 
[Brolin et al., 1992], where, using the same immunocytochemical 
assay, both LNCaP and PC3 cells were found to be ER and PgR- 
negative. However, this apparent discrepancy could simply be 
ascribed to the different conditions used for exposure to primary 
antibodies (1 h at 37°C as opposed to 24 h at 4°C in the present 
study).
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Presence of functional ER in human prostate cancer cells
was also inspected through immunofluorescence of the 27 kDa
hsp27, which has been reported to be a marker of oestrogen 
sensitivity in both breast and endometrial epithelial cells [King et 
a l ., 1987]. While LNCaP cells show an intensive hsp27 staining 
(see Figure 28, top), DU 145 cells appear to be hsp27-negative. A 
positive staining for hsp27, though less intense than in LNCaP
cells, is documented in PC3 cells (see Figure 28, bottom). This 
seemingly conflicts with the very low expression of both ER
protein and transcript in this cell line. Hsp27 appears to be 
qualitatively and quantitatively related to ER in several human 
tissues [King et a l ., 1987]. A linear correlation between ER content 
and hsp27 levels has been reported in human breast tumours,
although ER-poor tissues too exhibited a variable degree of hsp27
staining [Cano et a l , 1986]. In addition, although the relationship
between ER and hsp27 has been established within individual 
target tissues, it may be different in prostate.
2.3. M echanism s of oestrogen action
To ascertain whether or not the E2 -induced increase of 
growth seen in LNCaP cells is mediated via ER, cells were exposed 
to various E2 concentrations in presence or absence of the pure 
antioestrogen IC I-182,780. The evidence that the growth
response of LNCaP to oestradiol is completely abolished by 
addition of ICI-182 (see Figure 32) strongly supports the view 
that oestradiol acts via its own receptor. This finding is in accord 
to previous observation by Labrie's group, where the pure
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antioestrogen EM-139 not only reversed the androgen-induced 
increase of LNCaP proliferative activity, but also significantly 
inhibited basal cell growth [De Launoit et al., 1991]. There is an 
apparent discrepancy between growth data from DNA and 
thymidine uptake assays, in that, using 10% DHICT-FCS, only 1 
nM E2 noticeably increased growth of LNCaP cells, whilst cells 
grown in the presence of 5% CT-FCS were consistently stimulated 
by any E2 dose (from 1 0 11 up to 10_7M). This uneven result is 
bound to the different experimental conditions used and could be 
ascribed to the presence in stripped serum of as yet unidentified 
factor(s) which is dyalized off in DHICT-FCS.
The possibility that the E2-induced growth inhibition of PC3 
cells is mediated by TGFp has been investigated. Addition of 
neutralising anti-TG Fpi antibody in stringent experimental 
conditions provokes a remarkable increase (close to 300% of 
control: see Figure 3 IB ) of cell proliferation, revealing the 
presence of high levels of endogenous TGFp 1 in PC3 cells; 
oestradiol produces a reversal of this effect, which is almost 
complete at the 10‘7M dose (Figure 3 IB ). However, evaluation of 
possible regulation of TGFpi mRNA by E2 indicates that its 
expression in PC3 cells is unaffected by different doses (10-11 to 
10"7M) of E2 (see Figure 33); this is true at any incubation time 
(6, 24 or 72 h) used. Previous work [Knabbe et al., 1987] 
revealed that antioestrogens, such as TAM , do not affect TGFPi 
mRNA levels in the oestrogen-dependent MCF7 breast cancer 
cells, even though TGFpi production is increased (from 8 up to 27 
fold) in this cell line after TAM treatment. Recent experimental
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evidence has also indicated that E2 does not modify levels of 
TG Fpi mRNA either in ER positive breast cancer cell lines (MCF7, 
ZR75-1), or in ER negative cancer cells, like mammary M DA- 
MB231 [Arrick et al.y 1990] or endometrial HEC-50 [Anzai et al.,
1992]. It is of interest to note that these ER negative human
cancer cells have been reported to be exquisitely sensitive to 
TGFPi [Arteaga et al., 1988].
3. Growth Factor Studies
Recent experimental evidence has proposed a crucial role 
for both TGFa and TGFp in the onset of a transformed phenotype 
[G oustin et al., 1986]. The balance between these and other 
growth factors, as well as the presence of adequate functional 
growth factor receptors, may in turn direct the cancer cell to a 
quiescent or a progressive state.
Unfortunately, little is known about interaction between 
steroids and peptide growth factors in growth regulation of
target cancer cells from human breast or prostate. In vitro 
studies have demonstrated that non responsive, ER negative
breast cancer cells strongly differ from ER positive cells in terms
of both response to and production of various growth factors, 
such as IGF-I, TGFa and TGFp [Dickson et al., 1986; De Leon et al.,
1989]. Similarly, it has been recently reported that TG Fpi 
differentially affects growth of human prostate cancer cells, also 
depending on their steroid sensitivity [Wilding et al., 1989a].
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Furthermore, experimental evidence indicates that androgens 
and oestrogens may regulate production of peptide growth 
factors and expression of their receptors respectively in breast 
and prostate tumour cell lines [Traish & Wotiz, 1987; Lippman &  
Dickson, 1989].
3.1. Growth factor and growth factor receptor content
Presence of high affinity sites of EGF binding in all three 
cell lines studied is here documented using the radioreceptor 
assay (see Table 5). Overall, Kd and concentration values are in 
the order of those previously reported [Schuurmans et a l ., 1988a; 
MacDonald & Habib, 1992]. In particular, DU145 cells exhibit 
EGFR concentrations higher than those found in PC3 and LNCaP 
cells. This is in agreement with previous report indicating that 
DU145 cells contain a significantly higher number of EGFR 
binding sites than that expressed in LNCaP cells [MacDonald &  
Habib, 1992]. This evidence is further supported by results of 
Western blot analysis, indicating that DU 145 cells have the 
highest levels of EGFR expression, while PC3 and LNCaP cells 
respectively display intermediate and lower expression levels 
(see Figure 37).
Immunofluorescent staining revealed remarkable amounts 
of EGFR, TGFa and, to a lesser extent, of EGF in DU145 and LNCaP 
cells, whilst their levels in PC3 cells appeared to be much lower 
(see Table 6). On the other hand, appreciable TGFpi was detected 
in PC3 cells and, in far lower amounts, in LNCaP cells (Table 6). 
Recent observation has shown that DU 145 cell line secretes much
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greater amounts of EGF and EGF-related polypeptides into culture 
medium than do LNCaP cells [Connolly & Rose, 1990].
3.2. Growth factor effects on cell proliferation
T G F a  and TGFPi growth effects on prostate cancer cells 
were firstly assessed in routine medium after either 24 or 48 h 
incubation. The results presented here (see Figure 38A and B) 
indicate that there is a significantly different response by the
different cells to both growth factors, even in short-term 
experiments. The PC3 cells appear to be remarkably sensitive to 
the action of TGFa and TGFPi, whilst growth of LNCaP cells is 
minimally affected by either factor. Although some studies have 
previously reported that TGFa stimulates growth of LNCaP cells 
after 6-10 days exposure [Wilding et a l ., 1989b; Schuurmans et 
a l ., 1991], no evidence of an early response of this cell line to 
T G F a  has been thus far provided; in particular, Wilding and
colleagues showed that addition of 10 or 20 ng/ml TGFa did not
significantly increase the proliferative activity of LNCaP cells up 
to 3 days exposure [Wilding et a l ., 1989b].
DU 145 cells seem to have a peculiar behaviour. These cells 
respond to TG Fpi, although less than PC3 cells; this confirms 
previous observation by Wilding and colleagues [Wilding et a l ., 
1989a]. TGFPi effects are known to be dependent on culture 
conditions; however, the TGFp data from Wilding appear 
comparable to those reported here in spite of the different
experimental conditions used (respectively, routine IM E M
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medium plus 10% charcoal-stripped, sulphatase-treated FCS vs 
RPMI medium plus 10% FCS in the present work).
Conflicting reports on the effects of both TGFa and EGF on 
growth of DU145 cells exist. Anchorage-independent assays have 
shown that this cell line is stimulated by TGFa [Fernandez-Pol et 
a l.,  1986]; further, a mitogenic effect of EGF on DU145 cells has 
been recently observed [Connolly & Rose, 1991]. In contrast, 
other groups have found that both EGF and TGFa have very little 
effect on either DNA synthesis or tritiated thymidine 
incorporation by DU145 cells [MacDonald et al., 1990]. In the 
present study, after short-term incubation with increasing TGFa  
concentrations in routine culture medium, DU145 cells do not 
exhibit any significant growth stimulation (see Figure 38A).
In a separate set of experiments the growth effects of both
T G F a  (10 and 50 ng/ml) and TGFPi (1 and 5 ng/ml) were
investigated after 48 h and 6 days exposure using DHICT-FCS  
supplemented RPMI medium (see Experimental, Section 5.1.; 
Figures 39 and 40).
Surprisingly, while neither growth factor changes the 
proliferative activity of LNCaP cells, TGFa (50 ng/ml) produces a 
decrease (25%) of growth of DU 145 cells after 6 days. More, in 
PC3 cells, comparison of results from both 48 h and 6 days
experiments with those obtained using routine medium shows 
that the effects of TGFa are completely abolished and that those 
of TGFpi are markedly (about 50%) lessened.
This unexpected evidence may be ascribed to the use of
DHICT-FCS in this second set of experiments; since the molecular
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weight cut-off used for dialysis is of 12 kDa, it is reasonable to 
assume that presence of some as yet unidentified factor, which is 
lost during dialysis, is required for a complete accomplishment of 
both TGFa and TGFpi action. In particular, EGF and IGF-I appear 
to be likely candidates, since both would be readily removed 
from FCS by dialysis. Recent studies have shown that removal of 
EGF from the culture medium markedly reduces the growth 
inhibition induced by administration of TGFpi to cultured benign 
human prostatic epithelial cells [Sutkowski et a l ., 1992]. On the 
other hand, it is recognised that both EGF and TGFa can act in 
synergy with other growth factors [Rozengurt, 1986]; in this 
respect, the absence of IGF-I, which is known to behave as a 
"progression factor" during the cell cycle, may well impede 
completion of the growth stimulatory effects induced by TGFa or 
EGF. This assumption is also supported by the recent evidence 
that IG F-I significantly stimulates DNA sytnthesis in both DU 145 
and PC3 cells, while growth of LNCaP cells appears to be 
unchanged [Iwamura et a l , 1993]. Therefore, the lack of IGF-I 
from the culture medium could result in a noticeable decrease of 
basic proliferative activity of the above androgen-independent 
cells and/or seriously affect growth response of these cells to 
either TGFa or TGFpi.
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4. Steroid Metabolism
4.1. Androgens
Multiple sequential analysis of enzymes of testosterone 
metabolism in LNCaP, DU 145 and PC3 human prostate cancer 
cells has been carried out using a novel chromatographic 
approach [Castagnetta et a l ., 1991a]. The latter allows
measurement of both precursor degradation and rates of produtc 
formation in intact cultured cells, using physiological 
concentrations of radioactive steroids. Two main distinct patterns 
of testosterone metabolism are observed. Androgen receptor 
positive LNCaP and DU145 cells exhibit little oxidation of T to 
A4Ad through the 17pHSD enzyme and a relatively high 5 a -  
reductase (T — >D H T) activity; by contrast, androgen receptor 
negative, hormone unresponsive PC3 cells display extensive 
17pHSD oxidation to yield A4Ad and subsequent production of the 
5 a-reduced derivatives of the 17-keto series, while no 5 a -  
reduction of T to DHT can be detected (see Tables 7 and 8). The 
latter finding is noteworthy. Conversion of T by the 17p H S D  
activity in PC3 cells is remarkably shifted in favour of A4A d 
production (oxidative way), with a consequent formation of 5a - 
Adione. Although the possibility that DHT is quickly oxidised to 
5a-Adione via 17PHSD can not be excluded, this seems unlikely 
since that neither short nor longer incubation times reveal 
measurable DHT formation in this cell line (see Figure 45). 
Additionally, any production of DHT from T is also doubtful
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because no evidence of DHT derivatives, such as 3a/3p-diols, can 
be obtained at any incubation time.
There is overall consensus that 5a-reductase activity is 
distinctly decreased in human prostatic carcinoma with respect 
to both normal and hyperplastic tissues [Bartsch et a l ., 1990; 
K lein  et al., 1991]. Surprisingly, in spite of the decrease of 5a- 
reductase, these studies have found unchanged or even higher 
DHT concentrations in malignant with respect to benign prostate 
tissues, together with significantly higher intratum our 
testosterone levels than in nonmalignant prostate. This finding 
has been interpreted as a consequence of DHT "trapping" in 
nuclei of prostate cancer cells through binding to intact androgen 
receptors [Klein et al., 1991]. This assumption, however, is rather 
unlikely since both the detected DHT concentrations (in the order 
of pmol/mg DNA) and the assessed 5a-reductase levels (in the 
order of nmol/h/mg DNA) are far exceeding the AR binding 
capacity (in the order of fmol/mg DNA).
It ought to be emphasized that these classical enzymology
studies use artificial environments (cell lysates, pH and 
temperature, excess of substrate concentration, cofactors 
addition) and are optimized to yield the maximum conversion
rates for quantitation of a single enzyme activity. Therefore, this 
approach does not allow inspection of enzyme activity in intact 
cells and hence enzymology data are highly unlikely to resemble 
the in vivo condition. The present "live analysis" HPLC system, 
which allows quantitation of both undegraded substrate and 
formation of several metabolic products, may encompass the
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artifacts of classically measured enzymic reactions but, above all, 
may yield direct information about the metabolic direction in 
individual tissues and cells. The present data provide a likely 
explanation of the previously reported accumulation of both T 
and DHT in hormone-responsive prostate tumours [Geller &  
Albert, 19851. In fact, in androgen-responsive LNCaP cells, 
activities of either 17pHSD or 5a-reductase enzymes are directed 
in such a way that both T and DHT accumulate. Conversely, 
unresponsive PC3 cells favour oxidative degradation of T to A4Ad  
and its 5a-reduced derivative 5a-Adione, consequently removing 
the proper 5a-reductase substrate for DHT production. DU 145 
cells behave peculiarly. Like LNCaP, DU 145 cells metabolise 
poorly T and form appreciable DHT but, conversely, they do not 
produce conjugate androgens, as occurs in PC3 cells. The different 
amount of DHT produced by LNCaP and DU 145 cells may be 
accounted for by the remarkable levels of androgen conjugates 
(mostly testosterone) present in LNCaP cells, which eventually 
take testosterone away from any further metabolism.
The situation is further complicated by the fact that human 
prostate might contain several types of 5a-reductase enzyme 
[Rennie et a l 1983; Hudson, 1987]. More importantly, Martini 
and associates [Martini et al., 1990] demonstrated that the rat 
prostate contains two distinct 5a-reductase isoenzymes, having 
differential sensitivity to both ageing and 4-hydroxy-4- 
androstene-3,17-dione (4 0 H -A ), an inhibitor of both 5 a -  
reductase and aromatase prostatic enzymes. The two 5 a -  
reductases individually preside over formation of the 5a-reduced
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metabolites of the 17-OH series (DHT and 3a/3p-diols) and the 
17-keto series. This evidence comes in support of the present 
data suggesting that these two activities may be differently 
expressed and/or regulated in human prostate cancer cell lines.
4.2. Oestrogens
Rates and direction of oestradiol metabolism in LNCaP, 
DU145 and PC3 human prostate cancer cells have been 
investigated using the same RP-HPLC approach employed to 
analyse enzyme activities of testosterone metabolism in these 
systems.
Two opposite patterns of oestradiol metabolism are 
encountered. Androgen receptor positive, hormone responsive 
LNCaP and unresponsive DU145 cells display little degradation of 
labelled E2 and a relatively limited oxidation to E i; by contrast, 
androgen receptor negative, androgen unresponsive PC3 cells 
show extensive conversion of E2 to yield Ej and an appreciable 
formation of 16aO H Ei. This is true at either 24 or 72 h incubation 
(see Tables 9 and 10). Overall, the reductive metabolism appears 
to be highly prevalent in both LNCaP and DU145 cells and 
eventually leads to E2 accumulation; in contrast, the oxidative 
pathway, represented by Ei production, is clearly predominant in 
PC3 cells. This picture is peculiarly cognate to that observed with 
androgens, where oxidation of T to yield A4Ad and its 17keto 
derivatives is particularly evident in PC3 cells, while LNCaP and 
DU 145 cells metabolise T only slowly, producing a relatively high
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proportion of metabolites (D H T and 3a-d io l) through the 
reductive pathway.
Androgen metabolism and content of both benign and 
malignant human prostate tissues have been extensively 
compared by others. However, data in the literature concerning 
metabolic patterns of oestrogens in prostate tissues and cells are 
surprisingly rare [Robinette et a l ., 1978]. This is the first report 
describing the ability of cultured human prostate tumour cells to 
actively metabolise oestrogens in physiological environments. 
Previous studies indicated that prostatic tissues are endowed 
with enzymes of oestrogen metabolism. Early investigations 
revealed that BPH tissues may readily hydrolyse E iS  to Ei 
[Carlstrom et a l , 1980]; in addition, presence of 17J3HSD activity 
was documented in both normal [Acevedo & Goldzieher, 1965a] 
and diseased [Acevedo & Goldzieher, 1965b] human prostate 
gland. Therefore, regulation of the oestrogen milieu in the 
prostate may well involve cleavage of E iS  to Ei and the 
subsequent 17(3-reduction to yield E2 . In a more recent report, 
Orlowski and Clark [Orlowski & Clark, 1988] examined oestrogen 
metabolism in primary cultures of rat ventral epithelial and 
stromal cells using HPLC approach. The authors found that 
epithelial cells exhibit an almost equivalent reductive and 
oxidative 17J3HSD activity, whilst stromal cells preferentially 
form and maintain high levels of biologically active E2 .
The present results are noteworthy in that they clearly 
suggest that pathways of oestrogen and androgen metabolism are 
consistently and differently regulated in human prostate
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carcinoma cell lines according to whether they are hormone- 
sensitive.
5. Effects of Transforming Growth Factors on Metabolism  
of Steroid Hormones
5.1. T estosterone  metabolism
The influence of transforming growth factors on both rates 
and direction of testosterone metabolism in human prostate 
cancer cells has been investigated.
Effects of either TGFa or TGFpi vary markedly depending 
on the cell line studied (see Figures 49 to 51). While TGFa  
enhances the oxidative pathways in both LNCaP and DU 145 cells, 
it has opposite effects on the reductive metabolism of 
testosterone in these two cell lines. Therefore, in LNCaP cells 
T G F a  seems to act as a stimulator of the overall testosterone 
metabolism, whilst in DU145 cells it selectively favours the 
oxidative direction, also to the detriment of the reductive way. 
The effects of TGFPi on LNCaP and DU145 cells, although less 
pronounced, appear to be similar to those of TGFa, apart from a 
limited reduction of the oxidative pathways seen in LNCaP cells. 
In contrast, neither growth factor significantly changed patterns 
of androgen metabolism in PC3 cells, where the metabolic fate of 
testosterone remained dramatically oriented towards oxidation.
It has been previously reported that androgens induce both 
the secretion of a TGFa immunoreactive protein [Wilding et al 
1989b] and the overexpression of EGFR in LNCaP cells
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[Schuurmans et a l.y 1988b]; on the other hand, levels of both 
T G F p i mRNA and TGFp receptors are known to be down- 
modulated by androgens in prostatic tissues [Kyprianou & Isaacs, 
1988; Kyprianou & Isaacs, 1989a]. Therefore, it is conceivable 
that androgen action in LNCaP cells may result in an 
enhancement of TGFa and a reduction of TGFPi actions. This, on a 
metabolic standpoint, would imply an extension of either way of 
testosterone metabolism, leading mainly to higher amounts of 
both DHT and A4Ad available to the cells. The latter metabolite 
could in turn be converted to 5a-Adione and to further 17keto 
androgens (A and EpiA) or, alternatively, serve as substrate for 
aromatase to yield Ei and E2 . Although merely speculative, this 
last possibility is noteworthy because oestrogen effects on 
growth of LNCaP cells are at least equally important to those 
induced by androgens.
The DU 145 cell line represents a peculiar case. Although the 
presence of andogen binding sites is herein supported by both 
ligand binding assay and RT-PCR approaches, these cells fail to 
respond to either androgens (T  and DHT) or oestradiol. In this 
context, it has been proposed that growth of DU 145 cells may be
regulated via an autocrine mechanism, involving also TGFa
[Connolly & Rose, 1991]. In this cell line both TGFa and TGF(3i
produce an increase of the oxidative pathways of testosterone 
metabolism, with a correspondent decrease of the reductive way. 
The potential value of this variation in such a hormone-
unresponsive cell line, however, remains to be elucidated.
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5.2. Oestradiol  metabolism
The effects of both TGFa and TGFp i on oestradiol 
metabolism in human prostate cancer cells have been assessed.
In LNCaP cells (see Figure 52), both TGFa and TGFpi 
produce a reduction of the E2 oxidation to Ei and a consequent 
additional increase of accumulating E2 ; conversely, PC3 cells show 
a further E2 degradation and Ei formation in response to both 
growth factors (see Figure 54). In DU 145 cells, TGFa and TGFpi 
show a tendency to act oppositely, in that the former enhances 
while the latter reduces the oxidative metabolism of E2 (see  
Figure 53).
Although no data are currently available on paracrine 
regulation of oestrogen metabolism in human prostate tissues or 
cells, recent studies have investigated possible influence of 
several factors on 17pHSD activity in human breast tissues and 
mammary carcinoma cells. Firstly, M cNeill and colleagues 
[M cN eill et a l ., 1986b] showed that EGF, TGFs and breast tumour 
homogenates affect 17PHSD activity in human breast adipose 
tissues. Further studies revealed that either breast tumour 
cytosol or human breast fibroblast conditioned medium increase 
the reductive 17pHSD activity in MCF7 mammary carcinoma cells 
[Adams et a l 1988a; Singh et a l., 1989], suggesting that some 
diffusible factor is responsible for this effect. More recently, 
Singh and associates have found that IG F-I stimulates the 
17PHSD conversion of Ei to E2 in MCF7 cells and that this effect is 
strikingly enhanced by the combination of IG F-I and albumin 
[S ingh  et al., 1992]. Furthermore, it has been reported that
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addition of TGFa to nonmalignant human breast tissue in vitro 
significantly increases the reductive pathway of 17pHSD activity 
[Metha & Graves, 1992].
In the present work, both TGFa and TGFpi appear to stress 
the preferential direction of E2 metabolism in either LNCaP 
(reductive) or PC3 (oxidative) cells. This activity is more 
pronounced for TGFa in LNCaP cells and almost equivalent in PC3 
cells. This potentially leads to an increase of E2 accumulation in 
LNCaP cells and a consequent enhancement of the E2 -induced  
growth stimulation. On the other hand, while PC3 cells are 
sensitive to and possess specific cell surface receptor for either 
growth factor, their growth is unaffected by androgens but 
significantly inhibited by E2 ; therefore both TGFa and TGFpi 
would at the same time reinforce the prevalence of Ei formation 
(presumably via autocrine loops) and eventually remove the 
inhibitory influence of E2 . However, the biological value of such a 
noticeable Ei production in PC3 cells remains unclear.
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Although some results of the present work are preliminary 
and others may be difficult to explain, a few major inferences can 
be drawn. They primarily concern the potential role of both 
steroids and transforming growth factors and their receptors in 
the growth regulation and metabolic aptitudes of the human 
prostate cancer cell lines studied.
1. Cell Growth Regulation
The stimulatory effects exerted by both androgens (T  and 
DHT) and oestradiol on the proliferation of LNCaP cells clearly 
indicate, as expected, that this cell line is under an endocrine 
type of growth control.
However, neither T nor DHT induce proliferative activity in 
DU145 cells, despite the presence of apparently intact androgen 
receptors in this cell line (here supported by both ligand binding 
assay and RT-PCR approaches). This seemingly conflicting 
evidence provides relevant, interesting clues to the human 
androgen resistance syndromes. These clin ical entities, 
phenotypically ranging from a complete testicular feminization to 
undervirilized males, are associated with abnormalities of the 
androgen receptors [Griffin, 1991]. The latter include partial or 
complete gene deletions and splicing defects, leading to large- 
scale alterations of the primary structure of receptor, or single 
amino acid substitutions in both the hormone-binding and the 
DNA-binding domains (reviewed by [McPhaul, 1993]). In some
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patients having endocrine profiles and fam ily history of 
androgen resistance, receptor binding can be qualitatively and 
quantitatively normal; in these patients analysis of the androgen 
receptor gene shows an amino acid substitution in the DNA- 
binding domain, yielding a mutant receptor with minimal (if any) 
alteration of ligand binding but unable to activate a target 
reporter gene [Zoppi et a l., 1992]. Although partial deletions or 
larger rearrangements of the X chromosome, where the androgen 
receptor gene is located, occur rarely in human prostate cancer as 
compared to changes in other chromosomes, presence of more 
subtle defects, such as point mutations, may well cause structural 
and functional abnormalities of the receptor. In DU 145 cells, 
where the androgen receptor gene has been found to be normally 
present [Tilley et a l.y 1990], amino acid substitutions in the DNA- 
binding domain may lead to an impaired receptor function, 
without any apparent change of ligand binding characteristics.
Interestingly, the E2 -induced growth inhibition of PC3 cells, 
which may provide a meaningful interpretation on the efficacy of 
oestrogen treatment in androgen-refractory human prostate 
cancer, raises the question as to how E2 action is mediated. In 
this respect, further studies are needed to ascertain whether or 
not the growth inhibition induced by E2 involves different TGF6 
species; thus it is appropriate to determine whether E2 acts 
through a direct, receptor-mediated pathway or by alternative 
paracrine/autocrine mechanisms. Overall, when comparing 
responsive LNCaP to non responsive PC3 cells, transcript levels
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and intensity of staining and both quantitative and qualitative 
status of ER are significantly and consistently different.
The present data also indicate that the three prostate 
cancer cell lines respond differently to the same transforming 
growth factor and that, as far as TGF6 is concerned, this response 
appears to be inversely related to individual characteristics of
androgen sensitivity. Concerning TGFa, the growth effects seem 
to be not proportional to the EGF receptor content of cells; this 
apparent lack of correlation may suggest different levels of 
either endogenous growth factors or growth factor-binding 
proteins, and/or a diverse activity of membrane-bound protein 
kinases.
2. Steroid Metabolism
Overall, the present work consistently indicates that human 
prostate cancer cell lines, having different biochemical and 
biological features, are endowed with distinct aptitudes to
alternatively favour reductive or oxidative patterns of steroid 
metabolism. This evidence is highly reproducible, being found 
using different incubation intervals (24-72 h) and varying 
concentrations of the labelled precursor (0 .5-10xl0 '9M). There is 
a striking similarity between androgen and oestrogen metabolic 
patterns in human prostate cancer cells. This is reflected in a
surprising correspondence between the respective extents of
both oxidative and reductive reactions in androgen and oestrogen 
metabolisms for all three cell lines (see Figure 55).
3 4 7
F igu re 55. Reductive and oxidative pathways of steroid metabolism in 
prostate cancer cells. The diagram compares the relative extent of 
reductive and oxidative pathways of both androgen and oestrogen 
metabolism in LNCaP, DU145 and PC3 cells. For details see text.
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The finding that overall metabolism is remarkably shifted 
in favour of the reductive pathways in both LNCaP and DU 145 
cells, and of the oxidative pathways in PC3 cells, suggests that 
this uneven condition is strictly controlled in either hormone-
dependent or independent cells. Therefore, the variations 
induced by both TGFa and TGFPi on the extent of individual
reactions and, especially, on the overall direction of steroid 
metabolism in prostate tumour cells, although apparently 
moderate, appear worth noting. This could be significant in 
determining the actual concentration of biologically active 
m etabolites, which w ill also be influenced by the
microenvironment composition and the hormonal state of the 
cell.
Further studies are needed to clarify the potential
contribution of the stromal compartment and of other local 
paracrine factors in the regulation of enzyme activities that 
ultimately direct the metabolic fate of biologically active steroids 
in these systems.
3. The Cancer Iceberg
Many reasons may contribute to the lack of progress in 
cancer research. Differences in both methodologies and model 
systems used very often make difficult data comparison and 
combination. However, one major aspect is to my mind critical: 
the shortage of communication in science. I always thought that 
if  all the existing literature could be united in a single (capable
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F ig u re  56. The cancer iceberg. The cancer phenomenon could be 
depicted as an iceberg, whereby clinicians mainly contemplate the 
visible part, while researchers look mostly at the submerged mass. Only 
communication would provide each with a deeper knowledge.
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and capacious) uncorrupted intellect, many of the current 
enigmas in the cancer phenomenon could be, for sure, deciphered 
or, at least, may become more transparent.
Unfortunately, scientists throughout the world tend to 
communicate poorly. Let me say that some of them are often 
inclined to think they hold the truth while the rest of the world 
is wrong! An example in point is given by the problematic 
relationship which frequently isolates clinicians from basic 
researchers. Both of them commonly approach the cancer 
problem from rather separate standpoints; in this respect, as 
sketched in Figure 56, cancer could be depicted as an iceberg,
where clinical views are mainly directed towards the visible part, 
while researchers mostly look at the submerged mass. 
Intuitively, none of them would attain any decisive inference 
without the other's knowledge.
Although the recent progresses in computer science have
markedly eased and expanded the opportunities to gain a rapid 
access to large data collections, a critical problem remains bound 
to humans and to their way of thinking. Sadly, barriers of 
prejudice, also in science, are at times even more impenetrable 
than the economic and social ones.
In a world where the evergrowing fragmentation of
interests, competencies, responsibilities, or even ethnic realities, 
fatally leads to the seclusion of individuals, communication 
appears the only means to survive.
35  1
CITATIONS.
CITATIONS
CITATIONS
Abul-Hajj, Y.J. (1979). Relationship between estrogen receptors, 
1 7 p-hydroxysteroid dehydrogenase and estrogen content in 
human breast cancer. Steroids, 34: 217-225.
Abul-Hajj, Y.J. (1982). Formation of estradiol-17p fatty acyl 17- 
esters in mammary tumors. Steroids, 40: 149-155.
Abul-Hajj, Y.J., Iverson, R., & Kiang, D.T. (1979). Aromatisation of 
androgens by human breast cancer. Steroids, 33: 205-222.
Acevedo, H.F., & Goldzieher, J.W. (1965a). Further studies on the 
metabolism of 4-(4-14C)adrostene-3,17-dione by normal and 
pathological human tissue. Biochimica et Biophysica Acta, 97: 
5 6 4 -57 0 .
Acevedo, H.F., & Goldzieher, J.W. (1965b). The metabolism of 
(14C)estrone by hypertrophic and carcinomatous human prostate 
tissues. Biochimica et Biophysica Acta, 97: 571-578.
Adams, J.B. (1964). Enzymic synthesis of steroid sulphates. II. 
Presence of steroid sulphokinase in human mammary carcinoma 
extracts. Journal o f Clinical Endocrinology and Metabolism, 24: 
98 8 -996 .
Adams, J.B. (1967). Enzymic synthesis of steroid sulphates. V. On 
the binding of estrogens to estrogen sulphotransferase. 
Biochimica et Biophysica Acta, 146: 522-528.
Adams, J.B., & Poulos, A. (1967). Enzymic synthesis of steroid 
sulphates. I I I .  Isolation and properties of estrogen 
sulphotransferase of bovine adrenal glands. B io c h im ic a  et 
Biophysica Acta, 146: 493-508.
353
CITATIONS
Adams, J.B., & Edwards, A.M. (1968). Enzymic synthesis of steroid 
sulphates. V II. Association-dissociation equilibria in the steroid 
alcohol sulphotransferase of human adrenal gland extracts.
Biochimica et Biophysica Acta, 176: 122-140.
Adams, J.B., Pewnim, T., Chandra, D.P., Archibald, L., & Foo, M.S. 
(1979). A correlation between estrogen sulfotransferase levels 
and estrogen receptor status in human primary breast carcinoma. 
Cancer Research, 39: 5124-5126.
Adams, J.B., Hall, R.T., & Nott, S. (1986). Esterification-
deesterification of estradiol by human mammary cancer cells in
culture. Journal o f Steroid Biochemistry, 24: 1159-1162.
Adams, E.F., Newton, C.J., Tait, G.H., Braunsberg, H., Reed, M.J., &  
James, V .H .T . (1988a). Paracrine influence of human breast 
stromal fibroblasts on breast epithelial cells: secretion of a
polypeptide which stimulates reductive 1 7 p -o e s tra d io l  
dehydrogenase activity. International Journal o f Cancer, 42: 119- 
122.
Adams, J.B., Phillips, N.S., &  Hall, R. (1988b). Metabolic fate of 
estradiol in human mammary cancer cells in culture: estrogen 
sulfate formation and cooperativity exhibited by estrogen 
sulfotransferase. Molecular and Cellu lar Endocrinology, 58: 231- 
242.
Adams, J.B., Martyn, P., Lee, F.-T., Phillips, N.S., &  Smith, D.L. 
(1990). Metabolism of 17p-estradiol and the adrenal-derived 
estrogen 5-androstene-3p,17P-diol (hermaphrodiol) in human 
mammary cell lines. Annals o f the New York Academy o f  
Sciences, 595: 93-105.
Adler, A.A. (1934). Active and inactive forms of hormone 
promoting comb growth. N ature , 133: 798.
354
CITATIONS
Adlercreutz, H. (1990). Diet, breast cancer and sex hormone 
metabolism. Annals o f the New York Academy o f Sciences, 595: 
281 -290 .
Adlercreutz, H., Fotsis, T., Heikkinen, R., Dwyer, J.T., Woods, M., 
Goldin, B.R., & Gorbach, S.L. (1982). Excretion of the lignans 
enterolactone and enterodiol and of equol in omnivorous and 
vegetarian postmenopausal women and in women with breast 
cancer. Lancet, ii: 1295-1299.
Adlercreutz, H., Fotsis, T., Hamalainen, E., Bloigu, S., & Ollus, A. 
(1986). Urinary estrogen profile determination in young finnish 
vegetarian and omnivorous women. J o u rn a l o f  S te ro id  
B iochem is try , 24: 289-296.
Adlercreutz, H., Hockerstedt, K., Bannwart, C., Bloigu, S., 
Hamalainen, E., Fotsis, T., & Ollus, A. (1987). Effect of dietary 
components, including lignans and phytoestrogens, on 
enterohepatic circulation and liver metabolism of estrogens and 
on sex hormone binding globulin (SHBG). Journal o f  Steroid  
B io c h e m is try , 27: 1135-1144.
Allen, R.C., Zoghbi, H.Y., Moseley, A.B., Rosenblatt, H.M., &  Belmont, 
J.W. (1992). Methylation of Hpall and Hpal sites near the 
polymorphic CAG repeat in the human-androgen receptor gene 
correlates with X chromosome inactivation. American Journal o f  
Human Genetics, 51: 1229-1239.
Amento, E.P., & Beck, L.S. (1991). TGF-P and wound healing. In: 
Ciba Foundation Symposium 157: Clinical Applications o f  TG F-p.  
G.R. Bock &  J. Marsh (Ed.), pp. 115-129. Chichester: Wiley.
Anderson, D.C. (1974). Sex-hormone-binding globulin. C l in ic a l  
Endocrinology, 3: 69-96.
355
CITATIONS
Anderson, K .M ., & Liao, S. (1968). Selective retention of 
dihydrotestosterone by prostatic nuclei. N atu re ,  219: 277-279.
Anderson, T.J., Ferguson, D.J.P., & Raab, G.M. (1982). Cell turnover 
in the "resting" human breast: influence of parity, contraceptive 
pill, age and laterality. British Journal of Cancer, 46: 376-382.
Andres, J.L., Stanley, K., Cheifetz, S., & Massague, J. (1989). 
Membrane-anchored and soluble forms of betaglycan, a 
polymorphic proteoglycan that binds transforming growth factor- 
p. Journal o f Cell Biology, 109: 3137-3145.
Antakly, T., & Eisen, H.J. (1984). Immunocytochemical localization 
of glucocorticoid receptor in target cells. E n d o c r in o lo g y , 115: 
1984-1989 .
Antoniades, H.N. (1991). PDGF: a multifunctional growth factor. 
In: Clin ical Endocrinology and Metabolism, Vol. 5 (4 ):  G r o w th  
Factors in Endocrinology. D.M. Robertson & A.C. Herington (Ed.), 
pp. 595-613. London: Bailliere Tindall.
Antonio, P., Gabaldon, M., Lacomba, T., & Juan, A. (1974). Effect of 
the antiestrogen nafoxidine on the occurrence of estrogen- 
dependent renal tumours in hamster. H o rm o n e  M e ta b o l is m  
Research, 6: 522-524.
Anzai, Y., Gong, Y., Holinka, C.F., Murphy, L.J., Murphy, L.C., 
Kuramoto, H., & Gurpide, E. (1992). Effects of transforming 
growth factors and regulation of their mRNA levels in two human 
endometrial adenocarcinoma cell lines. Journa l o f  Steroid  
Biochemistry and Molecular Biology, 42: 449-455.
356
CITATIONS
Anzano, M.A., Roberts, A.B., Smith, J.M., Spom, M.B., &  De Larco, 
J.E. (1983). Sarcoma growth factor from conditioned medium is 
composed of both type alpha and type beta transforming growth 
factors. Proceedings of the National Academy o f Sciences o f  The 
United States of America., 80: 6264-6268.
Arafah, B.M., Gullino, P.M., Manni, A., & Pearson, O.H. (1980). 
Effect of ovariectomy on hormone receptors and growth of N- 
nitrosomethylurea-induced mammary tumours in the rat. C a n c e r  
Research, 40: 4628-4632.
Armenian, H.K., Lilienfeld, A.M., Diamond, E.L., &  Bross, I.D.J. 
(1974). Relation betwee benign prostatic hypertrophy and cancer 
of the prostate. Lancet, ii: 115-117.
Armstrong, B., & Doll, R. (1975). Environmental factors and cancer 
incidence and mortality in different countries, with special 
reference to dietary practices. International Journal o f  Cancer, 
15: 617-631.
Arrick, B.A., Korc, M., & Derynck, R. (1990). Differential regulation 
of expression of three transforming growth factor p species in 
human breast cancer cell lines by estradiol. Cancer Research, 50: 
299-303 .
Arteaga, C.L., Tandon, A.K., Von Hoff, D.D., &  Osborne, C.K. (1988). 
Transforming growth factor p: potential autocrine growth
inhibitor of estrogen receptor-negative human breast cancer 
cells. Cancer Research, 48: 3398-3904.
Ausubel, F.M., Brent, R., Kingston, R.E., Moore, D.D., Seidman, J.G., 
Smith, J.A., & Struhl, K. (Ed.). (1994). Current Protocols in 
M olecular Biology. New York: Green Publishing Associates and 
Wiley-Interscience
357
CITATIONS
Bajaj, M., Waterfield, M.D., Schlessinger, J., Taylor, W., & Blundell, 
T.L. (1987). On the tertiary structure of the extracellular domains 
of the EGF and insulin receptors. Biochimica et Biophysica Acta, 
916: 220-226.
Balkwill, F.R. (1989). Cytokines in cancer therapy. Oxford: Oxford 
University Press.
Bardin, C.W., Bullock, L., Schneider, G., Allison, J.E., & Stanley, A.J. 
(1970). Pseudoermaphrodite rat: end organ insensitivity to
testosterone. Science, 16: 1136-1137.
Barnes, D.M., Skinner, L.G., & Ribeiro, G.G. (1979). Triple hormone- 
receptor assay: a more accurate predictive tool for the treatment 
of advanced breast cancer .British Journal o f Cancer, 40: 682-686.
Barrandon, Y., & Green, H. (1987). Cell migration is essential for 
sustained growth of keratinocyte colonies: the roles of
transforming growth factor-a and epidermal growth factor. C e l l ,  
50: 1131-1137.
Barrett-Lee, P., Travers, M., Luqmani, Y., & Coombes, R.C. (1990). 
Transcripts fro transforming growth factors in human breast 
cancer: clinical correlates. British Journal o f Cancer, 61: 612-617.
Bartsch, W., Knabbe, C., & Voigt, K.D. (1983). Regulation and 
compartmentalization of androgens in rat prostate and muscle. 
Journal o f  Steroid Biochemistry, 19: 929-937.
Bartsch, W., Kozak, I., Gorenflos, P., Becker, H., &  Voigt, K.D. 
(1986). Concentrations of 3(3-hydroxy androgens in epithelium 
and stroma of benign hyperplastic and normal human prostate. 
The Prostate, 8: 3-10.
358
CITATIONS
Bartsch, G., Keen, F., Daxenbichler, G., Marth, C., Margreiter, R., 
Briinger, A., Sutter, T., & Rohr, H.P. (1987). Correlation of 
biochemical (receptors, endogenous tissue hormones) and 
quantitative morphologic (stereologic) findings in normal and 
hyperplastic human prostates. Journal of  Urology, 137: 559-564.
Bartsch, W., Klein, H., Schiemann, U., Bauer, H.W., & Voigt, K.D.
(1990). Enzymes of androgen formation and degradation in the 
human prostate. Annals of  the New York Academy o f  Sciences, 
595: 53-66.
Bascom, C.C., Wolfshohl, J.R., Coffey, R.J., Madisen, L., Webb, N.R., 
Purchio, A.R., Derynck, R., & Moses, H.L. (1989a). Complex 
regulation of transforming growth factor-pi, (52, and p3 mRNA  
expression in mouse fibroblasts and keratinocytes by 
transforming growth factors p i and p2. Molecular  and C el lu lar  
Biology,  9: 5508-5515.
Bascom, C.C., Sipes, N.J., Coffey, R.J., & Moses, H.L. (1989b). 
Regulation of epithelial cell proliferation by transforming growth 
factors. Journal of  Cellular Biochemistry, 39: 25-32.
Bauknecht, T., Kohler, M., Janz, I., & Pfleiderer, A. (1989). The 
occurrence of epidermal growth factor receptors and the 
characterisation of EGF-like factors in human ovarian, 
endometrial, cervical and breast cancer. Journa l  o f  Cancer  
Research and Clinical Oncology, 115: 193-199.
Baxter, R.C. (1986). The somatomedins: insulin-like growth 
factors. Advances in Clinical Chemistry, 25: 49-115.
Baxter, R.C., & Martin, J.L. (1989a). Binding proteins for the 
insulin-like growth factors: structure, regulation and function. 
Progress in Growth Factor Research, 1: 49-68.
359
CITATIONS
Baxter, R.C., & Martin, J.L. (1989b). Structure of the M r  140,000  
growth hormone-dependent insulin-like growth factor binding 
protein complex: determination by reconstitution and affinity 
labeling. Proceedings of  the National Academy of  Sciences of  The 
United States of  America., 86: 6898-6902.
Beato, M. (1989). Gene regulation by steroid hormones. Cel l ,  56: 
335-344 .
Beatson, G.T. (1896). On the treatment of inoperable cases of 
carcinoma of the mammary. Suggestion for a new method with 
illustrative cases. Lancet,  ii: 104-107.
Bell, G.I., Gerhard, D.S., Fong, N.M., Sanchez-Pescador, R., &  Rail, 
L.B. (1985). Isolation of the human insulin-like growth factor 
genes: insulin-like growth factor I I  and insulin genes are
contiguous. Proceedings of  the National Academy of  Sciences of  
The United States o f  America., 82: 6450-6454.
Beranek, P.A., Folkerd, E.J., Newton, C.J., Reed, M.J., Ghilchik, M.W., 
& James, V .H .T . (1985). The relationship between 17(3- 
hydroxysteroid dehydrogenase and breast tumour site and size. 
International Journal of  Cancer, 36: 685-688.
Bergkvist, L., Adami, H.-O., Persson, I., Hoover, R., &  Schairer, C. 
(1989a). The risk of breast cancer after estrogen and estrogen- 
progestin replacement. New England Journal o f  Medicine, 321: 
293 -297 .
Bergkvist, L., Adami, H.-O., Persson, I., Bergstrom, R., &  Krusemo, 
U.B. (1989b). Prognosis after breast cancer diagnosis in women 
exposed to estrogen and estrogen-progestogen replacement 
therapy. American Journal of  Epidemiology, 130: 221-228.
360
CITATIONS
Bern, H.A. (1963). Epithelial metaplasia in the prostate and other 
genital structures of male mammals. National  Cancer Institute 
M o n o g r a p h s , 12: 43-45.
Berns, E.M.J.J., de Boer, W., & Mulder, E. (1986). Androgen- 
dependent growth regulaation and release of specific protein(s) 
by the androgen receptor containing human prostate tumor cell 
line LNCaP. The Prostate, 9: 247-259.
Berry, S.J., & Isaacs, J.T. (1984). Comparative aspects of prostatic 
growth and androgen metabolism with aging in the rat versus 
the dog. E ndocr ino logy , 114: 511-520.
Betscholtz, C., Johnsson, A., Heldin, C.-H., Westermark, B., Lind, R., 
Urdea, M.S., Eddy, R., Shows, T.B., Philpott, K., Mellor, A.L., Knott, 
T.J., &  Scott, J. (1986). cDNA sequence and chromosomal 
localization of human platelet-derived growth factor A-chain and 
its expression in tumor cell lines. N ature ,  320: 695-699.
Beug, H., Hayman, M.J., &  Vennstrom, B. (1988). Mutational 
analysis of \ - e r b B  oncogene function. In: Oncogenes and Growth 
Control.  P Kahn & T Graf (Ed.), pp. 85-92. Berlin: Springer-Verlag.
Binoux, M., Hardouin, S., Lassare, C., &  Hossenlopp, P. (1982). 
Evidence for production by the liver of two IGF binding proteins 
with similar molecular weights but different affinities for IG F-I 
and II.  Their relationship with serum and cerebrospinal fluid 
binding proteins. Journal  o f  C l in ic a l  Endocr ino logy  and  
M e tab o l ism ,  55: 600-602.
Blacklock, N.J. (1982). The development and morphology of the 
prostate. In: The Endocrinology of  Prostate Tumours. R Ghanadian 
(Ed.), pp. 1-14. Lancaster: MTP Press.
361
CITATIONS
Blacklock, N.J., & Bouskill, K. (1977). The zonal anatomy of the 
prostate in man and the Rhesus monkey. Urological Research, 5: 
163-167.
Bland, K.I. (1987). Risk factors as an indicator for breast cancer 
screening in asymptomatic patients. M a tu r i t a s , 9: 135-161.
Blankenstein, M.A., Maitimu Smeele, I., Donker, G.H., Daroszewski, 
J., Milewicz, A., & Thijssen, J.H.H. (1992). Tissue androgens and 
the endocrine autonomy of breast cancer. Journal o f  Steroid 
Biochemistry and Molecular Biology ,43 : 167-171.
Blasband, A.J., Gilligan, D.M., Winchell, L.F., Wong, S.T., Luetteke, 
N.C., Rogers, K.T., &  Lee, D.C. (1990). Expression of the TGF-alpha 
integral membrane precursor induces transformation of NRK  
cells. Oncogene, 5: 1213-1221.
Bolton, N.J., Lahtonen, R., Hammond, G.L., &  Vihko, R. (1981). 
Distribution and concentrations of androgens in epithelial and 
stromal compartments of the human benign hypertrophic 
prostate. Journal o f  Endocrinology, 90: 125-131.
Bonney, R.C., Reed, M.J., Davidson, K., Beranek, P.A., &  James, 
V.H .T . (1983a). The relationship between 17p-hydroxysteroid  
dehydrogenase activity and oestrogen concentration in human 
breast tumours and in normal breast. Clin ica l  Endocrinology,  19: 
727-739 .
Bonney, R.C., Reed, M.J., & James, V.H.T. (1983b). Inhibition of 
1 7 p-hydroxysteroid dehydrogenase activ ity  in human 
endometrium by adrenal androgens. J o u rn a l  o f  Stero id  
Biochemistry,  18: 59-64.
362
CITATIONS
I
Bordin, S., & Petra, P.H. (1980). Immunocytochemical localization 
of the sex steroid-binding protein of plasma in tissues of the 
adult monkey Macaca nemestrina. Proceedings o f  the National  
Academy o f  Sciences o f  The United States of  America., 77: 5678- 
5683.
Bosland, M.C. (1992). Animal models for the study of prostate 
carcinogenesis. Journal o f  Cell Biochemistry, 16H: 89-98.
Bosland, M.C., Prinsen, M.K., & Kroes, R. (1983). Adenocarcinoma 
of the prostate induced by N-nitroso-N-methylurea in rats 
pretreated with cyproterone acetate and testosterone. C a n c e r  
Letters ,  18: 69-78.
Bosland, M.C., Prinsen, M.K., Dirksen, T.J., & Spit, B.J. (1990). 
Characterization of adenocarcinomas of the dorsolateral prostate 
induced in Wistar rats by N-methyl-N-nitrosourea, 7,12- 
dimethylbenz(a)anthracene, and 3,2'-dimethyl-4-aminobiphenyl, 
following sequential treatment with cyproterone acetate and 
testosterone proprionate. Cancer Research, 50: 700-709.
Bowman, S.P., Barnes, D.M ., & Blacklock, N.J. (1985). A mini­
column method for routine measurement of human prostatic 
androgen receptors. Journal  o f  Steroid Biochemistry,  23: 421- 
430.
Bowman, S.P., Barnes, D.M., Blacklock, N.J., &  Sullivan, P.J. (1986). 
Regional variation of cytosol androgen receptors throughout the 
diseased human prostate gland. The Prostate, 8: 167-180.
Boyd, F.T., & Massague, J. (1989). Transforming growth factor-p 
inhibition of epithelial cell proliferation linked to the expression 
of a 53-kD membrane receptor. Journal o f  Biological Chemistry,  
264: 2272-2278.
363
CITATIONS
Boyle, P., & Zaridze, D.G. (1993). Risk factors for prostate and 
testicular cancer. European Journal of  Cancer, 2 9 A: 1048-1055.
Brachmann, R., Lindquist, P.B., Nagashima, N., Kohr, W., Lipari, T., 
Napier, M., & Derynck, R. (1989). Transmembrane TGF-alpha 
precursors activate EGF/TGF-alpha receptors. Cell,  56: 691-700.
Bradford, M .M . (1976). A rapid and sensitive method for the 
quantitation of microgram quantities of protein utilizing the 
principle of protein-dye binding. Analy t ica l  Biochemistry,  72: 
248 -253 .
Bradlow, H.L. (1982). A reassessment of the role of breast tumor 
aromatization. Cancer Research, 42: 3382S-3386S.
Bradlow, H.L., Hershcopf, R.J., Martucci, C.P., &  Fishman, J. (1985). 
Estradiol 16a-hydroxylation in the mouse correlates with 
mammary tumor incidence and presence of murine mammary 
tumor virus: a possible model for the hormonal etiology of breast 
cancer in humans. Proceedings of  the N at iona l  Academy o f  
Sciences o f  The United States of  America., 82: 6295-6299.
Bradlow, H.L., Telang, N.T., Osborne, M.P., &  Michnovicz, J.J. 
(1991). Selective induction of cytochrome P450 enzymes in the 
prevention of breast cancer. In: Serono Symposia Publications  
f rom Raven Press, Vol. 74: The New Biology of  Steroid Hormones. 
R.H. Hochberg & F. Naftolin (Ed.), pp. 125-143. New York: Raven 
Press.
Breslow, N., Chan, C.W., Dhom, G., Drury, R.A.B., Franks, L.M ., 
Gellei, B., Lee, Y.S., Lundberg, S., Sparke, B., Sternby, N.H., &  
Tulinius, H. (1977). Latent carcinoma of prostate at autopsy in 
seven areas. International Journal of Cancer, 20: 680-688.
364
CITATIONS
Brewer, M.T., Stetler, G.L., Squires, C.H., Thompson, R.C., Busby, 
W .T., & Clemmons, D.R. (1988). Cloning, characterization and 
expression of a human insulin-like growth factor binding protein. 
Biochemical and Biophysical Research Communications, 152: 
1289-1297.
Brinkmann, A.O., Faber, P.W., van Rooij, H.C.J., Kuiper, G.G.J.M., Ris,
C., Klaassen, P., van der Korput, J.A.G.M., Voorhorst, M .M ., van 
Laar, J.H., Mulder, E., & Trapman, J. (1989). The human androgen 
receptor: domain structure, genomic organization and regulation 
of expression. Journal of  Steroid Biochemistry, 34: 307-310.
Brinton, L.A., Hoover, R., & Fraumeni, J.F. (1983). Epidemiology of 
minimal breast cancer. Journal of  American Medical Association, 
28: 483-487.
Brinton, L.A., Hoover, R., & Fraumeni, J.F. (1986). Menopausal 
estrogens and breast cancer risk: an expanded case-control study. 
British Journal of  Cancer, 54: 825-832.
Brisson, J., Verreault, R., Morrison, A.S., Tennina, S., &  Meyer, F.
(1989). Diet, mammographic features of breast tissue, and breast 
cancer risk. American Journal of  Epidemiology, 130: 14-24.
British Prostate Study Group (1979). Evaluation of plasma 
hormone concentration in relation to staging in patients with 
prostate cancer. British Journal of  Urology, 51: 382-389.
Brodie, A.M.H., Coombes, R.C., & Dowsett, M. (1987). Aromatase 
inhibitors: basic and clinical studies. J ourna l  o f  Steroid
B iochem istry , 27: 899-903.
Brolin, J., Skoog, L., &  Ekman, P. (1992). Immunohistochemistry 
and biochemistry in detection of androgen, progesterone and 
estrogen receptors in benign and malignant human prostatic 
tissue. The Prostate, 20: 281-295.
365
CITATIONS
Brooks, S.C., Christensen, C., Meyers, S., Corombos, J., &  Pack, B.A. 
(1983). Endocrine implications of endometrial estrogen 
sulfurylation. In: Steroids and Endometrial Cancer. V.M . Jasonni, 
I. Nenci, &  C. Flamigni (Ed.), pp. 145-155. New York: Raven Press.
Brown, P.D., Wakefield, L.M., Levinson, A.D., & Sporn, M.B. (1990). 
Physicochemical activation of recombinant latent transforming 
growth factor-betas 1, 2, and 3. Growth Factors, 3: 35-43.
Bruchovsky, N., & Wilson, J.D. (1969). The intracellular binding of 
testosterone and 5 a -a n d ro s ta n -17|3-ol-3-one by rat prostate. 
Journal o f  Biological Chemistry, 243: 5953-5960.
Bruchovsky, N., Lesser, B., van Doom, E., &  Craven, S. (1975). 
Hormonal effects on cell proliferation in rat prostate. V i t a m in s  
and Hormones, 33: 61-102.
Bruchovsky, N., &  Lieskovsky, G. (1979). Increased ratio 5a - 
reductase:3aP-hydroxysteroid dehydrogenase activities in the 
hyperplastic human prostate. Journal o f  Endocrinology, 80: 289- 
301.
Bruchovsky, N., Rennie, P.S., Batzold, F., Goldenberg, S.L., Fletcher, 
T., &  McLoughlin, M. (1988). Kinetic parameters of 5a-reductase 
in stroma and epithelium of normal, hyperplastic and 
carcinomatous human prostate. Journal o f  Cl inical Endocrinology  
and Metabolism, 67: 806-816.
Bui, Q.D., & Weisz, J. (1988). Identification of microsomal, organic 
hydroperoxide-dependent catechol estrogen form ation: 
comparison with NADPH-dependent mechanism. P h a r m a c o lo g y ,  
36: 356-364.
366
CITATIONS
Buirchell, B.J., & Hahnel, R. (1975). Metabolism of estradiol-17p in 
human endometrium during the menstrual cycle. Journa l  o f  
Steroid Biochemistry, 6: 1489-1494.
Bulbrook, R.D., Moore, J.W., Allen, B.S., Gravelle, I.H., Hayward, J.L., 
& Wang, D.Y. (1988). Sex-hormone-binding globulin and the 
natural history of breast cancer. Annals o f  the New York 
Academy o f  Sciences, 538: 248-256.
Bulbrook, R.D., Leake, R.E., & George, W.D. (1989). Oestrogens in 
the initiation and promotion of breast cancer. In: Oestrogen and  
the Human Breast. J.S. Beck (Ed.), 95B, pp. 67-76. Edinburgh: 
Royal Society of Edinburgh.
Burwen, S.J., & Jones, A.L. (1987). The association of polypeptide 
hormones and growth factors with the nuclei of target cells. 
Trends in Biochemical Sciences, 12: 159-162.
Buttyan, R., Zakeri, Z., Lockshin, R., &  Wolgemuth, D. (1988). 
Cascade induction of c-fos, c-myc and heat shock 70K transcripts 
during regression of the rat ventral prostate. M o l e c u l a r  
Endocrinology,  2: 650-657.
Byers, T., &  Graham, S. (1984). The epidemiology of diet and 
cancer. Advances in Cancer Research, 41: 1-69.
Cabot, A.T. (1896). The question of castration for enlarged 
prostate. Annals of  Surgery, 24: 265-309.
Camps, J.L., Chang, S.M., Hsu, T.C., Freeman, M.R., Hong, S.J., Zhau, 
H.E., von Eschenbach, A.C., & Chung, L.W.K. (1990). Fibroblast- 
mediated acceleration of human epithelial tumor growth in vivo. 
Proceedings of the National Academy of  Sciences o f  The United 
States o f  America., 87: 75-79.
367
CITATIONS
Cano, A., Coffer, A.I., Adatia, R., Millis, R.R., Rubens, R.D., &  King, 
R.J.B. (1986). Histochemical studies with an estrogen receptor- 
related protein in human breast tumors. Cancer  Research,  46: 
64 75 -6 48 0 .
Carlstrom, K.H., Skoldefors, H., & Tollbom, O.E. (1980). Metabolism 
of estrone sulfate by benign prostatic hyperplasia in vitro. 
Scandinavian Journal of  Urology and Nephrology, 14: 135-137.
Carruba, G., Rinaldi, F., Cassetti, A.M., Farruggio, R., Montesanti, A., 
Liquori, M., &  Castagnetta, L. (1994). 17p-HSD activity in relation 
to HS status of human cancer cells and its modulation by growth 
factors. In: Advances in Steroid Analysis, Vol. 6. S. Gorog (Ed.), 
pp. 357-363. Budapest: Akademiai Kiado.
Carson-Jurica, M.A., Schrader, W.T., & O'Malley, B. (1990). Steroid 
receptor family: structure and function. Endocrine Reviews, 11: 
201 - 220 .
Carter, H.B., &  Coffey, D.S. (1990). The prostate: an increasing 
medical problem. The Prostate, 16: 39-48.
Castagnetta, L., D'Agostino, G., Lo Casto, M., Traina, A., &  Leake, 
R.E. (1981). Breast cancer: a comparison of response to endocrine 
therapy and oestrogen excretion patterns including unusual 
metbolites. British Journal of  Cancer, 44: 670-674.
Castagnetta, L., Lo Casto, M., Mercadante, T., Polito, L., Cowan, S., &  
Leake, R.E. (1983). Intra-tumoural variation of oestrogen 
receptor status in endometrial cancer. British Journal o f  Cancer, 
47: 261-267.
Castagnetta, L., Traina, A., Ciaccio, M., Carruba, G., Polito, L., & Di 
Carlo, A. (1985). Modulation of oestrogen excretion profiles by 
adjuvant chemotherapy in pre- and postmenopausal breast 
cancer. Journal of  Steroid Biochemistry, 23: 1115-1122.
368
CITATIONS
Castagnetta, L., Carruba, G., Rossi, R., Calabro, M., Polito, L., Traina,
A., & Palazzotto, G. (1986a). Steroid excretion patterns in relation 
to the status of hormone-sensitivity and the prognosis of 
endometrial and breast cancer. Journal o f  Experimental and  
Clinical Cancer Research, 5: 421-425.
Castagnetta, L., Granata, O.M., Lo Casto, M., Miserendino, V., Calo, 
M., &  Carruba, G. (1986b). Estrone conversion rates by human 
endometrial cancer cell lines. Journal of  Steroid Biochemistry, 25: 
803-809 .
Castagnetta, L., Granata, O.M., Lo Casto, M., Mitchell, F., D'Agostino, 
G., & O'Hare, M. (1986c). Steroid profiles and optimization of HPLC 
chromatographic analytic procedure. Annals of  the New York 
Academy o f  Sciences, 464: 316-330.
Castagnetta, L., Lo Casto, M., Granata, O.M., Calabro, M., Ciaccio, M., 
& Leake, R.E. (1987a). Soluble and nuclear oestrogen receptor 
status of advanced endometrial cancer in relation to subsequent 
clinical prognosis. British Journal of  Cancer, 55: 543-546.
Castagnetta, L., Traina, A., Di Carlo, A., Latteri, A.M., Carruba, G., &  
Leake, R.E. (1987b). Heterogeneity of soluble and nuclear 
oestrogen receptor status of involved nodes in relation to 
primary breast cancer. European Journal o f  Cancer and Clinical  
Oncology,  23: 31-35.
Castagnetta, L., Traina, A., Di Carlo, A., Carruba, G., Lo Casto, M., &  
Leake, R.E. (1989b). Do multiple oestrogen receptor asays give 
significant additional information for the management of breast 
cancer? British Journal of  Cancer, 59: 636-638.
369
CITATIONS
Castagnetta, L., Carruba, G., Granata, O.M., Lo Casto, M., Arcuri, F., 
Mesiti, M ., &  Pavone-Macaluso, M. (1990). Prostate long-term 
epithelial cell lines: biological and biochemical features. Annals of  
the New York Academy of  Sciences, 595: 149-164.
Castagnetta, L., Granata, O.M., Lo Casto, M., Calabro, M., Arcuri, F., 
& Carruba, G. (1991a). Simple approach to measure metabolic 
pathways of steroids in living cells. Journal o f  Chromatography, 
572: 25-39.
Castagnetta, L., Carruba, G., Calabro, M., Polito, L., Blasi, L., &  
Pavone-Macaluso, M. (1991b). Androgen receptor assays in 
specimens of prostatic tissue obtained by transurethral resection 
and transvesical adenomectomy. Urological  Research,  19: 337- 
341.
Castagnetta, L., Carruba, G., Lo Casto, M., Arcuri, F., Calabro, M., 
Fecarotta, E., Cacciatore, M., & Pavone Macaluso, M. (1991c). 
Lessons from in vitro studies on human and canine prostate 
epithelial cell lines. In: EORTC Genitourinary Group Monograph 10 
- Urological Oncology: Reconstructive Surgery, Organ Conservation 
and Restoration o f  Function. P.H. Smith & M. Pavone-Macaluso 
(Ed.), 370, pp. 225-236. New York: Wiley-Liss.
Castagnetta, L., Carruba, G., Fecarotta, E., Lo Casto, M., Cusimano, 
R., & Pavone-Macaluso, M. (1992a). Soluble and nuclear type I 
and I I  androgen-binding sites in benign hyperplasia and cancer 
of the human prostate. Urological Research, 20: 127-132.
Castagnetta, L., Traina, A., Carruba, G., Fecarotta, E., Palazzotto, G., 
& Leake, R.E. (1992b). The prognosis of breast cancer patients in 
relation to the oestrogen receptor status of both primary disease 
and involved nodes. British Journal of  Cancer, 65: 167-170.
370
CITATIONS
Castagnetta, L., Granata, O.M., Polito, L., Blasi, L., Cannella, S., &  
Carruba, G. (1994). Different conversion metabolic rates of 
testosterone are associated to hormone-sensitive status and 
-response of human prostate cancer cells. Journal o f  Steroid  
B iochem is try , 49: (in press).
Catelli, M.-G., Binart, N., Vourc'h, C., Devin, J., &  Baulieu, E.E.
(1990). Possible functional interaction between steroid hormone 
receptors and heat shock protein Mr 90,000 (hsp90). In:
Activation o f  Hormone and Growth Factor Receptors. M.N. Alexis 
& C.E. Sekeris (Ed.), pp. 239-256. The Netherlands: Kluwer 
Academic Publishers.
Chaisiri, N., & Pierrepoint, C.G. (1980). Examination of the 
distribution of oestrogen receptor betwqeen stromal and 
epithelial compartments of the canine prostate. The Prostate, 1: 
357-366 .
Chang, C., Chodak, G., Sarac, E., Takeda, H., &  Liao, S. (1989). 
Androgen receptor: im m unolocalization  and m R N A
characterization. Journal of  Steroid Biochemistry, $ A: 311-313.
Chang, S.M ., &  Chung, L.K .W . (1989). Interaction between 
prostatic fibroblast and epithelial cells in culture: role of 
androgens. Endocrinology,  125: 2719-2727.
Chang, W., Upton, C., Hu, S.-L., Purchio, A.F., &  McFadden, G. 
(1987). The genome of shope fibroma virus, a tumorigenic 
poxvirus, contains a growth factor gene with sequence similarity 
to those encoding epidermal growth factor and transforming 
growth factor alpha. Molecular and Cellular B io lo g y , !  \ 535-540.
371
CITATIONS
Chegini, N., & Rao, C.V. (1985). Epidermal growth factor binding to 
amnion, chorion, decidua and placenta from mid- and term 
pregnancy: quantitative light microscopy autoradiographic
studies. Journal o f  Clinical Endocrinology and Metabolism, 61: 
5 29 -5 35 .
Cheifetz, S., Like, B., & Massague, J. (1986). Cellular distribution of 
type I and type II  receptors for transforming growth factor-p.
Journal of  Biological Chemistry, 261: 9972-9978.
Cheifetz, S., Weatherbee, J.A., Tsang, M.L.S., Anderson, J.K., Mole, 
J.E., & Massague, J. (1987). The transforming growth factor-p 
system, a complex pattern of crossreacting ligands and receptors. 
Cel l ,  48: 409-415.
Cheifetz, S., Andres, J.L., & Massague, J. (1988a). The transforming 
growth factor-p receptor type I I I  is a membrane proteoglycan. 
Domain structure of the receptor. Journal of  Biological Chemistry, 
263: 16984-16991.
Cheifetz, S., Ling, N., Guillemin, R., &  Massagu6, J. (1988b). A 
surface component on GH3 pituitary cells that recognizes 
transforming growth factor-p, activitn and inhibin. Journal  o f  
Biological Chemistry, 263: 17225-17228.
Cheifetz, S., & Massague, J. (1989). Transforming growth factor-b 
(TGF-b) receptor proteoglycan. Cell surface expression and ligand 
binding in the absence of glycosaminoglycan chains. Journal o f  
Biological Chemistry, 264: 12025-12028.
Chen, T.J., &  Leavitt, W.W. (1979). Nuclear progesterone receptor 
in hamster uterus: measurement by [3H]progesterone exchange 
during the estrous cycle. Endocrinology,  104: 1588-1597.
372
CITATIONS
Chenu, C., Pfeilschifter, J., Mundy, G.R., & Roodman, G.D. (1988). 
Transforming growth factor (3 inhibits formation of osteoclast-like 
cells in long-term human marrow cultures. Proceedings o f  the 
National Academy of Sciences of The United States of  America., 
85: 5683-5687.
Chung, L.W.K., & Coffey, D.S. (1978). Androgen glucuronide. I. 
Differences in its formation by human normal and benign 
hyperplastic prostates. Investigative Urology, 15: 385-388.
Chung, L .K .W ., & Cunha, G.R. (1983). Stromal-epithelial 
interactions. II. Regulation of prostatic growth by embryonic 
urogenital sinus mesenchyme. The Prostate, 4: 503-511.
Chung, L.K.W ., Matsuura, J., & Runner, M .N . (1984). Tissue 
interactions and prostatic growth. I. Induction of adult mouse 
prostatic hyperplasia by fetal urogenital sinus implants. B io lo g y  
o f  Reproduction, 31: 155-163.
Chung, L.W.K., Gleave, M.E., Hsieh, J.-T., Hong, S.-J., &  Zhau, H.E.
(1991). Reciprocal mesenchymal-epithelial interaction affecting 
prostate tumour growth and hormonal responsiveness. C a n c e r  
Surveys, 11: 91-121.
Ciocca, D.R., & Luque, E.H. (1991). Immunological evidence for the 
identity between the hsp27 estrogen-regulated heat shock 
protein and the p29 estrogen-receptor associated protein in 
breast and endometrial cancer. Breast Cancer Research and  
T re a tm e n t , 20: 33-42.
Claesson-Welsh, L., Hammacher, A., Westermark, B., Heldin, C.-H., 
&  Nister, M. (1989). Identification and structural analysis of the 
A-type receptor for platelet-derived growth factor. Journal  o f  
Biological Chemistry, 264: 1742-1747.
373
CITATIONS
Clark, J.H., Paszko, Z., & Peck, EJ.Jr. (1977). Nuclear binding and 
retention of the receptor estrogen complex: relation to the 
agonistic and antagonistic properties of estriol. E n d o c r i n o l o g y , 
100: 91-96.
Clark, J.H., & Peck, E.J.Jr. (1979). Characteristics of cytoplasmic 
and nuclear receptor forms. In: Monographs on Endocrinology  
Vol. 14: Female Sex Steroid Receptors and Function. F. Gross, A. 
Labhart, T. Mann, & J. Zander (Ed.), pp. 46-69. Berlin: Springer- 
Verlag.
Coffer, A.E., Lewis, K.M., Brockas, A.J., &  King, R.J.B. (1985). 
Monoclonal antibodies against a component related to soluble 
estrogen receptors. Cancer Research, 45: 3686-3693.
Coffey, R.J., Derynck, R., Wilcox, J.N., Bringman, T.S., Goustin, A.S., 
Moses, H.L., & Pittelkow., M.R. (1987). Production and
autoinduction of transforming growth factor-alpha in human 
keratinocytes. N ature ,  328: 817-820.
Coffey, R.J., Bascom, C.C., Sipes, N.J., Graves-Deal, R., Weissman, 
B.E., & Moses, H.L. (1988). Selective inhibition of growth-related 
gene expression in murine keratinocytes by transforming growth 
factor p .Molecular and Cellular Biology, 8: 3088-3093.
Cohen, K.L., & Nissley, S.P. (1976). The serum half-life of 
somatomedin activity. Evidence for growth hormone-dependence. 
Acta Endocrinologica, 83: 243-268.
Cohen, S. (1962). Isolation of a mouse submaxillary gland protein 
accelerating incisor eruption and eyelid opening in the new-born 
animal. Journal of  Biological Chemistry, 237: 1555-1562.
Cohen, S. (1965). The stimulation of epidermal proliferation by a 
specific protein (EGF). Developmental Biology, 12: 394-407.
374
CITATIONS
Colditz, G.A., Stampfer, M.J., Willet, W.C., Hennekens, C.H., Rosner,
B., & Speizer, F.E. (1990). Prospective study of estrogen 
replacement therapy and risk of breast cancer in postmenopausal 
women. Journal o f  the American Medical Association, 264: 2648- 
2653.
Coleman, S., Silberstein, G.B., & Daniel, C.W. (1988). Ductal 
morphogenesis in the mouse mammary gland: evidence
supporting a role for epidermal growth factor. D e v e l o p m e n t a l  
Bio logy,  127: 304-315.
Collett, M.S., Brugge, J.S., & Erikson, R.L. (1978). Characterization 
of a normal avian cell protein related to the avian sarcoma virus- 
transforming gene product. Cell,  15: 1363-1369.
Connolly, J.M., &  Rose, D.P. (1990). Production of epidermal 
growth factor and transforming growth factor-a by the 
androgen-responsive LNCaP human prostate cancer cell line. The  
Prostate,  16: 209-218.
Connolly, J.M., &  Rose, D.P. (1991). Autocrine regulation of DU145 
human prostate cancer cell growth by epidermal growth factor- 
related polypeptides. The Prostate, 19: 173-180.
Coombes, R.C., Goss, P., Dowsett, M., Gazet, J.C., &  Brodie, A. (1984). 
4-Hydroxyandrostenedione in treatment of postmenopausal 
patients with advanced breast cancer. Lancet ,  ii: 1237-1239.
Coughlin, S., Escobedo, J., & Williams, L. (1989). Role of 
phosphatidylinositol kinase in PDGF receptor signal transduction. 
Science,  1191 -1195 .:
Coulam, C.B., & Annegars, J.F. (1983). Chronic anovulation may 
increase postmenopausal breast cancer risk. Journal  o f  the 
American Medical Association, 249: 445-452.
375
CITATIONS
Courrier, R. (1950). In teract ions  Between Estrogens and  
Progesterone. Vitamins and Hormones. Advances in Research and 
Applications, Vol. V III, New York: Academic Press Inc.
Coussens, L., Yang-Feng, T.L., Liao, Y.-C., Chen, E., Gray, A., 
McGrath, J., Seeburg, P.H., Libermann, T.A., Schlessinger, J., 
Francke, U., Levinson, A., & Ullrich, A. (1985). Tyrosine kinase 
receptor with extensive homology to EGF receptor shares 
chromosomal location with neu oncogene. Science,  230: 1132- 
1139.
Cowan, L.D., Gordis, L., Tonascia, J.A., &  Jones, G.S. (1981). Breast 
cancer incidence in women with a history of progesterone 
deficiency. American Journal o f  Epidemiology, 114: 209-217.
Cunha, G.R., Chung, L.K.W., Shannon, J.M., &  Reese, B.A. (1980). 
Stromal-epithelial interactions in sex differentiation. Biology of  
Reproduction,  22: 19-42.
Cunha, G.R., & Chung, L .W .K . (1981). Stromal-epithelial 
interactions-L Induction of prostatic phenotype in urothelium of 
testicular feminized (T fm /Y ) mice. J o u rn a l  o f  S tero id  
Biochem istry , 14: 1317-1321.
Cunha, G.R., Donjacour, A.A., Cooke, P.S., Mee, S., Bigsby, R.M., 
Higgins, S.J., & Sugimura, Y. (1987). The endocrinology and 
developmental biology of the prostate. Endocrine Reviews,  8: 
338-362 .
Czech, M.P. (1989). Signal transmission by the insulin-like growth 
factors. Cell,  59: 235-238.
376
CITATIONS
Culig, Z., Klocker, H., Eberle, J., Kaspar, F., Hobisch, A., Cronauer, 
M .V., & Bartsch, G. (1993). The DNA sequence of the androgen 
receptor in prostatic tumor cell lines and tissue specimens 
assessed by means of the polymerase chain reaction. T h e  
Prostate,  22: 11-22.
D’Agostino, G., Mitchell, F., Castagnetta, L., & O'Hare, M.J. (1984). 
Solvent optimization for RP-HPLC of polar adrenal steroids using 
computer predicted retention for a modified COF procedure. 
Journal o f  Chromatography, 305: 13-26.
D'Agostino, G., Castagnetta, L., Mitchell, F., & O'Hare, M. (1985). 
Computer-aided mobile phase optimization and chromatogram 
simulation in high-performance liquid chromatography. J o u r n a l  
o f  Chromatography, 338: 1-23.
Danielpour, D., Dart, L.L., Flanders, K.C., Roberts, A.B., & Sporn, 
M.B. (1989). Immunodetection and quantitation of the two forms 
of transforming growth factor-beta (TGF-beta 1 and TGF-beta 2) 
secreted by cells in culture. Journal o f  Cel l  Physiology, 138.: 79- 
8 6 .
Dao, T.L. (1979). Metabolism of estrogens in breast cancer. 
Biochimica et Biophysica Acta, 560: 397-426.
Dao, T.L., & Libby, P.R. (1971). Enzymic synthesis of steroid 
sulphate by mammary cancer and its clinical implications. 
National Cancer Institute Monograph, 34: 205-210.
Daughaday, W .H., & Rotwein, P. (1989). Insulin-like growth 
factors I and II. Peptide, messenger ribonucleic acid and gene 
structures, serum and tissue concentrations. Endocrine Reviews,  
10: 68-91.
377
CITATIONS
Davies, P., &  Eaton, C.L. (1989). Binding of epidermal growth 
factor by human normal, hypertrophic and carcinomatous 
prostate. The Prostate, 14: 123-132.
De Caprio, J.A., Ludlow, J.W., Figge, J., Shew, J.-Y., Huang, C.-M., 
Lee, W.-H., Marsilio, E., Paucha, E., & Livingston, D.M. (1988). 
SV40 large tumor antigen forms a specific complex with the 
product of the retinoblastoma susceptibility gene. C el l ,  54: 275- 
283.
De Caprio, J.A., Ludlow, J.W., Lynch, D., Furukawa, Y., Griffin, J., 
Piwnica-Worms, H., Huang, C.M., & Livingston, D.M. (1989). The 
product of the retinoblastoma susceptibility gene has properties 
of a cell cycle regulatory element. Cell,  58: 1085-1095.
De Larco, J.E., &  Todaro, G.J. (1978). Growth factors from murine 
sarcoma virus-transformed cells. Proceedings o f  the Nat ional  
Academy of  Sciences of  The United States of  America., 75: 4001- 
4005.
De Launoit, Y., Veilleux, R., Dufour, M., Simard, J., &  Labrie, F.
(1991). Characteristics of the biphasic action of androgens and of 
the potent antiproliferative effect of the new pure antiestrogen 
E M -139 on cell cycle kinetic parameters in LNCaP human 
prostatic cancer cells. Cancer Research, 51: 5165-5170.
De Leon, D.D., Wilson, D.M., Bakker, B., Lamson, G., Hintz, R.L., &  
Rosenfeld, R.G. (1989). Characterization of insulin-like growth 
factor binding proteins from human breast cancer cells. 
Molecular  Endocrinology ,3 : 567-574.
Denison, S.H., Sands, A., & Tindall, D.J. (1989). A tyrosine 
aminotransferase glucocorticoid response element also mediated 
androgen enhancement of gene expression. E n d o c r in o lo g y ,  124: 
1091-1093.
378
CITATIONS
de Pagter-Holthuizen, P., Jansen, M., van der Kammen, R.A., van 
Schaik, F.M.A., & Sussenbach, J.S. (1988). Differential expression 
of the human insulin-like growth factor I I  gene. Characterization 
of the IG F-II mRNAs and an mRNA encoding a putative IG F-II 
associated protein. Biochimica et Biophysica Acta, 950: 282-295.
Derynck, R (1988). Transforming growth factor.Ce//, 54: 593-595.
Derynck, R., Roberts, A.V., Winkler, M.E., Chen, E.Y., & Goeddel,
D .V . (1984). Human transforming growth factor-a: precursor 
structure and expression in E. Coli. Cell ,  38: 287-297.
Derynck, R., Jarrett, J.A., Chen, E.Y., Eaton, D.H., Bell, J.R., Assoian, 
R.K., Roberts, A.B., Sporn, M.B., & Goeddel, D.V. (1985). Human 
transforming growth factor-beta cDNA sequence and expression 
in tumor cell lines. Nature ,  316: 701-705.
Derynck, R., Goeddel, D.V., Ullrich, A., Gutterman, J.U., Williams, 
R.D., Bringman, T.S., &  Berger, W.H. (1987). Synthesis of mRNAs 
fro transforming growth factors alpha and beta and the 
epidermal growth factor receptor by human tumours. C a n c e r  
Research,  47: 707-712.
Derynck, R., Lindquist, P.B., Lee, A., Wen, D., Tamm, J., Graycar, 
J.L., Rhee, L., Mason, A.J., Miller, D.A., Coffey, R.J., Moses, H.L., &  
Chen, E.Y. (1988). A new type of transforming growth factor-p, 
TGFp3. The EMBO Journal, 7: 3737-3743.
Deshpande, N., Carson, P., De Martino, L., & Tarquini, A. (1976). 
Biogenesis of steroid hormones by human mammary gland in  
vivo and in vitro. European Journal of  Cancer, 12: 271-276.
Dickson, C., Smith, R., Brookes, S., & Peters, G. (1984). 
Tumorigenesis by mouse mammary tumour virus: proviral
activation of a cellular gene in the common integration region 
int-2. Cell,  37: 529-536.
379
CITATIONS
Dickson, R.B., Bates, S.E., McManaway, M.E., &  Lippman, M.E. 
(1986). Characterization of estrogen responsive transforming 
activity in human breast cancer cell lines. Cancer Research, 46: 
1707-1713 .
Di Corleto, P.E., & Bowen-Pppe, D.F. (1983). Cultured endothelial 
cells produce a platelet-derived growth factor-like protein. 
Proceedings of  the National Academy of  Sciences of  The United  
States o f  America., 80: 1919-1923.
Digby, M., Zhang, X .Y., & Richards, R.I. (1989). Human prostate 
specific antigen (PSA) gene: structure and linkage to the
kallikrein-like gene, hGK-1. Nucleic Acids Research, 17: 2137- 
2145.
Di Marco, E., Pierce, J.H., Fleming, T.P., Kraus, M.H., Molloy, C.J., 
Aaronson, S.A., &  Di Fiore, P.P. (1989). Autocrine interaction 
between TGF-alpha and the EGF receptor: quantitative
requirements for induction of the malignant phenotype. 
Oncogene,  4: 831-838.
Di Monaco, M., Forte, C., Leonardi, L., Brignardello, E., &  Boccuzzi, 
G. (1991). Tamoxifen counteracts the stimulatory effect of 
dehydroepiandrosterone on the growth pf MCF-7 human breast 
cancer cell line. In: Serono Symposia Publications from  Raven 
Press, Vol. 74: The New Biology o f  Steroid Hormones. R.B. 
Hochberg & F. Naftolin (Ed.), pp. 349-350. New York: Raven Press.
Dobashi, Y., & Stern, D.F. (1991). Membrane-anchored forms of 
EGF stimulate focus formation and intercellular communication. 
Oncogene,  6: 1151-1159.
Donnelly, B.J., Lakey, W.H., & McBlain, W.A. (1983). Estrogen 
receptors in human benign prostatic hyperplasia. Journa l  o f  
U ro log y ,  130: 183-187.
380
CITATIONS
Doolittle, R.F., Hunkapiller, M.W., Hood, L.E., Devare, S.G., Robbins, 
K.C., Aaronson, S.A., & Antoniades, H.N. (1983). Simian sarcoma 
virus one gene, v-sis ,  is derived from the gene (or genes) 
encoding a platelet-derived growth factor. S cience ,  221: 275- 
277.
Dorfman, R.I. (1948). Studies on the bioassay of hormones the 
relative activity of the comb of various breeds of chicks to 
androgens. Endocrinology,  42: 7-14.
Downward, J., W aterfield, M .D ., & Parker, P. (1985).
Autophosphorylation and protein kinase C phosphorylation of the 
Epidermal Growth Factor Receptor. Journa l  o f  B io log ica l  
Chem is try ,  260: 14538-14546.
Drago, J.R. (1984). The induction of NB rat prostatic carcinomas. 
Anticancer Research, 4: 255-256.
Dupont, W.D., & Page, D.L. (1991a). An overview of the effect of 
oestrogen replacement therapy on breast cancer risk. In: 
Hormone Replacement Therapy and Breast Cancer Risk. R.D. 
Mann (Ed.), pp. 79-92. London: The Parthenon Publishing Group.
Dupont, W .D ., & Page, D.L. (1991b). Menopausal estrogen 
replacement therapy and breast cancer. Archives o f  In te rna l  
M e d ic in e ,  151: 67-72.
Dvorak, H.F. (1986). Tumors: wounds that do not heal. N e w
England Journal o f  Medicine, 315: 1650-1659.
Dyson, N., Howley, P.N., Miinger, K., & Harlow, E. (1989). The 
human papilloma virus-16 E7 oncoprotein is able to bind the 
retinoblastoma gene product. Science, 243: 643-646.
381
CITATIONS
Eaton, C.L., & Pierrepoint, C.G. (1982). Epithelial and fibroblastoid 
cell lines derived from the normal canine prostate. II .  Cell 
proliferation in response to steroid hormones. The Prostate, 3: 
493-506.
Eaton, C.L., Davies, P., & Phillips, M.E.A. (1988). Growth factor 
involvement and oncogene expression in prostatic tumours. 
Journal of  Steroid Biochemistry, 30: 341-345.
Eaton, C.L., & Griffiths, K. (1990). The role of endocrine therapy in 
prostatic cancer. In: Clinical Endocrinology and Metabolism:  
Endocrine Aspects of  Malignancy. S.M. Shalet (Ed.), Vol. 4 (1), pp. 
85-96. London: Bailliere Tindall.
Ek, B., Westermark, B., Wasteson, A., & Heldin, C.-H. (1982).
Stimulation of tyrosine-specific phosphorylation by platelet- 
derived growth factor. Nature ,  295: 419-420.
Ekman, P., Barrack, E.R., Greene, G.L., Jensen, E.V., &  Walsh, P.C. 
(1983). Estrogen receptors in human prostate: evidence for 
multiple binding sites. Journal o f  Clin ical Endocrinology and  
Metabol ism , 57: 166-176.
el Abed, A., Kerdelhue, B., Castanier, M., &  Scholler, R. (1987). 
Stim ulation of estradiol-17beta secretion by ,7 ,1 2 -
dimethylbenz(a)antracene during mammary tumor induction in
Sprague-Dawley rats. Journal of  Steroid Biochemistry, 26:  733- 
738.
Ellis, C., Moran, M., McCormick, F., & Pawson, T. (1990). 
Phosphorylation of GAP and GAP-associated proteins by
transforming and mitogenic tyrosine kinases. N a t u r e ,  343: 377- 
381.
382
CITATIONS
Elson, S.D., Browne, C.A., & Thornburn, G.D. (1984). Identification 
of epidermal growth factor-like activity in human male 
reproductive tissue and fluids. Journal of  Cl inical Endocrinology 
and Metabolism, 58: 589-594.
England, P., Skinner, L., Cottrell, K., & Sellwood, R. (1974). Serum 
o e s tra d io l-17(3 in women with benign and malignant breast 
disease. British Journal of Cancer, 30: 571-576.
Eriksson, H.C., Upchurch, S., Hardin, J.W., Peck, E.J.Jr., & Clark, J.H. 
(1978). Heterogeneity of estrogen receptors in the cytosol and 
nucler fractions of the rat uterus. Biochemical and Biophysical  
Research Communications, 81: 1-7.
Escobedo, J.A., & Williams, L.T. (1988). A PDGF receptor domain 
essential for mitogenesis but not for many other responses to 
PDGF. Nature,  335: 85-87.
Evans, M.R. (1988). The steroid and thyroid hormone receptor 
superfamily. Science, 240: 889-895.
Ewertz, M. (1988). Influence of noncontraceptive exogenous and 
endogenoussex hormones on breast cancer risk in Denmark. 
International Journal of  Cancer, 42: 832-838.
Fallon, J.H., Seroogy, K.B., Loughlin, S.E., Morrison, R.S., Bradshaw, 
R.A., Knauer, D.J., & Cunningham, D.D. (1984). Epidermal growth 
factor immunoreactive material in the central nervous system: 
location and development. Science, 224: 1107-1109.
Fang, S., Anderson, K.M., &  Liao, S. (1969). Receptor proteins for 
androgens: on the role of specific proteins in selective retention 
of 17(3-hydroxy-5a-androstan-3-one by rat ventral prostate in  
vivo  and in vitro. Journal of  Biological Chemistry, 244: 6584- 
6595.
383
CITATIONS
F a rn s w o rth , W .E . ( 1 9 7 3 ). H um an p ro s ta tic  
dehydroepiandrosterone sulfate sulfatase. Steroids,  21: 647-664.
Farnsworth, W .E., & Brown, J.R. (1963). Metabolism of
testosterone by the human prostate. Journal o f  the American 
Medical Association, 183: 436-439.
Faucher, C., Capdevielle, J., Canal, I., Ferrara, P., Mazarguil, H., 
McGuire, W.L., & Darbon, J.M. (1993). The 28-kDa protein whose 
phosphorylation is induced by protein kinase C activators in 
MCF-7 cells belongs to the family of low molecular mass heat 
shock proteins and is the estrogen-regulated 24-kDa protein. 
Journal o f  Biological Chemistry, 268: 15168-15173.
Fawell, S.E., Lees, J.A., White, R., & Parker, M.G. (1990). 
Characterization and colocalization of steroid binding and 
dimerization activities in the mouse estrogen receptor. C e l l ,  60: 
953-962 .
Fernandez-Pol, J.A., Klos, D.J., & Grant, G.A. (1986). Purification 
and biological properties of type a transforming growth factor 
from mouse transformed cells. Cancer Research, 46: 5153-5161.
Ferro, M.A. (1991). Use of intravenous stibestrol diphosphate in 
patients with prostatic carcinoma refractory to conventional 
hormonal manipulation. Urologic Clinics o f  North America, 18: 
139-143.
Fisher, D.A., & Lakshmanan, J. (1990). Metabolism and effects of 
epidermal growth factor and related growth factors in mammals. 
Endocrine Reviews, 11: 418-442.
Fishman, J. (1988). Nature and control of aromatisation in 
different tissues. In: Endocrine-Dependent Breast Cancer: Crit ical  
Assessment of  Recent Advances. R.J. Santen & E. Juhos (Ed.), pp. 
38-48. Bern: Hans Huber.
384
CITATIONS
Fishman, J., & Norton, B. (1975). Catechol estrogen formation in 
the central nervous system of the rat. E n d o c r i n o l o g y , 96: 1054- 
1059.
Fishman, J., Bradlow, H.L., Schneider, J., &  Kappas, A. (1980). 
Radiometric analysis of biological oxidations in man: sex
differences in estradiol metabolism. Proceedings of  the National  
Academy of  Sciences of  The United States of  America., 77: 4957- 
4960.
Fitzpatrick, D.R., Denhez, F., Kondaiah, P., & Akhurst, R.J. (1990). 
Differential expression of TGF beta isoforms in murine 
palatogenesis. D ev e lo pm en t , 109: 585-596.
Folca, P.J., Glascock, R.F., & Irvine, W.T. (1961). Studies with 
tritium labeled hexoestrol in advanced breast cancer. L a n c e t ,  ii: 
7 96 -798 .
Fortunati, N., Frairia, R., Berta, L., Fissore, F., Fazzari, A., Langfc, A., 
& Gaidano, G. (1991). Plasma membranes of human endometrium 
present specific receptors for sex steroid binding protein (SBP) 
and for the complex SBP-estradiol. In: Serono Symposia
Publications from Raven Press, Vol. 74: The New Biology o f  
Steroid Hormones. R.H. Hochberg & F. Naftolin (Ed.), pp. 351-354. 
New York: Raven Press.
Fowler, J.E., Lau, J.L.T., Ghash, L., Mills, S.E., &  Mounzer, A. (1988). 
Epidermal growth factor and prostatic carcinoma: an
immunihistocemical study. Journal of  Urology, 139: 857-861.
Fraley, E.E., Ecker, S., & Vincent, M .M . (1970). Spontaneous in 
vitro neoplastic transformation of adult human prostatic 
epithelium. Science, 170: 540-542.
385
CITATIONS
Franks, L.M. (1956). The spread of prostate cancer. Journal o f  
Pathology and Bacteriology., 72: 603-611.
Franks, L.M., Riddle, P.N., Carbonell, A.W., & Gey, G.O. (1970). A 
comparative study of the ultrastructure and lack of growth 
capacity of adult human prostate epithelium mechanically 
separated from its stroma,. Journal of  Pathology, 100: 113-119.
Frey, P., Forand, R., Maciag, T., & Shooter, E.M. (1979). The 
biosynthetic precursor of epidermal growth factor and the 
mechanism of its processing. Proceedings o f  the N a t io n a l  
Academy of Sciences of  The United States o f  America., 76: 6294- 
6298.
Froesch, E.R., Schmid, C., Schwander, J., & Zapf, J. (1985). Actions 
of insulin-like growth factors. Annual Reviews o f  Physiology, 47: 
443-467 .
Galbraith, R.A., & Michnovicz, J.J. (1989). The effects of cimetidine 
on the oxidative metabolism of estradiol. New England Journal o f  
M e d ic in e ,  321: 269-274.
Gasc, J.-M., Renoir, J.M., Radanyi, C., Joab, I., Tuohimaa, P., &  
Baulieu, E.-E. (1984). Progesterone receptor in the chick oviduct: 
an immunocytochemical study with antibodies to distinct 
receptor components. Journal of  Cell Biology, 99: 1193-1201.
Geller, J., Albert, J., Lopez, D., Geller, S., &  Niwayama, G. (1976). 
Comparison of androgen metabolites in benign prostatic 
hypertrophy (BPH) and normal prostate. Journal  o f  C l in ica l  
Endocrinology and Metabolism, 43: 686-688.
Geller, J., de la Vega, D.J., Albert, J.D., & Nachtsheim, D.A. (1984). 
Tissue dihydrotestosterone levels and clinical response to 
hormonal therapy in patients with advanced prostate cancer. 
Journal o f  Clinical Endocrinology and Metabolism, 58: 36-40.
386
CITATIONS
Geller, J., & Albert, J.D. (1985). DHT in prostate cancer tissue - a 
guide to management and therapy. The Prostate, 6: 19-25.
Gentry, L.E., Webb, N.R., Lim, G.J., Brunner, A.M., Ranchalis, J.E., 
Twardzik, D.R., Liobin, M.N., Marquardt, H., &  Purchio, A.F. (1987). 
Type 1 transforming growth factor beta: amplified expression 
and secretion of mature and precursor polypeptides in Chinese 
hamster ovary cells. Molecular and Cel lu lar  B io l o g y , ! :  3418- 
3427.
Gething, M.-J., & Sambrook, J. (1992). Protein folding in the cell. 
N atu re ,  355: 33-45.
Ghanadian, R. (1982). Hormonal control and rationale for 
endocrine therapy of prostate tumours. In: The Endocrinology o f  
Prostate Tumours. R. Ghanadian (Ed.), pp. 59-86. Lancaster: MTP 
Press.
Ghanadian, R., Auf, G., Williams, G., Davies, A., & Richards, B. 
(1981). Predicting the response of prostatic carcinoma to 
endocrine therapy. Lancet,  ii: 1418-1423.
Giguere, V., Yang, N., Segui, P., & Evans, R. (1988). Identification 
of a new class of steroid hormone receptors. N a tu re ,  331: 91-94.
Giorgi, E.P. (1967). Determination of free and conjugated 
oestrogens in fluid from human ovaries. Journal o f  Endocrinology,  
37: 211-219.
Glascock, R.F., & Hoekstra, W.G. (1959). Selective accumulation of 
tritium-labelled hexoestrol by the reproductive organs of 
immature female goats and sheep. Biochemical Journal,  72: 673- 
682.
387
CITATIONS
Gleave, M., Hsieh, J.-T., Gao, C., von Eschenbach, A.C., & Chung, 
L.W .K. (1991). Acceleration of human prostate cancer growth in  
vi vo  by factors produced by prostate and bone fibroblasts. 
Cancer Research, 51: 3753-3761.
Gomez, E.C., & Hsia, S.L. (1968). In vitro metabolism of 
testosterone-4-14C and A4-androstene-3,17-d ione-4-14C  in 
human skin. Biochemistry , 7: 24-32.
Goodman, M.J., Bulbrook, R.D., & Moore, J.W. (1988). The 
distribution of estradiol in the sera of Caucasian, Chinese, Filipina, 
Hawaiian and Japanese women living in Hawaii. European Journal  
of Cancer and Clinical Oncology, 24: 1855-1860.
Gorski, J., Toft, D., Shyamala, G., Smith, D., & Notides, A. (1968). 
Hormone receptors: studies on the interaction of estrogen with 
the uterus. Recent Progress in Hormone Research, 24: 45-80.
Gorski, J., Welshons, W., & Sakai, D. (1984). Remodeling the 
estrogen receptor model. Molecular and Cel lu lar  Endocrinology,  
36: 11-15.
Gorski, J., &  Hansen, J.C. (1987). The ’’one and only" step model of 
estrogen action. Steroids, 49: 461-475.
Goustin, A.S., Leof, E.B., Shipley, G.D., & Moses, H.L. (1986). Growth 
factors and cancer. Cancer Research, 46: 1015-1029.
Govindan, M .V . (1980). Immunofluorescence microscopy of the 
intracellular translocation ofglucocorticoid-receptor complexes in 
rat hepatoma (HTC) cells. Experimental Cell  Research, 127: 293- 
297.
Grattarola, R. (1964). The premenstrual endometrial pattern of 
women with breast cancer. Cancer,  17: 1119-1122.
388
CITATIONS
Gray, A., Dull, T.J., & Ullrich, A. (1983). Nucleotide sequence of 
epidermal growth factor cDNA predicts a 128,000 molecular 
weight precursor. N atu re ,  303: 722-725.
Graycar, J.L., Miller, D.A., Arrick, B.A., Lyons, R.M., & Moses, H.L. 
(1989). Human transforming growth factor-(33: recombinat
expression, purification, and biological activities in comparison 
with transforming growth factors-(31 and -(32. M o l e c u l a r  
Endocrinology,  3: 1977-1986.
Green, S., &  Chambon, P. (1991). The oestrogen receptor: from 
perceptio to mechanism. In: Nuclear Hormone Receptors. M.G. 
Parker (Ed.), pp. 15-38. London: Academic Press.
Greene, G.L. (1984). Application of immunochemical techniques to 
the analysis of estrogen receptor structure and function. In: 
Biochemical Actions o f  Hormones, Vol. 11. G. Litwack (Ed.), pp. 
207-239. New York: Academic Press.
Greene, G.L., & Jensen, E.V. (1982). Monoclonal antibodies as 
probes for estrogen receptor detection and characterization. 
Journal o f  Steroid Biochemistry, 16: 353-359.
Greene, G.L., Gilna, P., Waterfield, M., Baker, A., Hort, Y., &  Shine, J.
(1986). Sequence and expression of human estrogen receptor 
complementary DNA. Science, 231: 71-74.
Greenwald, P., Damon, A., Kirmss, V., & Polan, A.K. (1974). 
Physical and demographic features of men before developing 
cancer of the prostate. Journal of  the National Cancer Institute, 
53: 341-346.
Gregory, H. (1975). Isolation and structure of urogastrone and its 
relationship to epidermal growth factor. N atu re ,  275: 325-327.
389
CITATIONS
Griffin, J.E. (1991). Androgen resistance - the clinical and 
molecular spectrum. New England Journal of  Medicine, 326:  611- 
617.
Griffiths, K., Davies, P., Harper, M.E., Peeling, W.B., & Pierrepoint,
C.G. (1979). The etiology and endocrinology of prostate cancer. 
In: Endocrinology of  Cancer. Vol. 2. D. Rose (Ed.), pp. 1-55. Boca 
Raton: CRC Press.
Griffiths, K., Davies, P., Eaton, C.L., Harper, M.E., Peeling, W.B., 
Turkes, A.O., Turkes, A., Wilson, D.W., & Pierrepoint, C.G. (1987). 
Cancer of the prostate: endocrine factors. In: Oxford Reviews of  
Reproductive Biology.  JR Clarke (Ed.), pp. 192-259. Oxford: 
Oxford University Press.
Griffiths, K., Davies, P., Eaton, C.L., Harper, M.E., &  Pierrepoint, C.G. 
(1989). Oestrogens and the prostate. In: Urology: Cancer of  the 
Prostate.  S. Khoury & C. Chatelain (Ed.), pp. 308-332. Paris: FIIS 
&RPG.
Griffiths, K., Davies, P., Eaton, C.L., Harper, M.E., Turkes, A.O., &  
Peeling, W.B. (1991). Endocrine factors in the initiation, diagnosis, 
and treatment of prostatic cancer. In: E n d o c r in e -D e p e n d e n t
Tumors.  K.-D. Voigt & C. Knabbe (Ed.), pp. 83-130. New York: 
Raven Press.
Grodin, J.M., Siiteri, P.K., & MacDonald, P.C. (1973). Source of 
estrogen production in postmenopausal women. Journa l  o f  
Clinical Endocrinology and Metabolism, 36: 207-214.
Gschwendt, M., & Kittstein, W. (1980). Transformation of the 
estrogen-receptor complex from chick oviduct in two steps. 
Molecular and Cellular Endocrinology, 20: 251-260.
390
CITATIONS
Guichon, A.M., Loosfelt, H., Lescop, P., Sar, S., Atger, M., Perrot- 
Applanat, M., & Milgrom, E. (1989). Mechanisms of nuclear 
localization of the progesterone receptor: evidence for interaction 
between monomers. Cell,  5 7: 1147-1154.
Gullino, P.M., Pettigrew, H.M ., & Grantham, F.H. (1975). N- 
Nitrosomethylurea as mammary gland carcinogen in rat. J o u r n a l  
o f  the National Cancer Institute, 54: 401-414.
Gutman, A., & Wasylyk, B. (1991). Nuclear targets for
transcription regulation by oncogenes. Trends in Genetics,7 :  49- 
55.
Haddow, A. (1972). Molecular repair, wound healing, and 
carcinogenesis: tumor production a possible overhealing.
Advances in Cancer Research, 16: 181-234.
Haenzel, W., &  Kurihara, M. (1968). Studies of Japanese migrants. 
I. Mortality from cancer and other diseases among Japanese in 
the United States. Journal of  the National Cancer Institute, 40: 
43-68 .
Haley, J., Whittle, N., Bennett, P., Kinchington, D., Ullrich, A., &  
Waterfield, M.D. (1987). The human EGF receptor gene: structure 
of the llOkb locus and identification of sequences regulating its 
transcription. Oncogene Research, 1: 375-396.
Ham, J., Thomson, A., Needham, M., Webb, P., &  Parker, M.G.
(1988). Characterization of response elements for androgens, 
glucocorticoids and progestins in mouse mammary tumor virus. 
Nucleic Acids Research, 16: 5263-5277.
Hammond, G.L. (1978). Endogenous steroid levels in the human 
prostate from birth to old age: a comparison of normal and 
diseased tissue. Journal of  Endocrinology,78 : 7-19.
391
CITATIONS
Han, V.K.M ., Hunter, E.S., Pratt, R.M., Zedengui, J.G., & Lee, D.C.
(1987). Expression of rat transforming growth factor alpha mRNA 
during development occurs predominantly in the maternal 
decidua. Molecular and Cellular Biology,7 : 2335-2343.
Harper, M.E., Pike, A., Peeling, W.B., & Griffiths, K. (1974). Steroids 
of adrenal origin metabolized by human prostatic tissue in vivo 
and in vitro. Journal of  Endocrinology, 60: 117-125.
Hart, C.E., Forstrom, J.W., Kelly, J.D., Seifert, R.A., Smith, R.A., Ross, 
R., Murray, M.J., & Bowen-Pope, D.F. (1988). Two classes of PDGF 
receptor recognize different isoforms of PDGF. S c ie n c e , 240: 
1529-1531 .
Haug, E., Naess, O., & Gautvik, K.M. (1978). Receptors for 17(5- 
estradiol in prolactin-secreting rat pituitary cells. M olecu la r  and  
Cel lu lar  Endocrinology, 12: 81-95.
Hawkins, R.A., Roberts, M.M., & Forrest, A.P.M. (1980). Oestrogen 
receptors and breast cancer: current status. British Journal o f  
Surgery ,  67: 153-169.
Hawkins, R.A., Thomson, M.L., &  Killen, E. (1985). Oestrogen 
sulphate, adipose tissue and breast cancer. B reas t  C a n c e r  
Research and Treatment, 6: 75-87.
Heino, J., Ignotz, R.A., Hemler, M.E., Crouse, G., &  Massague, J.
(1989). Regulation of cell adhesion receptors by transforming 
growth factor-p. Concomitant regulation of integrins that share a 
common p i subunit. Journal of  Biological Chemistry, 264: 380- 
388.
392
CITATIONS
Heisermann, G.J., Wiley, H.S., Walsh, B.J., Ingraham, H.A., Fiol, C.J., 
& Gill, G.N. (1990). Mutational removal of the thr669 and ser671 
phosphorylation sites alters substrate specificity and ligand- 
induced internalization of the epidermal growth factor receptor. 
Journal of  Biological Chemistry, 265: 12820-12827.
Heldin, C.-H., Westermark, B., & Wasteson, A. (1979). Platelet- 
derived growth factor: purification and partial characterization.
Proceedings of the National Academy of  Sciences of  The United 
States o f  America., 76: 3722-3726.
Heldin, C.-H., Johnsson, A., Wennegren, S., Wernstedt, C., Betsholtz, 
C., & Westermark, B. (1986). A human osteosarcoma cell line 
secretes a growth factor structurally related to a homodimer of 
PDGF A-chain. Nature,  319: 511-514.
Heldin, C .-H ., Backstrom, G., Ostman, A., Hammacher, A., 
Ronnstrand, L., Rubin, K., Nister, M., & Westermark, B. (1988). 
Binding of different dimeric forms of PDGF to human fibroblasts: 
evidence for two separate receptor types. The E M B O  Journal,  1 : 
1387-1393.
Helin, K., Velu, T., Martin, P., Vass, W.C., Allevato, G, Lowy, D.R., &  
Beguinot, L. (1991). The biological activity of the human 
epidermal growth factor receptor is positively regulated by its C- 
terminal tyrosines. Oncogene, 6: 825-832.
Helmrich, S.P., Shapiro, S., Rosenberg, L., Kaufman, D.W., Slone, D., 
Bain, C., Miettinen, O.S., Stolley, P.D., Rosenshein, N.B., Knapp, R.C., 
Leavitt, T., Schottenfeld, D., Engle, R.L., & Levy, M. (1983). Risk 
factors for breast cancer. American Journal o f  Epidemiology, 117: 
35-45 .
393
CITATIONS
Herington, A.C. (1991). Insulin-like growth factors. In: Clinical  
Endocrinology and Metabolism, Vol. 5 (4): Growth Factors in 
Endocrinology.  D.M. Robertson & A.C. Herington (Ed.), pp. 531- 
551. London: Bailliere Tindall.
Heshmat, M.Y., Kaul, L., Kovi, T., Jackson, M.A., Jackson, A.G., Jones, 
G.W., Edson, M., Enterline, J.P., Worrell, R.G., & Perry, S.L. (1985). 
Nutrition and prostate cancer: a case-control study. The Prostate,  
6 : 7-17.
Heyns, W., Peeters, B., & Mous, J. (1977). Influence of androgens 
on the concentration of prostatic binding protein (PBP) and its 
mRNA in rat prostate. Biochemical and Biophysical Research  
Communicat ions,  77: 1492-1499.
Higashiyama, S., Abraham, J.A., M iller, J., Fiddles, J.C., &  
Klagsbrun, M. (1991). A heparin-binding growth factor secreted 
by macrophage-like cells that is related to EGF. Sc ience ,  251: 
936 -939 .
Higgins, J.R.A., & Gosling, J.A. (1989). Studies on the structure and 
intrinsic innervation of the normal human prostate. The Prostate  
(Supplement) ,  2: 5-16.
Hiipakka, R.A., & Liao, S. (1984). Modulation of androgen receptor 
activity in the rat ventral prostate. Annals o f  the New York 
Academy o f  Sciences, 43: 54-60.
Hiipakka, R.A., & Liao, S. (1988a). Intracellular inhibition of 
chromatin binding and transformation of androgen receptor by 
3'-deoxyadenosine. Journal o f  Biological Chemistry, 263: 17590- 
17595.
Hiipakka, R.A., & Liao, S. (1988b). Steroid receptor recycling and 
interaction with RNA. American Journal o f  Cl inical Oncology, 2: 
518 -522 .
394
CITATIONS
Hirayama, T. (1979). Epidemiology of prostate cancer with special 
reference to the role of diet. N a t i o n a l  C a n c e r  In s t i tu te  
M o n o g r a p h s , 53: 149-155.
Hochberg, R.B., Bandy, L., Ponticorvo, L., & Lieberman, S; (1977). 
Detection in bovine adrenal cortex of a lipoidal substance that 
yields pregenolone upon treatment with alkali. Proceedings o f  
the Nat ional  Academy of  Sciences of  The United States of  
A m e r ic a . ,  74: 941-945.
Hochberg, R.B., & Lieberman, S. (1980). Naturally occurring lipidal 
derivatives of steroids in the adrenal. In: Endocrinology.  I.A.
Cumming, J.W. Funder, & F.A.D. Mendelsohn (Ed.), pp. 291-294. 
Amsterdam: Elsevier Science.
Horoszewicz, J.S., Leong, S.S., Chu, T.M., Wajsman, Z.L., Friedman, 
M., Papsidero, L., Kim, J., Chai, L.S., Kataki, S., Arya, S.K., &  
Sandberg, A.A. (1980). The LNCaP cell line - a new model for 
studies on human prostatic carcinoma. In: Models fo r  Prostate 
Cancer.  G.P. Murphy (Ed.), pp. 115-132. New York: Alan R. Liss.
Horoszewicz, J.S., Leong, S.S., Kawinski, E., Karr, J.P., Rosenthal, H., 
Chu, T.M ., Mirand, E.A., & Murphy, G.P. (1983). LNCaP model of 
human prostatic carcinoma. Cancer Research, 43: 1809-1818.
Housley, P.R., & Pratt, W.B. (1983). Direct demonstration of 
glucocorticoid receptor phosphorylation by intact L-cells. J o u r n a l  
of Biological Chemistry, 258: 4630-4635.
Houston, B., Chisholm, G.D., & Habib, F.K. (1985). Evidence that 
human prostatic 5a-reductase is located exclusively in the 
nucleus. FEBS Letters, 185: 231-235.
395
CITATIONS
Howell, M .A . (1974). Factor analysis of international cancer 
mortality data and per capita food consumption. British Journal  
of Cancer, 29: 328-336.
Hrubec, Z., Boice, J.D., Monson, R.R., & Rosenstein, M. (1989). 
Breast cancer after multiple fluoroscopies - 2nd followup of 
Massachussetts with tuberculosis. Cancer Research, 49: 229-234.
Hryb, D.J., Khan, M.S., & Rosner, W. (1985). Testosterone-etradiol- 
binding globulin binds to human prostatic cell membranes.
Biochemical and Biophysical Research Communications,  128: 
432 -440 .
Hryb, D.J., Khan, M.S., Romas, N.A., & Rosner, W. (1990). The 
control of the interaction of sex hormone-binding globulin with 
its receptor by steroid hormones. Journal o f  Biological Chemistry, 
265: 6048-6054.
Hsing, A.W., & Comstock, G.W. (1993). Serological precursors of 
cancers: serum hormones and risk of subsequent prostate cancer. 
Cancer Epidemiology Biomarkers and Prevention, 2: 27-32.
Huang, J.S., Huang, S.S., Kennedy, B., & Deuel, T.F. (1982). Platelet- 
derived growth factor. Specific binding to target cells. Journal o f  
Biological Chemistry, 257: 8130-8136.
Huang, S.S., O'Grady, P., & Huang, J.S. (1988). Human transforming 
growth factor (3-a2-macroglobulin complex is a latent form of 
transforming growth factor. Journal of  Biological Chemistry, 263: 
1535-1541 .
Hudson, R.W. (1984). Comparison of 3 a -h y d ro x y s te ro id  
dehydrogenase activities in the microsomal fractions of 
hyperplastic, malignant and normal human prostatic tissue. 
Journal o f  Steroid Biochemistry, 20: 829-833.
396
CITATIONS
Hudson, R.W. (1987). Comparison of nuclear 5a -red u ctase  
activities in the stromal and epithelial fractions of human 
prostatic tissue. Journal of  Steroid Biochemistry, 26: 349-353.
Huggins, C., & Clark, P.J. (1940). Quantitative studies of prostatic 
secretion II. The effect of castration and of estrogen injection on 
the normal and on the hyperplastic prostate glands of dogs. 
Journal o f  Experimental Medicine, 72: 747-761.
Huggins, C., & Hodges, C.V. (1941). Studies on prostatic cancer. I. 
The effect of castration, of estrogen and of androgen injection on 
serum phosphatases in metastatic carcinoma of the prostate. 
Cancer Research, 1: 293-297.
Huggins, C., Stevens, R.E., & Hodges, C.V. (1941). Studies on 
prostatic cancer. II. The effects of castration on advanced 
carcinoma of the prostate gland. Archives o f  Surgery, 43: 209- 
223.
Huggins, C., & Jensen, E. (1955). The depression of estrone- 
induced uterine growth by phenolic estrogens with oxygenated 
functions at position 6 or 16: the impeded estrogens. Journal of  
Experimental Medicine,  102: 335-346.
Huggins, C., Grand, L.C., & Brillantes, F.P. (1961). Mammary cancer 
induced by a single feeding of polynuclearhydrocarbons and its 
suppression. N atu re ,  189: 204-207.
Hulka, B.S., Hammond, J.E., DiFerdinando, G., Mickey, D.D., Fried,
F.A., Checkoway, H., Stumpf, W.E., Beckman, W.C.Jr., & Clark, T.D.
(1987). Serum hormone levels among patients with prostatic 
carcinoma or benign prostatic hyperplasia and clinical controls. 
The Prostate, 11: 171-182.
Hunter, R. (1786). Observations on certain parts of  the animal  
oeconomy. London: Bibliotheka Osteriana.
397
CITATIONS
Huot, R .I., & Shain, S.A. (1988). Differential metabolism of 
dehydroepiandrosterone sulfate and estrogen conjugates by 
normal or malignant AXC/SSH rat prostate cells and effects of 
these steroid conjugates on cancer cell proliferation in vitro. 
Journal o f  Steroid Biochemistry, 29: 617-621.
Hutchison, K.A., Czar, M.J., Scherrer, L.C., & Pratt, W.B. (1992). 
Monovalent cation selectivity for ATP-dependent association of 
the glucocorticoid receptor with hsp70 and hsp90. Journal  o f  
Biological Chemistry, 261:  14047-14053.
Hutchison, K.A., Scherrer, L.C., Czar, M.J., Ning, Y.M., Sanchez, E.R., 
Leach, K.L., Deibel, M.R., & Pratt, W.B. (1993). FK506 binding to 
the 56-kilodalton immunophilin (Hsp56) in the glucocorticoid 
receptor heterocomplex has no effect on receptor folding or 
function. Biochemistry,  32: 3953-3957.
Hutchinson, L.A., Findlay, J.K., & Herington, A.C. (1988). Growth 
hormone and insulin-like growth factor-I accelerate PMSG- 
induced differentiation of granulosa cells. Molecular  and Cel lu lar  
Endocrinology,  55: 61-69.
Ignotz, R.A., &  Massague, J. (1986). Transforming growth factor-|3 
stimulates the expression of fibronectine and collagen and their 
incorporation into the extracellular matrix. Journal o f  Biological  
Chem is try ,  261: 4337-4345.
Iguchi, T., Fukazawa, Y., Tani, N., Sato, T., Ozawa, S., Takasugi, N., 
Shuin, T., Kubotal, Y., & Petrov, V. (1990). Effect of some 
hormonally active steroids upon the growth of LNCaP human 
prostate tumour cells in vitro. The Cancer Journal, 3: 184-191.
Imperato-McGinley, J. (1984). 5a-reductase deficiency in man. 
Progress in Cancer Research and Therapy., 31: 491-504.
398
CITATIONS
Irwin, K.L., Lee, N.C., Peterson, H.B., Rubin, G.L., Wingo, P.A., 
Mandel, M.G., & The Cancer and Steroid Hormone Study Group
(1988). Hysterectomy, tubal sterilization, and the risk of breast 
cancer. American Journal of  Epidemiology, 127: 1192-1201.
Isaacs, J.T. (1984). Antagonistic effect of androgen on prostatic 
cell death. The Prostate, S\ 545-558.
Isaacs, J.T, & Coffey, D.S. (1981). Adaptation vs selection as the 
mechanism responsible for the relapse of prostatic cancer to 
androgen ablation as studied in the Dunning R -3327H  
adenocarcinoma. Cancer Research, 41: 5070-5075.
Isaacs, J.T., Brendler, C.B., & Walsh, P.C. (1983). Changes in the 
metabolism of dihydrotestosterone in the hyperplastic human 
prostate. Journal o f  Clinical Endocrinology and Metabolism,  56: 
139-146.
Ito, T ., &  Horton, R. (1971). The source of plasma
dihydrotestosterone in man. Journal o f  Clinical Investigation, 50: 
1621-1627.
Iwamura, M., Sluss, P.M., Casamento, J.B., &  Cockett, A.T. (1993). 
Insulin-like growth factor I: action and receptor characterization 
in human prostate cancer cell lines. The Prostate, 22: 243-252.
Jakowlew, S.B., Dillard, P.J., Sporn, M.B., &  Roberts, A.B. (1988). 
Complementary deoxyribonucleic acid cloning of an mRNA  
encoding transforming growth factor-p 4 from chicken embryo 
chondrocytes. Molecular  Endocrinology,2 :  1186-1195.
James, V.H.T., McNeill, J.M., Beranek, P.A., Bonney, R.C., &  Reed, 
M.J. (1986). The role of tissue steroids in regulating aromatase 
and oestradiol 17p-hydroxysteroid dehydrogenase activities in 
breast and endometrial cancer. Journal o f  Steroid Biochemistry,  
25: 787-790.
399
CITATIONS
James, V.H.T., McNeill, J.M., Lai, L.C., Newton, C.J., Ghilchik, M.W., &  
Reed, M.J. (1987). Aromatase activity in normal breast and breast 
tumor tissues. In vivo and in vitro studies. S te r o id s , 50: 269- 
279.
James, V.H.T., Reed, M.J., Lai, L.C., Ghilchik, M.W ., Tait, G.H., 
Newton, C.J., & Coldham, N.G. (1990). Regulation of estrogen 
concentrations in human breast tissues. Annals o f  the New York 
Academy of  Sciences, 595: 227-235.
Jensen, E.V., & Jacobson, H .I. (1962). Basic guides to the 
mechanism of estrogen action. Recent Progress in Hormone  
Research,  18: 387-398.
Jensen, E.V., De Sombre, E.R., &  Jungblut, P.W. (1967). Estrogen 
receptors in hormone responsive tissues and tumors. In: 
Endogenous Factors Influencing Host-Tumor Balance.  R.W. 
Wissler, T.L. Doa, & S.Jr. Wood (Ed.), pp. 15-30. Chicago: 
University of Chicago Press.
Jensen, E.V., Suzuki, T., Kawashima, T., Stumpf, W.E., Jungblut, 
P.W., &  De Sombre, E. (1968). A two-step mechanism for the 
interaction of estradiol with rat uterus. Proceedings o f  the 
National Academy of  Sciences of  The United States o f  America.,  
59: 632-638.
Josso, N, & Picard, J.Y. (1986). Anti-M iillerian hormone.
Physiological Reviews, 66: 1038-1090.
Kaighn, M.E., Narayan, K.S., Ohnuki, Y., Lechner, J.F., & Jones, L.W. 
(1979). Establishment and characterization of a human prostatic 
carcinoma cell line (PC-3). Investigative Urology, 17: 16-23.
4 0 0
CITATIONS
Kajikawa, K., Yasui, W., Sumiyoshi, H., Yoshida, K., Nakayama, H., 
Ayhan, A., Yokozaki, H., Ito, H., & Tahara, E. (1991). Expression of 
epidermal growth factor in human tissues: immunohistochemical 
and biochemical analysis. Virchows Archives A: Pathological  
A n a t o m y , 418: 27-32.
Kalff, M ., Gross, B., & Beato, M. (1990). Progesterone receptor 
stimulates transcription of mouse mammary tumour virus in a 
cell-free system. N a t u r e , 344: 360-362.
Kanzaki, T., Olofsson, A., Moren, A., Wernstedt, C., Heilman, U., 
Miyazono, K., Claesson-Welsh, L., & Heldin, C.-H. (1990). TGF-pl 
binding protein: a component of the large latent complex of TGF- 
pi with multiple repeat sequences. Cel l ,  61: 1051-1061.
Kasselberg, A.G., Orth, D.N., Gray, M.E., & Stahlmann, M.T. (1985). 
Immunocytochemical localisation of human epidermal growth 
factor/urogastrone in several human tissues. J o u r n a l  o f  
Histochemistry and Cytochemistry, 33: 315-322.
Katzenellenbogen, B., & Leake, R.E. (1974). Distribution of the 
oestrogen-induced protein and of total protein between 
endometrial and myometrial fractions of the immature and 
mature rat uterus. Journal of  Endocrinology, 63: 439-449.
Kaufman, F.R., Stanczyk, F.Z., Matteri, R.K., Gentzschein, E., Delgado, 
C., &  Lobo, R.A. (1990). Dehydroepiandrosterone and
dehydroepiandrosterone sulfate metabolism in human genital 
skin. Ferti l i ty and Sterility, 54: 251-254.
Keating, M.T., & Williams, L.T. (1987). Processing of the platelet- 
derived growth factor receptor. Journal of  Biological Chemistry, 
2 6 2 :  7932-7937.
401
CITATIONS
Kehrl, J.H., Wakefield, L.M., Roberts, A.B., Jakowlew, S., Alvarez- 
Mon, M., Derynck, R., Sporn, M.B., & Fauci, A.S. (1986). Production 
of transforming growth factor p by human T lymphocytes and its 
potential role in the regulation of T cell growth. Journa l  o f  
Experimental Medicine,  163: 1037-1050.
Kelner, K.L., & Peck, E.J.Jr. (1981). Resolution of estrogen binding 
species in the hypothalamus and pituitary. Journal o f  Receptor  
Research,  2: 47-62.
Kennedy, D.L., Baum, C., & Forbes, M.F. (1985). Noncontraceptive 
estrogens and progestogens: use patterns over time. O b s te t r ic s  
and Gynecology, 65: 441-446.
Kerr, J.F.R., Wyllie, A.H., & Currie, A.R. (1972). Apoptosis: a basic 
biological phenomenon with wide-ranging implications in tissue 
kinetics. British Journal of  Cancer, 26: 239-257.
Kerr, L.D., Olashaw, N.E., & Matrisian, L.M. (1988). Transforming 
growth factor p i and cAMP inhibit transcription of epidermal 
growth factor- and oncogene-induced transin RNA. Journal o f  
Biological Chemistry, 263: 16999-17005.
Kimura, H., Fischer, W .H., & Schubert, D (1990). Structure, 
expression and function of schwannoma-derived growth factor. 
N a tu re ,  348: 257-260.
King, C.R., Borrello, I., Bellot, F., Comoglio, P., & Schlessinger, J.
(1988). EGF binding to its receptor triggers a rapid tyrosine 
phosphorylation of the erbB-2 protein in the mammary tumour 
cell line SK-BR-3. The EMBO Journal, 7: 1647-1651.
King, R.J.B., Gordon, J;, & Smith, J.A. (1964). The acetylation of 
testosterone by rat and mouse mammary tissue. Journa l  o f  
Endocrinology,  28: 345-346.
402
CITATIONS
King, R.J.B., & Mainwaring, W.I.P. (1974). Steroid Cell Interactions. 
London: Butterworths.
King, R.B.J., Finlay, J.R., Coffer, A.E., Millis, RR., & Rubens, R.D. 
(1987). Characterization and biological relevance of a 29-kDa 
oestrogen-related protein. Journal of  Steroid Biochemistry, 27: 
4 71 -475 .
King, R.J.B. (1992). Effects of steroid hormones and related 
compounds on gene transcription. Clinical Endocrinology, 36: 1- 
14.
King, W.J., &  Greene, G.L. (1984). Monoclonal antibodies localize 
oestrogen receptor in the nuclei of target cells. N a t u r e , 307: 745- 
747.
Kirschenbaum, A., Ren, M., & Levine, A.C. (1993). Enhanced 
androgen sensitivity in serum-free medium of a subline of the 
LNCaP human prostate cancer cell line. Steroids, 58: 439-444.
Kishimoto, Y. (1973). Fatty acid esters of testosterone in rat brain: 
identification, distribution, and some properties of enzymes 
which synthesize and hydrolyze the esters. A rch ives  o f  
Biochemistry and Biophysics, 159: 528-542.
Klein, H., Bressel, M., Kastendieck, H., & Voigt, K.D. (1988). 
Androgens, adrenal androgen precursors, and their metabolism 
in untreated primary tumors and lymph node metastases of 
human prostatic cancer. American Journal o f  Clinical Oncology, 
11: 830-836.
Klein, H., Molwitz, T., & Bartsch, W. (1989). Steroid sulfate 
sulfatase in human bening prostatic hyperplasia: characterization 
and quantification of the enzyme in epithelium and stroma. 
Journal o f  Steroid Biochemistry, 33: 195-200.
403
CITATIONS
Klein, H., Bressel, M., Kastendieck, H., & Voigt, K.D. (1991). 
Biochemical endocrinology of prostate cancer. In: Endocrine-  
Dependent Tumors. K.D. Voigt & C. Knabbe (Ed.), pp. 131-163. 
New York: Raven Press.
Knabbe, C., Lippman, M.E., Wakefield, L.M., Flanders, K.C., Kasid,
A., Derynck, R., & Dickson, R.B. (1987). Evidence that transforming 
growth factor-p is a hormonally regulated negative growth factor 
in human breast cancer cells. C e l l , 48: 417-428.
Koch, C.A., Anderson, D., Moran, M.F., Ellis, C., & Pawson, T. (1991). 
SH2 and SH3 domains: elements that control interactions of 
cytoplasmic signaling proteins. Science, 252: 668-674.
Kolonel, L.N., Hankin, J.H., Lee, J., Chu, S.Y., Nomura, A.M .Y., &  
Ward Hinds, M. (1981). Nutrient intakes in relation to cancer 
incidence in Hawaii. British Journal of  Cancer, 44: 332-339.
Komm, B.S., Terpening, C.M., Benz, D.J., Graeme, K.A., Gallegos, A., 
Korc, M., Greene, G.L., O’Malley, B.W., & Haussler, M.R. (1988). 
Estrogen binding, receptor mRNA, and biologic response in 
osteoblast-like osteosarcoma cells. Science, 241: 81-84.
Kommoss, F., Wintzer, H.O., von Kleist, S., Kohler, M., Walker, R., 
Langton, B., van Tran, K., Pfleiderer, A., & Bauknecht, T. (1990). 
In  situ distribution of transforming growth factor alpha in 
normal human tissues and in malignant tumours of the ovary.
Journal of Pathology, 162: 223-230.
Kondaiah, P., Sands, M.J., Smith, J.M., Fields, A., Roberts, A.B., 
Sporn, M.B., & Melton, D.A. (1990). Identification of a novel 
transforming growth factor-p mRNA in Xenopus laevis. J o u r n a l  
of Biological Chemistry, 265: 1089-1093.
Korenman, S.G. (1980). Oestrogen window hypothesis of the 
aetiology of breast cancer. Lancet, i: 700-701.
404
CITATIONS
Kraus, M.H., Issing, W., Miki, T., Popescu, N.C., & Aaronson, S.A.
(1989). Isolation and characterisation of ERBB3, a third member 
of the ERBB/epidermal growth factor receptor family: evidence 
for overexpression in a subset of human mammary tumours. 
Proceedings of  the National Academy of  Sciences o f  The United 
States o f  America., 86: 9193-9197.
Krieg, M ., Bartsch, W., Janssen, W., & Voigt, K.D. (1979). A 
comparative study of binding, metabolism and endogenous levels 
of androgens in normal, hyperplastic and carcinomatous human 
prostate. Journal o f  Steroid Biochemistry, 11: 615-624.
Krieg, M., Bartsch, W., Thomsen, M., & Voigt, K.D. (1983). 
Androgens and estrogens: their interaction with stroma and 
epithelium of human bening prostatic hyperplasia and normal 
prostate. Journal o f  Steroid Biochemistry, 19: 155-161.
Kris, R., Lax, I., Gullick, M., Waterfield, M.D., Ullrich, A., Fridkin, 
M ., & Schlessinger, J. (1985). Antibodies against a synthetic 
peptide as a probe for the kinase activity of the avian EGF 
receptor and \ - e r b B  proteins. Cell,  40: 619-625.
Kurachi, H., Okamoto, S., & Oka, T. (1985). Evidence for the 
involvement of the submandibular gland epidermal growth 
factor in mouse mammary tumorigenesis. Proceedings o f  the 
National Academy of  Sciences of  The United States of  America.,  
81: 5940-5943.
Kurokawa, M., Lynch, K., & Podolsky, D.K. (1987). Effects of 
growth factors on an intestinal epithelial cell line: transforming 
growth factor (3 inhibits proliferation and stimulates 
differentiation . B io c h e m ic a l  and B io p h y s ic a l  Research  
Communicat ions,  142: 775-782.
4 0 5
CITATIONS
Kyprianou, N., Williams, H., Peeling, W.B., Davies, P., & Griffiths, K.
(1986). Evaluation of biopsy techniques fro androgen receptor 
assay in human prostatic tissue. British Journal o f  Urology, 58: 
41 -44 .
Kyprianou, N., & Isaacs, J.T. (1988). Identification of a cellular 
receptor fro transforming growth factor-b in rat ventral prostate 
and its negative regulation by androgens. E n d o c r i n o l o g y , 123: 
2124-2131 .
Kyprianou, N., & Isaacs, J.T. (1989a). Expression of transforming 
growth factor-p in the rat ventral prostate during castration- 
induced programmed cell death. M o le c u la r  Endocr ino logy ,  3: 
1515-1522.
Kyprianou, N., & Isaacs, J.T. (1989b). Thymine-less death in 
androgen-independent prostatic cancer cells. Biochemical  and  
Biophysical Research Communications, 165: 73-81.
Kyprianou, N., English, H.F., & Isaacs, J.T. (1990). Programmed cell 
death during regression of PC-82 human prostate cancer 
following androgen ablation. Cancer Research, 50: 3748-3753.
Kyprianou, N., Martikainen, P., & Isaacs, J.T. (1991). Programmed 
cell death of normal and malignant prostatic cells. In: Endocrine-  
Dependent Tumors. K.-D. Voigt & C. Knabbe (Ed.), pp. 69-81. New 
York: Raven Press.
Labrie, F. (1991). Intracrinology. M o le c u la r  and C e l lu la r  
Endocrinology ,78 : C l 13-118.
Laiho, M., Saksela, O., Andreasen, P.A., & Keski-Oja, J. (1986). 
Enhanced production and extracellular deposition of the 
endothelial-type plasminogen activator inhibitor in cultured 
human lung fibroblasts by transfroming growth factor-p. J o u r n a l  
o f  Cell  Biology, 103: 2403-2410.
406
CITATIONS
Laiho, M., De Caprio, J.A., Ludlow, J.W., Livingston, D.M ., &  
Massague, J. (1990a). Growth inhibition by TGF-b linked to 
suppression of retinoblastoma protein phosphorylation. C el l ,  62: 
175-185.
Laiho, M., Weiss, F., & Massague, J. (1990b). Concomitant loss of 
transforming growth factor-p types I and II  in cell mutants 
resistant to TGF-p. Journal of Biological Chemistry, 265: 18518- 
18524.
Landry, J., Lambert, H., Zhou, M., Lavoie, J.N., Hickey, E., Weber, 
L.A., & Anderson, C.W. (1992). Human hsp27 is phosphorylated at 
serines 78 and 82 by heat shock and mitogen-activated kinases 
that recognize the same amino acid motif as S6 kinase II. J o u r n a l  
of  Biological Chemistry, 267: 794-803.
Langley, M.S., Hammond, G.L., Bardsley, A., Sellwood, R.A., &  
Anderso, D.C. (1985). Serum steroid binding proteins and the 
bioavailability of estradiol in relation to breast diseases. J o u r n a l  
of  the National Cancer Inst i tu te , !5: 823-829.
Lasne, C., Lu, Y.P., Orfila, L., Ventura, L., &  Chouroulinkov, I.
(1990). Study of various transforming effects of the anabolic 
agents trenbolone and testosterone on Syrian hamster embryo 
cells. Carcinogenesis, 11: 541-547.
La Vecchia, C., Decarli, A., Parazzini, F., Gentile, A., Liberati, C., &  
Francechi, S. (1986). Non-contraceptive oestrogens and the risk of 
breast cancer in women. International Journal o f  Cancer,  38: 
853-858 .
Leake, R.E., Laing, L., McArdle, C., & Smith, D.C. (1981). Soluble 
and nuclear oestrogen receptor status in human breast cancer in 
relation to prognosis. British Journal of  Cancer, 43: 67-72.
407
CITATIONS
Leake, R.E., Cowan, S., & Eason, R. (1987). Computer program for 
Scatchard analysis of protein:ligand interaction - use for 
determination of soluble and nuclear sterod receptor 
concentrations. In: Steroid Hormones: a Practical Approach. B. 
Green & R.E. Leake (Ed.), pp. 93-97. Oxford: IRL Press.
Leake, R.E., & Habib, F. (1987). Steroid hormone receptors: assay 
and characterization. In: Steroid Hormones: a Practical Approach. 
B. Green & R.E. Leake (Ed.), pp. 67-92. Oxford: IRL Press.
Leav, I., Merk, F.B., Ofner, P., Goodrich, G., Kwan, P.W.-L., Stein,
B.M., Sar, M., & Stumpf, W.E. (1978). Bipotentiality of response to 
sex hormones by the prostate of castrated or hypophysectomized 
dogs: direct effects of estrogen. American Journal o f  Pathology,  
93: 69-92.
Leav, I., Merk, F.B., Kwan, P.W.-L., & Ho, S.-M. (1989). Androgen- 
supported estrogen-enhanced epithelial proliferation in the 
prostates of intact Noble rats. The Prostate, 15: 23-40.
Lee, D.C., Rose, T.M., Webb, N.R., & Todaro, G.J. (1985a). Cloning 
and sequence analysis of a cDNA for rat transforming growth 
factor a . N atu re ,  313: 489-491.
Lee, D.C., Rochford, R., Todaro, G.J., & Villarreul, L.P. (1985b). 
Developmental expression of transforming growth factor alpha 
mRNA. Molecular and Cellular Biology, 5: 3644-3652.
Lee, S.-J. (1990). Identification of a novel member (GDF-1) of the 
transform ing growth factor-p superfamily. M o l e c u l a r  
Endocrinology,  4: 1034-1040.
408
CITATIONS
Lefebvre, P., Sablonniere, B., Tbarka, N., Formstecher, P., & 
Dautrevaux, M. (1989). Study of the heteromeric structure of the 
untransformed glucocorticoid receptor using chemical cross- 
linking and monoclonal antibodies against the 90K heat-shock 
protein. Biochemical and Biophysical Research Communications, 
159: 677-686.
Lemon, H.M ., Wotiz, H.H., Parsons, I., & Mozden, P.J. (1966). 
Reduced estriol secretion in patients with breast cancer prior to 
endocrine therapy. Journal of  the American Medical Association, 
196: 112-120.
Lepor, H., Ross, A., & Walsh, P.C. (1982). The influence of 
hormonal therapy on survival of men with advanced prostatic 
cancer. Journal of  Urology, 128: 335-340.
Leung, B.S., Fletcher, W.S., Lindell, T.D., Wood, D.C., &  Krippache, 
W. (1973). Predictability of response to endocrine ablation in 
advanced breast cancer. Archives of  Surgery, 106: 515-519.
Levell, M.J., Rowe, E., Glashan, R.W., Pidcock, N.B., & Siddall, J.K. 
(1985). Free testosterone in carcinoma of the prostate. T h e  
Prostate,  7: 363-367.
Levi-Montalcini, R., & Cohen, S. (1960). Effects of extracts of the 
mouse submaxillary salivary glands on the sympathetic system 
of mammals. Annals of  the New York Academy o f  Sciences, 85: 
324-341 .
Li, J.J., & Li, S.A. (1981). Estrogen-induced progesterone receptor 
in the Syrian hamster kidney. II. Modulation by synthetic 
progestins. Endocrinology,  108: 1751-1756.
Li, J.J., & Li, S.A. (1984). Estrogen-induced tumorigenesis in the 
Syrian hamster: roles for hormonal and carcinogenic activities. 
Archives o f  Toxicology, 55: 110-116.
409
CITATIONS
Li, J.J., & Li, S.A. (1987). Estrogen carcinogenesis in Syrian
hamster tissues: role of metabolism. Federation Proceedings, 46: 
1858-1863.
Li, J.J., & Li, S.A. (1990). Estrogen carcinogenesis in hamster
tissues: a critical review. Endocrine Reviews, 11: 524-531.
Li, J.J., & Nandi, S. (1990). Hormones and carcinogenesis: 
laboratory studies (Chap 225). In: Principles and Practice of
Endocrinology and Metabolism. K.L. Becker (Ed.), pp. 1643-1675. 
Philadelphia: J.B. Lippincott.
Li, R., & Adams, J.B. (1981). Aromatization of testosterone and
estrogen receptor levels in human breast cancer. Journa l  o f
Steroid Biochemistry, 14: 269-272.
Li, S.A., & Li, J.J. (1978). Estrogen-induced progesterone receptor
in the Syrian hamster kidney. I. Modulation by antiestrogens and
androgens. Endocrinology,  103: 2119-2128.
Liao, S. (1975). Cellular receptors for steroid hormone actions. 
International Review of  Cytology, 41: 87-172.
Liao, S., & Fang, S. (1969). Receptor proteins for androgens and 
the mode of action of androgens on gene transcription in ventral 
prostate. Vitamins and Hormones, 27: 17-90.
Liehr, J.G., Ulubelen, A.A., & Strobel, H.W. (1986). Cytochrome P- 
450-mediated redox cycling of estrogens. Journal o f  Biological  
Chemistry ,  261: 16865-16870.
Like, B., & Massague, J. (1986). The antiproliferative effect of 
type b transforming growth factor occurs at a level distal from 
receptors for growth-activating factors. Journal o f  Bio logical  
Chemistry ,  261: 13426-13429.
410
CITATIONS
Lin, C.R., Chen, W.S., Lazar, C.S., Carpenter, C.D., Gill, G.N., Evans, 
R.M., & Rosenfeld, M.G. (1986). Protein kinase C phosphorylation 
at Thr654 of the unoccupied EGF receptor and EGF binding 
regulate functional receptor loss by independent mechanisms. 
Cell,  44: 839-848.
Lindquist, S.A., & Craig, E.A. (1988). The heat-shock proteins. 
Annual Review of  Genetics, 22: 631-677.
Liotta, L.A. (1986). Tumor invasion and metastasis - role of the 
extracellular matrix. Cancer Research, 46: 1-2.
Lippman, M.E., & Dickson, R.B. (1989). Growth control of normal 
and malignant breast epithelium. In: Oestrogens and the Human  
Breast.  J.S. Beck (Ed.), Vol. 95, pp. 89-106. Edinburgh: The Royal 
Society of Edinburgh.
Lipton, A., Santner, S.J., Santen, R.J., Harvey, H.A., Feil, P.D., White- 
Hershey, D., Bartholomew, M.J., & Antle, C.E. (1987). Aromatase 
activity in primary and metastatic breast cancer. C a n c e r ,  59: 
779 -782 .
LLoyd, S.N., Brown, I.L., & Leake, R.E. (1992). Transforming 
growth factor-a expression in benign and malignant human 
prostatic disease. The International Journal of  Biological Markers.,  
7: 27-34.
Lo Casto, M ., Granata, O .M ., & Castagnetta, L. (1983).
Characterization of oestrogen receptors in some long-term tissue 
cultures. I tal ian Journal of  Biochemistry, 32: 211-213.
Lowry, O.H., Rosenbrough, N.J., Farr, A.L., & Randall, R.J. (1951). 
Protein measurement with the Folin phenol reagent. Journal o f  
Biological Chemistry, 193: 265-275.
41 1
CITATIONS
Lubahn, D.B., Joseph, D.R., Sullivan, P.M., Willard, H.F., French, F.S., 
& Wilson, E.M. (1988). Cloning of human androgen receptor 
complementary DNA and localisation to the X chromosome. 
Science , 240: 327-330.
Luu-The, V., Labrie, C., Zhao, H.-F., Couet, J., Lachance, Y., Simard, 
J., Cote, J., Leblanc, G., Lagace, L., Berube, D., Gagne, R., & Labrie, F. 
(1990a). Purification, cloning, complementary DNA structure, and 
predicted amino acid sequence of human estradiol 17(3- 
dehydrogenase. Annals of  the New York Academy of  Sciences, 
595: 40-52.
Luu-The, V., Labrie, C., Simard, J., Lachance, Y., Zhao, H.-F., Couet, 
J., Leblanc, G., & Labrie, F. (1990b). Structure of two in tandem 
17 P-hydroxysteroid dehydrogenase genes. M o l e c u l a r  
Endocrinology,  4: 268-275.
Lyons, K.M., Graycar, J.L., Lee, A., Hasmi, S., Lindquist, P.B., Chen, 
E.Y., Hogan, B.L.M., & Derynck, R. (1989a). Vgr-1, a mammalian 
gene related to Xenopus VG-1, is a member of the transforming 
growth factor p gene superfamily. Proceedings o f  the National  
Academy o f  Sciences of  The United States of  America., 86: 4554- 
4558.
Lyons, K.M ., Pelton, R.W., & Hogan, B.L.M. (1989b). Patterns of 
expression of murine Vgr-1 and BMP-2A RNA suggest that 
transforming growth factor-P-like genes coordinately regulate 
aspects of embryonic development. Genes and Development, 3: 
1657-1668 .
Lyons, R.M ., Keski-Oja, J., & Moses, H.L. (1988). Proteolytic 
activation of latent transforming growth factor-P from fibroblast- 
conditioned medium. Journal of  Cell Biology, 106: 1659-1665.
4 1 2
CITATIONS
MacDonald, A., Chisolm, G.D., & Habib, F.K. (1990). Production and 
response of a human prostate cancer cell line to transforming 
growth factor-like molecules. British Journal of  Cancer , 62: 579- 
584.
MacDonald, A., & Habib, F.K. (1992). Divergent responses to 
epidermal growth factor in hormone sensitive and insensitive 
human prostate cancer cell lines. British Journal o f  Cancer, 65: 
177-182.
Maclndoe, J.H., Woods, G., Jeffries, L., & Hinkhouse, M. (1988). The 
hydrolysis of estrone sulfate and dehydroepiandrosterone sulfate 
by MCF-7 human breast cancer cells. E ndocr ino logy ,  123: 1281- 
1287.
MacMahon, B., Cole, P., & Lin, T.M. (1970). Age at first birth and 
breast cancer risk. W HO Bulletin, 43: 209-221.
Mahoudeau, J.A., Bardin, C.W., & Lipsett, M .B. (1971). The 
m etabolic clearance rate and orig in  o f plasma 
dihydrotestosterone in man and its conversion to the 5 a -  
androstanediols. Journal of  Clinical Investigation, 50: 1338-1344.
Mainwaring, W.I.P. (1969). A soluble androgen receptor in the 
cytoplasm of rat prostate. Journal of  Endocrinology, 45: 531-541.
Manci, E.M., &  Gardner, W.A. (1986). Bruch's De Morbis Glandulae 
Prostatae: an early account of prostatic diseases (1835). T h e  
Prostate,  8: 103-121.
Mann, R.D. (1992). Hormone replacement therapy and breast 
cancer risk: studies of the last fifteen years. In: H orm one
Replacement Therapy and Breast Cancer Risk. R.D. Mann (Ed.), 
pp. 1-8. London: The Parthenon Publishing Group.
413
CITATIONS
Markaverich, B.M., & Clark, J.H. (1979). Two binding sites for 
estradiol in rat uterine nuclei: relationship to uterotropic
response. E n d oc r ino logy , 105: 1458-1462.
Marquardt, J., Hunkapiller, M.W., Hood, L., & Todaro, G.J. (1984). 
Rat transforming growth factor type 1: structure and relation to 
epidermal growth factor. Science, 223: 1079-1082.
Martikainen, P., & Isaacs, J.T. (1990). Role of calcium in the 
programmed death of rat prostatic glandular cells. The Prostate,  
17: 175-187.
Martikainen, P., Kyprianou, N., & Isaacs, J.T. (1990). Effect of 
transforming growth factor-p on proliferation and death of rat 
prostatic cells. Endocrinology,  127: 2963-2968.
Martin, P.M., & Sheridan, P.J. (1982). Towards a new model for 
the mechanism of action of steroids. J o u rn a l  o f  Steroid  
Biochem istry ,  16: 215-229.
Martinet, Y., Bitterman, P.B., Mornex, J.-F., Grotendorst, G., Martin, 
G.R., &  Crystal, R.G. (1986). Activated human monocytes express 
the c-sis proto-oncogene and release a mediator showing PDGF- 
like activity. N atu re ,  319: 158-160.
Martini, L., Celotti, F., Lechuga, M.J., Melcangi, R.C., Motta, M., 
Negri-Cesi, P., Poletti, A., & Zoppi, S. (1990). Androgen 
metabolism in different target tissues. Annals o f  the New York 
Academy o f  Sciences, 595: 184-198.
Martucci, C.P., & Fishman, J. (1979). Impact of continously 
administered catechol estrogens in uterine growth and luteinizing 
hormone secretion. Endocrinology,  105: 1288-1292.
Massague, J; (1990). The transforming growth factor-P family. 
Annual Review of  Cell Biology, 6: 597-641.
4 1 4
CITATIONS
Massague, J., & Kelly, B. (1986). Internalization of transforming 
growth factor-b and its receptor in BALB/c 3T3 fibroblasts. 
Journal o f  Cell Physiology, 128: 216-222.
Massague, J., Cheifetz, S., Boyd, F.T., & Andres, J.L. (1990). TGF-P 
receptor and TGF-b binding proteoglycans: recent progress in 
identifying their functional properties. Annals of  the New York 
Academy of  Sciences, 593: 59-72.
Massui, T., Wakefield, L.M., Lechner, J.F., LaVeck, M.A., Sporn, 
M.B., & Harris, C.C. (1986). Type P transforming growth factor is 
the primary differentiation-inducing serum factor for normal 
human bronchial epithelial cells. Proceedings o f  the Nat ional  
Academy o f  Sciences of  The United States of  America., 83: 2438- 
2442.
Matuo, Y., Nishi, N., & Wada, F. (1987). Growth factors in the 
prostate. Archives o f  Andrology, 19: 193-210.
Mauvais-Jarvis, P., Floch, H.H., & Bercovici, J.P. (1968). Studies on 
testosterone metabolism in human subjects with normal and 
pathological sexual differentiation. J o u rn a l  o f  C l in ic a l  
Endocrinology,  28: 460-471.
Mauvais-Jarvis, P., Kuttenn, F., Malet, C., & Gompel, A. (1990). 
Normal breast cells in culture. Effect of estrogens, progestins and 
antiestrogens. Annals of  the New York Academy of  Sciences, 595: 
117-129.
Maxfield, F.R., Davies, P.J.A., Klempner, L., Willingham, M.C., & 
Paston, I. (1979). Epidermal growth factor stimulation of DNA  
synthesis is potentiated by compounds that inhibit its clustering 
in coated pits. Proceedings of the National Academy of  Sciences of  
The United States of  America., 76: 5731-5735.
415
CITATIONS
McCormack, S.A., & Glasser, S.R. (1980). Differential response of 
individual uterine cell types from immature rats treated with 
estradiol. End ocr ino logy , 106: 1634-1649.
McFayden, I.J., Forrest, A.P.M., Prescott, R.J., Golder, M.P., Groom,
G.V., & Fahmy, D.R. (1976). Circulating hormone concentrations in 
women with breast cancer. Lancet,  i: 1100-1105.
McKeehan, W .L., Adams, P.S., & Rosser, M.P. (1984). Direct 
mitogenic effects of insulin, epidermal growth factor, 
glucocorticoid, cholera toxin, unknown pituitary factors and 
possibly prolactin, but not androgen, on normal prostate 
epithelial cells in serum-free, primary cell cultures. C a n c e r  
Research,  44: 1998-2010.
McNeal, J.E. (1972). The prostate and prostatic urethra: a 
morphologic synthesis. Journal o f  Urology, 107: 1008-1016.
McNeal, J.E. (1975). Structure and pathology of the prostate. In: 
Normal and Abnormal Growth of  the Prostate. M. Goland (Ed.), 
pp. 55-65. Springfield: Thomas.
McNeal, J.E. (1986). Intraductal dysplasia: a premalignant lesion 
of the prostate. Human Pathology, 17: 64-71.
McNeal, J.E. (1992). Cancer volume and site of origin of 
adenocarcinoma in the prostate: relationship to local and distant 
spread. Human Pathology, 23: 258-266.
McNeal, J.E. (1993). Prostatic microcarcinomas in relation to 
cancer origin and the evolution to clinical cancer. C a n c e r ,  71: 
984-991 .
416
CITATIONS
- McNeill, J.M., Reed, M.J., Beranek, P.A., Bonney, R.C., Ghilchik, 
M.W., Robinson, D.J., & James, V.H.T. (1986a). A comparison of the 
in vivo uptake and metabolism of 3H oestradiol by normal 
breast and breast tumour tissue in postmenopausal women.
International Journal of  Cancer, 38: 193-196.
McNeill, J.M., Reed, M.J., Beranek, P.A., Newton, C.J., Ghilchik,
M.W., & James, V.H.T. (1986b). The effect of epidermal growth 
factor, transforming growth factor and breast tumour
homogenates on the activity of oestradiol 17p-hydroxysteroid  
dehydrogenase in cultured adipose tissue. Cancer Letters, 31: 
213-219.
McPhaul, M.J. (1993). Mutations in steroid hormone receptors 
causing clinical disease. In: Frontiers in Molecular  Biology:  
Steroid Hormone Action. M.G. Parker (Ed.), pp. 186-208. Oxford: 
Oxford University Press.
McPherson, K., Vessey, M.P., Neil, A., Doll, R., Jones, L., &  Roberts, 
M. (1987). Early oral contraceptive use and breast cancer: 
theoretical effects of latency. Journal o f  Epidemiology and  
Community Health,  40: 289-294.
Meikle, A.W., Smith, J.A., & Stringham, J.D. (1987). Production, 
clearance and metabolism of testosterone in men with prostatic 
cancer. The Prostate, 10: 25-31.
Meirik, O., Lund, E., Adami, H.-O., Bergstrom, R., Christoffersen, T., 
& Bergsjo, P. (1986). Oral contraceptive use and breast cancer in 
young women. Lancet,  ii: 650-654.
Mendel, D.B., Bodwell, J.E., Gametchu, B., Harrison, R.W., &  Munck, 
A. (1986). Molybdate-stabilized nonactivated glucocorticoid- 
recptor complexes contain a 90-kDa nonsteroid-binding 
phosphoprotein that is lost on activation. Journal o f  Biological  
Chemistry ,  261: 3758-3763.
417
CITATIONS
Mendel, D.B., & Orti, E. (1988). Isoform composition and 
stoichiometry of the approximately 90-kDa heat shock protein 
associated with glucocorticoid receptors. Journal o f  Biological  
C h e m is t ry , 263: 6695-6702.
Metha, R.R., & Graves, J.M. (1992). Breast tumor-derived factors 
stimulate reduction of estrone to estradiol in nonmalignant 
breast tissue. Breast Cancer Research and Treatment, 23: 51-56.
Meyer, F., Brown, J.B., Morrison, A.S., & MacMahon, B. (1986). 
Endogenous sex hormones, prolactin and breast cancer in 
premenopausal women. Journal o f  the National Cancer Institute, 
77: 613-616.
Michel, G., Jung, I., Baulieu, E.-E., Aussel, C., & Uriel, J. (1974). Two 
high affinity estrogen binding proteins of different specificity in 
the immature rat uterus cytosol. Steroids, 24: 437-449.
Michnovicz, J.J., Hershcopf, R.J., Naganuma, H., Bradlow, H.L., &  
Fishman, J. (1986). Increased 2-hydroxylation of estradiol as a 
possible mechanism for the anti-estrogenic effect of cigarette 
smoking. New England Journal of  Medicine, 315: 1305-1309.
Miller, J.G. (1988). Diagnosis of stage A prostate cancer in the 
People's Republic of China. In: A Multidisciplinary Analysis of  
Controversies in the Management of Prostate Cancer. D.S. Coffey, 
M.I. Resnick, F.A. Dorr, & J.P. Karr (Ed.), pp. 17-24. New York: 
Plenum Press.
Miller, W.R. (1986). Steroid metabolism in breast cancer. In: 
Breast Cancer: Treatment and Prognosis. B.A. Stoll (Ed.), pp. 156- 
172. Oxford: Blackwell Scientific Publications 12.
Miller, W.R., Hawkins, R.A., & Forrest, A.P.M. (1982). Significance 
of aromatase in breast cancer. Cancer Research, 42: 3365-3368.
418
CITATIONS
Miller, W.R., & O’Neill, J.S. (1987). Mammary steroidogenesis: 
therapeutic implications. Nuclear Medicine and Biology, 14: 369- 
376.
Miller, W.R., & O'Neill, J.S. (1989). The relevance of local oestrogen 
metabolism within the breast. In: Oestrogen and the Human  
Breast. J.S. Beck (Ed.), 95B, pp. 203-217. Edinburgh: Royal Society 
of Edinburgh.
Minami, Y., Kawasaki, H., Miyata, Y., Suzuki, K., & Yahara, I.
(1991). Analysis of native forms and isoform compositions of the 
mouse 90-kDa heat shock protein, hsp90. Journal o f  Biological  
C h e m is t ry , 266: 10099-10103.
Miyazono, K., Heilman, U., Wernstedt, C., & Heldin, C.-H. (1988). 
Latent high molecular weight complex of transforming growth 
factor (31: purification from human platelets and structural
characterization. Journal o f  Biological Chemistry, 263: 6407- 
6415.
Miyazono, K., & Heldin, C.-H. (1989). Role for carbohydrate 
structures in TGF-pl latency. Nature ,  338: 158-160.
Mobbs, B.G. (1966). The uptake of tritiated oestradiol by 
dimethylbenzanthracene-induced mammary tumours of the rat. 
Journal o f  Endocrinology, 36: 409-413.
Mobbs, B.G., & Johnson, I.E. (1986). Quantitative relationships 
between cytosol and nuclear estrogen and progesterone receptors 
in the R3327 prostate adenocarcinoma of rats treated with 
diethylstilbestrol. The Prostate, 8: 256-264.
Montpetit, M .L ., Lawless, K.R., & Tenniswood, M. (1986). 
Androgen repressed messages in the rat ventral prostate.7/i e 
Prostate,  8: 25-36.
4 1 9
CITATIONS
Moore, D.H., Long, C.A., Vaidya, A.B., Sheffield, J.B., Dion, A.S., &  
Lasfargues, E.Y. (1979). Mammary tumour viruses. Advances in 
Cancer Research, 29: 347-418.
Moore, J.W., Clark, G.M.G., Bulbrook, R.D., Hayward, J.L., Murai, J.T., 
Hammond, G.L., & Siiteri, P.K. (1982). Serum concentrations of 
total oestradiol and non-protein-bound oestradiol in patients 
with breast cancer and controls. International Journal o f  Cancer, 
29:  17-21.
Moore, J.W., Clark, G.M.G., Takatani, O., Wakabayashi, Y., Hayward, 
J.L., & Bulbrook, R.D. (1983). Distribution of 17p*estradiol in the 
sera of normal British and Japanese women. Journal o f  the 
National Cancer Institute, 71: 749-754.
Moore, J.W., Clark, G.M.G., Ohare, S.A., Millis, R.R., Hayward, J.L., 
Quinlan, M.K., Wang, D.Y., & Bulbrook, R.D. (1986). The binding of 
oestradiol to blood proteins and the aetiology of breast cancer. 
International Journal o f  Cancer, 38: 625-630.
Morfin, R.F., De Stefano, S., Bercovici, J.P., & Floch, H.H. (1978). 
Comparison of testosterone, 5a-dihydrotestosterone, and 5a -  
an d ro s ta n e -3 p ,1 7p -d io l metabolism in human normal and 
hyperplastic prostates. Journal o f  Steroid Biochemistry, 9: 245- 
252.
Morrison, R.S., Kornblum, H.I., Leslie, F.M., &  Bradshaw, R.A.
(1987). Trophic stimulation of cultured neurons from neonatal 
rat brain by epidermal growth factor. Science, 238: 72-75.
Moses, H.L., Yang, E.Y., & Pietenpol, J.A. (1991). Regulation of 
epithelial proliferation by TGF-p. In: Ciba Foundation Symposium 
157: Clinical Applications of TGF-p. G.R. Bock & J. Marsh (Ed.), pp. 
66-80. Chichester: Wiley.
420
CITATIONS
Mueller, C.C., Herranen, A.M., & Jervell, K.F. (1958). Studies on the 
mechanism of action of estrogens. Recent Progress in Hormone  
I R esearch , 14: 95-139.
Muir, C.S., Waterhouse, J.A.H., Mack, T., Powell, J., &  Whelan, S. 
(Ed.). (1988). Cancer Incidence in Five Continents. Lyon: IARC
Muller, R.E., & Wotiz, H.H. (1979). Kinetics of estradiol entry into 
uterine cells. Endocrinology,  105: 1107-1114.
Murphy, J.B., Emmott, R.C., Hicks, L.L., & Walsh, P.C. (1980). 
Estrogen receptors in the human prostate, seminal vesicle, 
epididymis, testis and genital skin: a marker for estrogen- 
responsive tissues? Journal o f  C l in ica l  Endocrinology and  
M e ta b o l is m , 50: 938-947.
Murphy, L.J., Bell, G.I., & Friesen, H.G. (1987). Tissue distribution 
of insulin-like growth factor I and II  messenger ribonucleic acid 
in the adult rat. Endocrinology,  120: 1279-1282.
Murphy, L.J., & Friesen, H.G. (1988). Differential effects of 
estrogen and growth hromone on uterine and hepatic insulin-like 
growth factor I gene expression in in the ovariectomized 
hypophysectomized rat. Endocr ino logy , 122: 325-332.
Musey, V.C., Collins, D.C., Musey, P.I., Martino Saltzman, D., &  
Preedy, J.R.K. (1987). Long-term effect of a first pregnancy on the 
secretion of prolactin. New England Journal o f  Medicine,  316: 
229-234 .
Nicholson, R.I., Gotting, K.E., Gee, J., & Walker, K.J. (1988). Actions 
of oestrogens and antioestrogens on rat mammry gland 
development: relevance to breast cancer prevention. Journal o f  
Steroid Biochemistry, 30: 95-103.
4 2 1
CITATIONS
Nilsson, J., Sjolund, M., Palmberg, L., Thyberg, J., & Heldin, C.-H.
(1985). Arterial smooth muscle cells in primary culture produce 
a platelet-derived growth factor-like protein. Proceedings of  the 
National Academy of Sciences of  The United States o f  America.,  
82: 4418-4422.
Nishimoto, I., Murayama, Y., Katada, T., (Ji, M., & Ogata, E. (1989). 
Possible direct linkage of insulin-like growth factor I I  receptor 
with guanine nucleotide binding proteins. Journal o f  Biological  
Chemistry ,  264: 14029-14038.
Nishizuka, Y. (1984). The role of protein kinase C in cell surface 
signal transduction and tumour promotion. N a t u r e ,  308: 693- 
697.
Nishizuka, Y. (1988). The molecular heterogeneity of protein 
kinase C and its implications for cellular regulation. N a tu re ,  334: 
661-665 .
Nissley, S.P., & Rechler, M .M. (1984). Somatomedin/insulin-like 
growth factor tissue receptors. Journal o f  Clinical Endocrinology 
and Metabolism, 13: 13-68.
Noda, M., & Camilliere, J.J. (1989). In  vivo stimulation of bone 
formation by transforming growth factor-beta. E n d o c r i n o l o g y , 
12: 2991-2994.
Noble, R.L. (1977). The development of prostatic adenocarcinoma 
in the Nb rat following prolonged sex hormone administration.
Cancer Research, 37: 1929-1933.
Nomura, A.M .Y., Kolonel, L.N., Hirohata, T., & Lee, J. (1986). The 
association of replacement estrogens with breast cancer. 
International Journal of  Cancer, 37: 49-53.
422
CITATIONS
Northwood, I.C., Gonzales, F.A., Wartmann, M., Raden, D.L., & 
Davis, R.J. (1991). Isolation and characterization of two growth 
factor-stimulated protein kinases that phosphorylate the 
epidermal growth factor receptor at threonine 669. Journal o f  
Biological Chemistry, 266: 15266-15276.
Notides, A.C., & Nielsen, S. (1974). The molecular mechanism of 
the in vitro 4S to 5S transformation of the uterine estrogen 
receptor. Journal of  Biological Chemistry, 249: 1866-1873.
Nunez, M., Aedo, A.R., Landgren, B.-M., Cezan, S.Z., & Diczfalusy, E.
(1977). Studies of the pattern of circulatig steroids in the normal 
menstrual cycle. Acta Endocrinologica, 86: 621-633.
O’Connor-McCourt, M .D ., & Wakefield, L .M . (1987). Latent 
transforming growth factor-b in serum: a specific complex with 
a2-macroglobulin. Journal of  Biological Chemistry, 262 :  14090- 
14099.
Ohno, S. (1977). The Y-linked H-Y antigen locus and the X-linked 
Tfm locus as major regulatory genes pf the mammalian sex 
determining mechanism. Journal of  Steroid Biochemistry, 8: 585- 
592.
Ohnuki, Y., Marnell, M.M., Babcock, M.S., Lechner, J.F., &  Kaighn, 
M .E. (1980). Chromosomal analysis of human prostatic 
adenocarcinoma cell lines. Cancer Research, 40: 524-534.
Oishi, K., Okada, K., Yoshida, O., Yamabe, H., Ohno, Y., Hayes, R.B., &  
Schroeder, F.H. (1988). A case-control study of prostatic cancer 
with reference to dietary habits. The Prostate, 12: 179-190.
Okada, K., & Schroder, F.H. (1974). Human prostatic carcinoma in 
cel culture: preliminary report on the development and
characterization of an epithelial cell line. Urological Research, 2:
1 1 1 - 1 2 1 .
4 2 3
CITATIONS
Olea, N., Sakabe, K., Soto, A.M., & Sonnenschein, C. (1990). The 
proliferative effect of "anti-androgens" on the androgen-sensitive 
human prostate tumor cell line LNCaP. Endocr ino logy , 126: 1457- 
1463.
O'Malley, B. (1990). The steroid receptor superfamily: more 
excitement predicted for the future. Molecu lar  Endocrinology,  4: 
363-369 .
O'Malley, B., Sherman, M.R., & Toft, D.O. (1970). Progesterone 
"receptors" in the cytoplasm and nucleus of chick oviduct target 
tissue. Proceedings of  the National Academy of  Sciences o f  The 
United States of  America., 67: 501-508.
O'Malley, B., & Tsai, M.-J. (1992). Molecular pathways of steroid 
receptor action. Biology of  Reproduction, 46: 163-167.
O'Neill, J.S., & Miller, W.R. (1987). Aromatase activity in breast 
aipose tissue from women with benign and malignant breast 
disease. British Journal of Cancer, 56: 601-604.
Oppenheimer, J.H., Schwartz, H.L., Surks, M .I., Koerner, D., &  
Dillman, W .H. (1976). Nuclear receptors and the initiatio of 
thyroid hormone action. Recent Progress in Hormone Research, 
32: 529-565.
Orlowski, J., & Clark, A.F. (1988). Estrogen metabolism by 
primary cultures of rat ventral prostate epithelial and stromal 
cells. Journal of  Steroid Biochemistry, 29: 361-368.
Osborne, M.P., Karmali, R.A., Hershcopf, R.J., Bradlow, H.L., &  
Fishman, J. (1988). Omega-3 fatty acids: modulation of estrogen 
metabolism and potential for breast cancer prevention. C a n c e r  
Invest igat ion ,  8: 629-631.
424
CITATIONS
Ota, D.M., Jones, L.A., Jackson, G.L., Jackson, P.M., Kemp, K., &  
Bauman, D. (1986). Obesity, non-protein-bound oestradiol levels 
and distribution of oestradiol in the sera of breast cancer 
patients. Cancer ,  57: 558-562.
Owen, A.J., Pantazis, P., & Antoniades, H.N. (1984). Simian 
sarcoma virus-transformed cells secrete a mitogen identical to 
platelet-derived growth factor. Science, 225: 54-56.
Pack, B.A., & Brooks, S.C. (1970). Metabolism of estrogens and 
their sulfates in rat uterine minces. Endocr ino logy ,  87: 924-933.
Pack, B.A., &  Brooks, S.C. (1974). Cyclic activity of estrogen 
sulfotransferase in the gilt uterus. Endocr ino logy,  95: 1680-1690.
Panganiban, G.E.F., Rashka, K.E., Neitzel, M.D., &  Hoffmann, F.M. 
(1990). Biochemical characterization of the D r o s o p h i l a  dpp 
protein, a member of the transforming growth factor p family of 
growth factors. Molecular and Cellular Biology, 10: 2669-2677.
Papamichail, M., Ioannidis, C., Tsawdaroglou, N., & Sekeris, C.E.
(1981). Translocation of glucocorticoid receptor from the 
cytoplasm into the nucleus of phytoemmaglutinin-stimulated 
human lymphocytes in the absence of the hormone. E x p e r im e n ta l  
Cell Research, 133: 461-465.
Pardridge, W .M . (1981). Transport of protein-bound hormones 
into tissues in vivo. Endocrine Reviews, 2: 103-123.
Pardridge, W.M., & Landow, E.M. (1984). Tracer kinetic model of 
blood-brain barrier transport of plasma protein-bound ligands. 
Journal of  Clinical Investigation, 74: 745-752.
Parker, M.G. (1986). Mechanism of steroid hormone action.
Cancer Surveys, 5: 625-633.
425
CITATIONS
Parker, M.G., Needham, M., & White, R. (1982). Prostatic steroid 
binding proteins: gene duplication and steroid binding. N a t u r e , 
298: 92-94.
Parker, M.G., & Bakker, O. (1991). Nuclear hormone receptors: 
concluding remarks. In: Nucler Hormone Receptors. M.G. Parker 
(Ed.), pp. 377-396. London: Academic Press.
Parrish, R.F., Heston, W.D.W., Pletscher, L.S., Tackett, R., &  Fair, 
W.R. (1984). Prostate derived growth factors. In: New  
Approaches to the Study of  Benign Prostatic Hyperplasia. F.A. 
Kimball, A.E. Buhl, & D.B. Carter (Ed.), pp. 181-195. New York: 
Alan R. Liss.
Pascall, J.C., Jones, D.S.C., Doel, S.M., Clements, J.M., Hunter, M., 
Fallon, T., Edwards, M., & Brown, K.D. (1991). Cloning and 
characterization of a gene encoding pig epidermal growth factor. 
Journal o f  Molecular Endocrinology, 6: 63-70.
Pasqualini, J.R., & Kind, F.A. (1986). Hormones and the Fetus,
Vol. 1. Oxford: Pergamon Press.
Pasqualini, J.R., Geliy, C., & Nguyen, B.-L. (1990). Metabolism and
biological response of estrogen sulfates in hormone-dependent 
and hormone-independent mammary cancer cell lines. Annals o f  
the New York Academy of  Sciences, 595: 106-116.
Pathak, D.R., Speizer, F.E., Willett, W.C., Rosner, B., &  Lipnick, R.J.
(1986). Parity and breast cancer risk: possible effect on age at 
diagnosis. International Journal of  Cancer, 37: 21-25.
Paul, C., Skegg, D.C.G., Spears, G.F.S., & Kaldor, J.M. (1986). Oral 
contraceptives and breast cancer: a national study. B r i t i s h  
Medical  Journal, 293: 723-726.
Peacock, E.E. (1984). Wound Repair. Philadelphia: Saunders.
426
CITATIONS
Peck, E.J.Jr., Burgner, J., & Clark, J.H. (1973). Estrophilic binding 
sites of the uterus. Relation to uptake and retention of estradiol 
in vitro. B iochem is try , 12: 4596-4603.
Perdew, G.H., & Whitelaw, M.L. (1991). Evidence that the 90-kDa 
heat shock protein (hsp90) exists in cytosol in heteromeric 
complexes containing hsp70 and three other proteins with Mr 
63000, 56000 and 50000. Journal o f  Biological Chemistry, 266: 
6 7 0 8 -67 1 3 .
Perel, E., & Killinger, D.W. (1979). The interconversion and 
aromatization of androgens by human adipose tissue. Journal o f  
Steroid Biochemistry, 10: 623-627.
Perrot-Applanat, M., Logeat, F., Groyer-Picard, M.T., &  Milgrom, E. 
(1985). Immunocytochemical study of mammalian progesterone 
receptor using monoclonal antibodies. Endocr ino logy ,  116: 1473- 
1484.
Pertschuk, L.P., Eisenberg, K.B., Macchia, R.J., &  Feldman, J.G.
(1985). Heterogeneity of steroid binding sites in prostatic 
carcinoma: morphological demonstration and clinical implications. 
The Prostate, 6: 35-47.
Pewnim, T., Adams, J.B., & Ho, K.P. (1980). A relationship between 
estrogen sulfurylation and estrogen and progesterone receptor 
status in human mammary carcinoma. Cancer  Research,  40: 
1360-1362 .
Pfeffer, U., Fecarotta, E., Castagnetta, L., & Vidali, G. (1993). 
Estrogen receptor variant messenger RNA lacking exon 4 in 
estrogen-responsive human breast cancer cell lines. C a n c e r  
Research ,  53: 741-743.
427
CITATIONS
Picard, D., Kumar, V., Chambon, P., & Yamamoto, K.R. (1990).
Signal transduction by steroid hormones: nuclear localization is
differentially regulated in estrogen and glucocorticoid receptors. 
Cell Regulation, 1: 291-299.
Pietenpol, J.A., Stein, R.W., & Moran, E. (1990a). TGF-pi inhibition 
of c-myc  transcription and growth in keratinocytes is abrogated 
by viral transforming proteins with pRb  binding domains. C e l l , 
61: 777-785.
Pietenpol, J.A., Holt, J.T., Stein, R.W., & Moses, H.L. (1990b). 
Transforming growth factor pi suppression of the c-myc  gene 
transcription: role in inhibition of keratinocyte proliferation.
Proceedings of  the National Academy of  Sciences o f  The United
States o f  America., 87: 3758-3762.
Pietras, R.J., & Szego, C.M. (1979). Estrogen receptors in uterine 
plasma membrane. Journal o f  Steroid Biochemistry, 11: 1471- 
1483.
Pike, M.C., Henderson, B.E., Krailo, M.D., Duke, A., &  Roy, S. (1983). 
Breast cancer in young women and use of oral contraceptives: 
possible modifying effect of formulation and age at use. L a n c e t ,  
ii: 926-930.
Pircher, R., Jullien, P., & Lawrence, D.A. (1988). p-transforming  
growth factor is stored in human platelets as a latent high 
molecular weight complex. Biochemical and Biophysical Research 
Communicat ions,  136: 30-37.
Pledger, W.J., Stiles, C.D., Antoniades, H.N., & Scher, C.D. (1978). An 
ordered sequence of events is required before BALB/c 3T3 cells 
become committed to DNA synthesis. Proceedings of  the National  
Academy o f  Sciences of  The United States of  America., 75: 2839- 
2843.
428
CITATIONS
Plowman, G.D., Whitney, G.S., Neubauer, M.G., Green, J.M., 
McDonald, V.L., Todaro, G.J., & Shoyab, M. (1990). Molecular 
cloning and expression of an additional epidermal growth factor- 
related gene. Proceedings of the National Academy of  Sciences o f  
The United States of  America., S I :  4905-4909.
Pollard, M., & Luckert, P.H. (1986). Promotional effects of 
testosterone ad dietary fat on the development of autochthonous 
prostate cancer in rats. Cancer Letters, 32: 223-227.
Pollard, M., Luckert, P.H., & Schmidt, M.A. (1982). Induction of 
prostate adenocarcinoma in Lobund Wistar rats by testosterone. 
The Prostate, 3: 563-568.
Pollard, M ., Snyder, D .L ., & Luckert, P.H. (1987).
Dihydrotestosterone does not induce prostate adenocarcinoma in 
L-W  rats. The Prostate, 10: 325-331.
Pollow, K., Boquoi, E., Baumann, J., Schmidt-Gollwitzwer, M., &  
Pollow, P. (1977). Comparison of the in vitro conversion of 
estrad io l-17p to estrone in normal and neoplastic human breast 
tissue. Molecular and Cellular Endocrinology, 6: 333-348.
Ponta, H., Kennedy, N., Skroch, P., Hynes, N.E., & Groner, B. (1985). 
Hormonal response region in the mouse mammary tumour virus 
long terminal repeat can be dissociated from the proviral 
promoter and has enhancer properties. Proceedings o f  the 
National Academy of  Sciences of  The United States of  America.,  
82: 1020-1024.
Porter, C.D., &  Archard, L.C. (1987). Characterization and physical 
mapping of molluscum contagiosum virus DNA and location of a 
sequence capable of encoding a conserved domain of epidermal 
growth factor. Journal of  Genetic Virology, 68: 673-682.
429
CITATIONS
Pour, P., Althoff, J., Salmasi, S.Z., & Stepan, K. (1979). Spontaneous 
tumours and common diseases in three types of hamsters. 
Journal of  National Cancer Institute, 63: 797-811.
Pour, P.M., & Stepan, K. (1987). Induction of prostatic carcinomas 
and lower urinary tract neoplasms by combined treatment of 
intact and castrated rats with testosterone proprionate and N- 
nitrosobis(2-oxopropil)amine. Cancer Research, 47: 5699-5706.
Poutanen, M., Moncharmont, B., & Vihko, R. (1992). 17(3- 
Hydroxysteroid dehydrogenase gene expression in human breast 
cancer cells: regulation of expression by a progestin. C a n c e r  
Research,  52: 290-294.
Pratt, W .B. (1987). Transformation of glucocorticoid and 
progesterone receptors to the DNA-binding state. Journa l  o f  
Cel lu lar  Biochemistry, 35: 51-68.
Pratt, W.B. (1993). Role of heat-shock proteins in steroid receptor 
function. In: Frontiers in Molecular Biology: Steroid Hormone  
Action.  M.G. Parker (Ed.), pp. 64-93. Oxford: Oxford University 
Press.
Pratt, W.B., Jolly, D.J., Pratt, D.V., Hollenberg, S.M., Giguere, V., 
Cadepond, F.M., Schweizer-Groyer, G., Catelli, M.G., Evans, R.M., &  
Baulieu, E.-E. (1988). A region in the steroid binding domain 
determines formation of the non-DNA-binding, 9S glucocorticoid 
receptor complex. Journal of  Biological Chemistry, 263: 267-273.
Pratt, W.B., Scherrer, L.C., Hutchison, K.A., & Dalman, F.C. (1992). 
A model of glucocorticoid receptor unfolding and stabilization by 
a heat shock protein complex. Journal o f  Steroid Biochemistry 
and Molecular Biology, 41: 223-229.
430
CITATIONS
Prigent, S.A., & Lemoine, N.R. (1992). The type 1 (EGFR-related) 
family of growth factor receptors and their ligands. Progress in 
Growth Factor Research, 4: 1-24.
Prost, O., Turrel, M.O., Dahan, N., Craveur, C., & Adessi, G.L. (1984). 
Estrone and dehydroepiandrosterone sulfatase activities and 
plasma estrone sulfate levels in human breast carcinoma. C a n c e r  
Research,  44: 661-664.
Prudhomme, J.F., Malet, C., Gompel, A., Lalardrie, J.P., Ochoa, C., 
Boue, A., Mauvais-Jarvis, P., & Kuttenn, F. (1984). 17(3-
Hydroxysteroid dehydrogenase activity in human breast 
epithelial cell and fibroblast cultures. E n d o c r in o lo g y , 114: 1483- 
1488.
Pruitt, B., Rose, D.P., & Bryan, G.T. (1979). Hormone dependence of 
N-nitrosomethylurea (NMU)-induced rat mammary tumors: 
response to two modes of anti-estrogen therapy. Proceedings o f  
the American Association fo r  Cancer Research, 20: 87.
Pryor, M., Slattery, M.L., Robison, L.M ., & Egger, M. (1989). 
Adolescent diet and breast cancer in Utah. Cancer Research, 49: 
2161-2167 .
Purchio, A., Cooper, J., Brunner, A., Lioubin, M., Gentry, L.E., 
Kovacina, K., Roth, R., & Marquardt, H. (1988). Identification of 
mannose-6-phosphate in two asparagine-linked sugar chains of 
recombinant transforming growth factor-p 1 precursor. Journal of  
Biological Chemistry, 263: 14211-14215.
Purhoit, A., Riaz, A.A., Ghilchik, M.W., & Reed, M.J. (1992). The 
origin of oestrone sulphate in normal and malignant breast 
tissues in postmenopausal women. H o r m o n e  M e t a b o l i s m  
Research,  24: 532-536.
4 3  1
CITATIONS
Puri, R.K., Grandics, P., Dougherty, J.J., & Toft, D.O. (1982). 
Purification of "nontransformed" avian progesterone receptor and 
preliminary characterization. Journal o f  Biological Chemistry , 
257: 10831-10837.
Quarmby, V.E., Beckman, W.C.Jr., Wilson, E.M., & French, F.S.
(1987). Androgen regulation of c-myc messenger ribonucleic acid 
levels in rat ventral prostate. M olecu la r  Endocrinology,  1: 865- 
874.
Raam, S., Nemeth, E., Tamura, H., O'Brian, D.S., & Cohen, J.L.
(1982). Imunohistochemical localization of estrogen receptors in 
human mammary carcinoma using antibodies to the receptor 
protein. European Journal of Cancer and Clinical Oncology, 18: 1- 
12.
Raines, E.W., Bowen-Pope, D.F., & Ross, R. (1984). Plasma binding 
proteins for platelet-derived growth factor that inhibit its 
binding to cell-surface receptors. Proceedings o f  the Nat ional  
Academy of  Sciences of  The United States of  America., 81: 3424- 
3428.
Ramcharan, S., Pellegrin, F.A., Ray, R.M., &  Hsu, J.-P. (1980). The 
Walnut Creek Contraceptive Drug Study. A prospective study of 
the side effects of oral contraceptives. Journal o f  Reproductive  
M e dic in e ,  25: 360-366.
Rannikko, S., & Adlercreutz, H. (1983). Plasma estradiol, free 
testosterone, sex hormone binding capacity, and prolactin in 
benign prostatic hyperplasia and prostatic cancer. The Prostate,  
4: 223-229.
Rechler, M .M ., & Nissley, S.P. (1986). Insulin-like growth 
factor/somatomedin receptor subtypes: structure, function and
relationships to insulin receptors and IGF carrier proteins. 
Hormone Research, 24: 152-159.
4 3 2
CITATIONS
Redeuilh, G., Moncharmont, B., Secco, C., & Baulieu, E.-E. (1987). 
Subunit composition of the molybdate-stabilized "8-9S" 
nontransformed estradiol receptor purified from calf uterus. 
Journal of  Biological Chemistry, 262: 6969-6975.
Reed, M.J., Cheng, R.W., Noel, C.T., Dudley, H.A.F., & James, V.H.T.
(1983). Plasma levels of estrone, estrone sulphate and estradiol 
and the precentage of unbound estradiol in postmenopausal 
women with and without breast disease. Cancer Research,  43: 
3940-3943.
Reisner, A.H. (1985). Similarity between the vaccinia virus 19K 
early protein and epidermal growth factor. N a t u r e ,  313: 801- 
803.
Rennie, P.S., Bruchovsky, N., McLoughlin, M.G., Batzold, F.H., &  
Dunstan-Adams, E.E. (1983). Kinetic analysis of 5a-reductase  
isoenzymes in bening prostatic hyperplasia (BPH). Journal o f  
Steroid Biochemistry, 19: 169-173.
Rinderknecht, E., & Humbel, R.E. (1978a). The amino acid 
sequence of human insulin-like growth factor I and its structural 
homology with proinsulin. Journal of  Biological Chemistry, 253: 
2769-2776.
Rinderknecht, E., & Humbel, R.E. (1978b). Primary structure of 
insulin-like growth factor II. FEBS Letters, 89: 283-286.
Robbins, P.W., & Lipman, F. (1957). Isolation and identification of 
active sulfate. Journal o f  Biological Chemistry, 229: 837-851.
4 3 3
CITATIONS
Roberts, A.B., Lamib, L.C., Newton, D.L., Spom, M.B., De Larco, E., & 
Todaro, G.J. (1980). Transforming growth factors: isolation of
polypeptides from virally and chemically transformed cells by
acid ethanol extraction. Proceedings of the National Academy of
Sciences of The United States of America., 77: 3494-3498.
Roberts, A.B., Anzano, M.A., Lam, L.C., Smith, J.M., &  Sporn, M.B. 
(1981). New class of transforming growth factor potentiated by
epidermal growth factor: isolation from non-neoplastic tissues. 
Proceedings of  the National Academy of Sciences of  The United 
States of  America., 78: 5339-5343.
Roberts, A.B., Sporn, M.B., Assoian, R.K., Smith, J.M., Roche, N.S., 
Wakefield, L.M., Heine, U.I., Liotta, L.A., Falanga, V., Kehrl, J.H., & 
Fauci, A.S. (1986). Transforming growth factor type-beta: rapid 
induction of fibrosis and angiogenesis in vivo and stimulation of 
collagen formation in vitro. Proceedings of  the National Academy 
of  Sciences of  The United States of  America,, %'S: 4167-4171.
Roberts, Thompson, N.L., Heine, U., Flanders, C., &  Sporn, M.B.
(1988). Transforming growth factor-beta: possible role in
carcinogenesis. British Journal of  Cancer, 57: 594-600.
Roberts, A.B., & Sporn, M.B. (1990). The transforming growth 
factors-p. In: Handbook of Experimantal Pharmacology,  Vol. 
9511: Peptide Growth Factors and their Receptors. M.B. Sporn & 
A.M. Roberts (Ed.), pp. 419-472. Heidelberg: Springer-Verlag.
Roberts, A.B., Kim, S.-J., Noma, T., Glick, A.B., Lafyatis, R., 
Lechleider, R., Jakowlew, S.B., Geiser, A., O'Reilly, M.A., Danielpour, 
D., &  Sporn, M.B. (1991). Multiple forms of TGF-p: distinct 
promoters and differential expression. In: Ciba Foundation
Symposium 157: Clinical Applications of  TGF-p.  G.R. Bock & J. 
Marsh (Ed.), pp. 7-28. Chichester: Wiley.
4 3 4
CITATIONS
Roberts, K.D., Rochefort, J.G., Bleau, G., & Chapdelaine, A. (1980). 
Plasma estrone sulfate levels in postmenopausal women. 
Steroids, 35: 179-187.
Robertson, M. (1988). Molecular associations and comceptual 
connections. Nature ,  334: 100-102.
Robinette, C.L., McGraw, R.G., Cricco, R.P., & Mawhinney, M.G.
(1978). Localization, metabolism and binding of estrogens in the 
male rat. Archives o f  Biochemistry and Biophysics, 191: 517- 
524.
Romieu, I., Berlin, J.A., & Colditz, G. (1990). Oral contraceptives 
and breast cancer: review and meta-analysis. C a n c e r ,  66 :  2253- 
2263.
Rose, D.P., Pruitt, B., Stauber, P., Ertuk, E., &  Bryan, G.T. (1980). 
Influence of dosage schedule on the biological characteristics of 
N-nitrosomethylurea induced rat mammary tumors. C a n c e r  
Research,  40: 235-239.
Rose, D.P., Boyar, A.P., &  Wynder, E.L. (1986). International 
comparisons of mortality rates for cancer of the breast, ovary, 
prostate, colon, and per capita food consumption. C a n c e r ,  58: 
2363-2371.
Ross, R., Glomset, J.A., Kariya, B., & Harker, L. (1974). A platelet 
dependent serum factor that stimulates the proliferation of 
arterial smooth muscle cells in vitro. Proceedings of  the National  
Academy of  Sciences of  The United States of America., 71: 1207- 
1210 .
Ross, R., Raines, E.W., & Bowen-Pope, D.F. (1986). The biology of 
platelet-derived growth factor. Cell,  46: 155-169.
4 3 5
CITATIONS
Ross, R.K., Bernstein, L., Judd, H., Hanisch, R., Pike, M., & 
Henderson, B.E. (1986). Serum testosterone levels in healthy 
young black and white men. Journal of  the Nat ional  Cancer  
In s t i tu te , 76: 45-48.
Ross, R.K., Pike, M.C., Henderson, B.E., Mack, T.M., & ^obo, R.M.
(1989). Stroke prevention and oestrogen replacement therapy. 
L a n c e t , i: 505-509.
Ross, R.K., & Bernstein, L. (1991). Why can't we prove that 
hormone replacement therapy causes breast cancer? 
Methodological and biological challenges. In: H orm o ne
Replacement Therapy and Breast Cancer Risk. R.D. Mann (Ed.), 
pp. 241-252. London: The Parthenon Publishing Group.
Ross, R.K., Bernstein, L., Lobo, R.A., Shimizu, H., Stanczyk, F.Z., Pike, 
M.C., & Henderson, B.E. (1992). 5-alpha-reductase activity and 
risk of prostate cancer among Japanese and US white and black 
males. The Lancet, ii: 887-889.
Rotwein, P., Pollock, K.M., Didier, D.K., & Krivi, G.G. (1986a). 
Organization and sequence of the human insulin-like growth 
factor I gene. Journal o f  Biological Chemistry, 261: 4828-4832.
Rotwein, P. (1986b). Two insulin-like growth factor I messenger 
RNAs are expressed in human liver. Proceedings o f  the National  
Academy of  Sciences of  The United States of  America., 83: 77-81.
Roush, G.C., Holford, T.R., Schymura, M.J., & White, C. (1987). 
Cancer Risk and Incidence Trends. Washington: Hemisphere
Publishing.
Rousseau, G.G., Baxter, J D., Higgins, S.J., & Tomkins, G.M. (1973). 
Steroid-induced nuclear binding of glucocorticoid receptors in 
intact hepatoma cells. Journal of  Molecular Biology, 79: 539-554.
436
CITATIONS
Royal College of General Practitioners (1974). O ra l  Contraceptives 
and Health. New York: Pitman Publishing.
Rozengurt, E. (1986). Early signals in the mitogenic response. 
Science, 234: 161-166.
Ruoslahti, E., & Pierschbacher, M.D. (1987). New perspectives in 
cell adhesion: RGD and integrins. Science, 238: 491-497.
Rushmere, N.K, Parker, M.G., & Davies, P. (1987). Androgen 
receptor-binding regions of an androgen-responsive gene. 
Molecular and Cellular Endocrinology, 51: 259-265.
Russo, J., & Russo, I.H . (1987). Development of the human 
mammary gland. In: The M am m ary  G land,  Development,
Regulation and Function. M.C. Neville & C.W. Daniel (Ed.), pp. 67- 
93. London: Plenum Press.
Saffran, J., Loeser, B.K., Bohnett, S.A., &  Faber, L.E. (1976). Binding 
of progesterone receptor by nuclear preparations of rabbit and 
guinea pig uterus. Journal of  Biological  Chemistry, 251: 5607- 
5613.
Salmon, W.D., & Daughaday, W.H. (1957). A hormonally controlled 
serum factor which stimulates sulfate incorporation by cartilage 
in vitro. Journal o f  Laboratory and Clinical Medicine., 49: 825- 
836.
Samsoondar, J., Kobrin, M.S., & Kudlow, J.E. (1986). Alpha 
transforming growth factor secreted by untransformed bovine 
anterior pituitary cells in culture. Journal o f  Biological Chemistry, 
261: 14408-14413.
Sanchez, E.R. (1990). Hsp56: a novel heat shock protein associated 
with untransformed steroid receptor complexes. Journa l  o f  
Biological  Chemistry, 265: 22067-22070.
437
CITATIONS
Sanchez, E.R., Toft, D.O., Schlesinger, M.J., & Pratt, W.B. (1985). 
Evidence that the 90-kDa phosphoprotein associated with the 
untransformed L-cell glucocorticoid receptor is a murine heat
shock protein. Journal of  Biological Chemistry , 260: 12398-
12401.
Sanchez, E.R., Hirst, M., Scherrer, L.C., Tang, H.-Y., Welsh, M.J.,
Harmon, J.M., Simons, S.S.Jr., Ringold, G.M., & Pratt, W.B. (1990a).
Hormone-free mouse glucocorticoid receptors overexpressed in
Chinese hamster ovary cells are localized to the nucleus and are 
associated with both hsp70 and hsp90. Journal o f  B io logica l  
C h e m is t ry , 265: 20123-20130.
Sanchez, E.R., Faber, L.E., Henzel, W.J., & Pratt, W.B. (1990b). The 
56-59 kilodalton protein identified in untransformed steroid 
receptor complexes is a unique protein that exists in cytosol in a 
complex with both the 70- and 90-kilodalton heat shock proteins. 
Biochemistry,  29: 5145-5152.
Sandberg, A.A., & Kadohama, N. (1980). Regulation of prostate 
growth in organ culture. Progress in C l in ica l  and Bio logical  
Research,  37: 9-29.
Santen, R.J. (1986). Determinants of tissue estradiol levels in 
human breast cancer. Cancer Surveys, 6: 597-616.
Santen, R.J. (1988). Local estrogen production by human breast 
tumours. In: Endocrine-Dependent Breast Cancer:  C r i t ic a l
Assessment of  Recent Advances. R.J. Santen & E. Juhos (Ed.), pp. 
49-57. Bern: Hans Huber.
Santner, S.J., Feil, P.D., & Santen, R.J. (1984). In situ estrogen 
production via the estrone sulfatase pathway in breast tmors: 
relative importance versus the aromatase pathway. Journal o f  
Clinical Endocrinology and Metabolism, 59: 29-33.
438
CITATIONS
Santner, S.J., Leszczynski, D., Wright, C., Manni, A., Feil, P.D., &  
Santen, R.J. (1986). Estrone-sulfate: a potential source of estradiol 
in human breast cancer tissues. Breats Cancer Research and  
T re a tm e n t , 7: 89-94.
Savage, C.R., Inagami, T., & Cohen, S. (1972). The primary 
structure of epidermal growth factor. Journa l  o f  B io log ica l  
C h e m is t ry , 247: 7612-7621.
Savage, C.R., Hash, J.H., & Cohen, S. (1973). Epidermal growth 
factor: location of disulphide bonds. Journa l  o f  B io log ica l  
Chemistry ,  248: 7669-7672.
Savion, N., Vlodavsky, I., & Gospodarowicz, D. (1980). Role of the 
degradation process in the mitogenic effect of epidermal growth 
factor. Proceedings o f  the National Academy o f  Sciences o f  The 
United States of  America., 77: 1466-1470.
Schackney, S.E., McCormack, G.W., &  Curhural, G.J. (1978). Growth 
rate patterns of solid tumours and their relation to 
responsiveness to therapy. Annals o f  Internal Medic ine , 89: 107- 
113.
Schatz, F., & Hochberg, R.B. (1981). Lipoidal derivative of 
estradiol: the biosynthesis of a nonpolar estrogen metabolite.
Endocr ino logy, 109: 697-703.
Schechter, A.L., Stern, D.F., Vaidyanathan, L., Decker, S.J., Drebin, 
J.A., Greene, M.I., & Weinberg, R.A. (1984). The neu oncogene: an 
e r b B  -related gene encoding a 185,000-Mr tumour antigen. 
N atu re ,  312: 513-516.
Schlessinger, J. (1988). The epidermal growth factor as a 
multifunctional allosteric protein. Biochem is try , 27: 3119-3123.
439
CITATIONS
Schlesinger, M.J. (1990). Heat shock proteins. Journal o f  Biological 
Chemistry ,  265: 12111-12114.
Schneider, J., Kinne, D., Fracchia, A., Pierce, V., Anderson, K.E., 
Bradlow, H .L., & Fishman, J. (1982). Abnormal oxidative
metabolism of estradiol in women with breast cancer. 
Proceedings of  the National Academy of  Sciences of  The United 
States o f  America., 79: 3047-3051.
Schneider, J., Huh, M.M., Bradlow, H.L., & Fishman, J. (1984). 
Antiestrogen actionn of 2-hydroxyestrone on MCF-7 human 
breast cancer cells. Journal o f  Biological Chemistry, 259: 4840- 
4845.
Schreiber, A.B., Winkler, M.E., & Derynck, R. (1986). Transforming 
growth factor alpha: a more potent angiogenic mediator than 
epidermal growth factor. Science, 232: 1250-1253.
Schuh, S., Yonemoto, W., Brugge, J., Bauer, V.J., Riehl, R.M., 
Sullivan, W.P., & Toft, D.O. (1985). A 90000-dalton binding 
protein common to both steroid receptors and the Rous sarcoma 
virus transforming protein, pp60v-src. Journal  o f  B io log ica l  
C h e m is t ry , 260: 14292-14296.
Schultz, G.S., White, M., Mitchell, R., Brown, G., Lynch, J., Twardzik, 
D.R., & Todaro, G.J. (1987). Epidermal wound healing enhanced by 
transforming growth factor-alpha and vaccinia growth factor. 
Science, 235: 350-352.
Schulze, H., & Barrack, E.R. (1987). Immunocytochemical
localization of estrogen receptors in spontaneous and 
experimentally induced canine benign prostatic hyperplasia. Th e  
Prostate,  11: 145-162.
440
CITATIONS
Schuurmans, A.L.G., Bolt, J., Voorhorst, M.M., Blankenstein, R.A., & 
Mulder, E. (1988a). Regulation of growth and epidermal growth 
factor receptor levels of LNCaP prostate tumor cells by different 
steroids. International Journal of  Cancer, 42: 917-922.
Schuurmans, A.L.G., Bolt, J., & Mulder, E. (1988b). Androgens 
stimulate both growth-rate and epidermal growth factor receptor 
activity of the human prostate tumor cell line LNCaP, T h e  
Pro s ta te , 12: 55-64.
Schuurmans, A.L.G., Bolt, J., Veldscholte, J., & Mulder, E. (1991). 
Regulation of growth of LNCaP human prostate tumor cells by 
growth factors and steroid hormones. Journa l  o f  Steroid  
Biochemistry and Molecular Biology, 40: 193-197.
Schwartzman, R.B., & Cidlowski, J.A. (1993). Apoptosis: the 
biochemistry and molecular biology of programmed cell death. 
Endocrine Reviews, 14: 133-151.
Scott, J., Urdea, M., Quiroga, M., Sanchez-Pescador, R., Fong, N., 
Selby, M., Rutter, W.J., & Bell, G.I. (1983). Structure of mouse 
submaxillary messenger RNA encoding epidermal growth factor 
and several related proteins. Science, 221: 238-240.
Scott, J., Patterson, S., Rail, L., Bell, G.I., Crawford, R., Penschow, J., 
Niall, H., & Coughlan, J. (1985). The structure and biosynthesis of 
epidermal growth factor. Journal of  Cell  Science, 3: 19-28.
Segarini, P. (1991). TGF-p receptors. In: Ciba Foundation
Symposia: Clinical Applications of  TGF-p. GR Bock & J Marsh (Ed.), 
157, pp. Chichester: Wiley.
Segarini, P., & Seyedin, S.M. (1988). The high molecular weight 
receptor to transform ing growth factor-P contains 
glycosaminoglycan chains. Journal o f  Biological Chemistry, 263: 
8366-8370 .
4 4 1
CITATIONS
Seifert, R.A., Schwartz, S.M., & Bowen-Pope, D.F. (1984). 
Developmentally regulated production of platelet-derived growth 
factor-like molecules. Nature ,  311: 669-671.
Seifert, R.A., Hart, C.E., Philips, P.E., Forstrom, J.W., Ross, R., 
Murray, M.J., & Bowen-Pope, D.F. (1988). Two different subunits 
associate to create isoform-specific platelet-derived growth 
factor receptors. Journal o f  Biological Chemistry, 264: 8771 - 
8778.
Seyedin, P.R., Segarini, P., Rosen, D.M., Thompson, A.Y., Bentz, H., &  
Graycar, J. (1987). Cartilage-inducing factor-B is a unique protein 
structurally and functionally related to transforming growth 
factor-beta. Journal of  Biological Chemistry, 262: 1946-1949.
Sha, X., Brunner, A.M ., Purchio, A.F., & Gentry, L.E. (1989). 
Transforming growth factor p i: importance of glycosylation and 
acidic proteases for processing and secretion. M o l e c u l a r  
Endocrinology,  3: 1090-1098.
Shain, S.A., McCullough, B., & Segaloff, A. (1975). Spontaneous 
adenocarcinomas of the ventral prostate of aged AXC rats. J o u rn a l  
of  the National Cancer Institute, 55: 177-180.
Shankar, V., Ciardiello, F., Kim, N., Derynck, R., Liscia, D.S., Merlo, 
G., Langton, B.C., Sheer, D., Callahan, R., Bassin, R.H., Lippman, M.E., 
Hynes, N., & Salomon, D.S. (1989). Transformation of an 
established mouse mammary epithelial cell line with a human 
transforming growth factor alpha cD N A . M o l e c u l a r  
Carcinogenesis, 2: 1-11.
Shannon, J.M., & Cunha, G.R. (1984). Characterization of androgen 
binding and deoxyribonucleic acid synthesis in prostate-like 
structures induced in the urothelium of testicular feminized 
(Tfm /Y) mice. Biology of  Reproduction, 31: 175-183.
4 4 2
CITATIONS
Sharifi, R., & Kiefer, J. (1987). History of endocrine manipulation 
in the treatment of carcinoma of the prostate - who was first? 
Journal of  Endocrinological Investigation, 10: 2-91.
Sheridan, P.J., Buchanan, J.M., Anselmo, V.C., & Martin, P.M.
(1979). Equilibrium: the intracellular distribution of steroid
receptors. N a t u r e , 282: 579-582.
Sheridan, P.J., Buchanan, J.M., Anselmo, V.C., & Martin, P.M. 
(1981). Unbound progesterone receptors are in equilibrium  
between the nucleus and cytoplasm in cells of the rat uterus. 
Endocrinology,  108: 1533-1537.
Sherman, M.R. (1984). Structure of mammalian steroid receptors: 
evolving concepts and methodological developments. A n n u a l  
Review of  Physiology, 46: 83-105.
Sherman, B.M ., &  Korenman, S.G. (1974). Inadequate corpus 
luteum function: a pathophysiological interpretation of human 
breast cancer epidemiology. Cancer,  33: 1306-1312.
Sherman, B.M., Wallace, R.B., & Jochimsen, P.R. (1979). Hormonal 
regulation of the menstrual cycle in women with breast cancer: 
effect of adjuvant chemotherapy. Clinical Endocrinology, 10: 287- 
296.
Shipley, G.D., Pittelkow, M.R., Wille, J.J., Scott, R.E., & Moses, H.L.
(1986). Reversible inhibition of normal human prokeratinocyte 
proliferation by type p transforming growth factor-growth 
inhibitor in serum-free medium. Cancer Research,  46: 2068- 
2071.
4 4 3
CITATIONS
Shirai, T., Tagawa, Y., Fukushima, S., Asamoto, M., & Ito, N. (1987). 
Lack of tumorigenic response in the prostate gland of castrated 
F344 rats by 3,2'-dimethyl-4-aminobiphenyl given with 
methyltestosterone. Cancer Letters, 35: 1-6.
Shirai, T., Tagawa, Y., Fukushima, S., & Ito, N. (1988). Induction of 
prostate carcinoma at high incidence in F344 rats by 3,2'- 
dimethyl-4-aminobiphenyl. In: Carcinogenic and Mutagenic  
Responses to Aromatic Amines and Nitroarenes. C.M. King (Ed.), 
pp. 211-221. New York: Elsevier.
Shoyab, M.„ Plowman, G.D., McDonald, V.L., Bradley, J.G., & Todaro,
G.J. (1989). Structure and function of human amphiregulin: a 
member of epidermal growth factor family. Science,  243: 1074- 
1076.
Shyamala, G., & Gorski, J. (1969). Estrogen receptors in the rat 
uterus. Studies on the interaction of cytosol and nuclear binding 
sites. Journal of  Biological Chemistry,244: 1097-1103.
Siiteri, P.K., & Wilson, J.D. (1970). Dihydrotestosterone in prostatic 
hypertrophy. I. The form ation and content of 
dihydrotestosterone in the hypertrophic prostate of man. J o u r n a l  
of  Clinical Investigation, 49: 1737-1745.
Siiteri, P.K., Schwarz, B.E., Moriyama, I., Ashby, R., Linkie, D., &  
MacDonald, P.C. (1973). Estrogen binding in the rat and human.
Advances in Experimental Medicine and Biology,36 : 97-112.
Siiteri, P.K., Schwartz, B.E., & MacDonald, P.C. (1974). Estrogen 
receptors and the estrone hypothesis in relation to endometrial 
and breast cancer. Gynecologic Oncology, 2: 228-238.
4 4 4
CITATIONS
Siiteri, P.K., Hammond, G.L., & Nisker, J.A. (1981). Increased 
availability of serum estrogens in breast cancer: a new
hypothesis. In: Hormones and Breast Cancer. M.C. Pike, P.K. 
Siiteri, & C. Welsh (Ed.), pp. 87-106. New York: Cold Spring 
Harbour Laboratory.
Siiteri, P.K., Murai, J.T., Hammond, G.L., Nisker, J.A., Raymoure, 
W.J., & Kuhn, R.W. (1982). The serum transport of steroid 
hormones. Recent Progress in Hormone Research, 38: 457-463.
Siiteri, P.K., Simberg, N., & Murai, J.T. (1986). Estrogens and 
breast cancer. Annals of  the New York Academy o f  Sciences, 464: 
100-105.
Simpson, E.R., &  Mendelson, C.R. (1989). The regulation of 
oestrogen biostynthesis in human adipose tissue. In: Oestrogen 
and the Human Breast. J.S. Beck (Ed.), 95B, pp. 153-159. 
Edinburgh: Royal Society of Edinburgh.
Simpson, R.J., Smith, J.A., Moritz, R.L., O'Hare, M.J., Rudnand, P.S., 
Morrison, J.R., Lloyd, C.J., Greyo, B., Burgess, A.W., Nice, E.C., &  
Cobley, U.T. (1985). Rat epidermal growth factor: complete amino 
acid sequence. Homology with the corresponding murine and 
human proteins; isolation of a form truncated at both ends with 
full in vitro biological activity. European Journal o f  Biochemistry, 
153: 629-637.
Singh, A., Reed, M.J., Ghilchik, M.W., & James, V.H.T. (1989). The 
effect of breast tumour and normal breast tissue cytosols on 
oestradiol 17p-hydroxysteroid dehydrogenase activity. C a n c e r  
Letters ,  44: 45-48.
Singh, A., & Reed, M.J. (1991). Insulin-like growth factor type I 
and insulin-like growth factor I I  stimulate oestradiol-17p 
hyfroxysteroid dehydrogenase (reductive) activity in breast 
cancer cells. Journal of Endocrinology, 129: R5-R8.
445
CITATIONS
Singh, A., Blench, I., Morris, H.R., Savoy, L.A., & Reed, M.J. (1992). 
Synergistic interaction of growth factors and albumin in 
regulating estradiol synthesis in breast cancer cells. M o l e c u l a r  
and Cellular Endocrinology, 85: 165-173.
Sirett, D.A.N., Cowan, S.K., Janeczko, A.E., & Grant, J.K. (1980). 
Prostatic tissue distribution of 17p-hydroxy-5a-androstan-3-one  
and of androgen receptors in benign hyperplasia. Journa l  o f
Steroid Biochemistry, 13: 723-729.
Sitaras, N.M., Sariban, E., Bravo, M., Pantazis, P., & Antoniades,
H.N. (1988). Quantitative production of platelet-derived growth 
factor-like proteins by human prostate carcinoma cell lines. 
Cancer Research, 48: 1930-1935.
Skeet, R.G. (1976). Epidemiology of urological tumours. In: 
Scientific Foundation of  Urology, Vol. I I .  D.I. Williams & G.D. 
Chisholm (Ed.), pp. 199-211. London: Heinemann.
Skegg, D.C.G. (1988). Potential for bias in case-control studies of 
oral contracptives and breast cancer. American J ourna l  o f
E p id e m io lo g y , 127: 205-212.
Smith, D.F., Stensgard, B.A., Welch, W.J., & Toft, D.O. (1992). 
Assembly of progesterone receptor with heat shock proteins and
receptor activation are ATP-mediated events. J o u rn a l  o f
Biological Chemistry, 267: 1350-1355.
Smith, T., Chisholm, G.D., & Habib, F.K. (1982). Failure of human 
benign prostatic hyperplasia to aromatize testosterone. Journal of  
Steroid Biochemistry, 17: 119-120.
Sommers, S.C. (1955). Endocrine abnormalities in women with 
breast cancer. Laboratory Investigation, 4: 160-174.
446
CITATIONS
Sondik, E. (1988). Incidence, survival and mortality trends in 
prostate cancer. In: A Multidisciplinary Analysis of  Controversies 
in the Management of Prostate Cancer. DE Coffey, M I Resnick, & 
FA Dorr (Ed.), pp. 9-16. New York: Plenum Press.
Sonnenschein, C., Olea, N., Pasanen, M.E., & Soto, A.M. (1989). 
Negative control of cell proliferation: human prostate cancer cells 
and androgens. Cancer Research, 49: 3474-3481.
Sporn, M.B., & Todaro, G.J. (1980). Autocrine secretion and 
malignant transformation of cells. New England Journal  o f  
M e d ic in e ,  303: 878-880.
Sporn, M.B., & Roberts, A.B. (1985). Autocrine growth factors and 
cancer. N atu re ,  313: 745-747.
Sporn, M.B., & Roberts, A.B. (1988). peptide growth factors are 
multifucntional. N ature ,  332: 217-219.
Stadel, B.V., Rubin, G.L., Webster, L.A., Schlesselman, J.J., & Wingo, 
P.A. (1985). Oral contraceptives and breast cancer in young 
women. Lancet,  ii: 970-973.
Steinberg, K.K., Thacker, S.B., Smith, S.J., Stroup, D.F., Zack, M.W., 
Flanders, W.D., & Berkelman, R.L. (1991). A meta-analysis of the 
effect of estrogen replacement therapy on the risk of breast 
cancer. Journal of  the American Medical Association, 265: 1985- 
1990.
Stern, P.H., Krieger, M.S., Nissenson, R.A., Williams, R.D., Winkler, 
M.E., Derynck, R., & Strewler, G.J. (1985). Human transforming 
growth factor-alpha stimulates bone resorption in vitro. J o u r n a l  
of  Clinical Investigation, 76: 2016-2019.
Stiles, C.D. (1983). The molecular biology of platelet-derived 
growth factor. Cell,  33: 635-655.
447
CITATIONS
Stiles, C.D., Capone, G.T., Sher, C.D., Antoniades, H.N., van Wyk, J.J., 
& Pledger, W.J. (1979). Dual control of cell growth by 
somatomedins and 'competence factors'. Proceedings o f  the 
National Academy of  Sciences of  The United States of  America.,  
76: 1279-1283.
Stone, K.H., Mickey, D.D., Wunderli, H., Mickey, G.H., &  Paulson, D.F.
(1978). Isolation of a human prostate carcinoma cell line (DU  
145). International Journal of  Cancer, 21: 274-281.
Stone, N.N., Fair, W.R., & Fishman, J. (1986). Estrogen formation in 
human prostatic tissue from patients with and without benign 
prostatic hyperplasia. The Prostate, 9: 311-318.
Stoscheck, C.M., & king, L.E. (1986). Role of epidermal growth
factor in carcinogenesis. Cancer Research, 46: 1030-1037.
Strel'chyonok, O.A., Avvakumov, G.V., & Survilo, L.I. (1984). A 
recognition system for sex-hormone-binding protein-estradiol
complex in human decidual endometrium plasma membranes. 
Biochimica et Biophysica Acta, 802: 459-466.
Sutkowski, D.M ., Fong, C.-J., Sensibar, J.A., Rademaker, A.W., 
Sherwood, E.R., Kozlowski, J.M., & Lee, C. (1992). Interaction of 
epidermal growth factor and transforming growth factor beta in 
human prostatic epithelial cells in culture. The Prostate, 21: 133- 
143.
Swaneck, G.E., Alvarez, J.M., & Sufrin, G. (1982). Multiple species 
of estrogen binding sites in the nuclear fraction of the rat 
prostate. Biochemical and Biophysical Research Communications,
106: 1441-1447.
448
CITATIONS
Tai, P.K., Maeda, Y., Nakao, K., Wakim, N.G., Duhring, J.L., & Faber, 
L.E. (1986). A 59-kilodalton protein associated with progestin, 
estrogen, androgen, and glucocorticoid receptors. B io c h e m is t r y , 
25: 5269-5275.
Tai, P.K., Albers, M.W., Chang, H., Faber, L.E., & Schreiber, S.L.
(1992). Association of a 59-kilodalton immunophilin with the 
glucocorticoid receptor complex. Science, 256: 1315-1318.
Tait, G.H., Newton, C.J., Reed, M.J., & James, V.H.T. (1989). Multiple 
forms of 17(3-hydroxysteroid oxidoreductase in human breast 
tissue. Journal of  Molecular Endocrinology, 2: 71-80.
Takatani, O., Kosano, H., Okumoto, T., Akamatsu, K., Tamakuma, S., 
& Hiraide, H. (1987). Distribution of estradiol and percentage of 
free testosterone in sera of Japanese patients: preoperative 
breast cancer patients and normal controls. Journal o f  the
Nat iona l  Cancer Institute, 79: 1199-1204.
Tardivel-Lacombe, J., Egloff, M., Mazabraud, A., &  Degrelle, H.
(1984). Immunohistochemical detection of the sex steroid- 
binding plasma protein in human mammary carcinoma cells. 
Biochem ica l  and Biophysical Research Communications, 118: 
4 8 8 -4 9 4 .
Tashjian, A.H.Jr., Bancroft, F.C., & Levine, L. (1970). Production of 
both prolactin and growth hormone by clonal strains of rat
pituitary tumor cells. Differential effects of hydrocortisone and 
tissue extracts. Journal of  Cell  Biology, 47: 61-70.
Tasset, D., Tora, L., Fromental, C., Scheer, E., & Chambon, P. (1990).
Distinct classes of transcriptional activating domains function by
different mechanisms. Cell,  57: 1177-1187.
449
CITATIONS
Taylor, J.M., Mitchell, W.M., & Cohen, S. (1972). Epidermal growth 
factor: physical and chemical properties. Journal o f  Biological  
C h e m is t ry , 247: 5928-5934.
Taylor, J.M., Mitchell, W.M., & Cohen, S. (1974). Characterization 
of the high molecular weight form of epidermal growth factor. 
Journal of  Biological Chemistry, 249: 3198-3203.
Telang, N.T., Bradlow, H.L., Kurihara, H., & Osborne, M.P. (1989). 
In vitro biotransformation of estradiol by explant cultures of 
murine mammary tissues. Breast Cancer  Research and  
T r e a tm e n t , 13: 173-177.
ten Dijke, P., Iwata, K.K., Thorikay, M., Schwedes, J., Stewart, A., &  
Pieler, C. (1990). Molecular charcaterization of transforming 
growth factor type p3. Annals of  the New York Academy of  
Sciences, 593: 26-42.
Terenius, L. (1968). Selective retention of estrogen isomers in 
estrogen dependent breast tumors of rats demonstrated by i n 
vitro  methods. Cancer Research, 28: 328-334
The Cancer and Steroid Hormone Study, CDC and NICHD (1986). 
Oral contraceptive use and the risk of breast cancer. New England  
Journal of  Medicine, 315: 405-409.
Thijssen, J.H.H., Blankenstein, M.A., Daroszewski, J., &  Milewicz, A.
(1990). Steroids in normal and neoplastic breast tissues. A n n a ls  
of  the New York Academy of Sciences, 595: 222-226.
Thijssen, J.H.H., Blankenstein, M.A., Miller, W.R., & Milewicz, A.
(1987). Estrogens in tissues: uptake from the peripheral
circulation or local production. Steroids, 50: 297-306.
450
CITATIONS
Thijssen, van Landeghem, A.A.J., & Poortman, J. (1986).
Uptake and concentration of steroid hormones in mammary 
tissues. Annals of  the New York Academy of  Sciences, 464: 106- 
116.
Thompson, E.A.Jr., & Siiteri, P.K. (1974). The involvement of 
human placental microsomal cytochrome P-450 in aromatization. 
Journal of  Biological Chemistry, 249: 5373-5378.
Thorsen, T. (1979). Occupied and unoccupied nuclear oestradiol 
and progesterone cytosol receptors. Journa l  o f  Steroid  
Biochemistry,  10: 661-669.
Tilley, W.D., Wilson, C.M., Marcelli, M., & McPhaul, M.J. (1990). 
Androgen receptor gene expression in human prostate carcinoma 
cell lines. Cancer Research, 50: 5382-5386.
Tilson-Mallet, N., Santner, S.J., Feil, P.D., & Santen, R.J. (1983). 
Biological significance of aromatase activity in humann breast 
tumours. Journal of  Clinical Endocrinology and Metabolism,  57: 
1125-1128.
Toft, D., & Gorski, J. (1966). A receptor molecule for estrogens: 
isolation from the rat uterus and preliminary characterization. 
Proceedings of  the National Academy of  Sciences o f  The United 
States o f  America., 55: 1574-1581.
Tokunaga, M., Norman, J.E., Asano, M., Tokuoka, S., Ezaki, H., 
Nishimori, I., &  Tsuji, Y. (1979). Malignant breast tumors among 
atomic bomb survivors. Hiroshima and Nagasaki 1950-1974. 
Journal of  the National Cancer Institute, 62: 1347-1360.
Tong, P.K., Tollefsen, S., & Kornfeld, S. (1987). The cation 
independent mannose 6 phosphate receptor binds insulin-like 
growth factor II. Journal of  Biological Chemistry, 263: 2585- 
2588.
4 5 1
CITATIONS
Trachtenberg, G., Bujnovszky, P., & Walsh, P.C. (1982). Androgen 
receptor content of normal and hyperplastic human prostate. 
Journal of Clinical Endocrinology and Metabolism, 54: 17-21.
Traish, A.M., & Wotiz, H.H. (1987). Prostatic epidermal growth 
factor receptors and their regulation by androgens. 
Endocrinology,  121: 1461-1467.
Trapman, J., Ris-Stalpers, C., van der Korput, J.A., Kuiper, G.G., 
Faber, P.W., Romijn, J.C., Mulder, E., & Brinkmann, A.O. (1990). 
The androgen receptor: functional structure and expression in 
transplanted human prostate tumors and prostate tumor cell 
lines. Journal of  Steroid Biochemistry and Molecular Biology, 37: 
837-842 .
Trichopoulos, D., MacMahon, B., & Cole, P. (1972). Menopause and 
breast cancer risk. Journal o f  the National Cancer Institute, 48: 
605-613 .
Trichopoulos, D., Hsieh, C.C., & MacMahon, B. (1983). Age at any 
birth and breast cancer risk. International Journal of  Cancer, 31: 
701-704 .
Tsai, S.Y., Carlstedt-Duke, J.-A., Weigel, N .L., Dahlman, K., 
Gustafsson, J.-A., Tsai, M.-J., &  O'Malley, B. (1988). Molecular 
interactions of steroid hormone receptor with its enhancer 
element: evidence for receptor dimer formation. C e l l ,  55: 361- 
369.
Tsai, S.Y., Tsai, M.-J., & O'Malley, B. (1989). Cooperative binding of 
hormone receptors contributes to transcriptional synergism at 
steroid response elements. Cell,  S I :  443-448.
452
CITATIONS
Tseng, L., & Gurpide, E. (1975). Induction of human endometrial 
estradiol dehydrogenase by progestins. E n d o c r in o lo g y , 97: 825- 
833.
Tseng, L., & Liu, H.C. (1981). Stimulation of arylsulfotransferase 
activity by progestins in human endometrium in vitro. Journal of  
Clinical Endocrinology and Metabolism, 53: 418-421.
Tseng, L., Mazella, J., Lee, L.Y., & Stone, M.L. (1983). Estrogen 
sulfatase and estrogen sulfotransferase on human primary 
mammary carcinoma. Journal of  Steroid Biochemistry, 19: 1413- 
1417.
Tubiana, M., & Malaise, E.P. (1975). Growth rate and cell kinetics 
in human tumours: some prognostic and therapeutic implications. 
In: Sciebtific Foundation of Oncology. R. Symington & R.L. Carter 
(Ed.), pp. 126-136. Chicago: Year Book Medical Publishers.
Tucker, R.F., Shipley, G.D., Moses, H.L., & Holley, R.W. (1984). 
Growth inhibitor from BSC-1 cells closely related to platelet type 
beta transforming growth factor. Science, 226:  705-707.
Tunn, S., Schulze, H., & Krieg, M. (1993). 17p-hydroxysteroid  
oxidoreductase in epithelium and stroma of human prostate. 
Journal of Steroid Biochemistry and Molecular Biology, 46: 91- 
101.
Turcotte, G., Chapdelaine, A., Roberts, K.D., & Chevalier, S. (1988). 
Androgen binding as evidenced by a whole cell assay system 
using cultured canine prostatic epithelial cells. Journal o f  Steroid 
Biochemistry,  29: 69-76.
453
CITATIONS
Turkes, A.O., Peeling, W.B., Wilson, D.W., & Griffiths, K. (1988). 
Evaluation of different endocrine approaches in the treatment of 
prostatic carcinoma. In: New Developments in Biosciences 4. 
Endocrine Management of  Prostatic Carcinoma. H. Klosterhalfen 
(Ed.), pp. 75-86. Berlin: Walter de Gruyter & Co.
UK National Case-Control Study Group (1989). Oral contraceptive 
use and breast cancer risk in young women. Lancet,  i: 973-982.
Ullrich, A., Coussens, L., Hayflick, J.S., Dull, T.J., Gray, A., Tam, 
A.W ., Lee, J., Yarden, Y., Libermann, T.A., Schlessinger, J., 
Downward, J., Mayes, E.L.V., Whittle, N., Waterfield, M .D ., &  
Seeburg, P.H. (1984). Human epidermal growth factor receptor 
cDNA sequence and aberrant expression of the amplified gene in 
A431 epidermoid carcinoma cells. Nature ,  309: 418-425.
Unhjem, O., Tveter, K.J., & AAkvaag, A. (1969). Localization of an 
androge binding substance from the rat ventral prostate. A c t a  
Endocrinologica,  62: 153-160.
Upton, C., Macen, J.L., & McFadden, G. (1987). Mapping and 
sequencing of a gene frpm myxoma virus that is related to those 
encoding epidermal growth factor and transforming growth 
factor alpha. Journal of  Virology, 61: 1271-1275.
van Aubel, O.G.J.M., Bolt-de Vries, J., Blankenstein, M.A., ten Kate, 
F.J., &  Schroder, F.H. (1985). Nuclear androgen receptor content in 
biopsy specimens from histologically normal, hyperplastic and 
cancerous human prostatic tissue. The Prostate, 6: 185-194.
van de Vijver, M.J., & Nusse, R. (1991). The molecular biology of 
breast cancer. Biochimica et Biophysica Acta, 1072: 33-50.
van de Wiele, R.L., MacDonald, P.C., Gurpide, E., & Lieberman, S. 
(1963). Studies on the secretion and interconversion of the 
androgens. Recent Progress in Hormone Research, 19: 275-310.
4 5 4
CITATIONS
van Landeghem, A.A.J., Poortman, J., Nabuurs, M., & Thijssen, 
J.H.H. (1985a). Endogeneous concentration and subcellular 
distribution of estrogens in normal and malignant human breast
tissue. Cancer Research, 45: 2900-2906.
van Landeghem, A.A.J., Poortman, J., Nabuurs, M., & Thijssen, 
J.H.H. (1985b). Endogeneous concentration and subcellular 
distribution of androgens in normal and malignant human breast
tissue. Cancer Research, 45: 2907-2912.
van't Veer, P., Kolb, C.M., Verhoef, P., Kok, F.J., Schouten, E.G., 
Hermus, R.J.J., & Sturmans, F. (1990). Dietary fiber, beta-carotene 
and breast cancer: results from a case-control study.
International Journal of  Cancer, 45: 825-828.
Veldscholte, J., Voorhorst-Ogink, M.M., Bolt-de Vries, J., van Rooij, 
H.C.J., Trapman, J., &  Mulder, E. (1990a). Unusual specificity of the
androgen receptor in the human prostate tumor cell line LNCaP:
high affinity for progestagenic and estrogenic steroids. B ioch im ica  
et Biophysica Acta, 1052: 187-194.
Veldscholte, J., Ris-Stalpers, C., Kuiper, G.G., Jenster, G., Berrevoets, 
C., Claassen, E., van Rooij, H.C.J., Trapman, J., Brinkmann, A.O., &  
Mulder, E. (1990b). A mutation in the ligand binding domain of 
the androgen receptor of human LNCaP cells affects steroid 
binding characteristics and response to anti-androgens. 
Biochemical and Biophysical Research Communications, 173: 
534-540 .
Veomett, G., Prescott, D.M., Shay, J., & Porter, K.R. (1974). 
Reconstruction of mammalian cells from nuclear and cytoplasmic 
components separated by treatment with cytochalasin B. 
Proceedings of  the National Academy of  Sciences of  The United 
States o f  America., 71: 1999-2002.
4 5 5
CITATIONS
Vermeulen, A., & Verdonck, L. (1968). Studies on the binding of 
testosterone to human plasma. Steroids, 11: 609-635.
Vermeulen, A., Stoica, T., & Verdonck, L. (1971). The apparent 
free testosterone concentration, an index of androgenicity. 
Journal of  Clinical Endocrinology and Metabolism, 33: 759-767.
Vermeulen, A., Rubens, R., & Verdonck, L. (1972). Testosterone 
secretion and metabolism in male senescence. Journal o f  Clinical  
Endocrinology and Metabolism, 34: 730-735.
Vermeulen, A., Deslypere, J.P., Paridaens, R., Leclercq, G., Roy, F., 
& Heuson, J.C. (1986). Aromatase, 17(3-h y d ro x y  s te ro id  
dehydrogenase and intratissular sex hormone concentrations in 
cancerous and normal glandular breast tissue in postmenopausal 
women. European Journal of  Cancer and Clinical Oncology, 22:  
515-525 .
Vermeulen, A., & Deslypere, J.P. (1989). Biosynthesis of active 
oestrogens in the breast. In: Oestrogen and the Human Breast. 
J.S. Beck (Ed.), 95B, pp. 195-201. Edinburgh: Royal Society of 
Edinburgh.
Vessey, M.P. (1988). Oral contraception and cancer. In: 
Contraception - Science and Practice. M. Filshie & J. Guillebaud 
(Ed.), pp. 52-68. Guildford: Butterworth.
Vessey, M.P., McPherson, K., & Johnson, B. (1977). Mortality 
among women participating in the Oxford/Family Planning 
Association contraceptive study. Lancet,  ii: 731-735.
Vignon, F., Terqui, F., Westley, B., Derocq, D., & Rochefort, H. 
(1980). Effects of plasma estrogen sulfates in mammary cancer 
cells. Endocr ino logy , 106: 1079-1086.
456
CITATIONS
Vihko, R., & Apter, D. (1986). Hormonal profile and predisposition 
to breast caner. Reviews on Endocrine-Related Cancer, 23: 11-15.
Wahl, M., Nishibe, S., Suh, P., Rhee, S., & Carpenter, G. (1989). 
Epidermal growth factor stimulates tyrosine phosphorylation of 
phospholipase Ca independently of receptor internalisation and 
intracellular calcium. Proceedings of  the National Academy of  
Sciences of  The United States of  America., 86: 1568-1572.
Wahl, S.M., Hunt, D.A., Wakefield, L.M., McCartney-Francis, N., 
Wahl, L.M ., Roberts, A.B., & Sporn, M.B. (1987). Transforming 
growth factor type p induces monocyte chemotaxis and growth 
factor production. Proceedings o f  the Nat iona l  Academy o f  
Sciences of  The United States of  America., 84: 5788-5792.
Wakeling, A.E., Dukes, M., & Bowler, J. (1991). A potent speific 
pure antiestrogen with clinical potential. Cancer Research, SI :  
3867-3873 .
Walton, G.M., Chen, W.S., Rosenfeld, M.G., &  Gill, G.N. (1990). 
Analysis of deletions of the carboxyl terminus of the epidermal 
growth factor receptor reveals self-phosphorylation at tyrosine 
922 and enhanced in vivo tyrosine phosphorylation of cell 
substrates. Journal o f  Biological Chemistry, 265: 1750-1754.
Walsh, P.C., Hutchins, G.M., & Ewing, L.L. (1983). Tissue content of 
dihydrotestosterone in human prostatic hyerplasia is not 
supranormal. Journal of  Clinical Investigation, 72: 1772-1777.
Walters, M.R., Hunziker, W., & Norman, A.W. (1980). Unoccupied 
1,25-dihydroxyvitamin D3 receptors. Nuclear/cytosol ratio 
depends on ionic strength.Journal of Biological Chemistry. 255 ,  
Wang, L.H ., Tsai, S.Y., Sagami, I., & O'Malley, B. (1987). 
Purification and characterization of COUP transcription factor 
from HELA cells. Journal o f  Biological Chemistry, 262: 16080- 
16086.
457
CITATIONS
Watanabe, S., Lazar, E., & Sporn, M.B. (1987). Transfromation of 
normal rat kidney (NRK) cells by an infectious retrovirus 
carrying a synthetic rat type alpha transforming growth factor 
gene. Proceedings of  the National Academy of  Sciences o f  The 
United States of  America., 84: 1258-1262.
Weiner, D.B., Lin, J., Cohen, J.A., Williams, W .V., & Greene, M .I.
(1989). A point mutation in the neu oncogene mimics ligand 
induction of receptor aggregation. Nature ,  339: 230-231.
Weisz, J. (1991). Metabolism of estrogens by target cells: 
diversification and amplification of hormone action and the 
catecholestrogen hypothesis. In: Serono Symposia Publication  
from Raven Press, Vol. 74: The New Biology of  Steroid Hormones. 
R.B. Hochberg & F. Naftolin (Ed.), pp. 101-112. New York: Raven 
Press.
Welshons, W .V., Lieberman, M.E., & Gorski, J. (1984). Nuclear 
localization of unoccupied oestrogen receptors. N atu re ,  307: 747- 
749.
White, J.W. (1895). The results of double castration in 
hypertrophy of the prostate. Annals of  Surgery, 22: 1-80.
Whitmore, W.F. (1973). The natural history of prostatic cancer. 
Cancer ,  321: 1104-1112.
Whyte, P., Buchkovich, K.J., Horowitz, J.M., Friend, S.H., Raybuck, 
M., Weinberg, R.A., & Harlow, E. (1988). Association between an 
oncogene and an anti-oncogene: the adenovirus E1A proteins 
bind to the retinoblastoma gene product. N atu re ,  334: 124-129.
458
CITATIONS
WHO Collaborative Study of Neoplasia and Steroid Contraceptives
(1990). Breast cancer and combined oral contraceptives: results 
from a multinational study. British Journal of  Cancer, 61: 110- 
119.
Wilcox, J.N., & Derynck, R. (1988). Localisation of cells 
synthesising transforming growth factor-alpha mRNA in the 
mouse brain. Journal of  Neuroscience, 8: 1901-1904.
Wilding, G. (1992). The importance of steroid hormones in 
prostate cancer. Cancer Surveys, 14: 113-130.
Wilding, G., Zugmeier, G., Knabbe, C., Flanders, K., & Gelmann, E. 
(1989a). Differential effects of transforming growth factor p on 
human prostate cancer cells in vitro. M olecu lar  and C e l lu la r  
Endocrinology, 62: 79-87.
Wilding, G., Valverius, E., Knabbe, C., & Gelmann, E.P. (1989b). The 
role of transforming growth factor-a in human prostate cancer 
cell growth. The Prostate, 15: 1-12.
Wilking, N., Carlstrom, K., Gustafsson, S.A., Skoldefors, H., & 
Tollbone, O. (1980). Oestrogen receptors and metabolism of 
oestrone sulphate in human mammary carcinoma. E u r o p e a n  
Journal of  Cancer, 16: 1339-1344.
Wilson, J.D. (1980). The pathogenesis of benign prostatic 
hyperplasia. American Journal of  Medicine, 68: 745-747.
Wilson, J.D., & Walker, J.D. (1969). The conversion of testosterone 
to 5 androstan 17pol, 3one. Journal o f  Clinical Investigation, 48: 
371-379 .
W ittliff, J.L. (1984). Steroid-hormone receptors in breast cancer. 
Cancer,  53: 630-643.
459
CITATIONS
W ittliff, J.L., Hilf, R., Brooks, W.FJr., Savlov, E.D., Hall, T.C., &  
Orlando, R.A. (1972). Specific estrogen-binding capacity of the 
cytoplasmic receptor in normal and neoplastic tissues of humans. 
Cancer Research, 32: 1983-1992.
Wong, S.T., Winchell, L.F., McCune, B.K., Earp, H.S., Teixido, J., 
Massague, J., Herman, B., & Lee, D.C. (1989). The TGF-alpha 
precursor expressed on the cell surface binds to the EGF receptor 
on adjacent cells, leading to signal transduction. C e l l ,  56: 495- 
506.
Wozney, J.M., Rosen, V., Celeste, A.J., Mitsock, L.M., Whitters, M.J., 
Kriz, R.W., Hewick, R.M., & Wang, E.A. (1988). Novel regulators of 
bone formation: molecular clones and activities. Science ,  242: 
1528-1534.
Wrange, O., Okret, S., Radojcic, M., Carlstedt-Duke, J., &  Gustafsson, 
J.A. (1984). Characterization of the purified activated 
glucocorticoid receptor from rat liver cytosol. Journal o f  Biological 
Chem istry ,  259: 4534-4541.
Wrann, M .M ., & Fox, C.F. (1979). Identification of epidermal 
growth factor receptors in a hyperproducing epidermal 
carcinoma cell line. Journal o f  Biological Chemistry, 254: 8083- 
8086.
Wrann, M .M., Bodmer, S., de Martin, R., Siepl, C., Hofer-Warbinek, 
R., Frei, K., Hofer, E., & Fontana, A. (1987). T cell suppressor factor 
from human glioblastoma cells is a 12.5 KD protein closely 
related to transforming growth factor-beta. The EM B O  Journal, 6: 
1633-1636.
W yllie, A.H. (1980). Glucocorticoid induces in thymocytes a 
nuclease-like activity associated with the chromatin condensation 
of apoptosis. N ature ,  284: 555-556.
460
CITATIONS
Wyllie, A.H., Kerr, J.F.R., & Currie, A.R. (1973). Adrenocortical cell 
deletion: the role of ACTH. Journal of  Pathology, 111: 85-94.
Wyllie, A.H., Morris, R.G., Smith, A.L., & Dunlop, D. (1984).
Chromatin cleavage in apoptosis: association with condensed 
chromatin morphology and dependence on macromolecular 
synthesis. Journal of  Pathology, 142: 67-77.
Yamamoto, K.R. (1985). Steroid receptor regulated transcription 
of specific genes and gene networks. Annual Review o f  Genetics, 
19: 209-252.
Yamamoto, K.R., & Alberts, B.M. (1972). In vitro conversion of 
estradiol-receptor protein to its nuclear form: dependence on 
hormone and DNA. Proceedings of  the Nat ional Academy of
Sciences of  The United States of  America., 69: 2105-2109.
Yamamoto, T., Ikawa, S., Akiyama, T., Semba, K., Nomura, N., 
Miyajima, N., Saito, T., & Toyoshima, K. (1986). Similarity of
protein encoded by the human c -e rb B -2  gene to epidermal 
growth factor receptor. Nature ,  319: 230-234.
Yeh, L.C.C., Lee, A.J., Lee, N.E., Lam, K.W., & Lee, J.C. (1987). 
Molecular cloning of cDNA for human prostatic acid phosphatase. 
Gene,  60: 191-196.
Ying, S.-Y. (1988). Inhibins, activins and follicostatins: gonadal 
proteins modulating the secretion of follicle-stimulating hormone.
Endocrine Reviews, 9: 267-293.
Yu, S., & Fishman, J. (1985). Interactions of histones with 
estrogens. Covalent adduct formation with 16a-hydroxyestrone. 
B io c h e m is t ry , 29:  8017-8021.
4 6 1
CITATIONS
Zachary, I., & Rozengurt, E. (1985). Modulatyion of the epidermal 
growth factor receptor by mitogenic ligands: effects of bombesin 
and role of protein kinase C. Cancer Surveys, 4: 729-765.
Zaridze, D.G., Boyle, P., & Smans, M. (1984). International trends 
in prostatic cancer. International Journal of  Cancer, 33: 223-230.
Zava, D.T., & McGuire, W.L. (1977). Estrogen receptor. Unoccupied 
sites in nuclei of a breast tumor cell line. Journal  o f  Biological  
C h e m is t ry , 252: 3703-3708.
Zhou, M., Lambert, H., & Landry, J. (1993). Transient activation of 
a distinct serine protein kinase is responsible for 27-kDa heat 
shock protein phosphorylation in mitogen-stimulated and heat- 
shocked cells. Journal of  Biological Chemistry, 268: 35-43.
Zoppi, S., Marcelli, M., Deslypere, J.-P., Griffin, J.E., Wilson, J.D., &  
McPhaul, M.J. (1992). Amino acid substitutions in the DNA- 
binding domain of the human androgen receptor are a frequent 
cause of receptor positive androgen resistance. M o l e c u l a r  
Endocrinology,  6: 409-416.
Zumoff, B. (1981). Abnormal plasma hormone levels in women 
with breast cancer. In: Banbury Report No. 8: Hormones and 
Breast Cancer. M.C. Pike, P.K. Siiteri, & C.W. Welsh (Ed.), pp. 143- 
166. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory.
Zumoff, B., Bradlow, H.L., Gallagher, T.F., & Heilman, L. (1975). 
Hormone profiles in hormone-dependent cancers. C a n c e r  
Research,  35: 3365-3373.
Zumoff, B., Levin, J., Strain, G.W., Rosenfeld, R.S., O'Connor, J., 
Freed, S.Z., Kream, J., Whitmore, W.S., Fukushima, D.K., & Heilman, 
L. (1982). Abnormal levels of plasma hormones in men with 
prostate cancer. Evidence toward a "two-disease" theory. T h e  
Prostate,  3: 579-588.
462
CITATIONS
Zumstein, P., & Stiles, C.D. (1987). Molecular cloning of gene 
sequences that are regulated by insulin like growth factor I. 
Journal of  Biological Chemistry, 262: 11252-11260.
GLASGOW
university
library
463
